bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Gram - positive, Actinobacteria, Corynebacterium casei, C. variabile, cheese from dairy A, Brachybacterium alimentarum, Brevibacterium, cheeses from the farmhouses, dairies, B. permense, cheese from dairy A, B. linens, cheese from dairy B, B. aurantiacum, dairy, Brevibacterium spp ., dairy, coagulase negative, staphylococci, Staphylococcus saprophyticus, cheeses from dairies B, Staph . equorum, cheeses from dairies C, Gram - negative, Proteus vulgaris, Alcaligenes faecalis, dairy, surface yeast microbiota, yeast surface microbiota, farmhouse cheeses, cheese, industrial dairy, dairy, cheese from dairy A, Yarrowia lipolytica, Scopulariopsis brevicaulis, yeast microbiota, cheese from dairy B, Geotrichum spp ., Kluyveromyces marxianus, Debaryomyces hansenii, cheese from dairy C, D. hansenii, Geothrichum spp ., cheese from dairy D, D. hansenii	101_task2	Sentence: Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O" ]	Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii.	[ "Most", "species", "were", "Gram", "-", "positive", "Actinobacteria", "with", "Corynebacterium", "casei", "and", "/", "or", "C.", "variabile", "as", "the", "predominant", "(", "Table", "4", ")", ".", "Additionally", ",", "the", "cheese", "from", "dairy", "A", "was", "dominated", "by", "high", "of", "numbers", "of", "Brachybacterium", "alimentarum", ".", "Various", "Brevibacterium", "species", "were", "found", "on", "the", "cheeses", "from", "the", "farmhouses", "(", "dairies", "A", ",", "B", "and", "C", ")", ".", "B.", "permense", "was", "found", "on", "the", "cheese", "from", "dairy", "A", ",", "B.", "linens", "was", "found", "on", "the", "cheese", "from", "dairy", "B", "and", "B.", "aurantiacum", "was", "found", "on", "the", "cheese", "from", "dairy", "C.", "Brevibacterium", " ", "spp", ".", "could", "not", "be", "isolated", "on", "the", "cheese", "from", "dairy", "D.", "Furthermore", ",", "a", " ", "number", "of", "coagulase", "negative", "staphylococci", "were", "found", ",", "i.e", ".", ",", "Staphylococcus", "saprophyticus", "on", "the", "cheeses", "from", "dairies", "B", "and", "D", ",", "and", "Staph", ".", "equorum", "on", "the", "cheeses", "from", "dairies", "C", "and", "D.", "Finally", ",", "a", "number", "of", "Gram", "-", "negative", "bacteria", "species", "including", "Proteus", "vulgaris", "and", "Alcaligenes", "faecalis", "was", "found", "on", "the", "cheese", "from", "dairy", "C.Figure", "3", " ", "shows", "the", "grouping", "of", "the", "surface", "yeast", "microbiota", ".", "The", "yeast", "surface", " ", "microbiota", "on", "the", "three", "farmhouse", "cheeses", "consisted", "of", "two", "to", "four", " ", "groups", ",", "whereas", "the", "cheese", "produced", "at", "the", "industrial", "dairy", "(", "dairy", "D", ")", " ", "consisted", "of", "only", "one", "single", "group", ".", "The", "cheese", "from", "dairy", "A", "was", "equally", " ", "dominated", "by", "Yarrowia", "lipolytica", "and", "Scopulariopsis", "brevicaulis", ".", "The", "yeast", "microbiota", "on", "cheese", "from", "dairy", "B", "was", "primarily", "dominated", "by", "Geotrichum", "spp", ".", ",", "however", ",", "Kluyveromyces", "marxianus", "and", "Debaryomyces", "hansenii", "were", "additionally", "found", "in", "minor", "amounts", ".", "The", "cheese", "from", "dairy", "C", "was", "dominated", "by", "D.", "hansenii", "followed", "by", "a", "minor", "group", "of", "Geothrichum", "spp", ".", "Finally", ",", "the", "cheese", "from", "dairy", "D", "was", "entirely", "dominated", "by", "D.", "hansenii", "." ]	[ "Microorganism", "Habitat", "Phenotype" ]
histone is a Protein	42_task0	Sentence: The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome.	[ "The", "acetylation", "state", "of", "human", "fetal", "hemoglobin", "modulates", "the", "strength", "of", "its", "subunit", "interactions", ":", "long", "-", "range", "effects", "and", "implications", "for", "histone", "interactions", "in", "the", "nucleosome", ".", "\n", "The", "source", "of", "the", "70-fold", "increased", "tetramer", "strength", "of", "liganded", "fetal", "hemoglobin", "relative", "to", "that", "of", "adult", "hemoglobin", "between", "pH", "6.0", "and", "7.5", "reported", "earlier", "[", "Dumoulin", "et", "al", ".", "(", "1997", ")", "J.", "Biol", ".", "Chem", ".", "272", ",", "31326", "]", "has", "been", "identified", "as", "the", "N", "-", "terminal", "Gly", "residue", "of", "the", "gamma", "-", "chain", ",", "which", "is", "replaced", "by", "Val", "in", "adult", "hemoglobin", ".", "This", "was", "revealed", "by", "extending", "the", "study", "of", "the", "pH", "dependence", "of", "the", "tetramer", "-", "dimer", "equilibrium", "of", "these", "hemoglobins", "into", "the", "alkaline", "range", "as", "far", "as", "pH", "9", ".", "From", "pH", "7.5", "to", "9.0", ",", "the", "70-fold", "difference", "in", "the", "association", "equilibrium", "constant", "between", "hemoglobins", "F", "and", "A", "lessened", "progressively", ".", "This", "behavior", "was", "attributed", "to", "the", "difference", "in", "the", "pK(a", ")", "8.1", "of", "Gly-1(gamma", ")", "compared", "to", "the", "pK(a", ")", "7.1", "value", "of", "Val-1(beta", ")", "of", "hemoglobins", "F", "and", "A", ",", "respectively", ".", "Evidence", "for", "this", "conclusion", "was", "obtained", "by", "demonstrating", "that", "natural", "hemoglobin", "F(1", ")", ",", "which", "is", "specifically", "acetylated", "at", "Gly-1(gamma", ")", "and", "hence", "unable", "to", "be", "protonated", ",", "behaves", "like", "HbA", "and", "not", "HbF", "in", "its", "tetramer", "-", "dimer", "association", "properties", "over", "the", "pH", "range", "studied", ".", "An", "increased", "degree", "of", "protonation", "of", "the", "gamma", "-", "chain", "N", "-", "terminus", "of", "hemoglobin", "F", "from", "pH", "9.0", "to", "8.0", "is", "therefore", "suggested", "as", "responsible", "for", "its", "increased", "tetramer", "strength", "representing", "an", "example", "of", "transmission", "of", "a", "signal", "from", "its", "positively", "charged", "N", "-", "terminal", "tail", "to", "the", "distant", "subunit", "allosteric", "interface", "where", "the", "equilibrium", "constant", "is", "measured", ".", "An", "analogy", "is", "made", "between", "the", "effects", "of", "acetylation", "of", "the", "fetal", "hemoglobin", "tetramer", "on", "the", "strength", "of", "its", "subunit", "interactions", "and", "acetylation", "of", "some", "internal", "Lys", "residues", "within", "the", "N", "-", "terminal", "segments", "of", "the", "histone", "octamer", "around", "which", "DNA", "is", "wrapped", "in", "the", "nucleosome", ".", "\n" ]	[ "Protein" ]
histone is a Protein	42_task1	Sentence: The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome. Instructions: please typing these entity words according to sentence: histone Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome.	[ "The", "acetylation", "state", "of", "human", "fetal", "hemoglobin", "modulates", "the", "strength", "of", "its", "subunit", "interactions", ":", "long", "-", "range", "effects", "and", "implications", "for", "histone", "interactions", "in", "the", "nucleosome", ".", "\n", "The", "source", "of", "the", "70-fold", "increased", "tetramer", "strength", "of", "liganded", "fetal", "hemoglobin", "relative", "to", "that", "of", "adult", "hemoglobin", "between", "pH", "6.0", "and", "7.5", "reported", "earlier", "[", "Dumoulin", "et", "al", ".", "(", "1997", ")", "J.", "Biol", ".", "Chem", ".", "272", ",", "31326", "]", "has", "been", "identified", "as", "the", "N", "-", "terminal", "Gly", "residue", "of", "the", "gamma", "-", "chain", ",", "which", "is", "replaced", "by", "Val", "in", "adult", "hemoglobin", ".", "This", "was", "revealed", "by", "extending", "the", "study", "of", "the", "pH", "dependence", "of", "the", "tetramer", "-", "dimer", "equilibrium", "of", "these", "hemoglobins", "into", "the", "alkaline", "range", "as", "far", "as", "pH", "9", ".", "From", "pH", "7.5", "to", "9.0", ",", "the", "70-fold", "difference", "in", "the", "association", "equilibrium", "constant", "between", "hemoglobins", "F", "and", "A", "lessened", "progressively", ".", "This", "behavior", "was", "attributed", "to", "the", "difference", "in", "the", "pK(a", ")", "8.1", "of", "Gly-1(gamma", ")", "compared", "to", "the", "pK(a", ")", "7.1", "value", "of", "Val-1(beta", ")", "of", "hemoglobins", "F", "and", "A", ",", "respectively", ".", "Evidence", "for", "this", "conclusion", "was", "obtained", "by", "demonstrating", "that", "natural", "hemoglobin", "F(1", ")", ",", "which", "is", "specifically", "acetylated", "at", "Gly-1(gamma", ")", "and", "hence", "unable", "to", "be", "protonated", ",", "behaves", "like", "HbA", "and", "not", "HbF", "in", "its", "tetramer", "-", "dimer", "association", "properties", "over", "the", "pH", "range", "studied", ".", "An", "increased", "degree", "of", "protonation", "of", "the", "gamma", "-", "chain", "N", "-", "terminus", "of", "hemoglobin", "F", "from", "pH", "9.0", "to", "8.0", "is", "therefore", "suggested", "as", "responsible", "for", "its", "increased", "tetramer", "strength", "representing", "an", "example", "of", "transmission", "of", "a", "signal", "from", "its", "positively", "charged", "N", "-", "terminal", "tail", "to", "the", "distant", "subunit", "allosteric", "interface", "where", "the", "equilibrium", "constant", "is", "measured", ".", "An", "analogy", "is", "made", "between", "the", "effects", "of", "acetylation", "of", "the", "fetal", "hemoglobin", "tetramer", "on", "the", "strength", "of", "its", "subunit", "interactions", "and", "acetylation", "of", "some", "internal", "Lys", "residues", "within", "the", "N", "-", "terminal", "segments", "of", "the", "histone", "octamer", "around", "which", "DNA", "is", "wrapped", "in", "the", "nucleosome", ".", "\n" ]	[ "Protein" ]
histone	42_task2	Sentence: The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome.	[ "The", "acetylation", "state", "of", "human", "fetal", "hemoglobin", "modulates", "the", "strength", "of", "its", "subunit", "interactions", ":", "long", "-", "range", "effects", "and", "implications", "for", "histone", "interactions", "in", "the", "nucleosome", ".", "\n", "The", "source", "of", "the", "70-fold", "increased", "tetramer", "strength", "of", "liganded", "fetal", "hemoglobin", "relative", "to", "that", "of", "adult", "hemoglobin", "between", "pH", "6.0", "and", "7.5", "reported", "earlier", "[", "Dumoulin", "et", "al", ".", "(", "1997", ")", "J.", "Biol", ".", "Chem", ".", "272", ",", "31326", "]", "has", "been", "identified", "as", "the", "N", "-", "terminal", "Gly", "residue", "of", "the", "gamma", "-", "chain", ",", "which", "is", "replaced", "by", "Val", "in", "adult", "hemoglobin", ".", "This", "was", "revealed", "by", "extending", "the", "study", "of", "the", "pH", "dependence", "of", "the", "tetramer", "-", "dimer", "equilibrium", "of", "these", "hemoglobins", "into", "the", "alkaline", "range", "as", "far", "as", "pH", "9", ".", "From", "pH", "7.5", "to", "9.0", ",", "the", "70-fold", "difference", "in", "the", "association", "equilibrium", "constant", "between", "hemoglobins", "F", "and", "A", "lessened", "progressively", ".", "This", "behavior", "was", "attributed", "to", "the", "difference", "in", "the", "pK(a", ")", "8.1", "of", "Gly-1(gamma", ")", "compared", "to", "the", "pK(a", ")", "7.1", "value", "of", "Val-1(beta", ")", "of", "hemoglobins", "F", "and", "A", ",", "respectively", ".", "Evidence", "for", "this", "conclusion", "was", "obtained", "by", "demonstrating", "that", "natural", "hemoglobin", "F(1", ")", ",", "which", "is", "specifically", "acetylated", "at", "Gly-1(gamma", ")", "and", "hence", "unable", "to", "be", "protonated", ",", "behaves", "like", "HbA", "and", "not", "HbF", "in", "its", "tetramer", "-", "dimer", "association", "properties", "over", "the", "pH", "range", "studied", ".", "An", "increased", "degree", "of", "protonation", "of", "the", "gamma", "-", "chain", "N", "-", "terminus", "of", "hemoglobin", "F", "from", "pH", "9.0", "to", "8.0", "is", "therefore", "suggested", "as", "responsible", "for", "its", "increased", "tetramer", "strength", "representing", "an", "example", "of", "transmission", "of", "a", "signal", "from", "its", "positively", "charged", "N", "-", "terminal", "tail", "to", "the", "distant", "subunit", "allosteric", "interface", "where", "the", "equilibrium", "constant", "is", "measured", ".", "An", "analogy", "is", "made", "between", "the", "effects", "of", "acetylation", "of", "the", "fetal", "hemoglobin", "tetramer", "on", "the", "strength", "of", "its", "subunit", "interactions", "and", "acetylation", "of", "some", "internal", "Lys", "residues", "within", "the", "N", "-", "terminal", "segments", "of", "the", "histone", "octamer", "around", "which", "DNA", "is", "wrapped", "in", "the", "nucleosome", ".", "\n" ]	[ "Protein" ]
acute ischaemic stroke is a Participant_Condition, NMDA antagonist AR - R15896AR is a Intervention_Pharmacological, safety and tolerability is a Outcome_Other, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR is a Intervention_Pharmacological, animal models of ischaemic stroke is a Participant_Condition, placebo - controlled is a Intervention_Control, Two loading doses of 3.5 mg / kg of AR - R15896AR is a Intervention_Pharmacological, safety , tolerability and pharmacokinetics . is a Outcome_Other, Barthel Index ( BI ) is a Outcome_Other, NIH Stroke Scale ( NIHSS ) is a Outcome_Other, 103 patients is a Participant_Sample-size, Mortality is a Outcome_Mortality, Serious adverse events is a Outcome_Adverse-effects, side effects is a Outcome_Adverse-effects, vomiting is a Outcome_Adverse-effects, nausea is a Outcome_Adverse-effects, fever is a Outcome_Adverse-effects, agitation is a Outcome_Adverse-effects, dizziness is a Outcome_Adverse-effects, hallucinations is a Outcome_Adverse-effects, plasma concentrations of AR - R15896AR is a Outcome_Physical, high plasma levels is a Outcome_Physical	9104_task0	Sentence: Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population .	[ "Treatment", "of", "acute", "ischaemic", "stroke", "with", "the", "low", "-", "affinity", ",", "use", "-", "dependent", "NMDA", "antagonist", "AR", "-", "R15896AR", ".", "A", "safety", "and", "tolerability", "study", ".", "BACKGROUND", "AND", "PURPOSE", "A", "low", "-", "affinity", ",", "use", "-", "dependent", "N", "-", "Methyl", "-", "D", "-", "Aspartate", "(", "NMDA", ")", "antagonist", "AR", "-", "R15896AR", "has", "neuroprotective", "properties", "in", "animal", "models", "of", "ischaemic", "stroke", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "tolerability", "of", "a", "new", "and", "higher", "dosage", "regimen", "that", "would", "enable", "acute", "stroke", "patients", "to", "achieve", "and", "maintain", "neuroprotective", "plasma", "concentrations", ".", "METHODS", "A", "randomised", ",", "multi", "-", "centre", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "carried", "out", "at", "19", "centres", "in", "France", ",", "Germany", "and", "the", "Netherlands", "in", "patients", "with", "a", "clinical", "diagnosis", "of", "acute", "ischaemic", "stroke", ",", "and", "onset", "of", "symptoms", "within", "12", "hours", "before", "start", "of", "study", "drug", "administration", ".", "Two", "loading", "doses", "of", "3.5", "mg", "/", "kg", "of", "AR", "-", "R15896AR", "over", "60", "minutes", ",", "followed", "by", "a", "2.5", "mg", "/", "kg", "infusion", "over", "the", "next", "120", "minutes", "were", "given", ".", "Eight", "hours", "after", "the", "start", "of", "the", "loading", "dose", "infusion", ",", "the", "first", "maintenance", "dose", "(", "120", "mg", ")", "was", "administered", "over", "60", "minutes", ".", "Eight", "further", "maintenance", "infusions", "were", "administered", "at", "intervals", "of", "8", "hours", "over", "a", "total", "treatment", "period", "of", "3", "days", ".", "Main", "variables", "were", "safety", ",", "tolerability", "and", "pharmacokinetics", ".", "Follow", "-", "up", "assessments", "also", "included", "the", "Barthel", "Index", "(", "BI", ")", "and", "the", "NIH", "Stroke", "Scale", "(", "NIHSS", ")", "at", "4", "-", "7", "days", "after", "the", "end", "of", "the", "last", "infusion", "and", "at", "30", "days", "after", "the", "onset", "of", "stroke", ".", "RESULTS", "103", "patients", "with", "acute", "ischaemic", "stroke", "were", "randomised", "to", "either", "treatment", "with", "AR", "-", "R15896AR", "(", "70", "patients", ")", "or", "placebo", "(", "33", "patients", ")", ".", "Mortality", "was", "not", "significantly", "different", "in", "the", "AR", "-", "R15896AR", "group", "compared", "with", "the", "placebo", "group", "(", "10", "%", "vs", ".", "6", "%", ")", ".", "Serious", "adverse", "events", "during", "treatment", "due", "to", "psychiatric", "conditions", "were", "associated", "with", "AR", "-", "R15896AR", "(", "3", "vs", ".", "0", ")", ".", "Other", "side", "effects", "were", "more", "common", "in", "the", "group", "treated", "with", "AR", "-", "R15896AR", ":", "vomiting", "(", "29", "%", "vs", ".", "9", "%", ")", ",", "nausea", "(", "23", "%", "vs", ".", "12", "%", ")", ",", "fever", "(", "17", "%", "vs", ".", "12", "%", ")", ",", "agitation", "(", "7", "%", "vs", ".", "3", "%", ")", ",", "dizziness", "(", "7", "%", "vs", ".", "0", "%", ")", ",", "and", "hallucinations", "(", "6", "%", "vs", ".", "0", "%", ")", ".", "No", "significant", "difference", "between", "the", "two", "groups", "(", "with", "respect", "to", "the", "proportions", "of", "patients", "with", "favourable", "outcome", ")", "was", "detected", "in", "either", "the", "analysis", "of", "the", "BI", "or", "the", "NIHSS", ".", "Pharmacokinetic", "data", "showed", "that", "plasma", "concentrations", "of", "AR", "-", "R15896AR", "were", "in", "the", "expected", "neuroprotective", "range", ".", "CONCLUSION", "In", "most", "of", "the", "patients", "with", "acute", "stroke", "receiving", "AR", "-", "R15896AR", "the", "intended", "high", "plasma", "levels", "were", "reached", "within", "a", "short", "time", "period", ".", "However", ",", "active", "treatment", "produced", "more", "side", "effects", "than", "placebo", ",", "thus", "indicating", "safety", "concerns", "and", "tolerability", "issues", "for", "use", "in", "high", "doses", "in", "an", "acute", "stroke", "population", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Control", "Participant_Sample-size", "Outcome_Mortality" ]
acute ischaemic stroke is a Participant_Condition, NMDA antagonist AR - R15896AR is a Intervention_Pharmacological, safety and tolerability is a Outcome_Other, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR is a Intervention_Pharmacological, animal models of ischaemic stroke is a Participant_Condition, placebo - controlled is a Intervention_Control, Two loading doses of 3.5 mg / kg of AR - R15896AR is a Intervention_Pharmacological, safety , tolerability and pharmacokinetics . is a Outcome_Other, Barthel Index ( BI ) is a Outcome_Other, NIH Stroke Scale ( NIHSS ) is a Outcome_Other, 103 patients is a Participant_Sample-size, Mortality is a Outcome_Mortality, Serious adverse events is a Outcome_Adverse-effects, side effects is a Outcome_Adverse-effects, vomiting is a Outcome_Adverse-effects, nausea is a Outcome_Adverse-effects, fever is a Outcome_Adverse-effects, agitation is a Outcome_Adverse-effects, dizziness is a Outcome_Adverse-effects, hallucinations is a Outcome_Adverse-effects, plasma concentrations of AR - R15896AR is a Outcome_Physical, high plasma levels is a Outcome_Physical	9104_task1	Sentence: Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population . Instructions: please typing these entity words according to sentence: acute ischaemic stroke, NMDA antagonist AR - R15896AR, safety and tolerability, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR, animal models of ischaemic stroke, placebo - controlled, Two loading doses of 3.5 mg / kg of AR - R15896AR, safety , tolerability and pharmacokinetics ., Barthel Index ( BI ), NIH Stroke Scale ( NIHSS ), 103 patients, Mortality, Serious adverse events, side effects, vomiting, nausea, fever, agitation, dizziness, hallucinations, plasma concentrations of AR - R15896AR, high plasma levels Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population .	[ "Treatment", "of", "acute", "ischaemic", "stroke", "with", "the", "low", "-", "affinity", ",", "use", "-", "dependent", "NMDA", "antagonist", "AR", "-", "R15896AR", ".", "A", "safety", "and", "tolerability", "study", ".", "BACKGROUND", "AND", "PURPOSE", "A", "low", "-", "affinity", ",", "use", "-", "dependent", "N", "-", "Methyl", "-", "D", "-", "Aspartate", "(", "NMDA", ")", "antagonist", "AR", "-", "R15896AR", "has", "neuroprotective", "properties", "in", "animal", "models", "of", "ischaemic", "stroke", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "tolerability", "of", "a", "new", "and", "higher", "dosage", "regimen", "that", "would", "enable", "acute", "stroke", "patients", "to", "achieve", "and", "maintain", "neuroprotective", "plasma", "concentrations", ".", "METHODS", "A", "randomised", ",", "multi", "-", "centre", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "carried", "out", "at", "19", "centres", "in", "France", ",", "Germany", "and", "the", "Netherlands", "in", "patients", "with", "a", "clinical", "diagnosis", "of", "acute", "ischaemic", "stroke", ",", "and", "onset", "of", "symptoms", "within", "12", "hours", "before", "start", "of", "study", "drug", "administration", ".", "Two", "loading", "doses", "of", "3.5", "mg", "/", "kg", "of", "AR", "-", "R15896AR", "over", "60", "minutes", ",", "followed", "by", "a", "2.5", "mg", "/", "kg", "infusion", "over", "the", "next", "120", "minutes", "were", "given", ".", "Eight", "hours", "after", "the", "start", "of", "the", "loading", "dose", "infusion", ",", "the", "first", "maintenance", "dose", "(", "120", "mg", ")", "was", "administered", "over", "60", "minutes", ".", "Eight", "further", "maintenance", "infusions", "were", "administered", "at", "intervals", "of", "8", "hours", "over", "a", "total", "treatment", "period", "of", "3", "days", ".", "Main", "variables", "were", "safety", ",", "tolerability", "and", "pharmacokinetics", ".", "Follow", "-", "up", "assessments", "also", "included", "the", "Barthel", "Index", "(", "BI", ")", "and", "the", "NIH", "Stroke", "Scale", "(", "NIHSS", ")", "at", "4", "-", "7", "days", "after", "the", "end", "of", "the", "last", "infusion", "and", "at", "30", "days", "after", "the", "onset", "of", "stroke", ".", "RESULTS", "103", "patients", "with", "acute", "ischaemic", "stroke", "were", "randomised", "to", "either", "treatment", "with", "AR", "-", "R15896AR", "(", "70", "patients", ")", "or", "placebo", "(", "33", "patients", ")", ".", "Mortality", "was", "not", "significantly", "different", "in", "the", "AR", "-", "R15896AR", "group", "compared", "with", "the", "placebo", "group", "(", "10", "%", "vs", ".", "6", "%", ")", ".", "Serious", "adverse", "events", "during", "treatment", "due", "to", "psychiatric", "conditions", "were", "associated", "with", "AR", "-", "R15896AR", "(", "3", "vs", ".", "0", ")", ".", "Other", "side", "effects", "were", "more", "common", "in", "the", "group", "treated", "with", "AR", "-", "R15896AR", ":", "vomiting", "(", "29", "%", "vs", ".", "9", "%", ")", ",", "nausea", "(", "23", "%", "vs", ".", "12", "%", ")", ",", "fever", "(", "17", "%", "vs", ".", "12", "%", ")", ",", "agitation", "(", "7", "%", "vs", ".", "3", "%", ")", ",", "dizziness", "(", "7", "%", "vs", ".", "0", "%", ")", ",", "and", "hallucinations", "(", "6", "%", "vs", ".", "0", "%", ")", ".", "No", "significant", "difference", "between", "the", "two", "groups", "(", "with", "respect", "to", "the", "proportions", "of", "patients", "with", "favourable", "outcome", ")", "was", "detected", "in", "either", "the", "analysis", "of", "the", "BI", "or", "the", "NIHSS", ".", "Pharmacokinetic", "data", "showed", "that", "plasma", "concentrations", "of", "AR", "-", "R15896AR", "were", "in", "the", "expected", "neuroprotective", "range", ".", "CONCLUSION", "In", "most", "of", "the", "patients", "with", "acute", "stroke", "receiving", "AR", "-", "R15896AR", "the", "intended", "high", "plasma", "levels", "were", "reached", "within", "a", "short", "time", "period", ".", "However", ",", "active", "treatment", "produced", "more", "side", "effects", "than", "placebo", ",", "thus", "indicating", "safety", "concerns", "and", "tolerability", "issues", "for", "use", "in", "high", "doses", "in", "an", "acute", "stroke", "population", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Control", "Participant_Sample-size", "Outcome_Mortality" ]
acute ischaemic stroke, NMDA antagonist AR - R15896AR, safety and tolerability, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR, animal models of ischaemic stroke, placebo - controlled, Two loading doses of 3.5 mg / kg of AR - R15896AR, safety , tolerability and pharmacokinetics ., Barthel Index ( BI ), NIH Stroke Scale ( NIHSS ), 103 patients, Mortality, Serious adverse events, side effects, vomiting, nausea, fever, agitation, dizziness, hallucinations, plasma concentrations of AR - R15896AR, high plasma levels	9104_task2	Sentence: Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population .	[ "Treatment", "of", "acute", "ischaemic", "stroke", "with", "the", "low", "-", "affinity", ",", "use", "-", "dependent", "NMDA", "antagonist", "AR", "-", "R15896AR", ".", "A", "safety", "and", "tolerability", "study", ".", "BACKGROUND", "AND", "PURPOSE", "A", "low", "-", "affinity", ",", "use", "-", "dependent", "N", "-", "Methyl", "-", "D", "-", "Aspartate", "(", "NMDA", ")", "antagonist", "AR", "-", "R15896AR", "has", "neuroprotective", "properties", "in", "animal", "models", "of", "ischaemic", "stroke", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "tolerability", "of", "a", "new", "and", "higher", "dosage", "regimen", "that", "would", "enable", "acute", "stroke", "patients", "to", "achieve", "and", "maintain", "neuroprotective", "plasma", "concentrations", ".", "METHODS", "A", "randomised", ",", "multi", "-", "centre", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "carried", "out", "at", "19", "centres", "in", "France", ",", "Germany", "and", "the", "Netherlands", "in", "patients", "with", "a", "clinical", "diagnosis", "of", "acute", "ischaemic", "stroke", ",", "and", "onset", "of", "symptoms", "within", "12", "hours", "before", "start", "of", "study", "drug", "administration", ".", "Two", "loading", "doses", "of", "3.5", "mg", "/", "kg", "of", "AR", "-", "R15896AR", "over", "60", "minutes", ",", "followed", "by", "a", "2.5", "mg", "/", "kg", "infusion", "over", "the", "next", "120", "minutes", "were", "given", ".", "Eight", "hours", "after", "the", "start", "of", "the", "loading", "dose", "infusion", ",", "the", "first", "maintenance", "dose", "(", "120", "mg", ")", "was", "administered", "over", "60", "minutes", ".", "Eight", "further", "maintenance", "infusions", "were", "administered", "at", "intervals", "of", "8", "hours", "over", "a", "total", "treatment", "period", "of", "3", "days", ".", "Main", "variables", "were", "safety", ",", "tolerability", "and", "pharmacokinetics", ".", "Follow", "-", "up", "assessments", "also", "included", "the", "Barthel", "Index", "(", "BI", ")", "and", "the", "NIH", "Stroke", "Scale", "(", "NIHSS", ")", "at", "4", "-", "7", "days", "after", "the", "end", "of", "the", "last", "infusion", "and", "at", "30", "days", "after", "the", "onset", "of", "stroke", ".", "RESULTS", "103", "patients", "with", "acute", "ischaemic", "stroke", "were", "randomised", "to", "either", "treatment", "with", "AR", "-", "R15896AR", "(", "70", "patients", ")", "or", "placebo", "(", "33", "patients", ")", ".", "Mortality", "was", "not", "significantly", "different", "in", "the", "AR", "-", "R15896AR", "group", "compared", "with", "the", "placebo", "group", "(", "10", "%", "vs", ".", "6", "%", ")", ".", "Serious", "adverse", "events", "during", "treatment", "due", "to", "psychiatric", "conditions", "were", "associated", "with", "AR", "-", "R15896AR", "(", "3", "vs", ".", "0", ")", ".", "Other", "side", "effects", "were", "more", "common", "in", "the", "group", "treated", "with", "AR", "-", "R15896AR", ":", "vomiting", "(", "29", "%", "vs", ".", "9", "%", ")", ",", "nausea", "(", "23", "%", "vs", ".", "12", "%", ")", ",", "fever", "(", "17", "%", "vs", ".", "12", "%", ")", ",", "agitation", "(", "7", "%", "vs", ".", "3", "%", ")", ",", "dizziness", "(", "7", "%", "vs", ".", "0", "%", ")", ",", "and", "hallucinations", "(", "6", "%", "vs", ".", "0", "%", ")", ".", "No", "significant", "difference", "between", "the", "two", "groups", "(", "with", "respect", "to", "the", "proportions", "of", "patients", "with", "favourable", "outcome", ")", "was", "detected", "in", "either", "the", "analysis", "of", "the", "BI", "or", "the", "NIHSS", ".", "Pharmacokinetic", "data", "showed", "that", "plasma", "concentrations", "of", "AR", "-", "R15896AR", "were", "in", "the", "expected", "neuroprotective", "range", ".", "CONCLUSION", "In", "most", "of", "the", "patients", "with", "acute", "stroke", "receiving", "AR", "-", "R15896AR", "the", "intended", "high", "plasma", "levels", "were", "reached", "within", "a", "short", "time", "period", ".", "However", ",", "active", "treatment", "produced", "more", "side", "effects", "than", "placebo", ",", "thus", "indicating", "safety", "concerns", "and", "tolerability", "issues", "for", "use", "in", "high", "doses", "in", "an", "acute", "stroke", "population", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Control", "Participant_Sample-size", "Outcome_Mortality" ]
varenicline is a Intervention_Pharmacological, COPD patients is a Participant_Condition, chronic obstructive pulmonary disease ( COPD is a Participant_Condition, varenicline 1 mg b.i.d . is a Intervention_Pharmacological, placebo is a Intervention_Control, abstinence is a Outcome_Mental, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) is a Outcome_Physical, CCQ scores is a Outcome_Physical, CCQ Total Score is a Outcome_Physical, smokers with COPD is a Participant_Condition, continuous abstinence is a Outcome_Mental, CCQ Total Scores is a Outcome_Physical	50448_task0	Sentence: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) .	[ "Lung", "function", "and", "respiratory", "symptoms", "in", "a", "1-year", "randomized", "smoking", "cessation", "trial", "of", "varenicline", "in", "COPD", "patients", ".", "UNLABELLED", "There", "are", "few", "data", "concerning", "changes", "in", "lung", "function", "and", "respiratory", "symptoms", "in", "smokers", "with", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", "weeks", "to", "months", "after", "quitting", "smoking", ".", "We", "examined", "serial", "changes", "in", "spirometry", "and", "Clinical", "COPD", "Questionnaire", "(", "CCQ", ")", "scores", "(", "measuring", "respiratory", "symptoms", "and", "health", "-", "related", "quality", "of", "life", ")", "in", "COPD", "participants", "by", "smoking", "status", "during", "a", "smoking", "cessation", "trial", ".", "In", "this", "randomized", ",", "double", "-", "blind", "trial", ",", "smokers", "with", "mild", "-", "to", "-", "moderate", "COPD", "were", "treated", "with", "varenicline", "1", "mg", "b.i.d", ".", "or", "placebo", "for", "12", "weeks", "and", "followed", "to", "Week", "52", ".", "Primary", "endpoints", "of", "abstinence", "were", "previously", "reported", ".", "Secondary", "endpoints", "were", "mean", "changes", "from", "baseline", "in", "post", "-", "bronchodilator", "forced", "expired", "volume", "in", "1", "s", "(", "FEV", "(", "1", ")", ")", "and", "CCQ", "scores", ".", "Change", "from", "baseline", "in", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "was", "significantly", "improved", "in", "continuous", "abstainers", "(", "121.8", "mL", ")", "vs", ".", "continuous", "smokers", "(", "37.9", "mL", ")", "at", "Week", "12", "(", "P", "=", "0.0069", ")", ",", "but", "not", "at", "Weeks", "24", "or", "52", ".", "Mean", "change", "from", "baseline", "at", "Week", "12", "in", "CCQ", "Total", "Score", "was", "significantly", "better", "in", "continuous", "abstainers", "(", "-1.04", ")", "vs", ".", "continuous", "smokers", "(", "-0.53", ";", "P", "<", "0.0001", ")", ":", "this", "improvement", "was", "sustained", "at", "Weeks", "24", "and", "52", ".", "In", "a", "1-year", "cessation", "trial", "of", "smokers", "with", "COPD", ",", "continuous", "abstinence", "compared", "with", "continuous", "smoking", "significantly", "improved", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "at", "Week", "12", "(", "although", "the", "difference", "narrowed", "subsequently", ")", "and", "CCQ", "Total", "Scores", "at", "Week", "12", ",", "with", "sustained", "improvement", "thereafter", ".", "(", "TRIAL", "REGISTRY", "http", ":", "//www.clinicaltrials.gov", ";", "trial", "identifier", ":", "NCT00285012", ")", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mental", "Intervention_Control" ]
varenicline is a Intervention_Pharmacological, COPD patients is a Participant_Condition, chronic obstructive pulmonary disease ( COPD is a Participant_Condition, varenicline 1 mg b.i.d . is a Intervention_Pharmacological, placebo is a Intervention_Control, abstinence is a Outcome_Mental, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) is a Outcome_Physical, CCQ scores is a Outcome_Physical, CCQ Total Score is a Outcome_Physical, smokers with COPD is a Participant_Condition, continuous abstinence is a Outcome_Mental, CCQ Total Scores is a Outcome_Physical	50448_task1	Sentence: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) . Instructions: please typing these entity words according to sentence: varenicline, COPD patients, chronic obstructive pulmonary disease ( COPD, varenicline 1 mg b.i.d ., placebo, abstinence, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ), CCQ scores, CCQ Total Score, smokers with COPD, continuous abstinence, CCQ Total Scores Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) .	[ "Lung", "function", "and", "respiratory", "symptoms", "in", "a", "1-year", "randomized", "smoking", "cessation", "trial", "of", "varenicline", "in", "COPD", "patients", ".", "UNLABELLED", "There", "are", "few", "data", "concerning", "changes", "in", "lung", "function", "and", "respiratory", "symptoms", "in", "smokers", "with", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", "weeks", "to", "months", "after", "quitting", "smoking", ".", "We", "examined", "serial", "changes", "in", "spirometry", "and", "Clinical", "COPD", "Questionnaire", "(", "CCQ", ")", "scores", "(", "measuring", "respiratory", "symptoms", "and", "health", "-", "related", "quality", "of", "life", ")", "in", "COPD", "participants", "by", "smoking", "status", "during", "a", "smoking", "cessation", "trial", ".", "In", "this", "randomized", ",", "double", "-", "blind", "trial", ",", "smokers", "with", "mild", "-", "to", "-", "moderate", "COPD", "were", "treated", "with", "varenicline", "1", "mg", "b.i.d", ".", "or", "placebo", "for", "12", "weeks", "and", "followed", "to", "Week", "52", ".", "Primary", "endpoints", "of", "abstinence", "were", "previously", "reported", ".", "Secondary", "endpoints", "were", "mean", "changes", "from", "baseline", "in", "post", "-", "bronchodilator", "forced", "expired", "volume", "in", "1", "s", "(", "FEV", "(", "1", ")", ")", "and", "CCQ", "scores", ".", "Change", "from", "baseline", "in", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "was", "significantly", "improved", "in", "continuous", "abstainers", "(", "121.8", "mL", ")", "vs", ".", "continuous", "smokers", "(", "37.9", "mL", ")", "at", "Week", "12", "(", "P", "=", "0.0069", ")", ",", "but", "not", "at", "Weeks", "24", "or", "52", ".", "Mean", "change", "from", "baseline", "at", "Week", "12", "in", "CCQ", "Total", "Score", "was", "significantly", "better", "in", "continuous", "abstainers", "(", "-1.04", ")", "vs", ".", "continuous", "smokers", "(", "-0.53", ";", "P", "<", "0.0001", ")", ":", "this", "improvement", "was", "sustained", "at", "Weeks", "24", "and", "52", ".", "In", "a", "1-year", "cessation", "trial", "of", "smokers", "with", "COPD", ",", "continuous", "abstinence", "compared", "with", "continuous", "smoking", "significantly", "improved", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "at", "Week", "12", "(", "although", "the", "difference", "narrowed", "subsequently", ")", "and", "CCQ", "Total", "Scores", "at", "Week", "12", ",", "with", "sustained", "improvement", "thereafter", ".", "(", "TRIAL", "REGISTRY", "http", ":", "//www.clinicaltrials.gov", ";", "trial", "identifier", ":", "NCT00285012", ")", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mental", "Intervention_Control" ]
varenicline, COPD patients, chronic obstructive pulmonary disease ( COPD, varenicline 1 mg b.i.d ., placebo, abstinence, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ), CCQ scores, CCQ Total Score, smokers with COPD, continuous abstinence, CCQ Total Scores	50448_task2	Sentence: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) .	[ "Lung", "function", "and", "respiratory", "symptoms", "in", "a", "1-year", "randomized", "smoking", "cessation", "trial", "of", "varenicline", "in", "COPD", "patients", ".", "UNLABELLED", "There", "are", "few", "data", "concerning", "changes", "in", "lung", "function", "and", "respiratory", "symptoms", "in", "smokers", "with", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", "weeks", "to", "months", "after", "quitting", "smoking", ".", "We", "examined", "serial", "changes", "in", "spirometry", "and", "Clinical", "COPD", "Questionnaire", "(", "CCQ", ")", "scores", "(", "measuring", "respiratory", "symptoms", "and", "health", "-", "related", "quality", "of", "life", ")", "in", "COPD", "participants", "by", "smoking", "status", "during", "a", "smoking", "cessation", "trial", ".", "In", "this", "randomized", ",", "double", "-", "blind", "trial", ",", "smokers", "with", "mild", "-", "to", "-", "moderate", "COPD", "were", "treated", "with", "varenicline", "1", "mg", "b.i.d", ".", "or", "placebo", "for", "12", "weeks", "and", "followed", "to", "Week", "52", ".", "Primary", "endpoints", "of", "abstinence", "were", "previously", "reported", ".", "Secondary", "endpoints", "were", "mean", "changes", "from", "baseline", "in", "post", "-", "bronchodilator", "forced", "expired", "volume", "in", "1", "s", "(", "FEV", "(", "1", ")", ")", "and", "CCQ", "scores", ".", "Change", "from", "baseline", "in", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "was", "significantly", "improved", "in", "continuous", "abstainers", "(", "121.8", "mL", ")", "vs", ".", "continuous", "smokers", "(", "37.9", "mL", ")", "at", "Week", "12", "(", "P", "=", "0.0069", ")", ",", "but", "not", "at", "Weeks", "24", "or", "52", ".", "Mean", "change", "from", "baseline", "at", "Week", "12", "in", "CCQ", "Total", "Score", "was", "significantly", "better", "in", "continuous", "abstainers", "(", "-1.04", ")", "vs", ".", "continuous", "smokers", "(", "-0.53", ";", "P", "<", "0.0001", ")", ":", "this", "improvement", "was", "sustained", "at", "Weeks", "24", "and", "52", ".", "In", "a", "1-year", "cessation", "trial", "of", "smokers", "with", "COPD", ",", "continuous", "abstinence", "compared", "with", "continuous", "smoking", "significantly", "improved", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "at", "Week", "12", "(", "although", "the", "difference", "narrowed", "subsequently", ")", "and", "CCQ", "Total", "Scores", "at", "Week", "12", ",", "with", "sustained", "improvement", "thereafter", ".", "(", "TRIAL", "REGISTRY", "http", ":", "//www.clinicaltrials.gov", ";", "trial", "identifier", ":", "NCT00285012", ")", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mental", "Intervention_Control" ]
Patienten is an umlsterm, zeitintensiv is an umlsterm, Intensivmedizin is an umlsterm, Komplikationen is an umlsterm, Erkennung is an umlsterm, Aerzte is an umlsterm, Druckunterstuetzung is an umlsterm, Atemarbeit is an umlsterm	IntensiveMedizin.9036s055.ger.abstr_task0	Sentence: Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen .	[ "Die", "Entwoehnung", "von", "der", "Beatmung", "gestaltet", "sich", "bei", "ca", ".", "20", "%", "der", "beatmeten", "Patienten", "schwierig", "und", "sehr", "zeitintensiv", ",", "so", "dass", "sie", "von", "grosser", "Bedeutung", "fuer", "die", "moderne", "Intensivmedizin", "ist", ".", "Zur", "Vermeidung", "beatmungsassoziierter", "Komplikationen", "sollte", "die", "Entwoehnung", "so", "zuegig", "wie", "moeglich", "erfolgen", ".", "In", "multizentrischen", "Studien", "konnte", "gezeigt", "werden", ",", "dass", "Protokolle", "sowohl", "fuer", "die", "Erkennung", "des", "fruehesten", "Zeitpunkts", "zur", "Entwoehnung", "als", "auch", "fuer", "die", "Gestaltung", "der", "Entwoehnung", "erfolgversprechender", "sein", "koennen", ",", "als", "die", "alleinige", "klinische", "Einschaetzung", "und", "Betreuung", "der", "behandelnden", "Aerzte", ",", "so", "dass", "solche", "Protokolle", "wuenschenswert", "erscheinen", ".", "Es", "kann", "heute", "keine", "wissenschaftlich", "begruendete", "Praeferenz", "fuer", "ein", "bestimmtes", "Verfahren", "der", "Entwoehnung", "festgestellt", "werden", ",", "da", "sowohl", "T", "-", "Stueck", "-", "Versuche", "als", "auch", "die", "Anwendung", "einer", "geringen", "inspiratorischen", "Druckunterstuetzung", "zu", "guten", "Ergebnissen", "gefuehrt", "haben", ",", "wenn", "sie", "standardisiert", "durchgefuehrt", "wurden", ".", "Aus", "pathophysiologischen", "Ueberlegungen", "mag", "die", "Anwendung", "assistierter", "Verfahren", "zur", "Kompensation", "der", "zusaetzlichen", ",", "durch", "das", "Beatmungssystem", "bedingten", "Atemarbeit", "sinnvoll", "erscheinen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, zeitintensiv is an umlsterm, Intensivmedizin is an umlsterm, Komplikationen is an umlsterm, Erkennung is an umlsterm, Aerzte is an umlsterm, Druckunterstuetzung is an umlsterm, Atemarbeit is an umlsterm	IntensiveMedizin.9036s055.ger.abstr_task1	Sentence: Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen . Instructions: please typing these entity words according to sentence: Patienten, zeitintensiv, Intensivmedizin, Komplikationen, Erkennung, Aerzte, Druckunterstuetzung, Atemarbeit Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen .	[ "Die", "Entwoehnung", "von", "der", "Beatmung", "gestaltet", "sich", "bei", "ca", ".", "20", "%", "der", "beatmeten", "Patienten", "schwierig", "und", "sehr", "zeitintensiv", ",", "so", "dass", "sie", "von", "grosser", "Bedeutung", "fuer", "die", "moderne", "Intensivmedizin", "ist", ".", "Zur", "Vermeidung", "beatmungsassoziierter", "Komplikationen", "sollte", "die", "Entwoehnung", "so", "zuegig", "wie", "moeglich", "erfolgen", ".", "In", "multizentrischen", "Studien", "konnte", "gezeigt", "werden", ",", "dass", "Protokolle", "sowohl", "fuer", "die", "Erkennung", "des", "fruehesten", "Zeitpunkts", "zur", "Entwoehnung", "als", "auch", "fuer", "die", "Gestaltung", "der", "Entwoehnung", "erfolgversprechender", "sein", "koennen", ",", "als", "die", "alleinige", "klinische", "Einschaetzung", "und", "Betreuung", "der", "behandelnden", "Aerzte", ",", "so", "dass", "solche", "Protokolle", "wuenschenswert", "erscheinen", ".", "Es", "kann", "heute", "keine", "wissenschaftlich", "begruendete", "Praeferenz", "fuer", "ein", "bestimmtes", "Verfahren", "der", "Entwoehnung", "festgestellt", "werden", ",", "da", "sowohl", "T", "-", "Stueck", "-", "Versuche", "als", "auch", "die", "Anwendung", "einer", "geringen", "inspiratorischen", "Druckunterstuetzung", "zu", "guten", "Ergebnissen", "gefuehrt", "haben", ",", "wenn", "sie", "standardisiert", "durchgefuehrt", "wurden", ".", "Aus", "pathophysiologischen", "Ueberlegungen", "mag", "die", "Anwendung", "assistierter", "Verfahren", "zur", "Kompensation", "der", "zusaetzlichen", ",", "durch", "das", "Beatmungssystem", "bedingten", "Atemarbeit", "sinnvoll", "erscheinen", "." ]	[ "umlsterm" ]
Patienten, zeitintensiv, Intensivmedizin, Komplikationen, Erkennung, Aerzte, Druckunterstuetzung, Atemarbeit	IntensiveMedizin.9036s055.ger.abstr_task2	Sentence: Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen .	[ "Die", "Entwoehnung", "von", "der", "Beatmung", "gestaltet", "sich", "bei", "ca", ".", "20", "%", "der", "beatmeten", "Patienten", "schwierig", "und", "sehr", "zeitintensiv", ",", "so", "dass", "sie", "von", "grosser", "Bedeutung", "fuer", "die", "moderne", "Intensivmedizin", "ist", ".", "Zur", "Vermeidung", "beatmungsassoziierter", "Komplikationen", "sollte", "die", "Entwoehnung", "so", "zuegig", "wie", "moeglich", "erfolgen", ".", "In", "multizentrischen", "Studien", "konnte", "gezeigt", "werden", ",", "dass", "Protokolle", "sowohl", "fuer", "die", "Erkennung", "des", "fruehesten", "Zeitpunkts", "zur", "Entwoehnung", "als", "auch", "fuer", "die", "Gestaltung", "der", "Entwoehnung", "erfolgversprechender", "sein", "koennen", ",", "als", "die", "alleinige", "klinische", "Einschaetzung", "und", "Betreuung", "der", "behandelnden", "Aerzte", ",", "so", "dass", "solche", "Protokolle", "wuenschenswert", "erscheinen", ".", "Es", "kann", "heute", "keine", "wissenschaftlich", "begruendete", "Praeferenz", "fuer", "ein", "bestimmtes", "Verfahren", "der", "Entwoehnung", "festgestellt", "werden", ",", "da", "sowohl", "T", "-", "Stueck", "-", "Versuche", "als", "auch", "die", "Anwendung", "einer", "geringen", "inspiratorischen", "Druckunterstuetzung", "zu", "guten", "Ergebnissen", "gefuehrt", "haben", ",", "wenn", "sie", "standardisiert", "durchgefuehrt", "wurden", ".", "Aus", "pathophysiologischen", "Ueberlegungen", "mag", "die", "Anwendung", "assistierter", "Verfahren", "zur", "Kompensation", "der", "zusaetzlichen", ",", "durch", "das", "Beatmungssystem", "bedingten", "Atemarbeit", "sinnvoll", "erscheinen", "." ]	[ "umlsterm" ]
5'-iodoresiniferatoxin is a compound, PKC is a protein, chelerythrine is a compound, chloride is a compound	DS.d920_task0	Sentence: These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O" ]	These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg).	[ "These", "evoked", "expressions", "at", "both", "molecular", "and", "cellular", "levels", "were", "significantly", "inhibited", "after", "TRPV(1", ")", "receptors", "were", "blocked", "by", "5'-iodoresiniferatoxin", "(", "5", "microg", ")", "or", "PKC", "was", "inhibited", "by", "chelerythrine", "chloride", "(", "5", "microg", ")", "." ]	[ "compound", "protein" ]
5'-iodoresiniferatoxin is a compound, PKC is a protein, chelerythrine is a compound, chloride is a compound	DS.d920_task1	Sentence: These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg). Instructions: please typing these entity words according to sentence: 5'-iodoresiniferatoxin, PKC, chelerythrine, chloride Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O" ]	These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg).	[ "These", "evoked", "expressions", "at", "both", "molecular", "and", "cellular", "levels", "were", "significantly", "inhibited", "after", "TRPV(1", ")", "receptors", "were", "blocked", "by", "5'-iodoresiniferatoxin", "(", "5", "microg", ")", "or", "PKC", "was", "inhibited", "by", "chelerythrine", "chloride", "(", "5", "microg", ")", "." ]	[ "compound", "protein" ]
5'-iodoresiniferatoxin, PKC, chelerythrine, chloride	DS.d920_task2	Sentence: These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O" ]	These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg).	[ "These", "evoked", "expressions", "at", "both", "molecular", "and", "cellular", "levels", "were", "significantly", "inhibited", "after", "TRPV(1", ")", "receptors", "were", "blocked", "by", "5'-iodoresiniferatoxin", "(", "5", "microg", ")", "or", "PKC", "was", "inhibited", "by", "chelerythrine", "chloride", "(", "5", "microg", ")", "." ]	[ "compound", "protein" ]
insulin is a protein, glucose is a compound	DS.d1499_task0	Sentence: Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells.	[ "Activation", "of", "the", "Na+/K+-ATPase", "by", "insulin", "and", "glucose", "as", "a", "putative", "negative", "feedback", "mechanism", "in", "pancreatic", "beta", "-", "cells", "." ]	[ "protein", "compound" ]
insulin is a protein, glucose is a compound	DS.d1499_task1	Sentence: Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells. Instructions: please typing these entity words according to sentence: insulin, glucose Options: compound, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells.	[ "Activation", "of", "the", "Na+/K+-ATPase", "by", "insulin", "and", "glucose", "as", "a", "putative", "negative", "feedback", "mechanism", "in", "pancreatic", "beta", "-", "cells", "." ]	[ "protein", "compound" ]
insulin, glucose	DS.d1499_task2	Sentence: Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells.	[ "Activation", "of", "the", "Na+/K+-ATPase", "by", "insulin", "and", "glucose", "as", "a", "putative", "negative", "feedback", "mechanism", "in", "pancreatic", "beta", "-", "cells", "." ]	[ "protein", "compound" ]
healthy is a Condition, Healthy , without allergies and with the age of 18 years or above is a Scope, patients is a Person, Burn injury exceeding 6 - 8 Total Burned Surface Area % is a Scope	NCT02952378_inc_task0	Sentence: For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area % Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Condition	[ "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]	For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %	[ "For", "healthy", "individuals", ":", "Healthy", ",", "without", "allergies", "and", "with", "the", "age", "of", "18", "years", "or", "above", ".", "\n", "For", "patients", ":", "Burn", "injury", "exceeding", "6", "-", "8", "Total", "Burned", "Surface", "Area", "%", "\n" ]	[ "Scope", "Measurement", "Value", "Condition", "Person", "Negation" ]
healthy is a Condition, Healthy , without allergies and with the age of 18 years or above is a Scope, patients is a Person, Burn injury exceeding 6 - 8 Total Burned Surface Area % is a Scope	NCT02952378_inc_task1	Sentence: For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area % Instructions: please typing these entity words according to sentence: healthy, Healthy , without allergies and with the age of 18 years or above, patients, Burn injury exceeding 6 - 8 Total Burned Surface Area % Options: Scope, Person, Condition	[ "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]	For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %	[ "For", "healthy", "individuals", ":", "Healthy", ",", "without", "allergies", "and", "with", "the", "age", "of", "18", "years", "or", "above", ".", "\n", "For", "patients", ":", "Burn", "injury", "exceeding", "6", "-", "8", "Total", "Burned", "Surface", "Area", "%", "\n" ]	[ "Scope", "Measurement", "Value", "Condition", "Person", "Negation" ]
healthy, Healthy , without allergies and with the age of 18 years or above, patients, Burn injury exceeding 6 - 8 Total Burned Surface Area %	NCT02952378_inc_task2	Sentence: For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area % Instructions: please extract entity words from the input sentence	[ "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]	For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %	[ "For", "healthy", "individuals", ":", "Healthy", ",", "without", "allergies", "and", "with", "the", "age", "of", "18", "years", "or", "above", ".", "\n", "For", "patients", ":", "Burn", "injury", "exceeding", "6", "-", "8", "Total", "Burned", "Surface", "Area", "%", "\n" ]	[ "Scope", "Measurement", "Value", "Condition", "Person", "Negation" ]
Blutdruck is an umlsterm, Blutdrucks is an umlsterm, Blutdruckanstieg is an umlsterm, Weisskittel- is an umlsterm, Praxishochdruck is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Hypertonie is an umlsterm, Prognose is an umlsterm, Bluthochdruckpatienten is an umlsterm, Behandlung is an umlsterm, Blutdrucksenkung is an umlsterm, Medikamente is an umlsterm	MedizinischeKlinik.00950254.ger.abstr_task0	Sentence: Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben .	[ "Der", "menschliche", "Blutdruck", "unterliegt", "nicht", "nur", "infolge", "koerperlicher", "und", "psychischer", "Aktivitaet", "oder", "pharmakologischer", "Massnahmen", ",", "sondern", "auch", "spontan", "mehr", "oder", "weniger", "ausgepraegten", "Schwankungen", ".", "Diese", "Variabilitaet", "des", "arteriellen", "Blutdrucks", "ist", "sowohl", "von", "pathophysiologischem", "als", "auch", "von", "klinischem", "Interesse", ".", "Ein", "weithin", "bekanntes", "Beispiel", "fuer", "einen", "ausgepraegten", "Blutdruckanstieg", "ist", "als", "Weisskittel-", "oder", "Praxishochdruck", "\"", "\"", "gelaeufig", ".", "Diese", "gelegentlich", "ausgepraegte", "Blutdruckvariabilitaet", "kann", "durchaus", "Folgen", "fuer", "die", "Diagnostik", "und", "Therapie", "einer", "arteriellen", "Hypertonie", "haben", ".", "Einige", "Studien", "haben", "darueber", "hinaus", "gezeigt", ",", "dass", "das", "Ausmass", "hypertoner", "Endorganschaeden", "und", "auch", "die", "Prognose", "von", "Bluthochdruckpatienten", "signifikant", "mit", "der", "zirkadianen", "Blutdruckvariabilitaet", "assoziiert", "sind", ".", "Vor", "diesem", "Hintergrund", "ist", "zu", "diskutieren", ",", "inwieweit", "eine", "optimale", "antihypertensive", "Behandlung", "neben", "der", "eigentlichen", "Blutdrucksenkung", "auch", "die", "Blutdruckvariabilitaet", "optimieren", "muss", ",", "zumal", "die", "bislang", "untersuchten", "antihypertensiven", "Medikamente", ",", "wenn", "ueberhaupt", ",", "einen", "unguenstigen", "Effekt", "auf", "die", "Blutdruckvariabilitaet", "ausueben", "." ]	[ "umlsterm" ]
Blutdruck is an umlsterm, Blutdrucks is an umlsterm, Blutdruckanstieg is an umlsterm, Weisskittel- is an umlsterm, Praxishochdruck is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Hypertonie is an umlsterm, Prognose is an umlsterm, Bluthochdruckpatienten is an umlsterm, Behandlung is an umlsterm, Blutdrucksenkung is an umlsterm, Medikamente is an umlsterm	MedizinischeKlinik.00950254.ger.abstr_task1	Sentence: Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben . Instructions: please typing these entity words according to sentence: Blutdruck, Blutdrucks, Blutdruckanstieg, Weisskittel-, Praxishochdruck, Diagnostik, Therapie, Hypertonie, Prognose, Bluthochdruckpatienten, Behandlung, Blutdrucksenkung, Medikamente Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben .	[ "Der", "menschliche", "Blutdruck", "unterliegt", "nicht", "nur", "infolge", "koerperlicher", "und", "psychischer", "Aktivitaet", "oder", "pharmakologischer", "Massnahmen", ",", "sondern", "auch", "spontan", "mehr", "oder", "weniger", "ausgepraegten", "Schwankungen", ".", "Diese", "Variabilitaet", "des", "arteriellen", "Blutdrucks", "ist", "sowohl", "von", "pathophysiologischem", "als", "auch", "von", "klinischem", "Interesse", ".", "Ein", "weithin", "bekanntes", "Beispiel", "fuer", "einen", "ausgepraegten", "Blutdruckanstieg", "ist", "als", "Weisskittel-", "oder", "Praxishochdruck", "\"", "\"", "gelaeufig", ".", "Diese", "gelegentlich", "ausgepraegte", "Blutdruckvariabilitaet", "kann", "durchaus", "Folgen", "fuer", "die", "Diagnostik", "und", "Therapie", "einer", "arteriellen", "Hypertonie", "haben", ".", "Einige", "Studien", "haben", "darueber", "hinaus", "gezeigt", ",", "dass", "das", "Ausmass", "hypertoner", "Endorganschaeden", "und", "auch", "die", "Prognose", "von", "Bluthochdruckpatienten", "signifikant", "mit", "der", "zirkadianen", "Blutdruckvariabilitaet", "assoziiert", "sind", ".", "Vor", "diesem", "Hintergrund", "ist", "zu", "diskutieren", ",", "inwieweit", "eine", "optimale", "antihypertensive", "Behandlung", "neben", "der", "eigentlichen", "Blutdrucksenkung", "auch", "die", "Blutdruckvariabilitaet", "optimieren", "muss", ",", "zumal", "die", "bislang", "untersuchten", "antihypertensiven", "Medikamente", ",", "wenn", "ueberhaupt", ",", "einen", "unguenstigen", "Effekt", "auf", "die", "Blutdruckvariabilitaet", "ausueben", "." ]	[ "umlsterm" ]
Blutdruck, Blutdrucks, Blutdruckanstieg, Weisskittel-, Praxishochdruck, Diagnostik, Therapie, Hypertonie, Prognose, Bluthochdruckpatienten, Behandlung, Blutdrucksenkung, Medikamente	MedizinischeKlinik.00950254.ger.abstr_task2	Sentence: Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben .	[ "Der", "menschliche", "Blutdruck", "unterliegt", "nicht", "nur", "infolge", "koerperlicher", "und", "psychischer", "Aktivitaet", "oder", "pharmakologischer", "Massnahmen", ",", "sondern", "auch", "spontan", "mehr", "oder", "weniger", "ausgepraegten", "Schwankungen", ".", "Diese", "Variabilitaet", "des", "arteriellen", "Blutdrucks", "ist", "sowohl", "von", "pathophysiologischem", "als", "auch", "von", "klinischem", "Interesse", ".", "Ein", "weithin", "bekanntes", "Beispiel", "fuer", "einen", "ausgepraegten", "Blutdruckanstieg", "ist", "als", "Weisskittel-", "oder", "Praxishochdruck", "\"", "\"", "gelaeufig", ".", "Diese", "gelegentlich", "ausgepraegte", "Blutdruckvariabilitaet", "kann", "durchaus", "Folgen", "fuer", "die", "Diagnostik", "und", "Therapie", "einer", "arteriellen", "Hypertonie", "haben", ".", "Einige", "Studien", "haben", "darueber", "hinaus", "gezeigt", ",", "dass", "das", "Ausmass", "hypertoner", "Endorganschaeden", "und", "auch", "die", "Prognose", "von", "Bluthochdruckpatienten", "signifikant", "mit", "der", "zirkadianen", "Blutdruckvariabilitaet", "assoziiert", "sind", ".", "Vor", "diesem", "Hintergrund", "ist", "zu", "diskutieren", ",", "inwieweit", "eine", "optimale", "antihypertensive", "Behandlung", "neben", "der", "eigentlichen", "Blutdrucksenkung", "auch", "die", "Blutdruckvariabilitaet", "optimieren", "muss", ",", "zumal", "die", "bislang", "untersuchten", "antihypertensiven", "Medikamente", ",", "wenn", "ueberhaupt", ",", "einen", "unguenstigen", "Effekt", "auf", "die", "Blutdruckvariabilitaet", "ausueben", "." ]	[ "umlsterm" ]
recent onset rheumatoid arthritis is a participant, role is an outcome, disability , illness perceptions , pain and coping is an outcome	1398_task0	Sentence: The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome, participant	[ "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "B-outcome", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]	The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping .	[ "The", "course", "of", "depression", "in", "recent", "onset", "rheumatoid", "arthritis", ":", "the", "predictive", "role", "of", "disability", ",", "illness", "perceptions", ",", "pain", "and", "coping", "." ]	[ "outcome", "participant" ]
recent onset rheumatoid arthritis is a participant, role is an outcome, disability , illness perceptions , pain and coping is an outcome	1398_task1	Sentence: The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping . Instructions: please typing these entity words according to sentence: recent onset rheumatoid arthritis, role, disability , illness perceptions , pain and coping Options: outcome, participant	[ "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "B-outcome", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]	The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping .	[ "The", "course", "of", "depression", "in", "recent", "onset", "rheumatoid", "arthritis", ":", "the", "predictive", "role", "of", "disability", ",", "illness", "perceptions", ",", "pain", "and", "coping", "." ]	[ "outcome", "participant" ]
recent onset rheumatoid arthritis, role, disability , illness perceptions , pain and coping	1398_task2	Sentence: The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "B-outcome", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]	The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping .	[ "The", "course", "of", "depression", "in", "recent", "onset", "rheumatoid", "arthritis", ":", "the", "predictive", "role", "of", "disability", ",", "illness", "perceptions", ",", "pain", "and", "coping", "." ]	[ "outcome", "participant" ]
coronary artery occlusion is an umlsterm, angioplasty is an umlsterm, PTCA is an umlsterm, heparin is an umlsterm, aspirin is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, syndromes is an umlsterm, risk is an umlsterm, vessel is an umlsterm, thrombus is an umlsterm, role is an umlsterm, pathogenesis is an umlsterm, vessel is an umlsterm, Dipyridamole is an umlsterm, dilatation is an umlsterm, arteries is an umlsterm, platelet aggregation is an umlsterm, aspirin is an umlsterm, therapy is an umlsterm, dipyridamole is an umlsterm, incidence is an umlsterm, coronary artery occlusion is an umlsterm, PTCA is an umlsterm, Secondary is an umlsterm, myocardial infarction is an umlsterm, grafting is an umlsterm, death is an umlsterm	ZfuerKardiologie.70860961.eng.abstr_task0	Sentence: Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death .	[ "Even", "in", "the", "era", "of", "coronary", "stenting", ",", "acute", "coronary", "artery", "occlusion", "continues", "to", "represent", "a", "significant", "limitation", "of", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", ".", "Despite", "application", "of", "heparin", "and", "aspirin", ",", "abrupt", "vessel", "closure", "still", "occurs", "in", "2", "-", "8", "%", ",", "depending", "on", "the", "definition", "applied", ".", "Especially", "patients", "receiving", "PTCA", "for", "acute", "coronary", "syndromes", "are", "at", "high", "risk", "for", "abrupt", "vessel", "closure", ".", "The", "formation", "of", "an", "intracoronary", "thrombus", "plays", "a", "central", "role", "in", "the", "pathogenesis", "of", "abrupt", "vessel", "closure", ".", "Dipyridamole", "induces", "dilatation", "of", "coronary", "arteries", "and", "prevents", "platelet", "aggregation", "by", "a", "mechanism", "that", "differs", "from", "that", "of", "aspirin", ".", "The", "primary", "purpose", "of", "the", "study", "was", "to", "evaluate", "whether", "adjunctive", "local", "intracoronary", "therapy", "with", "dipyridamole", "could", "reduce", "the", "incidence", "of", "coronary", "artery", "occlusion", "following", "PTCA", ".", "Secondary", "endpoints", "were", "defined", "as", "myocardial", "infarction", ",", "necessity", "for", "bypass", "grafting", ",", "and", "death", "." ]	[ "umlsterm" ]
coronary artery occlusion is an umlsterm, angioplasty is an umlsterm, PTCA is an umlsterm, heparin is an umlsterm, aspirin is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, syndromes is an umlsterm, risk is an umlsterm, vessel is an umlsterm, thrombus is an umlsterm, role is an umlsterm, pathogenesis is an umlsterm, vessel is an umlsterm, Dipyridamole is an umlsterm, dilatation is an umlsterm, arteries is an umlsterm, platelet aggregation is an umlsterm, aspirin is an umlsterm, therapy is an umlsterm, dipyridamole is an umlsterm, incidence is an umlsterm, coronary artery occlusion is an umlsterm, PTCA is an umlsterm, Secondary is an umlsterm, myocardial infarction is an umlsterm, grafting is an umlsterm, death is an umlsterm	ZfuerKardiologie.70860961.eng.abstr_task1	Sentence: Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death . Instructions: please typing these entity words according to sentence: coronary artery occlusion, angioplasty, PTCA, heparin, aspirin, vessel, patients, PTCA, syndromes, risk, vessel, thrombus, role, pathogenesis, vessel, Dipyridamole, dilatation, arteries, platelet aggregation, aspirin, therapy, dipyridamole, incidence, coronary artery occlusion, PTCA, Secondary, myocardial infarction, grafting, death Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death .	[ "Even", "in", "the", "era", "of", "coronary", "stenting", ",", "acute", "coronary", "artery", "occlusion", "continues", "to", "represent", "a", "significant", "limitation", "of", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", ".", "Despite", "application", "of", "heparin", "and", "aspirin", ",", "abrupt", "vessel", "closure", "still", "occurs", "in", "2", "-", "8", "%", ",", "depending", "on", "the", "definition", "applied", ".", "Especially", "patients", "receiving", "PTCA", "for", "acute", "coronary", "syndromes", "are", "at", "high", "risk", "for", "abrupt", "vessel", "closure", ".", "The", "formation", "of", "an", "intracoronary", "thrombus", "plays", "a", "central", "role", "in", "the", "pathogenesis", "of", "abrupt", "vessel", "closure", ".", "Dipyridamole", "induces", "dilatation", "of", "coronary", "arteries", "and", "prevents", "platelet", "aggregation", "by", "a", "mechanism", "that", "differs", "from", "that", "of", "aspirin", ".", "The", "primary", "purpose", "of", "the", "study", "was", "to", "evaluate", "whether", "adjunctive", "local", "intracoronary", "therapy", "with", "dipyridamole", "could", "reduce", "the", "incidence", "of", "coronary", "artery", "occlusion", "following", "PTCA", ".", "Secondary", "endpoints", "were", "defined", "as", "myocardial", "infarction", ",", "necessity", "for", "bypass", "grafting", ",", "and", "death", "." ]	[ "umlsterm" ]
coronary artery occlusion, angioplasty, PTCA, heparin, aspirin, vessel, patients, PTCA, syndromes, risk, vessel, thrombus, role, pathogenesis, vessel, Dipyridamole, dilatation, arteries, platelet aggregation, aspirin, therapy, dipyridamole, incidence, coronary artery occlusion, PTCA, Secondary, myocardial infarction, grafting, death	ZfuerKardiologie.70860961.eng.abstr_task2	Sentence: Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death .	[ "Even", "in", "the", "era", "of", "coronary", "stenting", ",", "acute", "coronary", "artery", "occlusion", "continues", "to", "represent", "a", "significant", "limitation", "of", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", ".", "Despite", "application", "of", "heparin", "and", "aspirin", ",", "abrupt", "vessel", "closure", "still", "occurs", "in", "2", "-", "8", "%", ",", "depending", "on", "the", "definition", "applied", ".", "Especially", "patients", "receiving", "PTCA", "for", "acute", "coronary", "syndromes", "are", "at", "high", "risk", "for", "abrupt", "vessel", "closure", ".", "The", "formation", "of", "an", "intracoronary", "thrombus", "plays", "a", "central", "role", "in", "the", "pathogenesis", "of", "abrupt", "vessel", "closure", ".", "Dipyridamole", "induces", "dilatation", "of", "coronary", "arteries", "and", "prevents", "platelet", "aggregation", "by", "a", "mechanism", "that", "differs", "from", "that", "of", "aspirin", ".", "The", "primary", "purpose", "of", "the", "study", "was", "to", "evaluate", "whether", "adjunctive", "local", "intracoronary", "therapy", "with", "dipyridamole", "could", "reduce", "the", "incidence", "of", "coronary", "artery", "occlusion", "following", "PTCA", ".", "Secondary", "endpoints", "were", "defined", "as", "myocardial", "infarction", ",", "necessity", "for", "bypass", "grafting", ",", "and", "death", "." ]	[ "umlsterm" ]
monosodium urate is a compound, leucine is a compound, pyrin is a protein	DS.d115_task0	Sentence: Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.	[ "Recent", "studies", "suggest", "that", "crystals", "of", "monosodium", "urate", "(", "MSU", ")", ",", "deposited", "in", "joints", "of", "patients", "with", "acute", "gouty", "arthritis", ",", "activate", "the", "NACHT", "domain", ",", "leucine", "-", "rich", "repeat", "and", "pyrin", "domain", "-", "containing", "protein", "(", "NALP)3", "inflammasome", "." ]	[ "compound", "protein" ]
monosodium urate is a compound, leucine is a compound, pyrin is a protein	DS.d115_task1	Sentence: Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome. Instructions: please typing these entity words according to sentence: monosodium urate, leucine, pyrin Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.	[ "Recent", "studies", "suggest", "that", "crystals", "of", "monosodium", "urate", "(", "MSU", ")", ",", "deposited", "in", "joints", "of", "patients", "with", "acute", "gouty", "arthritis", ",", "activate", "the", "NACHT", "domain", ",", "leucine", "-", "rich", "repeat", "and", "pyrin", "domain", "-", "containing", "protein", "(", "NALP)3", "inflammasome", "." ]	[ "compound", "protein" ]
monosodium urate, leucine, pyrin	DS.d115_task2	Sentence: Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.	[ "Recent", "studies", "suggest", "that", "crystals", "of", "monosodium", "urate", "(", "MSU", ")", ",", "deposited", "in", "joints", "of", "patients", "with", "acute", "gouty", "arthritis", ",", "activate", "the", "NACHT", "domain", ",", "leucine", "-", "rich", "repeat", "and", "pyrin", "domain", "-", "containing", "protein", "(", "NALP)3", "inflammasome", "." ]	[ "compound", "protein" ]
Muskelgruppen is an umlsterm, Anschlagzeit is an umlsterm, Atracurium is an umlsterm, Muskelgruppen is an umlsterm, Atracurium is an umlsterm	DerAnaesthesist.90480602.ger.abstr_task0	Sentence: Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden .	[ "Fragestellung", ":", "Muskelrelaxanzien", "zeigen", "ein", "unterschiedliches", "pharmakodynamisches", "Wirkungsprofil", "an", "verschiedenen", "Muskelgruppen", ".", "Am", "M.", "adductor", "pollicis", "hat", "Cisatracurium", ",", "bis", "auf", "eine", "laengere", "Anschlagzeit", ",", "ein", "vergleichbares", "pharmakodynamisches", "Profil", "wie", "Atracurium", ".", "Untersuchungen", "an", "anderen", "Muskelgruppen", "wurden", "fuer", "Cisatracurium", "bisher", "nicht", "durchgefuehrt", ".", "In", "der", "vorliegenden", "klinischen", "Studie", "sollte", "daher", "die", "neuromuskulaere", "Wirkung", "von", "Cisatracurium", "am", "M.", "orbicularis", "oculi", "(", "OO", ")", "-", "dessen", "neuromuskulaere", "Reaktion", "annaehernd", "derjenigen", "des", "Diaphragmas", "und", "der", "Larynxmuskulatur", "entspricht", "-", "und", "am", "M.", "adductor", "pollicis", "(", "AP", ")", "im", "Vergleich", "mit", "Atracurium", "untersucht", "werden", "." ]	[ "umlsterm" ]
Muskelgruppen is an umlsterm, Anschlagzeit is an umlsterm, Atracurium is an umlsterm, Muskelgruppen is an umlsterm, Atracurium is an umlsterm	DerAnaesthesist.90480602.ger.abstr_task1	Sentence: Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden . Instructions: please typing these entity words according to sentence: Muskelgruppen, Anschlagzeit, Atracurium, Muskelgruppen, Atracurium Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden .	[ "Fragestellung", ":", "Muskelrelaxanzien", "zeigen", "ein", "unterschiedliches", "pharmakodynamisches", "Wirkungsprofil", "an", "verschiedenen", "Muskelgruppen", ".", "Am", "M.", "adductor", "pollicis", "hat", "Cisatracurium", ",", "bis", "auf", "eine", "laengere", "Anschlagzeit", ",", "ein", "vergleichbares", "pharmakodynamisches", "Profil", "wie", "Atracurium", ".", "Untersuchungen", "an", "anderen", "Muskelgruppen", "wurden", "fuer", "Cisatracurium", "bisher", "nicht", "durchgefuehrt", ".", "In", "der", "vorliegenden", "klinischen", "Studie", "sollte", "daher", "die", "neuromuskulaere", "Wirkung", "von", "Cisatracurium", "am", "M.", "orbicularis", "oculi", "(", "OO", ")", "-", "dessen", "neuromuskulaere", "Reaktion", "annaehernd", "derjenigen", "des", "Diaphragmas", "und", "der", "Larynxmuskulatur", "entspricht", "-", "und", "am", "M.", "adductor", "pollicis", "(", "AP", ")", "im", "Vergleich", "mit", "Atracurium", "untersucht", "werden", "." ]	[ "umlsterm" ]
Muskelgruppen, Anschlagzeit, Atracurium, Muskelgruppen, Atracurium	DerAnaesthesist.90480602.ger.abstr_task2	Sentence: Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden .	[ "Fragestellung", ":", "Muskelrelaxanzien", "zeigen", "ein", "unterschiedliches", "pharmakodynamisches", "Wirkungsprofil", "an", "verschiedenen", "Muskelgruppen", ".", "Am", "M.", "adductor", "pollicis", "hat", "Cisatracurium", ",", "bis", "auf", "eine", "laengere", "Anschlagzeit", ",", "ein", "vergleichbares", "pharmakodynamisches", "Profil", "wie", "Atracurium", ".", "Untersuchungen", "an", "anderen", "Muskelgruppen", "wurden", "fuer", "Cisatracurium", "bisher", "nicht", "durchgefuehrt", ".", "In", "der", "vorliegenden", "klinischen", "Studie", "sollte", "daher", "die", "neuromuskulaere", "Wirkung", "von", "Cisatracurium", "am", "M.", "orbicularis", "oculi", "(", "OO", ")", "-", "dessen", "neuromuskulaere", "Reaktion", "annaehernd", "derjenigen", "des", "Diaphragmas", "und", "der", "Larynxmuskulatur", "entspricht", "-", "und", "am", "M.", "adductor", "pollicis", "(", "AP", ")", "im", "Vergleich", "mit", "Atracurium", "untersucht", "werden", "." ]	[ "umlsterm" ]
cdc-2 is a Protein, cyclin E is a Protein, CD23 is a Protein, cyclin D2 is a Protein, CD40 is a Protein, IL4 is a Protein	384_task0	Sentence: The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.	[ "The", "normal", "cell", "cycle", "activation", "program", "is", "exploited", "during", "the", "infection", "of", "quiescent", "B", "lymphocytes", "by", "Epstein", "-", "Barr", "virus", ".", "\n", "B", "lymphocytes", "in", "the", "peripheral", "circulation", "are", "maintained", "in", "a", "non", "-", "proliferative", "state", ".", "Antigen", "recognition", "stimulates", "limited", "proliferation", ",", "whereas", "infection", "with", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "results", "in", "continual", "proliferation", "and", "the", "outgrowth", "of", "immortal", "cell", "lines", ".", "Because", "it", "is", "not", "clear", "at", "which", "point", "in", "cell", "cycle", "the", "peripheral", "B", "lymphocytes", "are", "arrested", ",", "we", "characterized", "the", "expression", "of", "several", "cell", "cycle", "-", "associated", "genes", "in", "quiescent", "and", "stimulated", "cells", ".", "We", "show", "that", "the", "expression", "of", "four", "cell", "genes", ",", "cdc-2", ",", "cyclin", "E", ",", "CD23", ",", "and", "cyclin", "D2", ",", "are", "up", "-", "regulated", "approximately", "100-fold", "as", "a", "result", "of", "EBV", "-", "mediated", "immortalization", ".", "Because", "these", "genes", "play", "a", "positive", "role", "in", "cell", "proliferation", ",", "we", "suggest", "that", "this", "regulatory", "switch", "contributes", "to", "controlling", "entry", "into", "the", "cell", "cycle", ".", "Transient", "stimulation", "of", "quiescent", "B", "lymphocytes", "with", "either", "a", "cocktail", "of", "anti", "-", "CD40", ",", "anti", "-", "IgM", ",", "and", "IL4", ",", "or", "EBV", "results", "in", "the", "rapid", "expression", "of", "the", "same", "four", "genes", ",", "suggesting", "that", ",", "after", "infection", ",", "EBV", "exploits", "the", "normal", "program", "of", "B", "-", "lymphocyte", "cell", "cycle", "activation", "." ]	[ "Protein" ]
cdc-2 is a Protein, cyclin E is a Protein, CD23 is a Protein, cyclin D2 is a Protein, CD40 is a Protein, IL4 is a Protein	384_task1	Sentence: The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation. Instructions: please typing these entity words according to sentence: cdc-2, cyclin E, CD23, cyclin D2, CD40, IL4 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.	[ "The", "normal", "cell", "cycle", "activation", "program", "is", "exploited", "during", "the", "infection", "of", "quiescent", "B", "lymphocytes", "by", "Epstein", "-", "Barr", "virus", ".", "\n", "B", "lymphocytes", "in", "the", "peripheral", "circulation", "are", "maintained", "in", "a", "non", "-", "proliferative", "state", ".", "Antigen", "recognition", "stimulates", "limited", "proliferation", ",", "whereas", "infection", "with", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "results", "in", "continual", "proliferation", "and", "the", "outgrowth", "of", "immortal", "cell", "lines", ".", "Because", "it", "is", "not", "clear", "at", "which", "point", "in", "cell", "cycle", "the", "peripheral", "B", "lymphocytes", "are", "arrested", ",", "we", "characterized", "the", "expression", "of", "several", "cell", "cycle", "-", "associated", "genes", "in", "quiescent", "and", "stimulated", "cells", ".", "We", "show", "that", "the", "expression", "of", "four", "cell", "genes", ",", "cdc-2", ",", "cyclin", "E", ",", "CD23", ",", "and", "cyclin", "D2", ",", "are", "up", "-", "regulated", "approximately", "100-fold", "as", "a", "result", "of", "EBV", "-", "mediated", "immortalization", ".", "Because", "these", "genes", "play", "a", "positive", "role", "in", "cell", "proliferation", ",", "we", "suggest", "that", "this", "regulatory", "switch", "contributes", "to", "controlling", "entry", "into", "the", "cell", "cycle", ".", "Transient", "stimulation", "of", "quiescent", "B", "lymphocytes", "with", "either", "a", "cocktail", "of", "anti", "-", "CD40", ",", "anti", "-", "IgM", ",", "and", "IL4", ",", "or", "EBV", "results", "in", "the", "rapid", "expression", "of", "the", "same", "four", "genes", ",", "suggesting", "that", ",", "after", "infection", ",", "EBV", "exploits", "the", "normal", "program", "of", "B", "-", "lymphocyte", "cell", "cycle", "activation", "." ]	[ "Protein" ]
cdc-2, cyclin E, CD23, cyclin D2, CD40, IL4	384_task2	Sentence: The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.	[ "The", "normal", "cell", "cycle", "activation", "program", "is", "exploited", "during", "the", "infection", "of", "quiescent", "B", "lymphocytes", "by", "Epstein", "-", "Barr", "virus", ".", "\n", "B", "lymphocytes", "in", "the", "peripheral", "circulation", "are", "maintained", "in", "a", "non", "-", "proliferative", "state", ".", "Antigen", "recognition", "stimulates", "limited", "proliferation", ",", "whereas", "infection", "with", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "results", "in", "continual", "proliferation", "and", "the", "outgrowth", "of", "immortal", "cell", "lines", ".", "Because", "it", "is", "not", "clear", "at", "which", "point", "in", "cell", "cycle", "the", "peripheral", "B", "lymphocytes", "are", "arrested", ",", "we", "characterized", "the", "expression", "of", "several", "cell", "cycle", "-", "associated", "genes", "in", "quiescent", "and", "stimulated", "cells", ".", "We", "show", "that", "the", "expression", "of", "four", "cell", "genes", ",", "cdc-2", ",", "cyclin", "E", ",", "CD23", ",", "and", "cyclin", "D2", ",", "are", "up", "-", "regulated", "approximately", "100-fold", "as", "a", "result", "of", "EBV", "-", "mediated", "immortalization", ".", "Because", "these", "genes", "play", "a", "positive", "role", "in", "cell", "proliferation", ",", "we", "suggest", "that", "this", "regulatory", "switch", "contributes", "to", "controlling", "entry", "into", "the", "cell", "cycle", ".", "Transient", "stimulation", "of", "quiescent", "B", "lymphocytes", "with", "either", "a", "cocktail", "of", "anti", "-", "CD40", ",", "anti", "-", "IgM", ",", "and", "IL4", ",", "or", "EBV", "results", "in", "the", "rapid", "expression", "of", "the", "same", "four", "genes", ",", "suggesting", "that", ",", "after", "infection", ",", "EBV", "exploits", "the", "normal", "program", "of", "B", "-", "lymphocyte", "cell", "cycle", "activation", "." ]	[ "Protein" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ) is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA	405_task0	Sentence: Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida.	[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "65", "años", ",", "alérgico", "al", "contraste", "yodado", ",", "exfumador", "con", "un", "consumo", "acumulado", "de", "70", "paquetes", "-", "año", ",", "sin", "hábito", "enólico", "ni", "factores", "de", "riesgo", "cardiovascular", ".", "Como", "antecedentes", "presentaba", "gota", "y", "litiasis", "renales", "de", "repetición", ";", "sin", "intervenciones", "quirúrgicas", ".", "Como", "medicación", "habitual", ":", "alopurinol", ",", "pregabalina", "y", "paracetamol", ".", "\n", "Su", "historia", "oncológica", "empieza", "en", "febrero", "de", "2016", ",", "estando", "asintomático", ",", "acude", "a", "un", "centro", "privado", "para", "realizar", "una", "analítica", "de", "control", ",", "en", "la", "que", "se", "objetiva", "un", "CEA", "elevado", "(", "788", "μg", "/", "l", ";", "normal", "<", "5,0", ")", ".", "Se", "indica", "realización", "de", "colonoscopia", ",", "que", "descarta", "neoplasia", "de", "colon", ".", "Tras", "ello", ",", "se", "realiza", "un", "TC", "toracoabdominal", ",", "en", "la", "que", "se", "observan", "3", "nódulos", "pulmonares", ",", "uno", "subpleural", "anterior", "en", "lóbulo", "superior", "derecho", ",", "irregular", "de", "24", "x", "17", "mm", ",", "otro", "espiculado", "yuxtacisural", "en", "lóbulo", "inferior", "izquierdo", "(", "LII", ")", "de", "18", "x", "13", "mm", ",", "y", "el", "último", "subsólido", "en", "LII", ".", "Además", ",", "se", "observan", "múltiples", "adenopatías", "patológicas", "supra", "e", "infradiafragmáticas", ".", "Ante", "estos", "hallazgos", ",", "se", "deriva", "a", "nuestro", "centro", ",", "donde", ",", "en", "comité", ",", "se", "decide", "la", "realización", "de", "mediastinoscopia", "para", "obtener", "diagnóstico", "histológico", ".", "Se", "puncionan", "dos", "adenopatías", "del", "nivel", "6", ",", "cuyo", "análisis", "anatomopatológico", "resulta", "positivo", "para", "adenocarcinoma", "de", "origen", "pulmonar", "(", "CK7", "y", "TTF1", "positivos", ")", ",", "cuya", "biología", "molecular", "es", "EFGR", "wild", "type", "y", "ALK", "no", "traslocado", ".", "\n", "Es", "valorado", "como", "adenocarcinoma", "de", "pulmón", "estadio", "IV", "(", "T1bN3M1b", ")", "y", ",", "dentro", "de", "comité", ",", "se", "decide", "iniciar", "tratamiento", "de", "1L", "dentro", "del", "ensayo", "clínico", "GO29436", "(", "CBCDA", "-", "taxol", "+", "bevacizumab", "vs", ".", "CBCDA", "-", "tazol", "+", "atezolizumab", "con", "o", "sin", "bevacizumab", ")", ",", "siendo", "aleatorizado", "a", "la", "rama", "CBCDA", "-", "taxol", "+", "bevacizumab", ".", "Se", "administraron", "6", "ciclos", "de", "CBCDA", "-", "taxol", "+", "bevacizumab", "cada", "3", "semanas", "(", "C1", "el", "06/05/2016", ",", "y", "C6", "25/08/2018", ")", ",", "sin", "toxicidades", "destacables", ".", "Posteriormente", ",", "continuó", "con", "bevacizumab", "de", "mantenimiento", "trisemanal", ",", "hasta", "aparición", "de", "toxicidad", "inaceptable", "o", "progresión", "de", "la", "enfermedad", ",", "presentando", "como", "mejor", "resultado", "una", "respuesta", "parcial", "del", "67", "%", "según", "criterios", "RECIST", "1,1", "el", "05/12/2016", ",", "manteniendo", "dicha", "respuesta", "en", "los", "TC", "posteriores", ".", "Continúa", "recibiendo", "bevacizumab", "de", "mantenimiento", "bien", "tolerado", ",", "hasta", "el", "C34", "(", "05/04/2018", ")", ",", "cuando", "aparece", "elevación", "de", "las", "transaminasas", "G1", ".", "Según", "el", "protocolo", "del", "estudio", ",", "se", "permite", "continuar", "con", "el", "tratamiento", ",", "por", "lo", "que", "se", "administra", "dicho", "ciclo", ".", "Tres", "semanas", "más", "tarde", ",", "el", "paciente", "acude", "a", "valorar", "el", "C35", ",", "el", "cual", "no", "se", "puede", "administrar", "debido", "a", "un", "empeoramiento", "de", "la", "hipertransaminasemia", "hasta", "G4", ".", "Es", "valorado", "en", "este", "momento", "como", "toxicidad", "farmacológica", "vs", ".", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "realiza", "un", "TC", "toracoabdominal", "que", "muestra", "enfermedad", "estable", "sin", "afectación", "hepática", ".", "\n", "El", "10/05/2018", "el", "paciente", "consulta", "por", "aparición", "de", "dolor", "en", "hipocondrio", "derecho", ",", "sin", "fiebre", "ni", "otra", "sintomatología", ".", "Se", "realiza", "analítica", "persistiendo", "hipertransaminasemia", "G4", ",", "con", "aparición", "de", "hiperbilirrubinemia", "G3", "y", "elevación", "de", "enzimas", "de", "colestasis", "G3", ".", "Se", "realiza", "ecografía", "abdominal", "urgente", "que", "muestra", "discreta", "dilatación", "de", "vía", "biliar", "intrahepática", "sin", "objetivar", "litiasis", "ni", "otra", "causa", "obstructiva", ".", "Ante", "la", "ausencia", "de", "signos", "de", "alarma", "en", "ese", "momento", ",", "se", "decide", "completar", "el", "estudio", "de", "forma", "ambulatoria", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "vuelve", "a", "consulta", "a", "los", "5", "días", "por", "persistencia", "del", "dolor", ",", "además", "de", "aparición", "de", "fiebre", ",", "prurito", ",", "coluria", ",", "acolia", "e", "ictericia", ".", "En", "la", "exploración", "física", ",", "destacaba", "ictericia", "conjuntiva", "y", "dolor", "en", "hipocondrio", "derecho", "con", "Murphy", "negativo", ".", "El", "resto", "de", "la", "exploración", "física", "fue", "anodina", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "nueva", "analítica", "en", "la", "que", "se", "observa", "un", "incremento", "de", "la", "bilirrubina", "hasta", "129", "mmol", "/", "l", ",", "además", "de", "un", "aumento", "de", "reactantes", "de", "fase", "aguda", "(", "PCR", "y", "leucocitosis", ")", ".", "Se", "repite", "la", "ecografía", "abdominal", ",", "sin", "cambios", "respecto", "a", "la", "previa", ".", "En", "esta", "ocasión", ",", "se", "orienta", "como", "colangitis", ",", "se", "inicia", "antibioterapia", "empírica", "con", "ertapenem", ",", "y", "se", "decide", "ingreso", "hospitalario", "para", "continuar", "tratamiento", "y", "completar", "estudio", "de", "hepatopatía", ".", "\n", "Como", "diagnóstico", "diferencial", "de", "la", "alteración", "de", "la", "bioquímica", "hepática", ",", "se", "plantearon", "las", "siguientes", "etiologías", ":", "infecciosa", "(", "vírica", ")", ",", "alcohólica", ",", "farmacológica", ",", "metabólica", "(", "enfermedad", "de", "Wilson", ",", "hemocromatosis", ",", "déficit", "de", "alfa-1", "antitripsina", ")", ",", "autoinmune", ",", "litiasis", "y", "neoplásica", ".", "Por", "ello", ",", "en", "primer", "lugar", "se", "realizaron", "serologías", "que", "descartaron", "etiología", "viral", "(", "VHA", ",", "VHB", ",", "VHC", ",", "VHE", ",", "HIV", ",", "CMV", "y", "VEB", ")", ".", "Posteriormente", ",", "se", "realizó", "estudio", "de", "Cu", ",", "ferritina", "y", "alfa-1", "antitripsina", ",", "con", "valores", "dentro", "de", "la", "normalidad", ",", "lo", "que", "descartó", "causa", "metabólica", ".", "Además", ",", "se", "realizó", "despistaje", "de", "etiología", "autoinmune", "con", "determinación", "de", "anticuerpos", "resultando", "todos", "negativos", ".", "El", "paciente", "no", "era", "consumidor", "de", "alcohol", ",", "por", "lo", "que", "se", "descartó", "de", "forma", "razonable", "la", "etiología", "enólica", ".", "Para", "descartar", "etiología", "tumoral", ",", "se", "realizó", "una", "PET", "/", "TC", ",", "no", "mostró", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "la", "etiología", "tumoral", "parecía", "poco", "probable", ".", "Más", "adelante", "se", "completó", "estudio", "mediante", "colangio", "-", "RM", "que", "mostró", "dilatación", "de", "la", "vía", "biliar", "intrahepática", ",", "sin", "litiasis", "ni", "lesiones", "tumorales", "responsables", "de", "dicha", "dilatación", ".", "Fue", "en", "dicha", "prueba", "donde", "se", "detectaron", "alteraciones", "de", "la", "vía", "biliar", "intrahepática", "sugestivas", "de", "colangitis", "esclerosante", "(", "CE", ")", ".", "\n", "El", "diagnóstico", "definitivo", "de", "CE", "debería", "ser", "por", "biopsia", "hepática", ",", "pero", "se", "consensuó", "que", ",", "dada", "la", "intensa", "colestasis", "del", "paciente", ",", "el", "alto", "riesgo", "de", "sangrado", "no", "superaba", "el", "beneficio", "potencial", "de", "un", "diagnóstico", "definitivo", ",", "motivo", "por", "el", "cual", "no", "se", "realizó", "dicha", "la", "biopsia", ".", "\n\n", "Diagnóstico", "\n", "Existen", "dos", "tipos", "fundamentales", "de", "CE", ":", "la", "primaria", "(", "diagnóstico", "de", "exclusión", ")", "y", "la", "secundaria", ".", "De", "entre", "las", "etiologías", "de", "la", "CES", "a", "descartar", "en", "nuestro", "paciente", ",", "las", "más", "destacables", "serían", "neoplásica", "y", "la", "farmacológica", ".", "En", "nuestro", "paciente", "ya", "se", "habían", "realizado", "una", "TC", "toracoabdominal", "y", "una", "PET", "/", "TC", "que", "descartaban", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "orientó", "como", "diagnóstico", "más", "probable", "CES", "farmacológico", "probablemente", "por", "bevacizumab", ".", "Aunque", "la", "CES", "por", "bevacizumab", "no", "es", "una", "toxicidad", "descrita", "en", "ficha", "médica", ",", "sí", "que", "existen", "dos", "case", "reports", "publicados", "en", "la", "literatura", "que", "relacionan", "este", "fármaco", "con", "dicho", "efecto", "adverso", ".", "\n\n", "Tratamiento", "\n", "Ante", "esta", "sospecha", "diagnóstica", "se", "empezó", "tratamiento", "específico", "con", "prednisona", ",", "y", "sintomático", "con", "resincolestiramina", "y", "fenobarbital", ",", "sin", "mejoría", "de", "la", "función", "hepática", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "el", "paciente", "asoció", "un", "cuadro", "de", "insuficiencia", "renal", "e", "hipertensión", "arterial", "(", "HTA", ")", ".", "Como", "parte", "del", "estudio", "de", "dicha", "alteración", ",", "se", "realizó", "un", "estudio", "de", "orina", "en", "24", "horas", "que", "detectó", "proteinuria", "(", "proteínas", "5,23", "g", "/", "día", ")", ",", "con", "microhematuria", "en", "el", "sedimento", "urinario", ".", "Ante", "estos", "hallazgos", ",", "y", "bajo", "la", "sospecha", "de", "glomerulopatía", ",", "se", "decidió", "realizar", "nuevo", "despistaje", "de", "autoinmunidad", "con", "anticuerpos", "negativos", ",", "y", "complemento", "e", "inmunoglobulinas", "dentro", "de", "la", "normalidad", ".", "Para", "el", "diagnóstico", "definitivo", "se", "realizó", "una", "biopsia", "renal", ",", "cuyo", "resultado", "fue", "de", "glomerulonefritis", "con", "depósitos", "de", "IgA", "y", "lambda", ",", "depósitos", "de", "lípidos", "y", "células", "espumosas", "en", "glomérulos", "y", "microangiopatía", "trombótica", "(", "MAT", ")", "con", "afectación", "exclusiva", "glomerular", ".", "La", "etiología", "de", "dichos", "hallazgos", "nuevamente", ",", "en", "el", "contexto", "de", "nuestro", "paciente", ",", "podría", "ser", "secundaria", "a", "neoplasia", "o", "a", "bevacizumab", ".", "Valorándose", "en", "este", "momento", "como", "HTA", ",", "síndrome", "nefrótico", "y", "MAT", "secundarios", "a", "bevacizumab", ",", "ya", "que", "los", "tres", "son", "efectos", "adversos", "conocidos", "de", "este", "fármaco", ",", "sin", "poder", "establecer", "la", "etiología", "de", "la", "glomerulonefritis", "IgA.", "\n", "Por", "otra", "parte", ",", "en", "los", "sucesivos", "controles", "se", "observó", "un", "aumento", "de", "la", "ferritina", "y", "los", "triglicéridos", "que", ",", "junto", "con", "la", "Anatomía", "Patológica", "obtenida", "de", "la", "biopsia", "renal", ",", "podría", "ser", "compatible", "con", "un", "síndrome", "hemofagocítico", ".", "Sin", "embargo", ",", "no", "cumplía", "criterios", "diagnósticos", ",", "como", "fiebre", ",", "esplenomegalia", "o", "citopenias", ",", "por", "lo", "que", "se", "decidió", "no", "completar", "el", "estudio", "mediante", "aspirado", "de", "médula", "ósea", ",", "por", "lo", "que", "no", "fue", "posible", "confirmar", "dicha", "sospecha", "diagnóstica", ".", "\n", "Finalmente", ",", "el", "paciente", "presentó", "evolución", "tórpida", "con", "empeoramiento", "grave", "de", "la", "función", "hepática", "y", "renal", "a", "pesar", "del", "tratamiento", "instaurado", ",", "con", "desarrollo", "de", "fracaso", "multiorgánico", ",", "siendo", "finalmente", "exitus", ".", "Se", "decidió", "solicitar", "necropsia", "para", "confirmar", "la", "etiología", "del", "cuadro", "que", "había", "sufrido", "el", "paciente", "en", "sus", "últimas", "semanas", "de", "vida", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ) is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA	405_task1	Sentence: Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida. Instructions: please typing these entity words according to sentence: neoplasia, adenocarcinoma, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ), neoplásica, tumoral, tumoral, tumorales, neoplásica, neoplasia Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida.	[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "65", "años", ",", "alérgico", "al", "contraste", "yodado", ",", "exfumador", "con", "un", "consumo", "acumulado", "de", "70", "paquetes", "-", "año", ",", "sin", "hábito", "enólico", "ni", "factores", "de", "riesgo", "cardiovascular", ".", "Como", "antecedentes", "presentaba", "gota", "y", "litiasis", "renales", "de", "repetición", ";", "sin", "intervenciones", "quirúrgicas", ".", "Como", "medicación", "habitual", ":", "alopurinol", ",", "pregabalina", "y", "paracetamol", ".", "\n", "Su", "historia", "oncológica", "empieza", "en", "febrero", "de", "2016", ",", "estando", "asintomático", ",", "acude", "a", "un", "centro", "privado", "para", "realizar", "una", "analítica", "de", "control", ",", "en", "la", "que", "se", "objetiva", "un", "CEA", "elevado", "(", "788", "μg", "/", "l", ";", "normal", "<", "5,0", ")", ".", "Se", "indica", "realización", "de", "colonoscopia", ",", "que", "descarta", "neoplasia", "de", "colon", ".", "Tras", "ello", ",", "se", "realiza", "un", "TC", "toracoabdominal", ",", "en", "la", "que", "se", "observan", "3", "nódulos", "pulmonares", ",", "uno", "subpleural", "anterior", "en", "lóbulo", "superior", "derecho", ",", "irregular", "de", "24", "x", "17", "mm", ",", "otro", "espiculado", "yuxtacisural", "en", "lóbulo", "inferior", "izquierdo", "(", "LII", ")", "de", "18", "x", "13", "mm", ",", "y", "el", "último", "subsólido", "en", "LII", ".", "Además", ",", "se", "observan", "múltiples", "adenopatías", "patológicas", "supra", "e", "infradiafragmáticas", ".", "Ante", "estos", "hallazgos", ",", "se", "deriva", "a", "nuestro", "centro", ",", "donde", ",", "en", "comité", ",", "se", "decide", "la", "realización", "de", "mediastinoscopia", "para", "obtener", "diagnóstico", "histológico", ".", "Se", "puncionan", "dos", "adenopatías", "del", "nivel", "6", ",", "cuyo", "análisis", "anatomopatológico", "resulta", "positivo", "para", "adenocarcinoma", "de", "origen", "pulmonar", "(", "CK7", "y", "TTF1", "positivos", ")", ",", "cuya", "biología", "molecular", "es", "EFGR", "wild", "type", "y", "ALK", "no", "traslocado", ".", "\n", "Es", "valorado", "como", "adenocarcinoma", "de", "pulmón", "estadio", "IV", "(", "T1bN3M1b", ")", "y", ",", "dentro", "de", "comité", ",", "se", "decide", "iniciar", "tratamiento", "de", "1L", "dentro", "del", "ensayo", "clínico", "GO29436", "(", "CBCDA", "-", "taxol", "+", "bevacizumab", "vs", ".", "CBCDA", "-", "tazol", "+", "atezolizumab", "con", "o", "sin", "bevacizumab", ")", ",", "siendo", "aleatorizado", "a", "la", "rama", "CBCDA", "-", "taxol", "+", "bevacizumab", ".", "Se", "administraron", "6", "ciclos", "de", "CBCDA", "-", "taxol", "+", "bevacizumab", "cada", "3", "semanas", "(", "C1", "el", "06/05/2016", ",", "y", "C6", "25/08/2018", ")", ",", "sin", "toxicidades", "destacables", ".", "Posteriormente", ",", "continuó", "con", "bevacizumab", "de", "mantenimiento", "trisemanal", ",", "hasta", "aparición", "de", "toxicidad", "inaceptable", "o", "progresión", "de", "la", "enfermedad", ",", "presentando", "como", "mejor", "resultado", "una", "respuesta", "parcial", "del", "67", "%", "según", "criterios", "RECIST", "1,1", "el", "05/12/2016", ",", "manteniendo", "dicha", "respuesta", "en", "los", "TC", "posteriores", ".", "Continúa", "recibiendo", "bevacizumab", "de", "mantenimiento", "bien", "tolerado", ",", "hasta", "el", "C34", "(", "05/04/2018", ")", ",", "cuando", "aparece", "elevación", "de", "las", "transaminasas", "G1", ".", "Según", "el", "protocolo", "del", "estudio", ",", "se", "permite", "continuar", "con", "el", "tratamiento", ",", "por", "lo", "que", "se", "administra", "dicho", "ciclo", ".", "Tres", "semanas", "más", "tarde", ",", "el", "paciente", "acude", "a", "valorar", "el", "C35", ",", "el", "cual", "no", "se", "puede", "administrar", "debido", "a", "un", "empeoramiento", "de", "la", "hipertransaminasemia", "hasta", "G4", ".", "Es", "valorado", "en", "este", "momento", "como", "toxicidad", "farmacológica", "vs", ".", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "realiza", "un", "TC", "toracoabdominal", "que", "muestra", "enfermedad", "estable", "sin", "afectación", "hepática", ".", "\n", "El", "10/05/2018", "el", "paciente", "consulta", "por", "aparición", "de", "dolor", "en", "hipocondrio", "derecho", ",", "sin", "fiebre", "ni", "otra", "sintomatología", ".", "Se", "realiza", "analítica", "persistiendo", "hipertransaminasemia", "G4", ",", "con", "aparición", "de", "hiperbilirrubinemia", "G3", "y", "elevación", "de", "enzimas", "de", "colestasis", "G3", ".", "Se", "realiza", "ecografía", "abdominal", "urgente", "que", "muestra", "discreta", "dilatación", "de", "vía", "biliar", "intrahepática", "sin", "objetivar", "litiasis", "ni", "otra", "causa", "obstructiva", ".", "Ante", "la", "ausencia", "de", "signos", "de", "alarma", "en", "ese", "momento", ",", "se", "decide", "completar", "el", "estudio", "de", "forma", "ambulatoria", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "vuelve", "a", "consulta", "a", "los", "5", "días", "por", "persistencia", "del", "dolor", ",", "además", "de", "aparición", "de", "fiebre", ",", "prurito", ",", "coluria", ",", "acolia", "e", "ictericia", ".", "En", "la", "exploración", "física", ",", "destacaba", "ictericia", "conjuntiva", "y", "dolor", "en", "hipocondrio", "derecho", "con", "Murphy", "negativo", ".", "El", "resto", "de", "la", "exploración", "física", "fue", "anodina", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "nueva", "analítica", "en", "la", "que", "se", "observa", "un", "incremento", "de", "la", "bilirrubina", "hasta", "129", "mmol", "/", "l", ",", "además", "de", "un", "aumento", "de", "reactantes", "de", "fase", "aguda", "(", "PCR", "y", "leucocitosis", ")", ".", "Se", "repite", "la", "ecografía", "abdominal", ",", "sin", "cambios", "respecto", "a", "la", "previa", ".", "En", "esta", "ocasión", ",", "se", "orienta", "como", "colangitis", ",", "se", "inicia", "antibioterapia", "empírica", "con", "ertapenem", ",", "y", "se", "decide", "ingreso", "hospitalario", "para", "continuar", "tratamiento", "y", "completar", "estudio", "de", "hepatopatía", ".", "\n", "Como", "diagnóstico", "diferencial", "de", "la", "alteración", "de", "la", "bioquímica", "hepática", ",", "se", "plantearon", "las", "siguientes", "etiologías", ":", "infecciosa", "(", "vírica", ")", ",", "alcohólica", ",", "farmacológica", ",", "metabólica", "(", "enfermedad", "de", "Wilson", ",", "hemocromatosis", ",", "déficit", "de", "alfa-1", "antitripsina", ")", ",", "autoinmune", ",", "litiasis", "y", "neoplásica", ".", "Por", "ello", ",", "en", "primer", "lugar", "se", "realizaron", "serologías", "que", "descartaron", "etiología", "viral", "(", "VHA", ",", "VHB", ",", "VHC", ",", "VHE", ",", "HIV", ",", "CMV", "y", "VEB", ")", ".", "Posteriormente", ",", "se", "realizó", "estudio", "de", "Cu", ",", "ferritina", "y", "alfa-1", "antitripsina", ",", "con", "valores", "dentro", "de", "la", "normalidad", ",", "lo", "que", "descartó", "causa", "metabólica", ".", "Además", ",", "se", "realizó", "despistaje", "de", "etiología", "autoinmune", "con", "determinación", "de", "anticuerpos", "resultando", "todos", "negativos", ".", "El", "paciente", "no", "era", "consumidor", "de", "alcohol", ",", "por", "lo", "que", "se", "descartó", "de", "forma", "razonable", "la", "etiología", "enólica", ".", "Para", "descartar", "etiología", "tumoral", ",", "se", "realizó", "una", "PET", "/", "TC", ",", "no", "mostró", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "la", "etiología", "tumoral", "parecía", "poco", "probable", ".", "Más", "adelante", "se", "completó", "estudio", "mediante", "colangio", "-", "RM", "que", "mostró", "dilatación", "de", "la", "vía", "biliar", "intrahepática", ",", "sin", "litiasis", "ni", "lesiones", "tumorales", "responsables", "de", "dicha", "dilatación", ".", "Fue", "en", "dicha", "prueba", "donde", "se", "detectaron", "alteraciones", "de", "la", "vía", "biliar", "intrahepática", "sugestivas", "de", "colangitis", "esclerosante", "(", "CE", ")", ".", "\n", "El", "diagnóstico", "definitivo", "de", "CE", "debería", "ser", "por", "biopsia", "hepática", ",", "pero", "se", "consensuó", "que", ",", "dada", "la", "intensa", "colestasis", "del", "paciente", ",", "el", "alto", "riesgo", "de", "sangrado", "no", "superaba", "el", "beneficio", "potencial", "de", "un", "diagnóstico", "definitivo", ",", "motivo", "por", "el", "cual", "no", "se", "realizó", "dicha", "la", "biopsia", ".", "\n\n", "Diagnóstico", "\n", "Existen", "dos", "tipos", "fundamentales", "de", "CE", ":", "la", "primaria", "(", "diagnóstico", "de", "exclusión", ")", "y", "la", "secundaria", ".", "De", "entre", "las", "etiologías", "de", "la", "CES", "a", "descartar", "en", "nuestro", "paciente", ",", "las", "más", "destacables", "serían", "neoplásica", "y", "la", "farmacológica", ".", "En", "nuestro", "paciente", "ya", "se", "habían", "realizado", "una", "TC", "toracoabdominal", "y", "una", "PET", "/", "TC", "que", "descartaban", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "orientó", "como", "diagnóstico", "más", "probable", "CES", "farmacológico", "probablemente", "por", "bevacizumab", ".", "Aunque", "la", "CES", "por", "bevacizumab", "no", "es", "una", "toxicidad", "descrita", "en", "ficha", "médica", ",", "sí", "que", "existen", "dos", "case", "reports", "publicados", "en", "la", "literatura", "que", "relacionan", "este", "fármaco", "con", "dicho", "efecto", "adverso", ".", "\n\n", "Tratamiento", "\n", "Ante", "esta", "sospecha", "diagnóstica", "se", "empezó", "tratamiento", "específico", "con", "prednisona", ",", "y", "sintomático", "con", "resincolestiramina", "y", "fenobarbital", ",", "sin", "mejoría", "de", "la", "función", "hepática", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "el", "paciente", "asoció", "un", "cuadro", "de", "insuficiencia", "renal", "e", "hipertensión", "arterial", "(", "HTA", ")", ".", "Como", "parte", "del", "estudio", "de", "dicha", "alteración", ",", "se", "realizó", "un", "estudio", "de", "orina", "en", "24", "horas", "que", "detectó", "proteinuria", "(", "proteínas", "5,23", "g", "/", "día", ")", ",", "con", "microhematuria", "en", "el", "sedimento", "urinario", ".", "Ante", "estos", "hallazgos", ",", "y", "bajo", "la", "sospecha", "de", "glomerulopatía", ",", "se", "decidió", "realizar", "nuevo", "despistaje", "de", "autoinmunidad", "con", "anticuerpos", "negativos", ",", "y", "complemento", "e", "inmunoglobulinas", "dentro", "de", "la", "normalidad", ".", "Para", "el", "diagnóstico", "definitivo", "se", "realizó", "una", "biopsia", "renal", ",", "cuyo", "resultado", "fue", "de", "glomerulonefritis", "con", "depósitos", "de", "IgA", "y", "lambda", ",", "depósitos", "de", "lípidos", "y", "células", "espumosas", "en", "glomérulos", "y", "microangiopatía", "trombótica", "(", "MAT", ")", "con", "afectación", "exclusiva", "glomerular", ".", "La", "etiología", "de", "dichos", "hallazgos", "nuevamente", ",", "en", "el", "contexto", "de", "nuestro", "paciente", ",", "podría", "ser", "secundaria", "a", "neoplasia", "o", "a", "bevacizumab", ".", "Valorándose", "en", "este", "momento", "como", "HTA", ",", "síndrome", "nefrótico", "y", "MAT", "secundarios", "a", "bevacizumab", ",", "ya", "que", "los", "tres", "son", "efectos", "adversos", "conocidos", "de", "este", "fármaco", ",", "sin", "poder", "establecer", "la", "etiología", "de", "la", "glomerulonefritis", "IgA.", "\n", "Por", "otra", "parte", ",", "en", "los", "sucesivos", "controles", "se", "observó", "un", "aumento", "de", "la", "ferritina", "y", "los", "triglicéridos", "que", ",", "junto", "con", "la", "Anatomía", "Patológica", "obtenida", "de", "la", "biopsia", "renal", ",", "podría", "ser", "compatible", "con", "un", "síndrome", "hemofagocítico", ".", "Sin", "embargo", ",", "no", "cumplía", "criterios", "diagnósticos", ",", "como", "fiebre", ",", "esplenomegalia", "o", "citopenias", ",", "por", "lo", "que", "se", "decidió", "no", "completar", "el", "estudio", "mediante", "aspirado", "de", "médula", "ósea", ",", "por", "lo", "que", "no", "fue", "posible", "confirmar", "dicha", "sospecha", "diagnóstica", ".", "\n", "Finalmente", ",", "el", "paciente", "presentó", "evolución", "tórpida", "con", "empeoramiento", "grave", "de", "la", "función", "hepática", "y", "renal", "a", "pesar", "del", "tratamiento", "instaurado", ",", "con", "desarrollo", "de", "fracaso", "multiorgánico", ",", "siendo", "finalmente", "exitus", ".", "Se", "decidió", "solicitar", "necropsia", "para", "confirmar", "la", "etiología", "del", "cuadro", "que", "había", "sufrido", "el", "paciente", "en", "sus", "últimas", "semanas", "de", "vida", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia, adenocarcinoma, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ), neoplásica, tumoral, tumoral, tumorales, neoplásica, neoplasia	405_task2	Sentence: Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida.	[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "65", "años", ",", "alérgico", "al", "contraste", "yodado", ",", "exfumador", "con", "un", "consumo", "acumulado", "de", "70", "paquetes", "-", "año", ",", "sin", "hábito", "enólico", "ni", "factores", "de", "riesgo", "cardiovascular", ".", "Como", "antecedentes", "presentaba", "gota", "y", "litiasis", "renales", "de", "repetición", ";", "sin", "intervenciones", "quirúrgicas", ".", "Como", "medicación", "habitual", ":", "alopurinol", ",", "pregabalina", "y", "paracetamol", ".", "\n", "Su", "historia", "oncológica", "empieza", "en", "febrero", "de", "2016", ",", "estando", "asintomático", ",", "acude", "a", "un", "centro", "privado", "para", "realizar", "una", "analítica", "de", "control", ",", "en", "la", "que", "se", "objetiva", "un", "CEA", "elevado", "(", "788", "μg", "/", "l", ";", "normal", "<", "5,0", ")", ".", "Se", "indica", "realización", "de", "colonoscopia", ",", "que", "descarta", "neoplasia", "de", "colon", ".", "Tras", "ello", ",", "se", "realiza", "un", "TC", "toracoabdominal", ",", "en", "la", "que", "se", "observan", "3", "nódulos", "pulmonares", ",", "uno", "subpleural", "anterior", "en", "lóbulo", "superior", "derecho", ",", "irregular", "de", "24", "x", "17", "mm", ",", "otro", "espiculado", "yuxtacisural", "en", "lóbulo", "inferior", "izquierdo", "(", "LII", ")", "de", "18", "x", "13", "mm", ",", "y", "el", "último", "subsólido", "en", "LII", ".", "Además", ",", "se", "observan", "múltiples", "adenopatías", "patológicas", "supra", "e", "infradiafragmáticas", ".", "Ante", "estos", "hallazgos", ",", "se", "deriva", "a", "nuestro", "centro", ",", "donde", ",", "en", "comité", ",", "se", "decide", "la", "realización", "de", "mediastinoscopia", "para", "obtener", "diagnóstico", "histológico", ".", "Se", "puncionan", "dos", "adenopatías", "del", "nivel", "6", ",", "cuyo", "análisis", "anatomopatológico", "resulta", "positivo", "para", "adenocarcinoma", "de", "origen", "pulmonar", "(", "CK7", "y", "TTF1", "positivos", ")", ",", "cuya", "biología", "molecular", "es", "EFGR", "wild", "type", "y", "ALK", "no", "traslocado", ".", "\n", "Es", "valorado", "como", "adenocarcinoma", "de", "pulmón", "estadio", "IV", "(", "T1bN3M1b", ")", "y", ",", "dentro", "de", "comité", ",", "se", "decide", "iniciar", "tratamiento", "de", "1L", "dentro", "del", "ensayo", "clínico", "GO29436", "(", "CBCDA", "-", "taxol", "+", "bevacizumab", "vs", ".", "CBCDA", "-", "tazol", "+", "atezolizumab", "con", "o", "sin", "bevacizumab", ")", ",", "siendo", "aleatorizado", "a", "la", "rama", "CBCDA", "-", "taxol", "+", "bevacizumab", ".", "Se", "administraron", "6", "ciclos", "de", "CBCDA", "-", "taxol", "+", "bevacizumab", "cada", "3", "semanas", "(", "C1", "el", "06/05/2016", ",", "y", "C6", "25/08/2018", ")", ",", "sin", "toxicidades", "destacables", ".", "Posteriormente", ",", "continuó", "con", "bevacizumab", "de", "mantenimiento", "trisemanal", ",", "hasta", "aparición", "de", "toxicidad", "inaceptable", "o", "progresión", "de", "la", "enfermedad", ",", "presentando", "como", "mejor", "resultado", "una", "respuesta", "parcial", "del", "67", "%", "según", "criterios", "RECIST", "1,1", "el", "05/12/2016", ",", "manteniendo", "dicha", "respuesta", "en", "los", "TC", "posteriores", ".", "Continúa", "recibiendo", "bevacizumab", "de", "mantenimiento", "bien", "tolerado", ",", "hasta", "el", "C34", "(", "05/04/2018", ")", ",", "cuando", "aparece", "elevación", "de", "las", "transaminasas", "G1", ".", "Según", "el", "protocolo", "del", "estudio", ",", "se", "permite", "continuar", "con", "el", "tratamiento", ",", "por", "lo", "que", "se", "administra", "dicho", "ciclo", ".", "Tres", "semanas", "más", "tarde", ",", "el", "paciente", "acude", "a", "valorar", "el", "C35", ",", "el", "cual", "no", "se", "puede", "administrar", "debido", "a", "un", "empeoramiento", "de", "la", "hipertransaminasemia", "hasta", "G4", ".", "Es", "valorado", "en", "este", "momento", "como", "toxicidad", "farmacológica", "vs", ".", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "realiza", "un", "TC", "toracoabdominal", "que", "muestra", "enfermedad", "estable", "sin", "afectación", "hepática", ".", "\n", "El", "10/05/2018", "el", "paciente", "consulta", "por", "aparición", "de", "dolor", "en", "hipocondrio", "derecho", ",", "sin", "fiebre", "ni", "otra", "sintomatología", ".", "Se", "realiza", "analítica", "persistiendo", "hipertransaminasemia", "G4", ",", "con", "aparición", "de", "hiperbilirrubinemia", "G3", "y", "elevación", "de", "enzimas", "de", "colestasis", "G3", ".", "Se", "realiza", "ecografía", "abdominal", "urgente", "que", "muestra", "discreta", "dilatación", "de", "vía", "biliar", "intrahepática", "sin", "objetivar", "litiasis", "ni", "otra", "causa", "obstructiva", ".", "Ante", "la", "ausencia", "de", "signos", "de", "alarma", "en", "ese", "momento", ",", "se", "decide", "completar", "el", "estudio", "de", "forma", "ambulatoria", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "vuelve", "a", "consulta", "a", "los", "5", "días", "por", "persistencia", "del", "dolor", ",", "además", "de", "aparición", "de", "fiebre", ",", "prurito", ",", "coluria", ",", "acolia", "e", "ictericia", ".", "En", "la", "exploración", "física", ",", "destacaba", "ictericia", "conjuntiva", "y", "dolor", "en", "hipocondrio", "derecho", "con", "Murphy", "negativo", ".", "El", "resto", "de", "la", "exploración", "física", "fue", "anodina", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "nueva", "analítica", "en", "la", "que", "se", "observa", "un", "incremento", "de", "la", "bilirrubina", "hasta", "129", "mmol", "/", "l", ",", "además", "de", "un", "aumento", "de", "reactantes", "de", "fase", "aguda", "(", "PCR", "y", "leucocitosis", ")", ".", "Se", "repite", "la", "ecografía", "abdominal", ",", "sin", "cambios", "respecto", "a", "la", "previa", ".", "En", "esta", "ocasión", ",", "se", "orienta", "como", "colangitis", ",", "se", "inicia", "antibioterapia", "empírica", "con", "ertapenem", ",", "y", "se", "decide", "ingreso", "hospitalario", "para", "continuar", "tratamiento", "y", "completar", "estudio", "de", "hepatopatía", ".", "\n", "Como", "diagnóstico", "diferencial", "de", "la", "alteración", "de", "la", "bioquímica", "hepática", ",", "se", "plantearon", "las", "siguientes", "etiologías", ":", "infecciosa", "(", "vírica", ")", ",", "alcohólica", ",", "farmacológica", ",", "metabólica", "(", "enfermedad", "de", "Wilson", ",", "hemocromatosis", ",", "déficit", "de", "alfa-1", "antitripsina", ")", ",", "autoinmune", ",", "litiasis", "y", "neoplásica", ".", "Por", "ello", ",", "en", "primer", "lugar", "se", "realizaron", "serologías", "que", "descartaron", "etiología", "viral", "(", "VHA", ",", "VHB", ",", "VHC", ",", "VHE", ",", "HIV", ",", "CMV", "y", "VEB", ")", ".", "Posteriormente", ",", "se", "realizó", "estudio", "de", "Cu", ",", "ferritina", "y", "alfa-1", "antitripsina", ",", "con", "valores", "dentro", "de", "la", "normalidad", ",", "lo", "que", "descartó", "causa", "metabólica", ".", "Además", ",", "se", "realizó", "despistaje", "de", "etiología", "autoinmune", "con", "determinación", "de", "anticuerpos", "resultando", "todos", "negativos", ".", "El", "paciente", "no", "era", "consumidor", "de", "alcohol", ",", "por", "lo", "que", "se", "descartó", "de", "forma", "razonable", "la", "etiología", "enólica", ".", "Para", "descartar", "etiología", "tumoral", ",", "se", "realizó", "una", "PET", "/", "TC", ",", "no", "mostró", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "la", "etiología", "tumoral", "parecía", "poco", "probable", ".", "Más", "adelante", "se", "completó", "estudio", "mediante", "colangio", "-", "RM", "que", "mostró", "dilatación", "de", "la", "vía", "biliar", "intrahepática", ",", "sin", "litiasis", "ni", "lesiones", "tumorales", "responsables", "de", "dicha", "dilatación", ".", "Fue", "en", "dicha", "prueba", "donde", "se", "detectaron", "alteraciones", "de", "la", "vía", "biliar", "intrahepática", "sugestivas", "de", "colangitis", "esclerosante", "(", "CE", ")", ".", "\n", "El", "diagnóstico", "definitivo", "de", "CE", "debería", "ser", "por", "biopsia", "hepática", ",", "pero", "se", "consensuó", "que", ",", "dada", "la", "intensa", "colestasis", "del", "paciente", ",", "el", "alto", "riesgo", "de", "sangrado", "no", "superaba", "el", "beneficio", "potencial", "de", "un", "diagnóstico", "definitivo", ",", "motivo", "por", "el", "cual", "no", "se", "realizó", "dicha", "la", "biopsia", ".", "\n\n", "Diagnóstico", "\n", "Existen", "dos", "tipos", "fundamentales", "de", "CE", ":", "la", "primaria", "(", "diagnóstico", "de", "exclusión", ")", "y", "la", "secundaria", ".", "De", "entre", "las", "etiologías", "de", "la", "CES", "a", "descartar", "en", "nuestro", "paciente", ",", "las", "más", "destacables", "serían", "neoplásica", "y", "la", "farmacológica", ".", "En", "nuestro", "paciente", "ya", "se", "habían", "realizado", "una", "TC", "toracoabdominal", "y", "una", "PET", "/", "TC", "que", "descartaban", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "orientó", "como", "diagnóstico", "más", "probable", "CES", "farmacológico", "probablemente", "por", "bevacizumab", ".", "Aunque", "la", "CES", "por", "bevacizumab", "no", "es", "una", "toxicidad", "descrita", "en", "ficha", "médica", ",", "sí", "que", "existen", "dos", "case", "reports", "publicados", "en", "la", "literatura", "que", "relacionan", "este", "fármaco", "con", "dicho", "efecto", "adverso", ".", "\n\n", "Tratamiento", "\n", "Ante", "esta", "sospecha", "diagnóstica", "se", "empezó", "tratamiento", "específico", "con", "prednisona", ",", "y", "sintomático", "con", "resincolestiramina", "y", "fenobarbital", ",", "sin", "mejoría", "de", "la", "función", "hepática", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "el", "paciente", "asoció", "un", "cuadro", "de", "insuficiencia", "renal", "e", "hipertensión", "arterial", "(", "HTA", ")", ".", "Como", "parte", "del", "estudio", "de", "dicha", "alteración", ",", "se", "realizó", "un", "estudio", "de", "orina", "en", "24", "horas", "que", "detectó", "proteinuria", "(", "proteínas", "5,23", "g", "/", "día", ")", ",", "con", "microhematuria", "en", "el", "sedimento", "urinario", ".", "Ante", "estos", "hallazgos", ",", "y", "bajo", "la", "sospecha", "de", "glomerulopatía", ",", "se", "decidió", "realizar", "nuevo", "despistaje", "de", "autoinmunidad", "con", "anticuerpos", "negativos", ",", "y", "complemento", "e", "inmunoglobulinas", "dentro", "de", "la", "normalidad", ".", "Para", "el", "diagnóstico", "definitivo", "se", "realizó", "una", "biopsia", "renal", ",", "cuyo", "resultado", "fue", "de", "glomerulonefritis", "con", "depósitos", "de", "IgA", "y", "lambda", ",", "depósitos", "de", "lípidos", "y", "células", "espumosas", "en", "glomérulos", "y", "microangiopatía", "trombótica", "(", "MAT", ")", "con", "afectación", "exclusiva", "glomerular", ".", "La", "etiología", "de", "dichos", "hallazgos", "nuevamente", ",", "en", "el", "contexto", "de", "nuestro", "paciente", ",", "podría", "ser", "secundaria", "a", "neoplasia", "o", "a", "bevacizumab", ".", "Valorándose", "en", "este", "momento", "como", "HTA", ",", "síndrome", "nefrótico", "y", "MAT", "secundarios", "a", "bevacizumab", ",", "ya", "que", "los", "tres", "son", "efectos", "adversos", "conocidos", "de", "este", "fármaco", ",", "sin", "poder", "establecer", "la", "etiología", "de", "la", "glomerulonefritis", "IgA.", "\n", "Por", "otra", "parte", ",", "en", "los", "sucesivos", "controles", "se", "observó", "un", "aumento", "de", "la", "ferritina", "y", "los", "triglicéridos", "que", ",", "junto", "con", "la", "Anatomía", "Patológica", "obtenida", "de", "la", "biopsia", "renal", ",", "podría", "ser", "compatible", "con", "un", "síndrome", "hemofagocítico", ".", "Sin", "embargo", ",", "no", "cumplía", "criterios", "diagnósticos", ",", "como", "fiebre", ",", "esplenomegalia", "o", "citopenias", ",", "por", "lo", "que", "se", "decidió", "no", "completar", "el", "estudio", "mediante", "aspirado", "de", "médula", "ósea", ",", "por", "lo", "que", "no", "fue", "posible", "confirmar", "dicha", "sospecha", "diagnóstica", ".", "\n", "Finalmente", ",", "el", "paciente", "presentó", "evolución", "tórpida", "con", "empeoramiento", "grave", "de", "la", "función", "hepática", "y", "renal", "a", "pesar", "del", "tratamiento", "instaurado", ",", "con", "desarrollo", "de", "fracaso", "multiorgánico", ",", "siendo", "finalmente", "exitus", ".", "Se", "decidió", "solicitar", "necropsia", "para", "confirmar", "la", "etiología", "del", "cuadro", "que", "había", "sufrido", "el", "paciente", "en", "sus", "últimas", "semanas", "de", "vida", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
psoriasis is a DISEASE, psoriasis is a DISEASE, psoriasis is a DISEASE	example-188_task0	Sentence: Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DISEASE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O" ]	Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.	[ "Effect", "of", "Efalizumab", "on", "neutrophil", "and", "monocyte", "functions", "in", "patients", "with", "psoriasis", ".", " ", "We", "evaluated", "the", "effect", "of", "efalizumab", "on", "neutrophil", "and", "monocyte", "functions", ".", "The", "in", "vitro", "pre", "-", "incubation", "with", "efalizumab", "concentrations", "similar", "to", "those", "reached", "during", "in", "vivo", "therapy", "almost", "completely", "saturated", "CD11a", "binding", "sites", "without", "affecting", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "or", "CD128b", ".", "There", "was", "a", "significant", "reduction", "in", "the", "chemotactic", "activity", "of", "the", "pre", "-", "treated", "cells", "toward", "three", "different", "chemo", "-", "attractants", ",", "whereas", "their", "phagocytic", "capacity", "and", "production", "of", "oxygen", "radicals", "remained", "unchanged", ".", "One", "month", "after", "the", "administration", "of", "efalizumab", "to", "five", "patients", "with", "psoriasis", "(", "T1", ")", "circulating", "neutrophil", "counts", "increased", "by", "34", "%", "from", "pre", "-", "therapy", "(", "T0", ")", "with", "no", "change", "in", "the", "number", "of", "monocytes", ".", "In", "the", "same", "patients", "the", "CD11a", "binding", "sites", "on", "phagocytes", "were", ">", "90", "%", "saturated", ",", "and", "there", "was", "also", "a", "significant", "down", "-", "modulation", "on", "neutrophils", "(", "44", "%", "of", "T0", ")", "and", "monocytes", "(", "63", "%", "of", "T0", ")", ".", "In", "line", "with", "in", "vitro", "results", ",", "efalizumab", "treatment", "caused", "a", "significant", "deficiency", "in", "the", "chemotactic", "properties", "of", "neutrophils", "and", "monocytes", ",", "but", "no", "changes", "in", "phagocytosis", ",", "oxidative", "burst", ",", "production", "of", "pro", "-", "inflammatory", "cytokines", "or", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "and", "CD128b", ".", "Our", "findings", "suggest", "that", "neutrophils", "and", "monocytes", "may", "be", "among", "the", "targets", "of", "efalizumab", "activity", "in", "patients", "with", "psoriasis", "." ]	[ "DISEASE" ]
psoriasis is a DISEASE, psoriasis is a DISEASE, psoriasis is a DISEASE	example-188_task1	Sentence: Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis. Instructions: please typing these entity words according to sentence: psoriasis, psoriasis, psoriasis Options: DISEASE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O" ]	Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.	[ "Effect", "of", "Efalizumab", "on", "neutrophil", "and", "monocyte", "functions", "in", "patients", "with", "psoriasis", ".", " ", "We", "evaluated", "the", "effect", "of", "efalizumab", "on", "neutrophil", "and", "monocyte", "functions", ".", "The", "in", "vitro", "pre", "-", "incubation", "with", "efalizumab", "concentrations", "similar", "to", "those", "reached", "during", "in", "vivo", "therapy", "almost", "completely", "saturated", "CD11a", "binding", "sites", "without", "affecting", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "or", "CD128b", ".", "There", "was", "a", "significant", "reduction", "in", "the", "chemotactic", "activity", "of", "the", "pre", "-", "treated", "cells", "toward", "three", "different", "chemo", "-", "attractants", ",", "whereas", "their", "phagocytic", "capacity", "and", "production", "of", "oxygen", "radicals", "remained", "unchanged", ".", "One", "month", "after", "the", "administration", "of", "efalizumab", "to", "five", "patients", "with", "psoriasis", "(", "T1", ")", "circulating", "neutrophil", "counts", "increased", "by", "34", "%", "from", "pre", "-", "therapy", "(", "T0", ")", "with", "no", "change", "in", "the", "number", "of", "monocytes", ".", "In", "the", "same", "patients", "the", "CD11a", "binding", "sites", "on", "phagocytes", "were", ">", "90", "%", "saturated", ",", "and", "there", "was", "also", "a", "significant", "down", "-", "modulation", "on", "neutrophils", "(", "44", "%", "of", "T0", ")", "and", "monocytes", "(", "63", "%", "of", "T0", ")", ".", "In", "line", "with", "in", "vitro", "results", ",", "efalizumab", "treatment", "caused", "a", "significant", "deficiency", "in", "the", "chemotactic", "properties", "of", "neutrophils", "and", "monocytes", ",", "but", "no", "changes", "in", "phagocytosis", ",", "oxidative", "burst", ",", "production", "of", "pro", "-", "inflammatory", "cytokines", "or", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "and", "CD128b", ".", "Our", "findings", "suggest", "that", "neutrophils", "and", "monocytes", "may", "be", "among", "the", "targets", "of", "efalizumab", "activity", "in", "patients", "with", "psoriasis", "." ]	[ "DISEASE" ]
psoriasis, psoriasis, psoriasis	example-188_task2	Sentence: Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O" ]	Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.	[ "Effect", "of", "Efalizumab", "on", "neutrophil", "and", "monocyte", "functions", "in", "patients", "with", "psoriasis", ".", " ", "We", "evaluated", "the", "effect", "of", "efalizumab", "on", "neutrophil", "and", "monocyte", "functions", ".", "The", "in", "vitro", "pre", "-", "incubation", "with", "efalizumab", "concentrations", "similar", "to", "those", "reached", "during", "in", "vivo", "therapy", "almost", "completely", "saturated", "CD11a", "binding", "sites", "without", "affecting", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "or", "CD128b", ".", "There", "was", "a", "significant", "reduction", "in", "the", "chemotactic", "activity", "of", "the", "pre", "-", "treated", "cells", "toward", "three", "different", "chemo", "-", "attractants", ",", "whereas", "their", "phagocytic", "capacity", "and", "production", "of", "oxygen", "radicals", "remained", "unchanged", ".", "One", "month", "after", "the", "administration", "of", "efalizumab", "to", "five", "patients", "with", "psoriasis", "(", "T1", ")", "circulating", "neutrophil", "counts", "increased", "by", "34", "%", "from", "pre", "-", "therapy", "(", "T0", ")", "with", "no", "change", "in", "the", "number", "of", "monocytes", ".", "In", "the", "same", "patients", "the", "CD11a", "binding", "sites", "on", "phagocytes", "were", ">", "90", "%", "saturated", ",", "and", "there", "was", "also", "a", "significant", "down", "-", "modulation", "on", "neutrophils", "(", "44", "%", "of", "T0", ")", "and", "monocytes", "(", "63", "%", "of", "T0", ")", ".", "In", "line", "with", "in", "vitro", "results", ",", "efalizumab", "treatment", "caused", "a", "significant", "deficiency", "in", "the", "chemotactic", "properties", "of", "neutrophils", "and", "monocytes", ",", "but", "no", "changes", "in", "phagocytosis", ",", "oxidative", "burst", ",", "production", "of", "pro", "-", "inflammatory", "cytokines", "or", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "and", "CD128b", ".", "Our", "findings", "suggest", "that", "neutrophils", "and", "monocytes", "may", "be", "among", "the", "targets", "of", "efalizumab", "activity", "in", "patients", "with", "psoriasis", "." ]	[ "DISEASE" ]
Europe is an umlsterm, ultrasonography is an umlsterm, diagnostic is an umlsterm, peritoneal lavage is an umlsterm, survey is an umlsterm, patients is an umlsterm, trauma is an umlsterm, patients is an umlsterm, emergency is an umlsterm, trauma is an umlsterm, operating room is an umlsterm, ultrasonography is an umlsterm, hemoperitoneum is an umlsterm, patients is an umlsterm, ultrasonography is an umlsterm, computed tomography is an umlsterm, evaluation is an umlsterm, sonography is an umlsterm, pathology is an umlsterm, hemoperitoneum is an umlsterm	DerRadiologe.80380693.eng.abstr_task0	Sentence: In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) .	[ "In", "Europe", "ultrasonography", "has", "displaced", "diagnostic", "peritoneal", "lavage", "(", "DPL", ")", "in", "the", "primary", "survey", "of", "polytraumatized", "patients", "with", "suspected", "abdominal", "trauma", ".", "Hemodynamically", "unstable", "patients", "who", "are", "brought", "to", "the", "emergency", "room", "with", "blunt", "abdominal", "trauma", "will", "go", "directly", "to", "the", "operating", "room", "after", "a", "rapid", "ultrasonography", "examination", "with", "evidence", "of", "hemoperitoneum", ".", "In", "hemodynamically", "stable", "patients", ",", "in", "addition", "to", "ultrasonography", ",", "computed", "tomography", "can", "be", "done", ".", "This", "is", "especially", "efficient", "if", "evaluation", "with", "sonography", "is", "not", "completely", "possible", "or", "shows", "little", "pathology", "(", "e.g", ".", "small", "amounts", "of", "hemoperitoneum", ")", "." ]	[ "umlsterm" ]
Europe is an umlsterm, ultrasonography is an umlsterm, diagnostic is an umlsterm, peritoneal lavage is an umlsterm, survey is an umlsterm, patients is an umlsterm, trauma is an umlsterm, patients is an umlsterm, emergency is an umlsterm, trauma is an umlsterm, operating room is an umlsterm, ultrasonography is an umlsterm, hemoperitoneum is an umlsterm, patients is an umlsterm, ultrasonography is an umlsterm, computed tomography is an umlsterm, evaluation is an umlsterm, sonography is an umlsterm, pathology is an umlsterm, hemoperitoneum is an umlsterm	DerRadiologe.80380693.eng.abstr_task1	Sentence: In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) . Instructions: please typing these entity words according to sentence: Europe, ultrasonography, diagnostic, peritoneal lavage, survey, patients, trauma, patients, emergency, trauma, operating room, ultrasonography, hemoperitoneum, patients, ultrasonography, computed tomography, evaluation, sonography, pathology, hemoperitoneum Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) .	[ "In", "Europe", "ultrasonography", "has", "displaced", "diagnostic", "peritoneal", "lavage", "(", "DPL", ")", "in", "the", "primary", "survey", "of", "polytraumatized", "patients", "with", "suspected", "abdominal", "trauma", ".", "Hemodynamically", "unstable", "patients", "who", "are", "brought", "to", "the", "emergency", "room", "with", "blunt", "abdominal", "trauma", "will", "go", "directly", "to", "the", "operating", "room", "after", "a", "rapid", "ultrasonography", "examination", "with", "evidence", "of", "hemoperitoneum", ".", "In", "hemodynamically", "stable", "patients", ",", "in", "addition", "to", "ultrasonography", ",", "computed", "tomography", "can", "be", "done", ".", "This", "is", "especially", "efficient", "if", "evaluation", "with", "sonography", "is", "not", "completely", "possible", "or", "shows", "little", "pathology", "(", "e.g", ".", "small", "amounts", "of", "hemoperitoneum", ")", "." ]	[ "umlsterm" ]
Europe, ultrasonography, diagnostic, peritoneal lavage, survey, patients, trauma, patients, emergency, trauma, operating room, ultrasonography, hemoperitoneum, patients, ultrasonography, computed tomography, evaluation, sonography, pathology, hemoperitoneum	DerRadiologe.80380693.eng.abstr_task2	Sentence: In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) .	[ "In", "Europe", "ultrasonography", "has", "displaced", "diagnostic", "peritoneal", "lavage", "(", "DPL", ")", "in", "the", "primary", "survey", "of", "polytraumatized", "patients", "with", "suspected", "abdominal", "trauma", ".", "Hemodynamically", "unstable", "patients", "who", "are", "brought", "to", "the", "emergency", "room", "with", "blunt", "abdominal", "trauma", "will", "go", "directly", "to", "the", "operating", "room", "after", "a", "rapid", "ultrasonography", "examination", "with", "evidence", "of", "hemoperitoneum", ".", "In", "hemodynamically", "stable", "patients", ",", "in", "addition", "to", "ultrasonography", ",", "computed", "tomography", "can", "be", "done", ".", "This", "is", "especially", "efficient", "if", "evaluation", "with", "sonography", "is", "not", "completely", "possible", "or", "shows", "little", "pathology", "(", "e.g", ".", "small", "amounts", "of", "hemoperitoneum", ")", "." ]	[ "umlsterm" ]
Behandlung is an umlsterm, Patienten is an umlsterm, Autoimmunkrankheiten is an umlsterm, Tierexperimentelle is an umlsterm, Fallberichte is an umlsterm, Patienten is an umlsterm, Stammzelltransplantation is an umlsterm, Rheumatismus is an umlsterm, Blut- is an umlsterm, Knochenmarktransplantation is an umlsterm, gezieltes is an umlsterm, Zeit is an umlsterm, Fallberichte is an umlsterm	ZfuerRheumatologie.70560173.ger.abstr_task0	Sentence: Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen .	[ "Autologe", "und", "allogene", "Stammzelltransplantationen", "werden", "heute", "intensiv", "diskutiert", "als", "moegliche", "Behandlung", "fuer", "Patienten", "mit", "schweren", "Autoimmunkrankheiten", ".", "Tierexperimentelle", "Daten", "und", "Fallberichte", "von", "Patienten", "mit", "gebesserter", "Autoimmunkrankheit", "nach", "Stammzelltransplantation", "wegen", "einer", "anderen", "Erkrankung", "unterstuetzen", "dieses", "Konzept", ".", "Um", "moeglichst", "bald", "klare", "Antworten", "auf", "die", "vielen", "offenen", "Fragen", "zu", "erhalten", ",", "haben", "die", "Europaeische", "Liga", "gegen", "Rheumatismus", "EULAR", "und", "die", "Europaeische", "Gruppe", "fuer", "Blut-", "und", "Knochenmarktransplantation", "EBMT", "gemeinsam", "Richtlinien", "fuer", "ein", "gezieltes", "Vorgehen", "erarbeitet", ".", "Sie", "werden", "hier", "vorgestellt", ".", "Klare", "Daten", "fehlen", "zur", "Zeit", ".", "Die", "noch", "vereinzelten", "Fallberichte", "sehen", "vielversprechend", "aus", "und", "erste", "Studien", "sind", "in", "Vorbereitung", ".", "In", "wenigen", "Jahren", "sollte", "es", "bei", "koordiniertem", "Vorgehen", "moeglich", "sein", ",", "den", "Stellenwert", "dieser", "Behandlungsmethode", "beurteilen", "zu", "koennen", "." ]	[ "umlsterm" ]
Behandlung is an umlsterm, Patienten is an umlsterm, Autoimmunkrankheiten is an umlsterm, Tierexperimentelle is an umlsterm, Fallberichte is an umlsterm, Patienten is an umlsterm, Stammzelltransplantation is an umlsterm, Rheumatismus is an umlsterm, Blut- is an umlsterm, Knochenmarktransplantation is an umlsterm, gezieltes is an umlsterm, Zeit is an umlsterm, Fallberichte is an umlsterm	ZfuerRheumatologie.70560173.ger.abstr_task1	Sentence: Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen . Instructions: please typing these entity words according to sentence: Behandlung, Patienten, Autoimmunkrankheiten, Tierexperimentelle, Fallberichte, Patienten, Stammzelltransplantation, Rheumatismus, Blut-, Knochenmarktransplantation, gezieltes, Zeit, Fallberichte Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen .	[ "Autologe", "und", "allogene", "Stammzelltransplantationen", "werden", "heute", "intensiv", "diskutiert", "als", "moegliche", "Behandlung", "fuer", "Patienten", "mit", "schweren", "Autoimmunkrankheiten", ".", "Tierexperimentelle", "Daten", "und", "Fallberichte", "von", "Patienten", "mit", "gebesserter", "Autoimmunkrankheit", "nach", "Stammzelltransplantation", "wegen", "einer", "anderen", "Erkrankung", "unterstuetzen", "dieses", "Konzept", ".", "Um", "moeglichst", "bald", "klare", "Antworten", "auf", "die", "vielen", "offenen", "Fragen", "zu", "erhalten", ",", "haben", "die", "Europaeische", "Liga", "gegen", "Rheumatismus", "EULAR", "und", "die", "Europaeische", "Gruppe", "fuer", "Blut-", "und", "Knochenmarktransplantation", "EBMT", "gemeinsam", "Richtlinien", "fuer", "ein", "gezieltes", "Vorgehen", "erarbeitet", ".", "Sie", "werden", "hier", "vorgestellt", ".", "Klare", "Daten", "fehlen", "zur", "Zeit", ".", "Die", "noch", "vereinzelten", "Fallberichte", "sehen", "vielversprechend", "aus", "und", "erste", "Studien", "sind", "in", "Vorbereitung", ".", "In", "wenigen", "Jahren", "sollte", "es", "bei", "koordiniertem", "Vorgehen", "moeglich", "sein", ",", "den", "Stellenwert", "dieser", "Behandlungsmethode", "beurteilen", "zu", "koennen", "." ]	[ "umlsterm" ]
Behandlung, Patienten, Autoimmunkrankheiten, Tierexperimentelle, Fallberichte, Patienten, Stammzelltransplantation, Rheumatismus, Blut-, Knochenmarktransplantation, gezieltes, Zeit, Fallberichte	ZfuerRheumatologie.70560173.ger.abstr_task2	Sentence: Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen .	[ "Autologe", "und", "allogene", "Stammzelltransplantationen", "werden", "heute", "intensiv", "diskutiert", "als", "moegliche", "Behandlung", "fuer", "Patienten", "mit", "schweren", "Autoimmunkrankheiten", ".", "Tierexperimentelle", "Daten", "und", "Fallberichte", "von", "Patienten", "mit", "gebesserter", "Autoimmunkrankheit", "nach", "Stammzelltransplantation", "wegen", "einer", "anderen", "Erkrankung", "unterstuetzen", "dieses", "Konzept", ".", "Um", "moeglichst", "bald", "klare", "Antworten", "auf", "die", "vielen", "offenen", "Fragen", "zu", "erhalten", ",", "haben", "die", "Europaeische", "Liga", "gegen", "Rheumatismus", "EULAR", "und", "die", "Europaeische", "Gruppe", "fuer", "Blut-", "und", "Knochenmarktransplantation", "EBMT", "gemeinsam", "Richtlinien", "fuer", "ein", "gezieltes", "Vorgehen", "erarbeitet", ".", "Sie", "werden", "hier", "vorgestellt", ".", "Klare", "Daten", "fehlen", "zur", "Zeit", ".", "Die", "noch", "vereinzelten", "Fallberichte", "sehen", "vielversprechend", "aus", "und", "erste", "Studien", "sind", "in", "Vorbereitung", ".", "In", "wenigen", "Jahren", "sollte", "es", "bei", "koordiniertem", "Vorgehen", "moeglich", "sein", ",", "den", "Stellenwert", "dieser", "Behandlungsmethode", "beurteilen", "zu", "koennen", "." ]	[ "umlsterm" ]
Lithotripsiegeraete is an umlsterm, Harnsteinbehandlung is an umlsterm, Lithotripsiesystemen is an umlsterm, Lithotripsiesysteme is an umlsterm, Therapien is an umlsterm, Komplikationen is an umlsterm, Haematome is an umlsterm, Mortalitaet is an umlsterm, Komplikationen is an umlsterm, Wahrscheinlichkeiten is an umlsterm, Steinzentren is an umlsterm	DerUrologeA.70360217.ger.abstr_task0	Sentence: Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist .	[ "Transportable", "Lithotripsiegeraete", "werden", "in", "zunehmendem", "Masse", "in", "urologischen", "Kliniken", "zur", "Harnsteinbehandlung", "eingesetzt", ",", "wenn", "kein", "festinstallierter", "Lithotriptor", "vorhanden", "ist", "bzw", ".", "eine", "solche", "Anschaffung", "als", "unrentabel", "angesehen", "wird", ".", "In", "der", "vorliegenden", "Studie", "wird", "ueberprueft", ",", "inwieweit", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "der", "ESWL", "mit", "transportablen", "Lithotripsiesystemen", "von", "den", "bekannten", "Komplikationsdichten", "aus", "etablierten", "Zentren", "verschieden", "ist", ".", "An", "bis", "zu", "54", "Kliniken", "wurde", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "transportabler", "Lithotripsiesysteme", "von", "1993", "-", "1995", "bei", "insgesamt", "12", "901", "Therapien", "erfasst", ".", "Schwerwiegende", "Komplikationen", "ergaben", "sich", "in", "insgesamt", "85", "Faellen", "(", "0,66", "%", ")", ".", "Die", "Mehrzahl", "davon", "(", "n", "=", "64", ")", "waren", "intra-", "oder", "perirenale", "Haematome", ";", "3", "mal", "musste", "nephrektomiert", "werden", ".", "Die", "Mortalitaet", "lag", "bei", "0", "%", ".", "Fuer", "die", "einzelnen", "Komplikationen", "lassen", "sich", "aus", "diesen", "Fallzahlen", "Wahrscheinlichkeiten", "ihres", "Auftretens", "berechnen", ".", "Insgesamt", "zeigt", "die", "Untersuchung", ",", "dass", "die", "ESWL", "mit", "mobilen", "Systemen", "mit", "der", "gleichen", "geringen", "Komplikationsrate", "angewendet", "werden", "kann", ",", "wie", "sie", "von", "etablierten", "Steinzentren", "bekannt", "ist", "." ]	[ "umlsterm" ]
Lithotripsiegeraete is an umlsterm, Harnsteinbehandlung is an umlsterm, Lithotripsiesystemen is an umlsterm, Lithotripsiesysteme is an umlsterm, Therapien is an umlsterm, Komplikationen is an umlsterm, Haematome is an umlsterm, Mortalitaet is an umlsterm, Komplikationen is an umlsterm, Wahrscheinlichkeiten is an umlsterm, Steinzentren is an umlsterm	DerUrologeA.70360217.ger.abstr_task1	Sentence: Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist . Instructions: please typing these entity words according to sentence: Lithotripsiegeraete, Harnsteinbehandlung, Lithotripsiesystemen, Lithotripsiesysteme, Therapien, Komplikationen, Haematome, Mortalitaet, Komplikationen, Wahrscheinlichkeiten, Steinzentren Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist .	[ "Transportable", "Lithotripsiegeraete", "werden", "in", "zunehmendem", "Masse", "in", "urologischen", "Kliniken", "zur", "Harnsteinbehandlung", "eingesetzt", ",", "wenn", "kein", "festinstallierter", "Lithotriptor", "vorhanden", "ist", "bzw", ".", "eine", "solche", "Anschaffung", "als", "unrentabel", "angesehen", "wird", ".", "In", "der", "vorliegenden", "Studie", "wird", "ueberprueft", ",", "inwieweit", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "der", "ESWL", "mit", "transportablen", "Lithotripsiesystemen", "von", "den", "bekannten", "Komplikationsdichten", "aus", "etablierten", "Zentren", "verschieden", "ist", ".", "An", "bis", "zu", "54", "Kliniken", "wurde", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "transportabler", "Lithotripsiesysteme", "von", "1993", "-", "1995", "bei", "insgesamt", "12", "901", "Therapien", "erfasst", ".", "Schwerwiegende", "Komplikationen", "ergaben", "sich", "in", "insgesamt", "85", "Faellen", "(", "0,66", "%", ")", ".", "Die", "Mehrzahl", "davon", "(", "n", "=", "64", ")", "waren", "intra-", "oder", "perirenale", "Haematome", ";", "3", "mal", "musste", "nephrektomiert", "werden", ".", "Die", "Mortalitaet", "lag", "bei", "0", "%", ".", "Fuer", "die", "einzelnen", "Komplikationen", "lassen", "sich", "aus", "diesen", "Fallzahlen", "Wahrscheinlichkeiten", "ihres", "Auftretens", "berechnen", ".", "Insgesamt", "zeigt", "die", "Untersuchung", ",", "dass", "die", "ESWL", "mit", "mobilen", "Systemen", "mit", "der", "gleichen", "geringen", "Komplikationsrate", "angewendet", "werden", "kann", ",", "wie", "sie", "von", "etablierten", "Steinzentren", "bekannt", "ist", "." ]	[ "umlsterm" ]
Lithotripsiegeraete, Harnsteinbehandlung, Lithotripsiesystemen, Lithotripsiesysteme, Therapien, Komplikationen, Haematome, Mortalitaet, Komplikationen, Wahrscheinlichkeiten, Steinzentren	DerUrologeA.70360217.ger.abstr_task2	Sentence: Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist .	[ "Transportable", "Lithotripsiegeraete", "werden", "in", "zunehmendem", "Masse", "in", "urologischen", "Kliniken", "zur", "Harnsteinbehandlung", "eingesetzt", ",", "wenn", "kein", "festinstallierter", "Lithotriptor", "vorhanden", "ist", "bzw", ".", "eine", "solche", "Anschaffung", "als", "unrentabel", "angesehen", "wird", ".", "In", "der", "vorliegenden", "Studie", "wird", "ueberprueft", ",", "inwieweit", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "der", "ESWL", "mit", "transportablen", "Lithotripsiesystemen", "von", "den", "bekannten", "Komplikationsdichten", "aus", "etablierten", "Zentren", "verschieden", "ist", ".", "An", "bis", "zu", "54", "Kliniken", "wurde", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "transportabler", "Lithotripsiesysteme", "von", "1993", "-", "1995", "bei", "insgesamt", "12", "901", "Therapien", "erfasst", ".", "Schwerwiegende", "Komplikationen", "ergaben", "sich", "in", "insgesamt", "85", "Faellen", "(", "0,66", "%", ")", ".", "Die", "Mehrzahl", "davon", "(", "n", "=", "64", ")", "waren", "intra-", "oder", "perirenale", "Haematome", ";", "3", "mal", "musste", "nephrektomiert", "werden", ".", "Die", "Mortalitaet", "lag", "bei", "0", "%", ".", "Fuer", "die", "einzelnen", "Komplikationen", "lassen", "sich", "aus", "diesen", "Fallzahlen", "Wahrscheinlichkeiten", "ihres", "Auftretens", "berechnen", ".", "Insgesamt", "zeigt", "die", "Untersuchung", ",", "dass", "die", "ESWL", "mit", "mobilen", "Systemen", "mit", "der", "gleichen", "geringen", "Komplikationsrate", "angewendet", "werden", "kann", ",", "wie", "sie", "von", "etablierten", "Steinzentren", "bekannt", "ist", "." ]	[ "umlsterm" ]
Funktionsdiagnostik is an umlsterm, Blasen- is an umlsterm, Harntrakt is an umlsterm, Nierenfunktion is an umlsterm, Harnkontinenz is an umlsterm, Blasenentleerung is an umlsterm, Patienten is an umlsterm, Geburt is an umlsterm, Spina bifida is an umlsterm, Myelomeningozele is an umlsterm	DerUrologeA.90380010.ger.abstr_task0	Sentence: Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]	Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt .	[ "Neurogene", "Blasenentleerungsstoerungen", "im", "Kindesalter", "sind", "in", "der", "Mehrzahl", "der", "Faelle", "Folgen", "dysrhapischer", "Hemmungsmissbildungen", ".", "Die", "urologische", "Funktionsdiagnostik", "zielt", "in", "erster", "Linie", "auf", "die", "Feststellung", "der", "mit", "der", "Grunderkrankung", "verbundenen", "Blasen-", "und", "Sphinkterfunktion", "sowie", "assoziierter", "Stoerungen", "am", "oberen", "Harntrakt", ".", "Therapeutisches", "Hauptziel", "bleibt", "neben", "dem", "Erhalt", "der", "Nierenfunktion", "das", "Erreichen", "der", "Harnkontinenz", "und", "eine", "individuell", "angepasste", "Form", "der", "Blasenentleerung", ",", "die", "auch", "den", "uebrigen", "koerperlichen", "Behinderungen", "sowie", "der", "sozialen", "und", "persoenlichen", "Situation", "des", "Betroffenen", "Rechnung", "traegt", ".", "Anhand", "von", "190", "Patienten", ",", "die", "seit", "Geburt", "in", "unserer", "Klinik", "betreut", "werden", ",", "wird", "die", "Entwicklung", "der", "neurogenen", "Blasenfunktionsstoerung", "durch", "Spina", "bifida", "und", "Myelomeningozele", "aufgezeigt", "." ]	[ "umlsterm" ]
Funktionsdiagnostik is an umlsterm, Blasen- is an umlsterm, Harntrakt is an umlsterm, Nierenfunktion is an umlsterm, Harnkontinenz is an umlsterm, Blasenentleerung is an umlsterm, Patienten is an umlsterm, Geburt is an umlsterm, Spina bifida is an umlsterm, Myelomeningozele is an umlsterm	DerUrologeA.90380010.ger.abstr_task1	Sentence: Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt . Instructions: please typing these entity words according to sentence: Funktionsdiagnostik, Blasen-, Harntrakt, Nierenfunktion, Harnkontinenz, Blasenentleerung, Patienten, Geburt, Spina bifida, Myelomeningozele Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]	Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt .	[ "Neurogene", "Blasenentleerungsstoerungen", "im", "Kindesalter", "sind", "in", "der", "Mehrzahl", "der", "Faelle", "Folgen", "dysrhapischer", "Hemmungsmissbildungen", ".", "Die", "urologische", "Funktionsdiagnostik", "zielt", "in", "erster", "Linie", "auf", "die", "Feststellung", "der", "mit", "der", "Grunderkrankung", "verbundenen", "Blasen-", "und", "Sphinkterfunktion", "sowie", "assoziierter", "Stoerungen", "am", "oberen", "Harntrakt", ".", "Therapeutisches", "Hauptziel", "bleibt", "neben", "dem", "Erhalt", "der", "Nierenfunktion", "das", "Erreichen", "der", "Harnkontinenz", "und", "eine", "individuell", "angepasste", "Form", "der", "Blasenentleerung", ",", "die", "auch", "den", "uebrigen", "koerperlichen", "Behinderungen", "sowie", "der", "sozialen", "und", "persoenlichen", "Situation", "des", "Betroffenen", "Rechnung", "traegt", ".", "Anhand", "von", "190", "Patienten", ",", "die", "seit", "Geburt", "in", "unserer", "Klinik", "betreut", "werden", ",", "wird", "die", "Entwicklung", "der", "neurogenen", "Blasenfunktionsstoerung", "durch", "Spina", "bifida", "und", "Myelomeningozele", "aufgezeigt", "." ]	[ "umlsterm" ]
Funktionsdiagnostik, Blasen-, Harntrakt, Nierenfunktion, Harnkontinenz, Blasenentleerung, Patienten, Geburt, Spina bifida, Myelomeningozele	DerUrologeA.90380010.ger.abstr_task2	Sentence: Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]	Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt .	[ "Neurogene", "Blasenentleerungsstoerungen", "im", "Kindesalter", "sind", "in", "der", "Mehrzahl", "der", "Faelle", "Folgen", "dysrhapischer", "Hemmungsmissbildungen", ".", "Die", "urologische", "Funktionsdiagnostik", "zielt", "in", "erster", "Linie", "auf", "die", "Feststellung", "der", "mit", "der", "Grunderkrankung", "verbundenen", "Blasen-", "und", "Sphinkterfunktion", "sowie", "assoziierter", "Stoerungen", "am", "oberen", "Harntrakt", ".", "Therapeutisches", "Hauptziel", "bleibt", "neben", "dem", "Erhalt", "der", "Nierenfunktion", "das", "Erreichen", "der", "Harnkontinenz", "und", "eine", "individuell", "angepasste", "Form", "der", "Blasenentleerung", ",", "die", "auch", "den", "uebrigen", "koerperlichen", "Behinderungen", "sowie", "der", "sozialen", "und", "persoenlichen", "Situation", "des", "Betroffenen", "Rechnung", "traegt", ".", "Anhand", "von", "190", "Patienten", ",", "die", "seit", "Geburt", "in", "unserer", "Klinik", "betreut", "werden", ",", "wird", "die", "Entwicklung", "der", "neurogenen", "Blasenfunktionsstoerung", "durch", "Spina", "bifida", "und", "Myelomeningozele", "aufgezeigt", "." ]	[ "umlsterm" ]
Age is a Person, 60 - 85 years is a Value, right - handed is a Observation, Major depression is a Condition, unipolar is a Qualifier, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria is a Scope, Age is a Person, onset of first episode is a Condition, = 50 years is a Value, three is a Multiplier, depressive episodes is a Condition, depression is a Condition, 24-Item Hamilton Depression Rating Scale is a Measurement, HDRS is a Measurement, = 20 is a Value	NCT01728194_inc_task0	Sentence: Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Observation, Multiplier, Scope, Measurement	[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Multiplier", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "O", "O" ]	Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.	[ "Age", ":", "60", "-", "85", "years", ",", "right", "-", "handed", ";", "\n", "Diagnosis", ":", "Major", "depression", ",", "unipolar", "(", "by", "Structured", "Clinical", "Interview", "for", "Diagnostic", "and", "Statistical", "Manual", "(", "DSM)IV", "(", "SCID", "-", "R", ")", "and", "DSM", "-", "IV", "criteria", ")", ";", "\n", "Age", "of", "onset", "of", "first", "episode", "=", "50", "years", "with", "up", "to", "three", "depressive", "episodes", ";", "\n", "Severity", "of", "depression", ":", "A", "24-Item", "Hamilton", "Depression", "Rating", "Scale", "(", "HDRS", ")", "=", "20", ".", "\n" ]	[ "Scope", "Measurement", "Condition", "Observation", "Value", "Qualifier", "Multiplier", "Person" ]
Age is a Person, 60 - 85 years is a Value, right - handed is a Observation, Major depression is a Condition, unipolar is a Qualifier, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria is a Scope, Age is a Person, onset of first episode is a Condition, = 50 years is a Value, three is a Multiplier, depressive episodes is a Condition, depression is a Condition, 24-Item Hamilton Depression Rating Scale is a Measurement, HDRS is a Measurement, = 20 is a Value	NCT01728194_inc_task1	Sentence: Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20. Instructions: please typing these entity words according to sentence: Age, 60 - 85 years, right - handed, Major depression, unipolar, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria, Age, onset of first episode, = 50 years, three, depressive episodes, depression, 24-Item Hamilton Depression Rating Scale, HDRS, = 20 Options: Condition, Qualifier, Value, Person, Observation, Multiplier, Scope, Measurement	[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Multiplier", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "O", "O" ]	Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.	[ "Age", ":", "60", "-", "85", "years", ",", "right", "-", "handed", ";", "\n", "Diagnosis", ":", "Major", "depression", ",", "unipolar", "(", "by", "Structured", "Clinical", "Interview", "for", "Diagnostic", "and", "Statistical", "Manual", "(", "DSM)IV", "(", "SCID", "-", "R", ")", "and", "DSM", "-", "IV", "criteria", ")", ";", "\n", "Age", "of", "onset", "of", "first", "episode", "=", "50", "years", "with", "up", "to", "three", "depressive", "episodes", ";", "\n", "Severity", "of", "depression", ":", "A", "24-Item", "Hamilton", "Depression", "Rating", "Scale", "(", "HDRS", ")", "=", "20", ".", "\n" ]	[ "Scope", "Measurement", "Condition", "Observation", "Value", "Qualifier", "Multiplier", "Person" ]
Age, 60 - 85 years, right - handed, Major depression, unipolar, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria, Age, onset of first episode, = 50 years, three, depressive episodes, depression, 24-Item Hamilton Depression Rating Scale, HDRS, = 20	NCT01728194_inc_task2	Sentence: Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20. Instructions: please extract entity words from the input sentence	[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Multiplier", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "O", "O" ]	Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.	[ "Age", ":", "60", "-", "85", "years", ",", "right", "-", "handed", ";", "\n", "Diagnosis", ":", "Major", "depression", ",", "unipolar", "(", "by", "Structured", "Clinical", "Interview", "for", "Diagnostic", "and", "Statistical", "Manual", "(", "DSM)IV", "(", "SCID", "-", "R", ")", "and", "DSM", "-", "IV", "criteria", ")", ";", "\n", "Age", "of", "onset", "of", "first", "episode", "=", "50", "years", "with", "up", "to", "three", "depressive", "episodes", ";", "\n", "Severity", "of", "depression", ":", "A", "24-Item", "Hamilton", "Depression", "Rating", "Scale", "(", "HDRS", ")", "=", "20", ".", "\n" ]	[ "Scope", "Measurement", "Condition", "Observation", "Value", "Qualifier", "Multiplier", "Person" ]
Patienten is an umlsterm, Leitende Arzt is an umlsterm, Rechtsprechung is an umlsterm, Organisation is an umlsterm, Arzt is an umlsterm	DerGynaekologe.90320927.ger.abstr_task0	Sentence: Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben .	[ "Fuer", "Schaeden", "an", "Patienten", "durch", "Organisationsfehler", "in", "seiner", "Abteilung", "muss", "der", "Leitende", "Arzt", ",", "in", "der", "Regel", "der", "Chefarzt", ",", "haften", ".", "In", "der", "Rechtsprechung", "genuegt", "bereits", "die", "Vermutung", ",", "dass", "ein", "Fehler", "aufgrund", "einer", "mangelnden", "Organisation", "entstanden", "ist", ",", "um", "den", "Verantwortlichen", "-", "naemlich", "den", "Chefarzt", "-", "haftbar", "zu", "machen", ".", "Daher", "muss", "der", "Leitendende", "Arzt", "in", "der", "Lage", "sein", ",", "strukturelle", "Organisationsmaengel", "zu", "erkennen", "und", "diese", "durch", "Schulung", "seiner", "Mitarbeiter", "zu", "beheben", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Leitende Arzt is an umlsterm, Rechtsprechung is an umlsterm, Organisation is an umlsterm, Arzt is an umlsterm	DerGynaekologe.90320927.ger.abstr_task1	Sentence: Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben . Instructions: please typing these entity words according to sentence: Patienten, Leitende Arzt, Rechtsprechung, Organisation, Arzt Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben .	[ "Fuer", "Schaeden", "an", "Patienten", "durch", "Organisationsfehler", "in", "seiner", "Abteilung", "muss", "der", "Leitende", "Arzt", ",", "in", "der", "Regel", "der", "Chefarzt", ",", "haften", ".", "In", "der", "Rechtsprechung", "genuegt", "bereits", "die", "Vermutung", ",", "dass", "ein", "Fehler", "aufgrund", "einer", "mangelnden", "Organisation", "entstanden", "ist", ",", "um", "den", "Verantwortlichen", "-", "naemlich", "den", "Chefarzt", "-", "haftbar", "zu", "machen", ".", "Daher", "muss", "der", "Leitendende", "Arzt", "in", "der", "Lage", "sein", ",", "strukturelle", "Organisationsmaengel", "zu", "erkennen", "und", "diese", "durch", "Schulung", "seiner", "Mitarbeiter", "zu", "beheben", "." ]	[ "umlsterm" ]
Patienten, Leitende Arzt, Rechtsprechung, Organisation, Arzt	DerGynaekologe.90320927.ger.abstr_task2	Sentence: Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben .	[ "Fuer", "Schaeden", "an", "Patienten", "durch", "Organisationsfehler", "in", "seiner", "Abteilung", "muss", "der", "Leitende", "Arzt", ",", "in", "der", "Regel", "der", "Chefarzt", ",", "haften", ".", "In", "der", "Rechtsprechung", "genuegt", "bereits", "die", "Vermutung", ",", "dass", "ein", "Fehler", "aufgrund", "einer", "mangelnden", "Organisation", "entstanden", "ist", ",", "um", "den", "Verantwortlichen", "-", "naemlich", "den", "Chefarzt", "-", "haftbar", "zu", "machen", ".", "Daher", "muss", "der", "Leitendende", "Arzt", "in", "der", "Lage", "sein", ",", "strukturelle", "Organisationsmaengel", "zu", "erkennen", "und", "diese", "durch", "Schulung", "seiner", "Mitarbeiter", "zu", "beheben", "." ]	[ "umlsterm" ]
self - reported is a Qualifier, healthy is a Condition, adults is a Person, between is a Value, ages is a Person, fluent in English is a Observation	NCT02589353_inc_task0	Sentence: self-reported healthy adults between the ages of 18-60 who are fluent in English. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Observation	[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "B-Person", "B-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O" ]	self-reported healthy adults between the ages of 18-60 who are fluent in English.	[ "self", "-", "reported", "healthy", "adults", "between", "the", "ages", "of", "18", "-", "60", "who", "are", "fluent", "in", "English", ".", "\n" ]	[ "Observation", "Qualifier", "Condition", "Value", "Person" ]
self - reported is a Qualifier, healthy is a Condition, adults is a Person, between is a Value, ages is a Person, fluent in English is a Observation	NCT02589353_inc_task1	Sentence: self-reported healthy adults between the ages of 18-60 who are fluent in English. Instructions: please typing these entity words according to sentence: self - reported, healthy, adults, between, ages, fluent in English Options: Condition, Qualifier, Value, Person, Observation	[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "B-Person", "B-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O" ]	self-reported healthy adults between the ages of 18-60 who are fluent in English.	[ "self", "-", "reported", "healthy", "adults", "between", "the", "ages", "of", "18", "-", "60", "who", "are", "fluent", "in", "English", ".", "\n" ]	[ "Observation", "Qualifier", "Condition", "Value", "Person" ]
self - reported, healthy, adults, between, ages, fluent in English	NCT02589353_inc_task2	Sentence: self-reported healthy adults between the ages of 18-60 who are fluent in English. Instructions: please extract entity words from the input sentence	[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "B-Person", "B-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O" ]	self-reported healthy adults between the ages of 18-60 who are fluent in English.	[ "self", "-", "reported", "healthy", "adults", "between", "the", "ages", "of", "18", "-", "60", "who", "are", "fluent", "in", "English", ".", "\n" ]	[ "Observation", "Qualifier", "Condition", "Value", "Person" ]
Etanercept is a Intervention_Pharmacological, adults is a Participant_Age, rheumatoid arthritis : is a Participant_Condition, safety is a Outcome_Other, efficacy is a Outcome_Other, etanercept is a Intervention_Pharmacological, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) is a Participant_Condition, 714 is a Participant_Sample-size, 581 is a Participant_Sample-size, 388 is a Participant_Sample-size, Rates of serious adverse events is a Outcome_Adverse-effects, serious infections is a Outcome_Adverse-effects, cancer is a Outcome_Physical, deaths is a Outcome_Mortality, 356 is a Participant_Sample-size, response rates is a Outcome_Other, 167 is a Participant_Sample-size, Doses is a Outcome_Other, safety profile is a Outcome_Other, rates of adverse events is a Outcome_Adverse-effects	25688_task0	Sentence: Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Pharmacological", "O", "O", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .	[ "Etanercept", "treatment", "in", "adults", "with", "established", "rheumatoid", "arthritis", ":", "7", "years", "of", "clinical", "experience", ".", "OBJECTIVE", "To", "evaluate", "safety", "and", "efficacy", "of", "longterm", "etanercept", "treatment", "in", "patients", "with", "disease", "modifying", "antirheumatic", "drug", "(", "DMARD", ")", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Safety", "results", "are", "reported", "for", "714", "patients", "who", "received", "etanercept", "in", "one", "of", "7", "initial", "trials", "or", "a", "longterm", "extension", ".", "Efficacy", "results", "are", "reported", "for", "581", "patients", "who", "enrolled", "in", "the", "extension", ".", "RESULTS", "Of", "the", "714", "patients", "enrolled", "in", "the", "initial", "trials", ",", "581", "(", "81", "%", ")", "enrolled", "in", "the", "extension", ",", "and", "388", "(", "54", "%", ")", "patients", "are", "continuing", "to", "receive", "etanercept", "therapy", ".", "The", "longest", "individual", "treatment", "was", "8.2", "years", ",", "with", "3139", "total", "patient", "-", "years", "of", "etanercept", "exposure", ".", "Rates", "of", "serious", "adverse", "events", "(", "overall", "rate=14.8", "events/100", "patient", "-", "yrs", ")", ",", "serious", "infections", "(", "overall", "rate=4.2", "events/100", "patient", "-", "yrs", ")", ",", "cancer", "(", "overall", "rate=1.0", "events/100", "patient", "-", "yrs", ")", ",", "and", "deaths", "(", "overall", "rate=0.7", "events/100", "patient", "-", "yrs", ")", "were", "stable", "each", "year", ",", "through", "8", "years", "of", "etanercept", "exposure", ".", "For", "356", "patients", "who", "completed", "6", "years", "of", "etanercept", "treatment", ",", "response", "rates", "were", "ACR20=73", "%", ",", "ACR50=52", "%", ",", "ACR70=27", "%", ",", "DAS28", "CRP", "good", "response=52", "%", ",", "and", "DAS28", "CRP", "remission=37", "%", "of", "patients", ".", "Similar", "responses", "occurred", "in", "167", "patients", "who", "completed", "Year", "7", ".", "Doses", "of", "concomitant", "methotrexate", "or", "corticosteroids", "were", "reduced", "in", "many", "patients", "who", "maintained", "clinical", "responses", ".", "CONCLUSION", "The", "safety", "profile", "of", "etanercept", "was", "consistent", "over", "time", ",", "with", "rates", "of", "adverse", "events", "similar", "to", "those", "reported", "for", "patients", "with", "RA", "in", "general", ".", "Durable", "clinical", "responses", "were", "observed", "in", "some", "patients", "for", "7", "years", "or", "more", ".", "The", "benefit", "-", "to", "-", "risk", "ratio", "for", "longterm", "etanercept", "treatment", "remains", "highly", "favorable", "." ]	[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
Etanercept is a Intervention_Pharmacological, adults is a Participant_Age, rheumatoid arthritis : is a Participant_Condition, safety is a Outcome_Other, efficacy is a Outcome_Other, etanercept is a Intervention_Pharmacological, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) is a Participant_Condition, 714 is a Participant_Sample-size, 581 is a Participant_Sample-size, 388 is a Participant_Sample-size, Rates of serious adverse events is a Outcome_Adverse-effects, serious infections is a Outcome_Adverse-effects, cancer is a Outcome_Physical, deaths is a Outcome_Mortality, 356 is a Participant_Sample-size, response rates is a Outcome_Other, 167 is a Participant_Sample-size, Doses is a Outcome_Other, safety profile is a Outcome_Other, rates of adverse events is a Outcome_Adverse-effects	25688_task1	Sentence: Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable . Instructions: please typing these entity words according to sentence: Etanercept, adults, rheumatoid arthritis :, safety, efficacy, etanercept, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ), 714, 581, 388, Rates of serious adverse events, serious infections, cancer, deaths, 356, response rates, 167, Doses, safety profile, rates of adverse events Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Pharmacological", "O", "O", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .	[ "Etanercept", "treatment", "in", "adults", "with", "established", "rheumatoid", "arthritis", ":", "7", "years", "of", "clinical", "experience", ".", "OBJECTIVE", "To", "evaluate", "safety", "and", "efficacy", "of", "longterm", "etanercept", "treatment", "in", "patients", "with", "disease", "modifying", "antirheumatic", "drug", "(", "DMARD", ")", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Safety", "results", "are", "reported", "for", "714", "patients", "who", "received", "etanercept", "in", "one", "of", "7", "initial", "trials", "or", "a", "longterm", "extension", ".", "Efficacy", "results", "are", "reported", "for", "581", "patients", "who", "enrolled", "in", "the", "extension", ".", "RESULTS", "Of", "the", "714", "patients", "enrolled", "in", "the", "initial", "trials", ",", "581", "(", "81", "%", ")", "enrolled", "in", "the", "extension", ",", "and", "388", "(", "54", "%", ")", "patients", "are", "continuing", "to", "receive", "etanercept", "therapy", ".", "The", "longest", "individual", "treatment", "was", "8.2", "years", ",", "with", "3139", "total", "patient", "-", "years", "of", "etanercept", "exposure", ".", "Rates", "of", "serious", "adverse", "events", "(", "overall", "rate=14.8", "events/100", "patient", "-", "yrs", ")", ",", "serious", "infections", "(", "overall", "rate=4.2", "events/100", "patient", "-", "yrs", ")", ",", "cancer", "(", "overall", "rate=1.0", "events/100", "patient", "-", "yrs", ")", ",", "and", "deaths", "(", "overall", "rate=0.7", "events/100", "patient", "-", "yrs", ")", "were", "stable", "each", "year", ",", "through", "8", "years", "of", "etanercept", "exposure", ".", "For", "356", "patients", "who", "completed", "6", "years", "of", "etanercept", "treatment", ",", "response", "rates", "were", "ACR20=73", "%", ",", "ACR50=52", "%", ",", "ACR70=27", "%", ",", "DAS28", "CRP", "good", "response=52", "%", ",", "and", "DAS28", "CRP", "remission=37", "%", "of", "patients", ".", "Similar", "responses", "occurred", "in", "167", "patients", "who", "completed", "Year", "7", ".", "Doses", "of", "concomitant", "methotrexate", "or", "corticosteroids", "were", "reduced", "in", "many", "patients", "who", "maintained", "clinical", "responses", ".", "CONCLUSION", "The", "safety", "profile", "of", "etanercept", "was", "consistent", "over", "time", ",", "with", "rates", "of", "adverse", "events", "similar", "to", "those", "reported", "for", "patients", "with", "RA", "in", "general", ".", "Durable", "clinical", "responses", "were", "observed", "in", "some", "patients", "for", "7", "years", "or", "more", ".", "The", "benefit", "-", "to", "-", "risk", "ratio", "for", "longterm", "etanercept", "treatment", "remains", "highly", "favorable", "." ]	[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
Etanercept, adults, rheumatoid arthritis :, safety, efficacy, etanercept, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ), 714, 581, 388, Rates of serious adverse events, serious infections, cancer, deaths, 356, response rates, 167, Doses, safety profile, rates of adverse events	25688_task2	Sentence: Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "O", "O", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .	[ "Etanercept", "treatment", "in", "adults", "with", "established", "rheumatoid", "arthritis", ":", "7", "years", "of", "clinical", "experience", ".", "OBJECTIVE", "To", "evaluate", "safety", "and", "efficacy", "of", "longterm", "etanercept", "treatment", "in", "patients", "with", "disease", "modifying", "antirheumatic", "drug", "(", "DMARD", ")", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Safety", "results", "are", "reported", "for", "714", "patients", "who", "received", "etanercept", "in", "one", "of", "7", "initial", "trials", "or", "a", "longterm", "extension", ".", "Efficacy", "results", "are", "reported", "for", "581", "patients", "who", "enrolled", "in", "the", "extension", ".", "RESULTS", "Of", "the", "714", "patients", "enrolled", "in", "the", "initial", "trials", ",", "581", "(", "81", "%", ")", "enrolled", "in", "the", "extension", ",", "and", "388", "(", "54", "%", ")", "patients", "are", "continuing", "to", "receive", "etanercept", "therapy", ".", "The", "longest", "individual", "treatment", "was", "8.2", "years", ",", "with", "3139", "total", "patient", "-", "years", "of", "etanercept", "exposure", ".", "Rates", "of", "serious", "adverse", "events", "(", "overall", "rate=14.8", "events/100", "patient", "-", "yrs", ")", ",", "serious", "infections", "(", "overall", "rate=4.2", "events/100", "patient", "-", "yrs", ")", ",", "cancer", "(", "overall", "rate=1.0", "events/100", "patient", "-", "yrs", ")", ",", "and", "deaths", "(", "overall", "rate=0.7", "events/100", "patient", "-", "yrs", ")", "were", "stable", "each", "year", ",", "through", "8", "years", "of", "etanercept", "exposure", ".", "For", "356", "patients", "who", "completed", "6", "years", "of", "etanercept", "treatment", ",", "response", "rates", "were", "ACR20=73", "%", ",", "ACR50=52", "%", ",", "ACR70=27", "%", ",", "DAS28", "CRP", "good", "response=52", "%", ",", "and", "DAS28", "CRP", "remission=37", "%", "of", "patients", ".", "Similar", "responses", "occurred", "in", "167", "patients", "who", "completed", "Year", "7", ".", "Doses", "of", "concomitant", "methotrexate", "or", "corticosteroids", "were", "reduced", "in", "many", "patients", "who", "maintained", "clinical", "responses", ".", "CONCLUSION", "The", "safety", "profile", "of", "etanercept", "was", "consistent", "over", "time", ",", "with", "rates", "of", "adverse", "events", "similar", "to", "those", "reported", "for", "patients", "with", "RA", "in", "general", ".", "Durable", "clinical", "responses", "were", "observed", "in", "some", "patients", "for", "7", "years", "or", "more", ".", "The", "benefit", "-", "to", "-", "risk", "ratio", "for", "longterm", "etanercept", "treatment", "remains", "highly", "favorable", "." ]	[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
Abstract is an umlsterm, female is an umlsterm, patient is an umlsterm, itching is an umlsterm, dermatitis is an umlsterm, disease is an umlsterm, Therapy is an umlsterm, DADPS is an umlsterm, lymph node is an umlsterm, enlargement is an umlsterm, splenomegaly is an umlsterm, lymph node is an umlsterm, biopsy is an umlsterm, Histopathology is an umlsterm, lymph node is an umlsterm, bone marrow is an umlsterm, diagnosis is an umlsterm, angioimmunoblastic lymphadenopathy is an umlsterm, T - cell lymphoma is an umlsterm, skin is an umlsterm, lymphoma is an umlsterm, skin is an umlsterm, cells is an umlsterm, case report is an umlsterm, skin is an umlsterm, literature is an umlsterm	DerHautarzt.40450562.eng.abstr_task0	Sentence: Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature .	[ "Abstract", ".", "A", "62-year", "-", "old", "female", "patient", "presented", "with", "bullous", ",", "intensely", "itching", "cutaneous", "lesions", ",", "which", "clinically", "and", "histopathologically", "resembled", "dermatitis", "herpetiformis", "(", "Duhring", "'s", "disease", ")", ".", "Therapy", "with", "DADPS", "was", "unsuccessful", ".", "Because", "of", "associated", "cervical", "lymph", "node", "enlargement", "and", "splenomegaly", ",", "a", "lymph", "node", "biopsy", "was", "taken", ".", "Histopathology", "of", "a", "lymph", "node", "and", "of", "the", "bone", "marrow", "confirmed", "the", "diagnosis", ":", "angioimmunoblastic", "lymphadenopathy", "(", "AILD", ")", "-type", "T", "-", "cell", "lymphoma", ".", "Intensely", "pruritic", "associated", "skin", "eruptions", "are", "typical", "for", "this", "peculiar", "kind", "of", "lymphoma", ".", "These", "skin", "lesions", "are", "due", "to", "inflammatory", "cells", "and", "not", "to", "neoplastic", "infiltrations", ".", "This", "case", "report", "is", "the", "first", "report", "of", "AILD", "with", "bullous", "skin", "lesions", "to", "appear", "in", "the", "literature", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, female is an umlsterm, patient is an umlsterm, itching is an umlsterm, dermatitis is an umlsterm, disease is an umlsterm, Therapy is an umlsterm, DADPS is an umlsterm, lymph node is an umlsterm, enlargement is an umlsterm, splenomegaly is an umlsterm, lymph node is an umlsterm, biopsy is an umlsterm, Histopathology is an umlsterm, lymph node is an umlsterm, bone marrow is an umlsterm, diagnosis is an umlsterm, angioimmunoblastic lymphadenopathy is an umlsterm, T - cell lymphoma is an umlsterm, skin is an umlsterm, lymphoma is an umlsterm, skin is an umlsterm, cells is an umlsterm, case report is an umlsterm, skin is an umlsterm, literature is an umlsterm	DerHautarzt.40450562.eng.abstr_task1	Sentence: Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature . Instructions: please typing these entity words according to sentence: Abstract, female, patient, itching, dermatitis, disease, Therapy, DADPS, lymph node, enlargement, splenomegaly, lymph node, biopsy, Histopathology, lymph node, bone marrow, diagnosis, angioimmunoblastic lymphadenopathy, T - cell lymphoma, skin, lymphoma, skin, cells, case report, skin, literature Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature .	[ "Abstract", ".", "A", "62-year", "-", "old", "female", "patient", "presented", "with", "bullous", ",", "intensely", "itching", "cutaneous", "lesions", ",", "which", "clinically", "and", "histopathologically", "resembled", "dermatitis", "herpetiformis", "(", "Duhring", "'s", "disease", ")", ".", "Therapy", "with", "DADPS", "was", "unsuccessful", ".", "Because", "of", "associated", "cervical", "lymph", "node", "enlargement", "and", "splenomegaly", ",", "a", "lymph", "node", "biopsy", "was", "taken", ".", "Histopathology", "of", "a", "lymph", "node", "and", "of", "the", "bone", "marrow", "confirmed", "the", "diagnosis", ":", "angioimmunoblastic", "lymphadenopathy", "(", "AILD", ")", "-type", "T", "-", "cell", "lymphoma", ".", "Intensely", "pruritic", "associated", "skin", "eruptions", "are", "typical", "for", "this", "peculiar", "kind", "of", "lymphoma", ".", "These", "skin", "lesions", "are", "due", "to", "inflammatory", "cells", "and", "not", "to", "neoplastic", "infiltrations", ".", "This", "case", "report", "is", "the", "first", "report", "of", "AILD", "with", "bullous", "skin", "lesions", "to", "appear", "in", "the", "literature", "." ]	[ "umlsterm" ]
Abstract, female, patient, itching, dermatitis, disease, Therapy, DADPS, lymph node, enlargement, splenomegaly, lymph node, biopsy, Histopathology, lymph node, bone marrow, diagnosis, angioimmunoblastic lymphadenopathy, T - cell lymphoma, skin, lymphoma, skin, cells, case report, skin, literature	DerHautarzt.40450562.eng.abstr_task2	Sentence: Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature .	[ "Abstract", ".", "A", "62-year", "-", "old", "female", "patient", "presented", "with", "bullous", ",", "intensely", "itching", "cutaneous", "lesions", ",", "which", "clinically", "and", "histopathologically", "resembled", "dermatitis", "herpetiformis", "(", "Duhring", "'s", "disease", ")", ".", "Therapy", "with", "DADPS", "was", "unsuccessful", ".", "Because", "of", "associated", "cervical", "lymph", "node", "enlargement", "and", "splenomegaly", ",", "a", "lymph", "node", "biopsy", "was", "taken", ".", "Histopathology", "of", "a", "lymph", "node", "and", "of", "the", "bone", "marrow", "confirmed", "the", "diagnosis", ":", "angioimmunoblastic", "lymphadenopathy", "(", "AILD", ")", "-type", "T", "-", "cell", "lymphoma", ".", "Intensely", "pruritic", "associated", "skin", "eruptions", "are", "typical", "for", "this", "peculiar", "kind", "of", "lymphoma", ".", "These", "skin", "lesions", "are", "due", "to", "inflammatory", "cells", "and", "not", "to", "neoplastic", "infiltrations", ".", "This", "case", "report", "is", "the", "first", "report", "of", "AILD", "with", "bullous", "skin", "lesions", "to", "appear", "in", "the", "literature", "." ]	[ "umlsterm" ]
Lap4 is a protein, cadmium is a compound	DS.d854_task0	Sentence: Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]	Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress.	[ "Here", ",", "we", "proposed", "that", "Lap4", ",", "a", "vacuolar", "amino", "peptidase", ",", "is", "involved", "in", "glutathione", "catabolism", "under", "cadmium", "stress", "." ]	[ "compound", "protein" ]
Lap4 is a protein, cadmium is a compound	DS.d854_task1	Sentence: Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress. Instructions: please typing these entity words according to sentence: Lap4, cadmium Options: compound, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]	Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress.	[ "Here", ",", "we", "proposed", "that", "Lap4", ",", "a", "vacuolar", "amino", "peptidase", ",", "is", "involved", "in", "glutathione", "catabolism", "under", "cadmium", "stress", "." ]	[ "compound", "protein" ]
Lap4, cadmium	DS.d854_task2	Sentence: Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]	Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress.	[ "Here", ",", "we", "proposed", "that", "Lap4", ",", "a", "vacuolar", "amino", "peptidase", ",", "is", "involved", "in", "glutathione", "catabolism", "under", "cadmium", "stress", "." ]	[ "compound", "protein" ]
Twenty - two patients with a history of recently diagnosed RA of less than 2 years is a participant, clinical outcome and process measures is an outcome	1357_task0	Sentence: Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome, participant	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .	[ "Twenty", "-", "two", "patients", "with", "a", "history", "of", "recently", "diagnosed", "RA", "of", "less", "than", "2", "years", "were", "assessed", "on", "a", "variety", "of", "clinical", "outcome", "and", "process", "measures", "on", "six", "assessment", "occasions", "over", "a", "21-month", "period", "." ]	[ "participant", "outcome" ]
Twenty - two patients with a history of recently diagnosed RA of less than 2 years is a participant, clinical outcome and process measures is an outcome	1357_task1	Sentence: Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period . Instructions: please typing these entity words according to sentence: Twenty - two patients with a history of recently diagnosed RA of less than 2 years, clinical outcome and process measures Options: outcome, participant	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .	[ "Twenty", "-", "two", "patients", "with", "a", "history", "of", "recently", "diagnosed", "RA", "of", "less", "than", "2", "years", "were", "assessed", "on", "a", "variety", "of", "clinical", "outcome", "and", "process", "measures", "on", "six", "assessment", "occasions", "over", "a", "21-month", "period", "." ]	[ "participant", "outcome" ]
Twenty - two patients with a history of recently diagnosed RA of less than 2 years, clinical outcome and process measures	1357_task2	Sentence: Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period . Instructions: please extract entity words from the input sentence	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .	[ "Twenty", "-", "two", "patients", "with", "a", "history", "of", "recently", "diagnosed", "RA", "of", "less", "than", "2", "years", "were", "assessed", "on", "a", "variety", "of", "clinical", "outcome", "and", "process", "measures", "on", "six", "assessment", "occasions", "over", "a", "21-month", "period", "." ]	[ "participant", "outcome" ]
Arp1 is a protein, Golgi - associated betaIII is a protein-isoform, spectrin is a protein-family, Arp1 is a protein, betaIII spectrin is a protein-isoform	1.0alpha7.train.510_task0	Sentence: To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-isoform, protein, protein-family	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "O", "O" ]	To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin.	[ " ", "To", "test", "this", "hypothesis", ",", "we", "have", "examined", "the", "interaction", "of", " ", "Arp1", "with", "the", "Golgi", "-", "associated", "betaIII", "isoform", "of", " ", "spectrin", "and", "demonstrated", "that", " ", "Arp1", "binds", "directly", "to", " ", "betaIII", "spectrin", ".", " " ]	[ "protein-isoform", "protein-family", "organelle", "protein" ]
Arp1 is a protein, Golgi - associated betaIII is a protein-isoform, spectrin is a protein-family, Arp1 is a protein, betaIII spectrin is a protein-isoform	1.0alpha7.train.510_task1	Sentence: To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin. Instructions: please typing these entity words according to sentence: Arp1, Golgi - associated betaIII, spectrin, Arp1, betaIII spectrin Options: protein-isoform, protein, protein-family	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "O", "O" ]	To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin.	[ " ", "To", "test", "this", "hypothesis", ",", "we", "have", "examined", "the", "interaction", "of", " ", "Arp1", "with", "the", "Golgi", "-", "associated", "betaIII", "isoform", "of", " ", "spectrin", "and", "demonstrated", "that", " ", "Arp1", "binds", "directly", "to", " ", "betaIII", "spectrin", ".", " " ]	[ "protein-isoform", "protein-family", "organelle", "protein" ]
Arp1, Golgi - associated betaIII, spectrin, Arp1, betaIII spectrin	1.0alpha7.train.510_task2	Sentence: To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "O", "O" ]	To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin.	[ " ", "To", "test", "this", "hypothesis", ",", "we", "have", "examined", "the", "interaction", "of", " ", "Arp1", "with", "the", "Golgi", "-", "associated", "betaIII", "isoform", "of", " ", "spectrin", "and", "demonstrated", "that", " ", "Arp1", "binds", "directly", "to", " ", "betaIII", "spectrin", ".", " " ]	[ "protein-isoform", "protein-family", "organelle", "protein" ]
Group cognitive behavioural therapy is a Intervention_Other, and is a Intervention_Pharmacological, group recreational activity is a Intervention_Other, adults is a Participant_Age, autism spectrum disorders is a Participant_Condition, groups of 6 - 8 patients is a Participant_Sample-size, 68 is a Participant_Sample-size, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health is a Outcome_Physical, psychiatric symptoms is a Outcome_Physical, dropout rate is a Outcome_Physical, efficacy is a Outcome_Other, Cognitive behavioural therapy is a Intervention_Educational	61594_task0	Sentence: Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Intervention_Pharmacological", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout .	[ "Group", "cognitive", "behavioural", "therapy", "and", "group", "recreational", "activity", "for", "adults", "with", "autism", "spectrum", "disorders", ":", "a", "preliminary", "randomized", "controlled", "trial", ".", "Although", "adults", "with", "autism", "spectrum", "disorder", "are", "an", "increasingly", "identified", "patient", "population", ",", "few", "treatment", "options", "are", "available", ".", "This", "preliminary", "randomized", "controlled", "open", "trial", "with", "a", "parallel", "design", "developed", "two", "group", "interventions", "for", "adults", "with", "autism", "spectrum", "disorders", "and", "intelligence", "within", "the", "normal", "range", ":", "cognitive", "behavioural", "therapy", "and", "recreational", "activity", ".", "Both", "interventions", "comprised", "36", "weekly", "3-h", "sessions", "led", "by", "two", "therapists", "in", "groups", "of", "6", "-", "8", "patients", ".", "A", "total", "of", "68", "psychiatric", "patients", "with", "autism", "spectrum", "disorders", "participated", "in", "the", "study", ".", "Outcome", "measures", "were", "Quality", "of", "Life", "Inventory", ",", "Sense", "of", "Coherence", "Scale", ",", "Rosenberg", "Self", "-", "Esteem", "Scale", "and", "an", "exploratory", "analysis", "on", "measures", "of", "psychiatric", "health", ".", "Participants", "in", "both", "treatment", "conditions", "reported", "an", "increased", "quality", "of", "life", "at", "post", "-", "treatment", "(", "d", "=", "0.39", ",", "p", "<", "0.001", ")", ",", "with", "no", "difference", "between", "interventions", ".", "No", "amelioration", "of", "psychiatric", "symptoms", "was", "observed", ".", "The", "dropout", "rate", "was", "lower", "with", "cognitive", "behavioural", "therapy", "than", "with", "recreational", "activity", ",", "and", "participants", "in", "cognitive", "behavioural", "therapy", "rated", "themselves", "as", "more", "generally", "improved", ",", "as", "well", "as", "more", "improved", "regarding", "expression", "of", "needs", "and", "understanding", "of", "difficulties", ".", "Both", "interventions", "appear", "to", "be", "promising", "treatment", "options", "for", "adults", "with", "autism", "spectrum", "disorder", ".", "The", "interventions", "'", "similar", "efficacy", "may", "be", "due", "to", "the", "common", "elements", ",", "structure", "and", "group", "setting", ".", "Cognitive", "behavioural", "therapy", "may", "be", "additionally", "beneficial", "in", "terms", "of", "increasing", "specific", "skills", "and", "minimizing", "dropout", "." ]	[ "Outcome_Physical", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Participant_Age", "Intervention_Pharmacological" ]
Group cognitive behavioural therapy is a Intervention_Other, and is a Intervention_Pharmacological, group recreational activity is a Intervention_Other, adults is a Participant_Age, autism spectrum disorders is a Participant_Condition, groups of 6 - 8 patients is a Participant_Sample-size, 68 is a Participant_Sample-size, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health is a Outcome_Physical, psychiatric symptoms is a Outcome_Physical, dropout rate is a Outcome_Physical, efficacy is a Outcome_Other, Cognitive behavioural therapy is a Intervention_Educational	61594_task1	Sentence: Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout . Instructions: please typing these entity words according to sentence: Group cognitive behavioural therapy, and, group recreational activity, adults, autism spectrum disorders, groups of 6 - 8 patients, 68, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health, psychiatric symptoms, dropout rate, efficacy, Cognitive behavioural therapy Options: Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Intervention_Pharmacological", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout .	[ "Group", "cognitive", "behavioural", "therapy", "and", "group", "recreational", "activity", "for", "adults", "with", "autism", "spectrum", "disorders", ":", "a", "preliminary", "randomized", "controlled", "trial", ".", "Although", "adults", "with", "autism", "spectrum", "disorder", "are", "an", "increasingly", "identified", "patient", "population", ",", "few", "treatment", "options", "are", "available", ".", "This", "preliminary", "randomized", "controlled", "open", "trial", "with", "a", "parallel", "design", "developed", "two", "group", "interventions", "for", "adults", "with", "autism", "spectrum", "disorders", "and", "intelligence", "within", "the", "normal", "range", ":", "cognitive", "behavioural", "therapy", "and", "recreational", "activity", ".", "Both", "interventions", "comprised", "36", "weekly", "3-h", "sessions", "led", "by", "two", "therapists", "in", "groups", "of", "6", "-", "8", "patients", ".", "A", "total", "of", "68", "psychiatric", "patients", "with", "autism", "spectrum", "disorders", "participated", "in", "the", "study", ".", "Outcome", "measures", "were", "Quality", "of", "Life", "Inventory", ",", "Sense", "of", "Coherence", "Scale", ",", "Rosenberg", "Self", "-", "Esteem", "Scale", "and", "an", "exploratory", "analysis", "on", "measures", "of", "psychiatric", "health", ".", "Participants", "in", "both", "treatment", "conditions", "reported", "an", "increased", "quality", "of", "life", "at", "post", "-", "treatment", "(", "d", "=", "0.39", ",", "p", "<", "0.001", ")", ",", "with", "no", "difference", "between", "interventions", ".", "No", "amelioration", "of", "psychiatric", "symptoms", "was", "observed", ".", "The", "dropout", "rate", "was", "lower", "with", "cognitive", "behavioural", "therapy", "than", "with", "recreational", "activity", ",", "and", "participants", "in", "cognitive", "behavioural", "therapy", "rated", "themselves", "as", "more", "generally", "improved", ",", "as", "well", "as", "more", "improved", "regarding", "expression", "of", "needs", "and", "understanding", "of", "difficulties", ".", "Both", "interventions", "appear", "to", "be", "promising", "treatment", "options", "for", "adults", "with", "autism", "spectrum", "disorder", ".", "The", "interventions", "'", "similar", "efficacy", "may", "be", "due", "to", "the", "common", "elements", ",", "structure", "and", "group", "setting", ".", "Cognitive", "behavioural", "therapy", "may", "be", "additionally", "beneficial", "in", "terms", "of", "increasing", "specific", "skills", "and", "minimizing", "dropout", "." ]	[ "Outcome_Physical", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Participant_Age", "Intervention_Pharmacological" ]
Group cognitive behavioural therapy, and, group recreational activity, adults, autism spectrum disorders, groups of 6 - 8 patients, 68, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health, psychiatric symptoms, dropout rate, efficacy, Cognitive behavioural therapy	61594_task2	Sentence: Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Intervention_Pharmacological", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout .	[ "Group", "cognitive", "behavioural", "therapy", "and", "group", "recreational", "activity", "for", "adults", "with", "autism", "spectrum", "disorders", ":", "a", "preliminary", "randomized", "controlled", "trial", ".", "Although", "adults", "with", "autism", "spectrum", "disorder", "are", "an", "increasingly", "identified", "patient", "population", ",", "few", "treatment", "options", "are", "available", ".", "This", "preliminary", "randomized", "controlled", "open", "trial", "with", "a", "parallel", "design", "developed", "two", "group", "interventions", "for", "adults", "with", "autism", "spectrum", "disorders", "and", "intelligence", "within", "the", "normal", "range", ":", "cognitive", "behavioural", "therapy", "and", "recreational", "activity", ".", "Both", "interventions", "comprised", "36", "weekly", "3-h", "sessions", "led", "by", "two", "therapists", "in", "groups", "of", "6", "-", "8", "patients", ".", "A", "total", "of", "68", "psychiatric", "patients", "with", "autism", "spectrum", "disorders", "participated", "in", "the", "study", ".", "Outcome", "measures", "were", "Quality", "of", "Life", "Inventory", ",", "Sense", "of", "Coherence", "Scale", ",", "Rosenberg", "Self", "-", "Esteem", "Scale", "and", "an", "exploratory", "analysis", "on", "measures", "of", "psychiatric", "health", ".", "Participants", "in", "both", "treatment", "conditions", "reported", "an", "increased", "quality", "of", "life", "at", "post", "-", "treatment", "(", "d", "=", "0.39", ",", "p", "<", "0.001", ")", ",", "with", "no", "difference", "between", "interventions", ".", "No", "amelioration", "of", "psychiatric", "symptoms", "was", "observed", ".", "The", "dropout", "rate", "was", "lower", "with", "cognitive", "behavioural", "therapy", "than", "with", "recreational", "activity", ",", "and", "participants", "in", "cognitive", "behavioural", "therapy", "rated", "themselves", "as", "more", "generally", "improved", ",", "as", "well", "as", "more", "improved", "regarding", "expression", "of", "needs", "and", "understanding", "of", "difficulties", ".", "Both", "interventions", "appear", "to", "be", "promising", "treatment", "options", "for", "adults", "with", "autism", "spectrum", "disorder", ".", "The", "interventions", "'", "similar", "efficacy", "may", "be", "due", "to", "the", "common", "elements", ",", "structure", "and", "group", "setting", ".", "Cognitive", "behavioural", "therapy", "may", "be", "additionally", "beneficial", "in", "terms", "of", "increasing", "specific", "skills", "and", "minimizing", "dropout", "." ]	[ "Outcome_Physical", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Participant_Age", "Intervention_Pharmacological" ]
fluticasone propionate is a CHEMICAL	9563368_task0	Sentence: Development of fluticasone propionate and comparison with other inhaled corticosteroids. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]	Development of fluticasone propionate and comparison with other inhaled corticosteroids.	[ "Development", "of", "fluticasone", "propionate", "and", "comparison", "with", "other", "inhaled", "corticosteroids", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
fluticasone propionate is a CHEMICAL	9563368_task1	Sentence: Development of fluticasone propionate and comparison with other inhaled corticosteroids. Instructions: please typing these entity words according to sentence: fluticasone propionate Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]	Development of fluticasone propionate and comparison with other inhaled corticosteroids.	[ "Development", "of", "fluticasone", "propionate", "and", "comparison", "with", "other", "inhaled", "corticosteroids", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
fluticasone propionate	9563368_task2	Sentence: Development of fluticasone propionate and comparison with other inhaled corticosteroids. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]	Development of fluticasone propionate and comparison with other inhaled corticosteroids.	[ "Development", "of", "fluticasone", "propionate", "and", "comparison", "with", "other", "inhaled", "corticosteroids", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Granulocyte - macrophage colony - stimulating factor is a Intervention_Pharmacological, influenza vaccination is a Intervention_Pharmacological, stem cell transplant is a Participant_Condition, granulocyte - macrophage colony - stimulating factor ( GM - CSF ) is a Intervention_Physical, serological response is a Outcome_Physical, 117 is a Participant_Sample-size, undergone stem cell transplantation is a Participant_Condition, SCT is a Participant_Condition, vaccine response is a Outcome_Physical, levels of influenza hemagglutination - inhibition ( HAI ) antibodies is a Outcome_Physical, IgG antibodies is a Outcome_Physical, ELISA is a Outcome_Physical, antibody response is a Outcome_Physical, influenza A is a Outcome_Physical, SCT patients is a Participant_Condition, influenza B vaccine is a Intervention_Pharmacological	2670_task0	Sentence: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent .	[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "as", "immunomodulating", "factor", "together", "with", "influenza", "vaccination", "in", "stem", "cell", "transplant", "patients", ".", "The", "effect", "of", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "on", "the", "serological", "response", "at", "influenza", "vaccination", "was", "studied", "in", "117", "patients", "who", "had", "undergone", "stem", "cell", "transplantation", "(", "SCT", ")", ".", "The", "vaccine", "response", "was", "evaluated", "as", "significant", "increases", "in", "levels", "of", "influenza", "hemagglutination", "-", "inhibition", "(", "HAI", ")", "antibodies", "and", "of", "IgG", "antibodies", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "There", "was", "no", "difference", "in", "antibody", "response", "to", "either", "influenza", "A", "or", "B", "in", "64", "patients", "who", "received", "GM", "-", "CSF", "at", "vaccination", ",", "compared", "with", "the", "53", "who", "did", "not", ".", "In", "the", "subgroup", "of", "allogeneic", "SCT", "patients", ",", "HAI", "showed", "that", "the", "response", "rate", "to", "the", "influenza", "B", "vaccine", "was", "significantly", "higher", "in", "the", "treatment", "group", "(", "P", "<", ".05", ")", ".", "ELISA", "showed", "that", "autologous", "SCT", "patients", "with", "breast", "cancer", "who", "received", "GM", "-", "CSF", "had", "a", "better", "response", "to", "influenza", "A", "(", "P", "<", ".05", ")", "and", "B", "(", "P", "<", ".01", ")", ".", "At", "early", "vaccination", ",", "4", "-", "12", "months", "after", "stem", "cell", "transplantation", ",", "these", "responses", "were", "more", "pronounced", ".", "GM", "-", "CSF", "appears", "to", "improve", "the", "response", "to", "influenza", "vaccination", "in", "some", "groups", "of", "SCT", "patients", ",", "but", "only", "to", "a", "limited", "extent", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Granulocyte - macrophage colony - stimulating factor is a Intervention_Pharmacological, influenza vaccination is a Intervention_Pharmacological, stem cell transplant is a Participant_Condition, granulocyte - macrophage colony - stimulating factor ( GM - CSF ) is a Intervention_Physical, serological response is a Outcome_Physical, 117 is a Participant_Sample-size, undergone stem cell transplantation is a Participant_Condition, SCT is a Participant_Condition, vaccine response is a Outcome_Physical, levels of influenza hemagglutination - inhibition ( HAI ) antibodies is a Outcome_Physical, IgG antibodies is a Outcome_Physical, ELISA is a Outcome_Physical, antibody response is a Outcome_Physical, influenza A is a Outcome_Physical, SCT patients is a Participant_Condition, influenza B vaccine is a Intervention_Pharmacological	2670_task1	Sentence: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent . Instructions: please typing these entity words according to sentence: Granulocyte - macrophage colony - stimulating factor, influenza vaccination, stem cell transplant, granulocyte - macrophage colony - stimulating factor ( GM - CSF ), serological response, 117, undergone stem cell transplantation, SCT, vaccine response, levels of influenza hemagglutination - inhibition ( HAI ) antibodies, IgG antibodies, ELISA, antibody response, influenza A, SCT patients, influenza B vaccine Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent .	[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "as", "immunomodulating", "factor", "together", "with", "influenza", "vaccination", "in", "stem", "cell", "transplant", "patients", ".", "The", "effect", "of", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "on", "the", "serological", "response", "at", "influenza", "vaccination", "was", "studied", "in", "117", "patients", "who", "had", "undergone", "stem", "cell", "transplantation", "(", "SCT", ")", ".", "The", "vaccine", "response", "was", "evaluated", "as", "significant", "increases", "in", "levels", "of", "influenza", "hemagglutination", "-", "inhibition", "(", "HAI", ")", "antibodies", "and", "of", "IgG", "antibodies", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "There", "was", "no", "difference", "in", "antibody", "response", "to", "either", "influenza", "A", "or", "B", "in", "64", "patients", "who", "received", "GM", "-", "CSF", "at", "vaccination", ",", "compared", "with", "the", "53", "who", "did", "not", ".", "In", "the", "subgroup", "of", "allogeneic", "SCT", "patients", ",", "HAI", "showed", "that", "the", "response", "rate", "to", "the", "influenza", "B", "vaccine", "was", "significantly", "higher", "in", "the", "treatment", "group", "(", "P", "<", ".05", ")", ".", "ELISA", "showed", "that", "autologous", "SCT", "patients", "with", "breast", "cancer", "who", "received", "GM", "-", "CSF", "had", "a", "better", "response", "to", "influenza", "A", "(", "P", "<", ".05", ")", "and", "B", "(", "P", "<", ".01", ")", ".", "At", "early", "vaccination", ",", "4", "-", "12", "months", "after", "stem", "cell", "transplantation", ",", "these", "responses", "were", "more", "pronounced", ".", "GM", "-", "CSF", "appears", "to", "improve", "the", "response", "to", "influenza", "vaccination", "in", "some", "groups", "of", "SCT", "patients", ",", "but", "only", "to", "a", "limited", "extent", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Granulocyte - macrophage colony - stimulating factor, influenza vaccination, stem cell transplant, granulocyte - macrophage colony - stimulating factor ( GM - CSF ), serological response, 117, undergone stem cell transplantation, SCT, vaccine response, levels of influenza hemagglutination - inhibition ( HAI ) antibodies, IgG antibodies, ELISA, antibody response, influenza A, SCT patients, influenza B vaccine	2670_task2	Sentence: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent .	[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "as", "immunomodulating", "factor", "together", "with", "influenza", "vaccination", "in", "stem", "cell", "transplant", "patients", ".", "The", "effect", "of", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "on", "the", "serological", "response", "at", "influenza", "vaccination", "was", "studied", "in", "117", "patients", "who", "had", "undergone", "stem", "cell", "transplantation", "(", "SCT", ")", ".", "The", "vaccine", "response", "was", "evaluated", "as", "significant", "increases", "in", "levels", "of", "influenza", "hemagglutination", "-", "inhibition", "(", "HAI", ")", "antibodies", "and", "of", "IgG", "antibodies", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "There", "was", "no", "difference", "in", "antibody", "response", "to", "either", "influenza", "A", "or", "B", "in", "64", "patients", "who", "received", "GM", "-", "CSF", "at", "vaccination", ",", "compared", "with", "the", "53", "who", "did", "not", ".", "In", "the", "subgroup", "of", "allogeneic", "SCT", "patients", ",", "HAI", "showed", "that", "the", "response", "rate", "to", "the", "influenza", "B", "vaccine", "was", "significantly", "higher", "in", "the", "treatment", "group", "(", "P", "<", ".05", ")", ".", "ELISA", "showed", "that", "autologous", "SCT", "patients", "with", "breast", "cancer", "who", "received", "GM", "-", "CSF", "had", "a", "better", "response", "to", "influenza", "A", "(", "P", "<", ".05", ")", "and", "B", "(", "P", "<", ".01", ")", ".", "At", "early", "vaccination", ",", "4", "-", "12", "months", "after", "stem", "cell", "transplantation", ",", "these", "responses", "were", "more", "pronounced", ".", "GM", "-", "CSF", "appears", "to", "improve", "the", "response", "to", "influenza", "vaccination", "in", "some", "groups", "of", "SCT", "patients", ",", "but", "only", "to", "a", "limited", "extent", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
LDL is a GENE-N, Cholesterol is a CHEMICAL, low - density lipoprotein is a GENE-N, cholesterol is a CHEMICAL, LDL is a GENE-N, HMG - CoA reductase is a GENE-Y, LDL is a GENE-N, LDL is a GENE-N, LDL is a GENE-N, ezetimibe is a CHEMICAL, bile acid is a CHEMICAL, fibrates is a CHEMICAL, LDL is a GENE-N, LDL is a GENE-N	32226_task0	Sentence: LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "B-GENE-N", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.	[ "LDL", "Cholesterol", "Goals", "in", "High", "-", "Risk", "Patients", ":", "How", "Low", "Do", "We", "Go", "and", "How", "Do", "We", "Get", "There", "?", "\n", "It", "is", "widely", "recognised", "that", "low", "-", "density", "lipoprotein", "cholesterol", "(", "LDL", "-", "C", ")", "is", "one", "of", "the", "most", "important", "and", "modifiable", "risk", "factors", "for", "cardiovascular", "disease", "(", "CVD", ")", ".", "Statins", "(", "HMG", "-", "CoA", "reductase", "inhibitors", ")", "have", "consistently", "been", "shown", "to", "decrease", "both", "LDL", "-", "C", "and", "CVD", "risk", "in", "almost", "all", "patient", "categories", ",", "with", "the", "exception", "of", "heart", "and", "kidney", "failure", "as", "well", "as", "advanced", "aortic", "stenosis", ".", "As", "a", "consequence", ",", "statins", "have", "become", "the", "cornerstone", "in", "current", "prevention", "guidelines", ".", "In", "patients", "who", "do", "not", "reach", "the", "LDL", "-", "C", "target", ",", "combination", "therapy", "with", "additional", "LDL", "-", "C", "lowering", "drugs", "(", "e.g", ".", "ezetimibe", ",", "bile", "acid", "sequestrants", "or", "fibrates", ")", "should", "be", "considered", ".", "Guidelines", "provide", "different", "LDL", "-", "C", "levels", "to", "strive", "for", ",", "depending", "on", "the", "CVD", "risk", ".", "In", "this", "review", ",", "we", "describe", "the", "rationale", "for", "these", "LDL", "-", "C", "targets", "and", "how", "these", "goals", "might", "be", "reached", "by", "current", "and", "future", "therapies", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
LDL is a GENE-N, Cholesterol is a CHEMICAL, low - density lipoprotein is a GENE-N, cholesterol is a CHEMICAL, LDL is a GENE-N, HMG - CoA reductase is a GENE-Y, LDL is a GENE-N, LDL is a GENE-N, LDL is a GENE-N, ezetimibe is a CHEMICAL, bile acid is a CHEMICAL, fibrates is a CHEMICAL, LDL is a GENE-N, LDL is a GENE-N	32226_task1	Sentence: LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies. Instructions: please typing these entity words according to sentence: LDL, Cholesterol, low - density lipoprotein, cholesterol, LDL, HMG - CoA reductase, LDL, LDL, LDL, ezetimibe, bile acid, fibrates, LDL, LDL Options: GENE-Y, GENE-N, CHEMICAL	[ "B-GENE-N", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.	[ "LDL", "Cholesterol", "Goals", "in", "High", "-", "Risk", "Patients", ":", "How", "Low", "Do", "We", "Go", "and", "How", "Do", "We", "Get", "There", "?", "\n", "It", "is", "widely", "recognised", "that", "low", "-", "density", "lipoprotein", "cholesterol", "(", "LDL", "-", "C", ")", "is", "one", "of", "the", "most", "important", "and", "modifiable", "risk", "factors", "for", "cardiovascular", "disease", "(", "CVD", ")", ".", "Statins", "(", "HMG", "-", "CoA", "reductase", "inhibitors", ")", "have", "consistently", "been", "shown", "to", "decrease", "both", "LDL", "-", "C", "and", "CVD", "risk", "in", "almost", "all", "patient", "categories", ",", "with", "the", "exception", "of", "heart", "and", "kidney", "failure", "as", "well", "as", "advanced", "aortic", "stenosis", ".", "As", "a", "consequence", ",", "statins", "have", "become", "the", "cornerstone", "in", "current", "prevention", "guidelines", ".", "In", "patients", "who", "do", "not", "reach", "the", "LDL", "-", "C", "target", ",", "combination", "therapy", "with", "additional", "LDL", "-", "C", "lowering", "drugs", "(", "e.g", ".", "ezetimibe", ",", "bile", "acid", "sequestrants", "or", "fibrates", ")", "should", "be", "considered", ".", "Guidelines", "provide", "different", "LDL", "-", "C", "levels", "to", "strive", "for", ",", "depending", "on", "the", "CVD", "risk", ".", "In", "this", "review", ",", "we", "describe", "the", "rationale", "for", "these", "LDL", "-", "C", "targets", "and", "how", "these", "goals", "might", "be", "reached", "by", "current", "and", "future", "therapies", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
LDL, Cholesterol, low - density lipoprotein, cholesterol, LDL, HMG - CoA reductase, LDL, LDL, LDL, ezetimibe, bile acid, fibrates, LDL, LDL	32226_task2	Sentence: LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies. Instructions: please extract entity words from the input sentence	[ "B-GENE-N", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.	[ "LDL", "Cholesterol", "Goals", "in", "High", "-", "Risk", "Patients", ":", "How", "Low", "Do", "We", "Go", "and", "How", "Do", "We", "Get", "There", "?", "\n", "It", "is", "widely", "recognised", "that", "low", "-", "density", "lipoprotein", "cholesterol", "(", "LDL", "-", "C", ")", "is", "one", "of", "the", "most", "important", "and", "modifiable", "risk", "factors", "for", "cardiovascular", "disease", "(", "CVD", ")", ".", "Statins", "(", "HMG", "-", "CoA", "reductase", "inhibitors", ")", "have", "consistently", "been", "shown", "to", "decrease", "both", "LDL", "-", "C", "and", "CVD", "risk", "in", "almost", "all", "patient", "categories", ",", "with", "the", "exception", "of", "heart", "and", "kidney", "failure", "as", "well", "as", "advanced", "aortic", "stenosis", ".", "As", "a", "consequence", ",", "statins", "have", "become", "the", "cornerstone", "in", "current", "prevention", "guidelines", ".", "In", "patients", "who", "do", "not", "reach", "the", "LDL", "-", "C", "target", ",", "combination", "therapy", "with", "additional", "LDL", "-", "C", "lowering", "drugs", "(", "e.g", ".", "ezetimibe", ",", "bile", "acid", "sequestrants", "or", "fibrates", ")", "should", "be", "considered", ".", "Guidelines", "provide", "different", "LDL", "-", "C", "levels", "to", "strive", "for", ",", "depending", "on", "the", "CVD", "risk", ".", "In", "this", "review", ",", "we", "describe", "the", "rationale", "for", "these", "LDL", "-", "C", "targets", "and", "how", "these", "goals", "might", "be", "reached", "by", "current", "and", "future", "therapies", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
alpha - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, cadherin is a Gene/protein/RNA	846_task0	Sentence: Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.	[ "Transfection", "of", "alpha", "-", "catenin", "-", "deficient", "colon", "carcinoma", "cells", "recruited", "E", "-", "cadherin", "and", "beta", "-", "catenin", "to", "cell", "-", "cell", "contacts", "and", "functional", "cadherin", "-", "mediated", "cell", "-", "cell", "adhesion", "was", "restored", "in", "this", "way", "." ]	[ "Gene/protein/RNA" ]
alpha - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, cadherin is a Gene/protein/RNA	846_task1	Sentence: Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way. Instructions: please typing these entity words according to sentence: alpha - catenin, E - cadherin, beta - catenin, cadherin Options: Gene/protein/RNA	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.	[ "Transfection", "of", "alpha", "-", "catenin", "-", "deficient", "colon", "carcinoma", "cells", "recruited", "E", "-", "cadherin", "and", "beta", "-", "catenin", "to", "cell", "-", "cell", "contacts", "and", "functional", "cadherin", "-", "mediated", "cell", "-", "cell", "adhesion", "was", "restored", "in", "this", "way", "." ]	[ "Gene/protein/RNA" ]
alpha - catenin, E - cadherin, beta - catenin, cadherin	846_task2	Sentence: Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.	[ "Transfection", "of", "alpha", "-", "catenin", "-", "deficient", "colon", "carcinoma", "cells", "recruited", "E", "-", "cadherin", "and", "beta", "-", "catenin", "to", "cell", "-", "cell", "contacts", "and", "functional", "cadherin", "-", "mediated", "cell", "-", "cell", "adhesion", "was", "restored", "in", "this", "way", "." ]	[ "Gene/protein/RNA" ]
implantation is an umlsterm, eyeball is an umlsterm, United States is an umlsterm, hydroxyapatite is an umlsterm, orbital implant is an umlsterm, Germany is an umlsterm, aim is an umlsterm, postoperative complications is an umlsterm, cosmetic is an umlsterm	DerOpthalmologe.00970091.eng.abstr_task0	Sentence: Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results .	[ "Background", ":", "Since", "its", "first", "implantation", "as", "an", "eyeball", "replacement", "in", "the", "United", "States", "in", "1985", ",", "hydroxyapatite", "has", "been", "rarely", "used", "as", "an", "orbital", "implant", "in", "Germany", ".", "The", "aim", "of", "the", "study", "was", "to", "collect", "data", "on", "long", "-", "term", "tolerance", ",", "postoperative", "complications", "and", "the", "cosmetic", "end", "results", "." ]	[ "umlsterm" ]
implantation is an umlsterm, eyeball is an umlsterm, United States is an umlsterm, hydroxyapatite is an umlsterm, orbital implant is an umlsterm, Germany is an umlsterm, aim is an umlsterm, postoperative complications is an umlsterm, cosmetic is an umlsterm	DerOpthalmologe.00970091.eng.abstr_task1	Sentence: Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results . Instructions: please typing these entity words according to sentence: implantation, eyeball, United States, hydroxyapatite, orbital implant, Germany, aim, postoperative complications, cosmetic Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results .	[ "Background", ":", "Since", "its", "first", "implantation", "as", "an", "eyeball", "replacement", "in", "the", "United", "States", "in", "1985", ",", "hydroxyapatite", "has", "been", "rarely", "used", "as", "an", "orbital", "implant", "in", "Germany", ".", "The", "aim", "of", "the", "study", "was", "to", "collect", "data", "on", "long", "-", "term", "tolerance", ",", "postoperative", "complications", "and", "the", "cosmetic", "end", "results", "." ]	[ "umlsterm" ]
implantation, eyeball, United States, hydroxyapatite, orbital implant, Germany, aim, postoperative complications, cosmetic	DerOpthalmologe.00970091.eng.abstr_task2	Sentence: Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results .	[ "Background", ":", "Since", "its", "first", "implantation", "as", "an", "eyeball", "replacement", "in", "the", "United", "States", "in", "1985", ",", "hydroxyapatite", "has", "been", "rarely", "used", "as", "an", "orbital", "implant", "in", "Germany", ".", "The", "aim", "of", "the", "study", "was", "to", "collect", "data", "on", "long", "-", "term", "tolerance", ",", "postoperative", "complications", "and", "the", "cosmetic", "end", "results", "." ]	[ "umlsterm" ]

Gram - positive, Actinobacteria, Corynebacterium casei, C. variabile, cheese from dairy A, Brachybacterium alimentarum, Brevibacterium, cheeses from the farmhouses, dairies, B. permense, cheese from dairy A, B. linens, cheese from dairy B, B. aurantiacum, dairy, Brevibacterium spp ., dairy, coagulase negative, staphylococci, Staphylococcus saprophyticus, cheeses from dairies B, Staph . equorum, cheeses from dairies C, Gram - negative, Proteus vulgaris, Alcaligenes faecalis, dairy, surface yeast microbiota, yeast surface microbiota, farmhouse cheeses, cheese, industrial dairy, dairy, cheese from dairy A, Yarrowia lipolytica, Scopulariopsis brevicaulis, yeast microbiota, cheese from dairy B, Geotrichum spp ., Kluyveromyces marxianus, Debaryomyces hansenii, cheese from dairy C, D. hansenii, Geothrichum spp ., cheese from dairy D, D. hansenii

101_task2

Sentence: Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O" ]

Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii.

[ "Most", "species", "were", "Gram", "-", "positive", "Actinobacteria", "with", "Corynebacterium", "casei", "and", "/", "or", "C.", "variabile", "as", "the", "predominant", "(", "Table", "4", ")", ".", "Additionally", ",", "the", "cheese", "from", "dairy", "A", "was", "dominated", "by", "high", "of", "numbers", "of", "Brachybacterium", "alimentarum", ".", "Various", "Brevibacterium", "species", "were", "found", "on", "the", "cheeses", "from", "the", "farmhouses", "(", "dairies", "A", ",", "B", "and", "C", ")", ".", "B.", "permense", "was", "found", "on", "the", "cheese", "from", "dairy", "A", ",", "B.", "linens", "was", "found", "on", "the", "cheese", "from", "dairy", "B", "and", "B.", "aurantiacum", "was", "found", "on", "the", "cheese", "from", "dairy", "C.", "Brevibacterium", " ", "spp", ".", "could", "not", "be", "isolated", "on", "the", "cheese", "from", "dairy", "D.", "Furthermore", ",", "a", " ", "number", "of", "coagulase", "negative", "staphylococci", "were", "found", ",", "i.e", ".", ",", "Staphylococcus", "saprophyticus", "on", "the", "cheeses", "from", "dairies", "B", "and", "D", ",", "and", "Staph", ".", "equorum", "on", "the", "cheeses", "from", "dairies", "C", "and", "D.", "Finally", ",", "a", "number", "of", "Gram", "-", "negative", "bacteria", "species", "including", "Proteus", "vulgaris", "and", "Alcaligenes", "faecalis", "was", "found", "on", "the", "cheese", "from", "dairy", "C.Figure", "3", " ", "shows", "the", "grouping", "of", "the", "surface", "yeast", "microbiota", ".", "The", "yeast", "surface", " ", "microbiota", "on", "the", "three", "farmhouse", "cheeses", "consisted", "of", "two", "to", "four", " ", "groups", ",", "whereas", "the", "cheese", "produced", "at", "the", "industrial", "dairy", "(", "dairy", "D", ")", " ", "consisted", "of", "only", "one", "single", "group", ".", "The", "cheese", "from", "dairy", "A", "was", "equally", " ", "dominated", "by", "Yarrowia", "lipolytica", "and", "Scopulariopsis", "brevicaulis", ".", "The", "yeast", "microbiota", "on", "cheese", "from", "dairy", "B", "was", "primarily", "dominated", "by", "Geotrichum", "spp", ".", ",", "however", ",", "Kluyveromyces", "marxianus", "and", "Debaryomyces", "hansenii", "were", "additionally", "found", "in", "minor", "amounts", ".", "The", "cheese", "from", "dairy", "C", "was", "dominated", "by", "D.", "hansenii", "followed", "by", "a", "minor", "group", "of", "Geothrichum", "spp", ".", "Finally", ",", "the", "cheese", "from", "dairy", "D", "was", "entirely", "dominated", "by", "D.", "hansenii", "." ]

[ "Microorganism", "Habitat", "Phenotype" ]

histone is a Protein

42_task0

Sentence: The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome.

[ "The", "acetylation", "state", "of", "human", "fetal", "hemoglobin", "modulates", "the", "strength", "of", "its", "subunit", "interactions", ":", "long", "-", "range", "effects", "and", "implications", "for", "histone", "interactions", "in", "the", "nucleosome", ".", "\n", "The", "source", "of", "the", "70-fold", "increased", "tetramer", "strength", "of", "liganded", "fetal", "hemoglobin", "relative", "to", "that", "of", "adult", "hemoglobin", "between", "pH", "6.0", "and", "7.5", "reported", "earlier", "[", "Dumoulin", "et", "al", ".", "(", "1997", ")", "J.", "Biol", ".", "Chem", ".", "272", ",", "31326", "]", "has", "been", "identified", "as", "the", "N", "-", "terminal", "Gly", "residue", "of", "the", "gamma", "-", "chain", ",", "which", "is", "replaced", "by", "Val", "in", "adult", "hemoglobin", ".", "This", "was", "revealed", "by", "extending", "the", "study", "of", "the", "pH", "dependence", "of", "the", "tetramer", "-", "dimer", "equilibrium", "of", "these", "hemoglobins", "into", "the", "alkaline", "range", "as", "far", "as", "pH", "9", ".", "From", "pH", "7.5", "to", "9.0", ",", "the", "70-fold", "difference", "in", "the", "association", "equilibrium", "constant", "between", "hemoglobins", "F", "and", "A", "lessened", "progressively", ".", "This", "behavior", "was", "attributed", "to", "the", "difference", "in", "the", "pK(a", ")", "8.1", "of", "Gly-1(gamma", ")", "compared", "to", "the", "pK(a", ")", "7.1", "value", "of", "Val-1(beta", ")", "of", "hemoglobins", "F", "and", "A", ",", "respectively", ".", "Evidence", "for", "this", "conclusion", "was", "obtained", "by", "demonstrating", "that", "natural", "hemoglobin", "F(1", ")", ",", "which", "is", "specifically", "acetylated", "at", "Gly-1(gamma", ")", "and", "hence", "unable", "to", "be", "protonated", ",", "behaves", "like", "HbA", "and", "not", "HbF", "in", "its", "tetramer", "-", "dimer", "association", "properties", "over", "the", "pH", "range", "studied", ".", "An", "increased", "degree", "of", "protonation", "of", "the", "gamma", "-", "chain", "N", "-", "terminus", "of", "hemoglobin", "F", "from", "pH", "9.0", "to", "8.0", "is", "therefore", "suggested", "as", "responsible", "for", "its", "increased", "tetramer", "strength", "representing", "an", "example", "of", "transmission", "of", "a", "signal", "from", "its", "positively", "charged", "N", "-", "terminal", "tail", "to", "the", "distant", "subunit", "allosteric", "interface", "where", "the", "equilibrium", "constant", "is", "measured", ".", "An", "analogy", "is", "made", "between", "the", "effects", "of", "acetylation", "of", "the", "fetal", "hemoglobin", "tetramer", "on", "the", "strength", "of", "its", "subunit", "interactions", "and", "acetylation", "of", "some", "internal", "Lys", "residues", "within", "the", "N", "-", "terminal", "segments", "of", "the", "histone", "octamer", "around", "which", "DNA", "is", "wrapped", "in", "the", "nucleosome", ".", "\n" ]

[ "Protein" ]

histone is a Protein

42_task1

Sentence: The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome. Instructions: please typing these entity words according to sentence: histone Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome.

[ "The", "acetylation", "state", "of", "human", "fetal", "hemoglobin", "modulates", "the", "strength", "of", "its", "subunit", "interactions", ":", "long", "-", "range", "effects", "and", "implications", "for", "histone", "interactions", "in", "the", "nucleosome", ".", "\n", "The", "source", "of", "the", "70-fold", "increased", "tetramer", "strength", "of", "liganded", "fetal", "hemoglobin", "relative", "to", "that", "of", "adult", "hemoglobin", "between", "pH", "6.0", "and", "7.5", "reported", "earlier", "[", "Dumoulin", "et", "al", ".", "(", "1997", ")", "J.", "Biol", ".", "Chem", ".", "272", ",", "31326", "]", "has", "been", "identified", "as", "the", "N", "-", "terminal", "Gly", "residue", "of", "the", "gamma", "-", "chain", ",", "which", "is", "replaced", "by", "Val", "in", "adult", "hemoglobin", ".", "This", "was", "revealed", "by", "extending", "the", "study", "of", "the", "pH", "dependence", "of", "the", "tetramer", "-", "dimer", "equilibrium", "of", "these", "hemoglobins", "into", "the", "alkaline", "range", "as", "far", "as", "pH", "9", ".", "From", "pH", "7.5", "to", "9.0", ",", "the", "70-fold", "difference", "in", "the", "association", "equilibrium", "constant", "between", "hemoglobins", "F", "and", "A", "lessened", "progressively", ".", "This", "behavior", "was", "attributed", "to", "the", "difference", "in", "the", "pK(a", ")", "8.1", "of", "Gly-1(gamma", ")", "compared", "to", "the", "pK(a", ")", "7.1", "value", "of", "Val-1(beta", ")", "of", "hemoglobins", "F", "and", "A", ",", "respectively", ".", "Evidence", "for", "this", "conclusion", "was", "obtained", "by", "demonstrating", "that", "natural", "hemoglobin", "F(1", ")", ",", "which", "is", "specifically", "acetylated", "at", "Gly-1(gamma", ")", "and", "hence", "unable", "to", "be", "protonated", ",", "behaves", "like", "HbA", "and", "not", "HbF", "in", "its", "tetramer", "-", "dimer", "association", "properties", "over", "the", "pH", "range", "studied", ".", "An", "increased", "degree", "of", "protonation", "of", "the", "gamma", "-", "chain", "N", "-", "terminus", "of", "hemoglobin", "F", "from", "pH", "9.0", "to", "8.0", "is", "therefore", "suggested", "as", "responsible", "for", "its", "increased", "tetramer", "strength", "representing", "an", "example", "of", "transmission", "of", "a", "signal", "from", "its", "positively", "charged", "N", "-", "terminal", "tail", "to", "the", "distant", "subunit", "allosteric", "interface", "where", "the", "equilibrium", "constant", "is", "measured", ".", "An", "analogy", "is", "made", "between", "the", "effects", "of", "acetylation", "of", "the", "fetal", "hemoglobin", "tetramer", "on", "the", "strength", "of", "its", "subunit", "interactions", "and", "acetylation", "of", "some", "internal", "Lys", "residues", "within", "the", "N", "-", "terminal", "segments", "of", "the", "histone", "octamer", "around", "which", "DNA", "is", "wrapped", "in", "the", "nucleosome", ".", "\n" ]

[ "Protein" ]

histone

42_task2

Sentence: The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The acetylation state of human fetal hemoglobin modulates the strength of its subunit interactions: long-range effects and implications for histone interactions in the nucleosome. The source of the 70-fold increased tetramer strength of liganded fetal hemoglobin relative to that of adult hemoglobin between pH 6.0 and 7.5 reported earlier [Dumoulin et al. (1997) J. Biol. Chem. 272, 31326] has been identified as the N-terminal Gly residue of the gamma-chain, which is replaced by Val in adult hemoglobin. This was revealed by extending the study of the pH dependence of the tetramer-dimer equilibrium of these hemoglobins into the alkaline range as far as pH 9. From pH 7.5 to 9.0, the 70-fold difference in the association equilibrium constant between hemoglobins F and A lessened progressively. This behavior was attributed to the difference in the pK(a) 8.1 of Gly-1(gamma) compared to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively. Evidence for this conclusion was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly-1(gamma) and hence unable to be protonated, behaves like HbA and not HbF in its tetramer-dimer association properties over the pH range studied. An increased degree of protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested as responsible for its increased tetramer strength representing an example of transmission of a signal from its positively charged N-terminal tail to the distant subunit allosteric interface where the equilibrium constant is measured. An analogy is made between the effects of acetylation of the fetal hemoglobin tetramer on the strength of its subunit interactions and acetylation of some internal Lys residues within the N-terminal segments of the histone octamer around which DNA is wrapped in the nucleosome.

[ "The", "acetylation", "state", "of", "human", "fetal", "hemoglobin", "modulates", "the", "strength", "of", "its", "subunit", "interactions", ":", "long", "-", "range", "effects", "and", "implications", "for", "histone", "interactions", "in", "the", "nucleosome", ".", "\n", "The", "source", "of", "the", "70-fold", "increased", "tetramer", "strength", "of", "liganded", "fetal", "hemoglobin", "relative", "to", "that", "of", "adult", "hemoglobin", "between", "pH", "6.0", "and", "7.5", "reported", "earlier", "[", "Dumoulin", "et", "al", ".", "(", "1997", ")", "J.", "Biol", ".", "Chem", ".", "272", ",", "31326", "]", "has", "been", "identified", "as", "the", "N", "-", "terminal", "Gly", "residue", "of", "the", "gamma", "-", "chain", ",", "which", "is", "replaced", "by", "Val", "in", "adult", "hemoglobin", ".", "This", "was", "revealed", "by", "extending", "the", "study", "of", "the", "pH", "dependence", "of", "the", "tetramer", "-", "dimer", "equilibrium", "of", "these", "hemoglobins", "into", "the", "alkaline", "range", "as", "far", "as", "pH", "9", ".", "From", "pH", "7.5", "to", "9.0", ",", "the", "70-fold", "difference", "in", "the", "association", "equilibrium", "constant", "between", "hemoglobins", "F", "and", "A", "lessened", "progressively", ".", "This", "behavior", "was", "attributed", "to", "the", "difference", "in", "the", "pK(a", ")", "8.1", "of", "Gly-1(gamma", ")", "compared", "to", "the", "pK(a", ")", "7.1", "value", "of", "Val-1(beta", ")", "of", "hemoglobins", "F", "and", "A", ",", "respectively", ".", "Evidence", "for", "this", "conclusion", "was", "obtained", "by", "demonstrating", "that", "natural", "hemoglobin", "F(1", ")", ",", "which", "is", "specifically", "acetylated", "at", "Gly-1(gamma", ")", "and", "hence", "unable", "to", "be", "protonated", ",", "behaves", "like", "HbA", "and", "not", "HbF", "in", "its", "tetramer", "-", "dimer", "association", "properties", "over", "the", "pH", "range", "studied", ".", "An", "increased", "degree", "of", "protonation", "of", "the", "gamma", "-", "chain", "N", "-", "terminus", "of", "hemoglobin", "F", "from", "pH", "9.0", "to", "8.0", "is", "therefore", "suggested", "as", "responsible", "for", "its", "increased", "tetramer", "strength", "representing", "an", "example", "of", "transmission", "of", "a", "signal", "from", "its", "positively", "charged", "N", "-", "terminal", "tail", "to", "the", "distant", "subunit", "allosteric", "interface", "where", "the", "equilibrium", "constant", "is", "measured", ".", "An", "analogy", "is", "made", "between", "the", "effects", "of", "acetylation", "of", "the", "fetal", "hemoglobin", "tetramer", "on", "the", "strength", "of", "its", "subunit", "interactions", "and", "acetylation", "of", "some", "internal", "Lys", "residues", "within", "the", "N", "-", "terminal", "segments", "of", "the", "histone", "octamer", "around", "which", "DNA", "is", "wrapped", "in", "the", "nucleosome", ".", "\n" ]

[ "Protein" ]

acute ischaemic stroke is a Participant_Condition, NMDA antagonist AR - R15896AR is a Intervention_Pharmacological, safety and tolerability is a Outcome_Other, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR is a Intervention_Pharmacological, animal models of ischaemic stroke is a Participant_Condition, placebo - controlled is a Intervention_Control, Two loading doses of 3.5 mg / kg of AR - R15896AR is a Intervention_Pharmacological, safety , tolerability and pharmacokinetics . is a Outcome_Other, Barthel Index ( BI ) is a Outcome_Other, NIH Stroke Scale ( NIHSS ) is a Outcome_Other, 103 patients is a Participant_Sample-size, Mortality is a Outcome_Mortality, Serious adverse events is a Outcome_Adverse-effects, side effects is a Outcome_Adverse-effects, vomiting is a Outcome_Adverse-effects, nausea is a Outcome_Adverse-effects, fever is a Outcome_Adverse-effects, agitation is a Outcome_Adverse-effects, dizziness is a Outcome_Adverse-effects, hallucinations is a Outcome_Adverse-effects, plasma concentrations of AR - R15896AR is a Outcome_Physical, high plasma levels is a Outcome_Physical

9104_task0

Sentence: Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population .

[ "Treatment", "of", "acute", "ischaemic", "stroke", "with", "the", "low", "-", "affinity", ",", "use", "-", "dependent", "NMDA", "antagonist", "AR", "-", "R15896AR", ".", "A", "safety", "and", "tolerability", "study", ".", "BACKGROUND", "AND", "PURPOSE", "A", "low", "-", "affinity", ",", "use", "-", "dependent", "N", "-", "Methyl", "-", "D", "-", "Aspartate", "(", "NMDA", ")", "antagonist", "AR", "-", "R15896AR", "has", "neuroprotective", "properties", "in", "animal", "models", "of", "ischaemic", "stroke", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "tolerability", "of", "a", "new", "and", "higher", "dosage", "regimen", "that", "would", "enable", "acute", "stroke", "patients", "to", "achieve", "and", "maintain", "neuroprotective", "plasma", "concentrations", ".", "METHODS", "A", "randomised", ",", "multi", "-", "centre", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "carried", "out", "at", "19", "centres", "in", "France", ",", "Germany", "and", "the", "Netherlands", "in", "patients", "with", "a", "clinical", "diagnosis", "of", "acute", "ischaemic", "stroke", ",", "and", "onset", "of", "symptoms", "within", "12", "hours", "before", "start", "of", "study", "drug", "administration", ".", "Two", "loading", "doses", "of", "3.5", "mg", "/", "kg", "of", "AR", "-", "R15896AR", "over", "60", "minutes", ",", "followed", "by", "a", "2.5", "mg", "/", "kg", "infusion", "over", "the", "next", "120", "minutes", "were", "given", ".", "Eight", "hours", "after", "the", "start", "of", "the", "loading", "dose", "infusion", ",", "the", "first", "maintenance", "dose", "(", "120", "mg", ")", "was", "administered", "over", "60", "minutes", ".", "Eight", "further", "maintenance", "infusions", "were", "administered", "at", "intervals", "of", "8", "hours", "over", "a", "total", "treatment", "period", "of", "3", "days", ".", "Main", "variables", "were", "safety", ",", "tolerability", "and", "pharmacokinetics", ".", "Follow", "-", "up", "assessments", "also", "included", "the", "Barthel", "Index", "(", "BI", ")", "and", "the", "NIH", "Stroke", "Scale", "(", "NIHSS", ")", "at", "4", "-", "7", "days", "after", "the", "end", "of", "the", "last", "infusion", "and", "at", "30", "days", "after", "the", "onset", "of", "stroke", ".", "RESULTS", "103", "patients", "with", "acute", "ischaemic", "stroke", "were", "randomised", "to", "either", "treatment", "with", "AR", "-", "R15896AR", "(", "70", "patients", ")", "or", "placebo", "(", "33", "patients", ")", ".", "Mortality", "was", "not", "significantly", "different", "in", "the", "AR", "-", "R15896AR", "group", "compared", "with", "the", "placebo", "group", "(", "10", "%", "vs", ".", "6", "%", ")", ".", "Serious", "adverse", "events", "during", "treatment", "due", "to", "psychiatric", "conditions", "were", "associated", "with", "AR", "-", "R15896AR", "(", "3", "vs", ".", "0", ")", ".", "Other", "side", "effects", "were", "more", "common", "in", "the", "group", "treated", "with", "AR", "-", "R15896AR", ":", "vomiting", "(", "29", "%", "vs", ".", "9", "%", ")", ",", "nausea", "(", "23", "%", "vs", ".", "12", "%", ")", ",", "fever", "(", "17", "%", "vs", ".", "12", "%", ")", ",", "agitation", "(", "7", "%", "vs", ".", "3", "%", ")", ",", "dizziness", "(", "7", "%", "vs", ".", "0", "%", ")", ",", "and", "hallucinations", "(", "6", "%", "vs", ".", "0", "%", ")", ".", "No", "significant", "difference", "between", "the", "two", "groups", "(", "with", "respect", "to", "the", "proportions", "of", "patients", "with", "favourable", "outcome", ")", "was", "detected", "in", "either", "the", "analysis", "of", "the", "BI", "or", "the", "NIHSS", ".", "Pharmacokinetic", "data", "showed", "that", "plasma", "concentrations", "of", "AR", "-", "R15896AR", "were", "in", "the", "expected", "neuroprotective", "range", ".", "CONCLUSION", "In", "most", "of", "the", "patients", "with", "acute", "stroke", "receiving", "AR", "-", "R15896AR", "the", "intended", "high", "plasma", "levels", "were", "reached", "within", "a", "short", "time", "period", ".", "However", ",", "active", "treatment", "produced", "more", "side", "effects", "than", "placebo", ",", "thus", "indicating", "safety", "concerns", "and", "tolerability", "issues", "for", "use", "in", "high", "doses", "in", "an", "acute", "stroke", "population", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Control", "Participant_Sample-size", "Outcome_Mortality" ]

acute ischaemic stroke is a Participant_Condition, NMDA antagonist AR - R15896AR is a Intervention_Pharmacological, safety and tolerability is a Outcome_Other, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR is a Intervention_Pharmacological, animal models of ischaemic stroke is a Participant_Condition, placebo - controlled is a Intervention_Control, Two loading doses of 3.5 mg / kg of AR - R15896AR is a Intervention_Pharmacological, safety , tolerability and pharmacokinetics . is a Outcome_Other, Barthel Index ( BI ) is a Outcome_Other, NIH Stroke Scale ( NIHSS ) is a Outcome_Other, 103 patients is a Participant_Sample-size, Mortality is a Outcome_Mortality, Serious adverse events is a Outcome_Adverse-effects, side effects is a Outcome_Adverse-effects, vomiting is a Outcome_Adverse-effects, nausea is a Outcome_Adverse-effects, fever is a Outcome_Adverse-effects, agitation is a Outcome_Adverse-effects, dizziness is a Outcome_Adverse-effects, hallucinations is a Outcome_Adverse-effects, plasma concentrations of AR - R15896AR is a Outcome_Physical, high plasma levels is a Outcome_Physical

9104_task1

Sentence: Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population . Instructions: please typing these entity words according to sentence: acute ischaemic stroke, NMDA antagonist AR - R15896AR, safety and tolerability, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR, animal models of ischaemic stroke, placebo - controlled, Two loading doses of 3.5 mg / kg of AR - R15896AR, safety , tolerability and pharmacokinetics ., Barthel Index ( BI ), NIH Stroke Scale ( NIHSS ), 103 patients, Mortality, Serious adverse events, side effects, vomiting, nausea, fever, agitation, dizziness, hallucinations, plasma concentrations of AR - R15896AR, high plasma levels Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population .

[ "Treatment", "of", "acute", "ischaemic", "stroke", "with", "the", "low", "-", "affinity", ",", "use", "-", "dependent", "NMDA", "antagonist", "AR", "-", "R15896AR", ".", "A", "safety", "and", "tolerability", "study", ".", "BACKGROUND", "AND", "PURPOSE", "A", "low", "-", "affinity", ",", "use", "-", "dependent", "N", "-", "Methyl", "-", "D", "-", "Aspartate", "(", "NMDA", ")", "antagonist", "AR", "-", "R15896AR", "has", "neuroprotective", "properties", "in", "animal", "models", "of", "ischaemic", "stroke", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "tolerability", "of", "a", "new", "and", "higher", "dosage", "regimen", "that", "would", "enable", "acute", "stroke", "patients", "to", "achieve", "and", "maintain", "neuroprotective", "plasma", "concentrations", ".", "METHODS", "A", "randomised", ",", "multi", "-", "centre", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "carried", "out", "at", "19", "centres", "in", "France", ",", "Germany", "and", "the", "Netherlands", "in", "patients", "with", "a", "clinical", "diagnosis", "of", "acute", "ischaemic", "stroke", ",", "and", "onset", "of", "symptoms", "within", "12", "hours", "before", "start", "of", "study", "drug", "administration", ".", "Two", "loading", "doses", "of", "3.5", "mg", "/", "kg", "of", "AR", "-", "R15896AR", "over", "60", "minutes", ",", "followed", "by", "a", "2.5", "mg", "/", "kg", "infusion", "over", "the", "next", "120", "minutes", "were", "given", ".", "Eight", "hours", "after", "the", "start", "of", "the", "loading", "dose", "infusion", ",", "the", "first", "maintenance", "dose", "(", "120", "mg", ")", "was", "administered", "over", "60", "minutes", ".", "Eight", "further", "maintenance", "infusions", "were", "administered", "at", "intervals", "of", "8", "hours", "over", "a", "total", "treatment", "period", "of", "3", "days", ".", "Main", "variables", "were", "safety", ",", "tolerability", "and", "pharmacokinetics", ".", "Follow", "-", "up", "assessments", "also", "included", "the", "Barthel", "Index", "(", "BI", ")", "and", "the", "NIH", "Stroke", "Scale", "(", "NIHSS", ")", "at", "4", "-", "7", "days", "after", "the", "end", "of", "the", "last", "infusion", "and", "at", "30", "days", "after", "the", "onset", "of", "stroke", ".", "RESULTS", "103", "patients", "with", "acute", "ischaemic", "stroke", "were", "randomised", "to", "either", "treatment", "with", "AR", "-", "R15896AR", "(", "70", "patients", ")", "or", "placebo", "(", "33", "patients", ")", ".", "Mortality", "was", "not", "significantly", "different", "in", "the", "AR", "-", "R15896AR", "group", "compared", "with", "the", "placebo", "group", "(", "10", "%", "vs", ".", "6", "%", ")", ".", "Serious", "adverse", "events", "during", "treatment", "due", "to", "psychiatric", "conditions", "were", "associated", "with", "AR", "-", "R15896AR", "(", "3", "vs", ".", "0", ")", ".", "Other", "side", "effects", "were", "more", "common", "in", "the", "group", "treated", "with", "AR", "-", "R15896AR", ":", "vomiting", "(", "29", "%", "vs", ".", "9", "%", ")", ",", "nausea", "(", "23", "%", "vs", ".", "12", "%", ")", ",", "fever", "(", "17", "%", "vs", ".", "12", "%", ")", ",", "agitation", "(", "7", "%", "vs", ".", "3", "%", ")", ",", "dizziness", "(", "7", "%", "vs", ".", "0", "%", ")", ",", "and", "hallucinations", "(", "6", "%", "vs", ".", "0", "%", ")", ".", "No", "significant", "difference", "between", "the", "two", "groups", "(", "with", "respect", "to", "the", "proportions", "of", "patients", "with", "favourable", "outcome", ")", "was", "detected", "in", "either", "the", "analysis", "of", "the", "BI", "or", "the", "NIHSS", ".", "Pharmacokinetic", "data", "showed", "that", "plasma", "concentrations", "of", "AR", "-", "R15896AR", "were", "in", "the", "expected", "neuroprotective", "range", ".", "CONCLUSION", "In", "most", "of", "the", "patients", "with", "acute", "stroke", "receiving", "AR", "-", "R15896AR", "the", "intended", "high", "plasma", "levels", "were", "reached", "within", "a", "short", "time", "period", ".", "However", ",", "active", "treatment", "produced", "more", "side", "effects", "than", "placebo", ",", "thus", "indicating", "safety", "concerns", "and", "tolerability", "issues", "for", "use", "in", "high", "doses", "in", "an", "acute", "stroke", "population", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Control", "Participant_Sample-size", "Outcome_Mortality" ]

acute ischaemic stroke, NMDA antagonist AR - R15896AR, safety and tolerability, N - Methyl - D - Aspartate ( NMDA ) antagonist AR - R15896AR, animal models of ischaemic stroke, placebo - controlled, Two loading doses of 3.5 mg / kg of AR - R15896AR, safety , tolerability and pharmacokinetics ., Barthel Index ( BI ), NIH Stroke Scale ( NIHSS ), 103 patients, Mortality, Serious adverse events, side effects, vomiting, nausea, fever, agitation, dizziness, hallucinations, plasma concentrations of AR - R15896AR, high plasma levels

9104_task2

Sentence: Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Treatment of acute ischaemic stroke with the low-affinity , use-dependent NMDA antagonist AR-R15896AR . A safety and tolerability study . BACKGROUND AND PURPOSE A low-affinity , use-dependent N-Methyl-D-Aspartate ( NMDA ) antagonist AR-R15896AR has neuroprotective properties in animal models of ischaemic stroke . The aim of the present study was to examine the safety and tolerability of a new and higher dosage regimen that would enable acute stroke patients to achieve and maintain neuroprotective plasma concentrations . METHODS A randomised , multi-centre , double-blind , placebo-controlled , parallel group study was carried out at 19 centres in France , Germany and the Netherlands in patients with a clinical diagnosis of acute ischaemic stroke , and onset of symptoms within 12 hours before start of study drug administration . Two loading doses of 3.5 mg/kg of AR-R15896AR over 60 minutes , followed by a 2.5 mg/kg infusion over the next 120 minutes were given . Eight hours after the start of the loading dose infusion , the first maintenance dose ( 120 mg ) was administered over 60 minutes . Eight further maintenance infusions were administered at intervals of 8 hours over a total treatment period of 3 days . Main variables were safety , tolerability and pharmacokinetics . Follow-up assessments also included the Barthel Index ( BI ) and the NIH Stroke Scale ( NIHSS ) at 4-7 days after the end of the last infusion and at 30 days after the onset of stroke . RESULTS 103 patients with acute ischaemic stroke were randomised to either treatment with AR-R15896AR ( 70 patients ) or placebo ( 33 patients ) . Mortality was not significantly different in the AR-R15896AR group compared with the placebo group ( 10 % vs. 6 % ) . Serious adverse events during treatment due to psychiatric conditions were associated with AR-R15896AR ( 3 vs. 0 ) . Other side effects were more common in the group treated with AR-R15896AR : vomiting ( 29 % vs. 9 % ) , nausea ( 23 % vs. 12 % ) , fever ( 17 % vs. 12 % ) , agitation ( 7 % vs. 3 % ) , dizziness ( 7 % vs. 0 % ) , and hallucinations ( 6 % vs. 0 % ) . No significant difference between the two groups ( with respect to the proportions of patients with favourable outcome ) was detected in either the analysis of the BI or the NIHSS . Pharmacokinetic data showed that plasma concentrations of AR-R15896AR were in the expected neuroprotective range . CONCLUSION In most of the patients with acute stroke receiving AR-R15896AR the intended high plasma levels were reached within a short time period . However , active treatment produced more side effects than placebo , thus indicating safety concerns and tolerability issues for use in high doses in an acute stroke population .

[ "Treatment", "of", "acute", "ischaemic", "stroke", "with", "the", "low", "-", "affinity", ",", "use", "-", "dependent", "NMDA", "antagonist", "AR", "-", "R15896AR", ".", "A", "safety", "and", "tolerability", "study", ".", "BACKGROUND", "AND", "PURPOSE", "A", "low", "-", "affinity", ",", "use", "-", "dependent", "N", "-", "Methyl", "-", "D", "-", "Aspartate", "(", "NMDA", ")", "antagonist", "AR", "-", "R15896AR", "has", "neuroprotective", "properties", "in", "animal", "models", "of", "ischaemic", "stroke", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "examine", "the", "safety", "and", "tolerability", "of", "a", "new", "and", "higher", "dosage", "regimen", "that", "would", "enable", "acute", "stroke", "patients", "to", "achieve", "and", "maintain", "neuroprotective", "plasma", "concentrations", ".", "METHODS", "A", "randomised", ",", "multi", "-", "centre", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "carried", "out", "at", "19", "centres", "in", "France", ",", "Germany", "and", "the", "Netherlands", "in", "patients", "with", "a", "clinical", "diagnosis", "of", "acute", "ischaemic", "stroke", ",", "and", "onset", "of", "symptoms", "within", "12", "hours", "before", "start", "of", "study", "drug", "administration", ".", "Two", "loading", "doses", "of", "3.5", "mg", "/", "kg", "of", "AR", "-", "R15896AR", "over", "60", "minutes", ",", "followed", "by", "a", "2.5", "mg", "/", "kg", "infusion", "over", "the", "next", "120", "minutes", "were", "given", ".", "Eight", "hours", "after", "the", "start", "of", "the", "loading", "dose", "infusion", ",", "the", "first", "maintenance", "dose", "(", "120", "mg", ")", "was", "administered", "over", "60", "minutes", ".", "Eight", "further", "maintenance", "infusions", "were", "administered", "at", "intervals", "of", "8", "hours", "over", "a", "total", "treatment", "period", "of", "3", "days", ".", "Main", "variables", "were", "safety", ",", "tolerability", "and", "pharmacokinetics", ".", "Follow", "-", "up", "assessments", "also", "included", "the", "Barthel", "Index", "(", "BI", ")", "and", "the", "NIH", "Stroke", "Scale", "(", "NIHSS", ")", "at", "4", "-", "7", "days", "after", "the", "end", "of", "the", "last", "infusion", "and", "at", "30", "days", "after", "the", "onset", "of", "stroke", ".", "RESULTS", "103", "patients", "with", "acute", "ischaemic", "stroke", "were", "randomised", "to", "either", "treatment", "with", "AR", "-", "R15896AR", "(", "70", "patients", ")", "or", "placebo", "(", "33", "patients", ")", ".", "Mortality", "was", "not", "significantly", "different", "in", "the", "AR", "-", "R15896AR", "group", "compared", "with", "the", "placebo", "group", "(", "10", "%", "vs", ".", "6", "%", ")", ".", "Serious", "adverse", "events", "during", "treatment", "due", "to", "psychiatric", "conditions", "were", "associated", "with", "AR", "-", "R15896AR", "(", "3", "vs", ".", "0", ")", ".", "Other", "side", "effects", "were", "more", "common", "in", "the", "group", "treated", "with", "AR", "-", "R15896AR", ":", "vomiting", "(", "29", "%", "vs", ".", "9", "%", ")", ",", "nausea", "(", "23", "%", "vs", ".", "12", "%", ")", ",", "fever", "(", "17", "%", "vs", ".", "12", "%", ")", ",", "agitation", "(", "7", "%", "vs", ".", "3", "%", ")", ",", "dizziness", "(", "7", "%", "vs", ".", "0", "%", ")", ",", "and", "hallucinations", "(", "6", "%", "vs", ".", "0", "%", ")", ".", "No", "significant", "difference", "between", "the", "two", "groups", "(", "with", "respect", "to", "the", "proportions", "of", "patients", "with", "favourable", "outcome", ")", "was", "detected", "in", "either", "the", "analysis", "of", "the", "BI", "or", "the", "NIHSS", ".", "Pharmacokinetic", "data", "showed", "that", "plasma", "concentrations", "of", "AR", "-", "R15896AR", "were", "in", "the", "expected", "neuroprotective", "range", ".", "CONCLUSION", "In", "most", "of", "the", "patients", "with", "acute", "stroke", "receiving", "AR", "-", "R15896AR", "the", "intended", "high", "plasma", "levels", "were", "reached", "within", "a", "short", "time", "period", ".", "However", ",", "active", "treatment", "produced", "more", "side", "effects", "than", "placebo", ",", "thus", "indicating", "safety", "concerns", "and", "tolerability", "issues", "for", "use", "in", "high", "doses", "in", "an", "acute", "stroke", "population", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Control", "Participant_Sample-size", "Outcome_Mortality" ]

varenicline is a Intervention_Pharmacological, COPD patients is a Participant_Condition, chronic obstructive pulmonary disease ( COPD is a Participant_Condition, varenicline 1 mg b.i.d . is a Intervention_Pharmacological, placebo is a Intervention_Control, abstinence is a Outcome_Mental, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) is a Outcome_Physical, CCQ scores is a Outcome_Physical, CCQ Total Score is a Outcome_Physical, smokers with COPD is a Participant_Condition, continuous abstinence is a Outcome_Mental, CCQ Total Scores is a Outcome_Physical

50448_task0

Sentence: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) .

[ "Lung", "function", "and", "respiratory", "symptoms", "in", "a", "1-year", "randomized", "smoking", "cessation", "trial", "of", "varenicline", "in", "COPD", "patients", ".", "UNLABELLED", "There", "are", "few", "data", "concerning", "changes", "in", "lung", "function", "and", "respiratory", "symptoms", "in", "smokers", "with", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", "weeks", "to", "months", "after", "quitting", "smoking", ".", "We", "examined", "serial", "changes", "in", "spirometry", "and", "Clinical", "COPD", "Questionnaire", "(", "CCQ", ")", "scores", "(", "measuring", "respiratory", "symptoms", "and", "health", "-", "related", "quality", "of", "life", ")", "in", "COPD", "participants", "by", "smoking", "status", "during", "a", "smoking", "cessation", "trial", ".", "In", "this", "randomized", ",", "double", "-", "blind", "trial", ",", "smokers", "with", "mild", "-", "to", "-", "moderate", "COPD", "were", "treated", "with", "varenicline", "1", "mg", "b.i.d", ".", "or", "placebo", "for", "12", "weeks", "and", "followed", "to", "Week", "52", ".", "Primary", "endpoints", "of", "abstinence", "were", "previously", "reported", ".", "Secondary", "endpoints", "were", "mean", "changes", "from", "baseline", "in", "post", "-", "bronchodilator", "forced", "expired", "volume", "in", "1", "s", "(", "FEV", "(", "1", ")", ")", "and", "CCQ", "scores", ".", "Change", "from", "baseline", "in", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "was", "significantly", "improved", "in", "continuous", "abstainers", "(", "121.8", "mL", ")", "vs", ".", "continuous", "smokers", "(", "37.9", "mL", ")", "at", "Week", "12", "(", "P", "=", "0.0069", ")", ",", "but", "not", "at", "Weeks", "24", "or", "52", ".", "Mean", "change", "from", "baseline", "at", "Week", "12", "in", "CCQ", "Total", "Score", "was", "significantly", "better", "in", "continuous", "abstainers", "(", "-1.04", ")", "vs", ".", "continuous", "smokers", "(", "-0.53", ";", "P", "<", "0.0001", ")", ":", "this", "improvement", "was", "sustained", "at", "Weeks", "24", "and", "52", ".", "In", "a", "1-year", "cessation", "trial", "of", "smokers", "with", "COPD", ",", "continuous", "abstinence", "compared", "with", "continuous", "smoking", "significantly", "improved", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "at", "Week", "12", "(", "although", "the", "difference", "narrowed", "subsequently", ")", "and", "CCQ", "Total", "Scores", "at", "Week", "12", ",", "with", "sustained", "improvement", "thereafter", ".", "(", "TRIAL", "REGISTRY", "http", ":", "//www.clinicaltrials.gov", ";", "trial", "identifier", ":", "NCT00285012", ")", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mental", "Intervention_Control" ]

varenicline is a Intervention_Pharmacological, COPD patients is a Participant_Condition, chronic obstructive pulmonary disease ( COPD is a Participant_Condition, varenicline 1 mg b.i.d . is a Intervention_Pharmacological, placebo is a Intervention_Control, abstinence is a Outcome_Mental, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) is a Outcome_Physical, CCQ scores is a Outcome_Physical, CCQ Total Score is a Outcome_Physical, smokers with COPD is a Participant_Condition, continuous abstinence is a Outcome_Mental, CCQ Total Scores is a Outcome_Physical

50448_task1

Sentence: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) . Instructions: please typing these entity words according to sentence: varenicline, COPD patients, chronic obstructive pulmonary disease ( COPD, varenicline 1 mg b.i.d ., placebo, abstinence, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ), CCQ scores, CCQ Total Score, smokers with COPD, continuous abstinence, CCQ Total Scores Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) .

[ "Lung", "function", "and", "respiratory", "symptoms", "in", "a", "1-year", "randomized", "smoking", "cessation", "trial", "of", "varenicline", "in", "COPD", "patients", ".", "UNLABELLED", "There", "are", "few", "data", "concerning", "changes", "in", "lung", "function", "and", "respiratory", "symptoms", "in", "smokers", "with", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", "weeks", "to", "months", "after", "quitting", "smoking", ".", "We", "examined", "serial", "changes", "in", "spirometry", "and", "Clinical", "COPD", "Questionnaire", "(", "CCQ", ")", "scores", "(", "measuring", "respiratory", "symptoms", "and", "health", "-", "related", "quality", "of", "life", ")", "in", "COPD", "participants", "by", "smoking", "status", "during", "a", "smoking", "cessation", "trial", ".", "In", "this", "randomized", ",", "double", "-", "blind", "trial", ",", "smokers", "with", "mild", "-", "to", "-", "moderate", "COPD", "were", "treated", "with", "varenicline", "1", "mg", "b.i.d", ".", "or", "placebo", "for", "12", "weeks", "and", "followed", "to", "Week", "52", ".", "Primary", "endpoints", "of", "abstinence", "were", "previously", "reported", ".", "Secondary", "endpoints", "were", "mean", "changes", "from", "baseline", "in", "post", "-", "bronchodilator", "forced", "expired", "volume", "in", "1", "s", "(", "FEV", "(", "1", ")", ")", "and", "CCQ", "scores", ".", "Change", "from", "baseline", "in", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "was", "significantly", "improved", "in", "continuous", "abstainers", "(", "121.8", "mL", ")", "vs", ".", "continuous", "smokers", "(", "37.9", "mL", ")", "at", "Week", "12", "(", "P", "=", "0.0069", ")", ",", "but", "not", "at", "Weeks", "24", "or", "52", ".", "Mean", "change", "from", "baseline", "at", "Week", "12", "in", "CCQ", "Total", "Score", "was", "significantly", "better", "in", "continuous", "abstainers", "(", "-1.04", ")", "vs", ".", "continuous", "smokers", "(", "-0.53", ";", "P", "<", "0.0001", ")", ":", "this", "improvement", "was", "sustained", "at", "Weeks", "24", "and", "52", ".", "In", "a", "1-year", "cessation", "trial", "of", "smokers", "with", "COPD", ",", "continuous", "abstinence", "compared", "with", "continuous", "smoking", "significantly", "improved", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "at", "Week", "12", "(", "although", "the", "difference", "narrowed", "subsequently", ")", "and", "CCQ", "Total", "Scores", "at", "Week", "12", ",", "with", "sustained", "improvement", "thereafter", ".", "(", "TRIAL", "REGISTRY", "http", ":", "//www.clinicaltrials.gov", ";", "trial", "identifier", ":", "NCT00285012", ")", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mental", "Intervention_Control" ]

varenicline, COPD patients, chronic obstructive pulmonary disease ( COPD, varenicline 1 mg b.i.d ., placebo, abstinence, post - bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ), CCQ scores, CCQ Total Score, smokers with COPD, continuous abstinence, CCQ Total Scores

50448_task2

Sentence: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients . UNLABELLED There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease ( COPD ) weeks to months after quitting smoking . We examined serial changes in spirometry and Clinical COPD Questionnaire ( CCQ ) scores ( measuring respiratory symptoms and health-related quality of life ) in COPD participants by smoking status during a smoking cessation trial . In this randomized , double-blind trial , smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d . or placebo for 12 weeks and followed to Week 52 . Primary endpoints of abstinence were previously reported . Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s ( FEV ( 1 ) ) and CCQ scores . Change from baseline in post-bronchodilator FEV ( 1 ) was significantly improved in continuous abstainers ( 121.8 mL ) vs. continuous smokers ( 37.9 mL ) at Week 12 ( P = 0.0069 ) , but not at Weeks 24 or 52 . Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers ( -1.04 ) vs. continuous smokers ( -0.53 ; P < 0.0001 ) : this improvement was sustained at Weeks 24 and 52 . In a 1-year cessation trial of smokers with COPD , continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV ( 1 ) at Week 12 ( although the difference narrowed subsequently ) and CCQ Total Scores at Week 12 , with sustained improvement thereafter . ( TRIAL REGISTRY http : //www.clinicaltrials.gov ; trial identifier : NCT00285012 ) .

[ "Lung", "function", "and", "respiratory", "symptoms", "in", "a", "1-year", "randomized", "smoking", "cessation", "trial", "of", "varenicline", "in", "COPD", "patients", ".", "UNLABELLED", "There", "are", "few", "data", "concerning", "changes", "in", "lung", "function", "and", "respiratory", "symptoms", "in", "smokers", "with", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", "weeks", "to", "months", "after", "quitting", "smoking", ".", "We", "examined", "serial", "changes", "in", "spirometry", "and", "Clinical", "COPD", "Questionnaire", "(", "CCQ", ")", "scores", "(", "measuring", "respiratory", "symptoms", "and", "health", "-", "related", "quality", "of", "life", ")", "in", "COPD", "participants", "by", "smoking", "status", "during", "a", "smoking", "cessation", "trial", ".", "In", "this", "randomized", ",", "double", "-", "blind", "trial", ",", "smokers", "with", "mild", "-", "to", "-", "moderate", "COPD", "were", "treated", "with", "varenicline", "1", "mg", "b.i.d", ".", "or", "placebo", "for", "12", "weeks", "and", "followed", "to", "Week", "52", ".", "Primary", "endpoints", "of", "abstinence", "were", "previously", "reported", ".", "Secondary", "endpoints", "were", "mean", "changes", "from", "baseline", "in", "post", "-", "bronchodilator", "forced", "expired", "volume", "in", "1", "s", "(", "FEV", "(", "1", ")", ")", "and", "CCQ", "scores", ".", "Change", "from", "baseline", "in", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "was", "significantly", "improved", "in", "continuous", "abstainers", "(", "121.8", "mL", ")", "vs", ".", "continuous", "smokers", "(", "37.9", "mL", ")", "at", "Week", "12", "(", "P", "=", "0.0069", ")", ",", "but", "not", "at", "Weeks", "24", "or", "52", ".", "Mean", "change", "from", "baseline", "at", "Week", "12", "in", "CCQ", "Total", "Score", "was", "significantly", "better", "in", "continuous", "abstainers", "(", "-1.04", ")", "vs", ".", "continuous", "smokers", "(", "-0.53", ";", "P", "<", "0.0001", ")", ":", "this", "improvement", "was", "sustained", "at", "Weeks", "24", "and", "52", ".", "In", "a", "1-year", "cessation", "trial", "of", "smokers", "with", "COPD", ",", "continuous", "abstinence", "compared", "with", "continuous", "smoking", "significantly", "improved", "post", "-", "bronchodilator", "FEV", "(", "1", ")", "at", "Week", "12", "(", "although", "the", "difference", "narrowed", "subsequently", ")", "and", "CCQ", "Total", "Scores", "at", "Week", "12", ",", "with", "sustained", "improvement", "thereafter", ".", "(", "TRIAL", "REGISTRY", "http", ":", "//www.clinicaltrials.gov", ";", "trial", "identifier", ":", "NCT00285012", ")", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mental", "Intervention_Control" ]

Patienten is an umlsterm, zeitintensiv is an umlsterm, Intensivmedizin is an umlsterm, Komplikationen is an umlsterm, Erkennung is an umlsterm, Aerzte is an umlsterm, Druckunterstuetzung is an umlsterm, Atemarbeit is an umlsterm

IntensiveMedizin.9036s055.ger.abstr_task0

Sentence: Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen .

[ "Die", "Entwoehnung", "von", "der", "Beatmung", "gestaltet", "sich", "bei", "ca", ".", "20", "%", "der", "beatmeten", "Patienten", "schwierig", "und", "sehr", "zeitintensiv", ",", "so", "dass", "sie", "von", "grosser", "Bedeutung", "fuer", "die", "moderne", "Intensivmedizin", "ist", ".", "Zur", "Vermeidung", "beatmungsassoziierter", "Komplikationen", "sollte", "die", "Entwoehnung", "so", "zuegig", "wie", "moeglich", "erfolgen", ".", "In", "multizentrischen", "Studien", "konnte", "gezeigt", "werden", ",", "dass", "Protokolle", "sowohl", "fuer", "die", "Erkennung", "des", "fruehesten", "Zeitpunkts", "zur", "Entwoehnung", "als", "auch", "fuer", "die", "Gestaltung", "der", "Entwoehnung", "erfolgversprechender", "sein", "koennen", ",", "als", "die", "alleinige", "klinische", "Einschaetzung", "und", "Betreuung", "der", "behandelnden", "Aerzte", ",", "so", "dass", "solche", "Protokolle", "wuenschenswert", "erscheinen", ".", "Es", "kann", "heute", "keine", "wissenschaftlich", "begruendete", "Praeferenz", "fuer", "ein", "bestimmtes", "Verfahren", "der", "Entwoehnung", "festgestellt", "werden", ",", "da", "sowohl", "T", "-", "Stueck", "-", "Versuche", "als", "auch", "die", "Anwendung", "einer", "geringen", "inspiratorischen", "Druckunterstuetzung", "zu", "guten", "Ergebnissen", "gefuehrt", "haben", ",", "wenn", "sie", "standardisiert", "durchgefuehrt", "wurden", ".", "Aus", "pathophysiologischen", "Ueberlegungen", "mag", "die", "Anwendung", "assistierter", "Verfahren", "zur", "Kompensation", "der", "zusaetzlichen", ",", "durch", "das", "Beatmungssystem", "bedingten", "Atemarbeit", "sinnvoll", "erscheinen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, zeitintensiv is an umlsterm, Intensivmedizin is an umlsterm, Komplikationen is an umlsterm, Erkennung is an umlsterm, Aerzte is an umlsterm, Druckunterstuetzung is an umlsterm, Atemarbeit is an umlsterm

IntensiveMedizin.9036s055.ger.abstr_task1

Sentence: Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen . Instructions: please typing these entity words according to sentence: Patienten, zeitintensiv, Intensivmedizin, Komplikationen, Erkennung, Aerzte, Druckunterstuetzung, Atemarbeit Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen .

[ "Die", "Entwoehnung", "von", "der", "Beatmung", "gestaltet", "sich", "bei", "ca", ".", "20", "%", "der", "beatmeten", "Patienten", "schwierig", "und", "sehr", "zeitintensiv", ",", "so", "dass", "sie", "von", "grosser", "Bedeutung", "fuer", "die", "moderne", "Intensivmedizin", "ist", ".", "Zur", "Vermeidung", "beatmungsassoziierter", "Komplikationen", "sollte", "die", "Entwoehnung", "so", "zuegig", "wie", "moeglich", "erfolgen", ".", "In", "multizentrischen", "Studien", "konnte", "gezeigt", "werden", ",", "dass", "Protokolle", "sowohl", "fuer", "die", "Erkennung", "des", "fruehesten", "Zeitpunkts", "zur", "Entwoehnung", "als", "auch", "fuer", "die", "Gestaltung", "der", "Entwoehnung", "erfolgversprechender", "sein", "koennen", ",", "als", "die", "alleinige", "klinische", "Einschaetzung", "und", "Betreuung", "der", "behandelnden", "Aerzte", ",", "so", "dass", "solche", "Protokolle", "wuenschenswert", "erscheinen", ".", "Es", "kann", "heute", "keine", "wissenschaftlich", "begruendete", "Praeferenz", "fuer", "ein", "bestimmtes", "Verfahren", "der", "Entwoehnung", "festgestellt", "werden", ",", "da", "sowohl", "T", "-", "Stueck", "-", "Versuche", "als", "auch", "die", "Anwendung", "einer", "geringen", "inspiratorischen", "Druckunterstuetzung", "zu", "guten", "Ergebnissen", "gefuehrt", "haben", ",", "wenn", "sie", "standardisiert", "durchgefuehrt", "wurden", ".", "Aus", "pathophysiologischen", "Ueberlegungen", "mag", "die", "Anwendung", "assistierter", "Verfahren", "zur", "Kompensation", "der", "zusaetzlichen", ",", "durch", "das", "Beatmungssystem", "bedingten", "Atemarbeit", "sinnvoll", "erscheinen", "." ]

[ "umlsterm" ]

Patienten, zeitintensiv, Intensivmedizin, Komplikationen, Erkennung, Aerzte, Druckunterstuetzung, Atemarbeit

IntensiveMedizin.9036s055.ger.abstr_task2

Sentence: Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die Entwoehnung von der Beatmung gestaltet sich bei ca. 20% der beatmeten Patienten schwierig und sehr zeitintensiv , so dass sie von grosser Bedeutung fuer die moderne Intensivmedizin ist . Zur Vermeidung beatmungsassoziierter Komplikationen sollte die Entwoehnung so zuegig wie moeglich erfolgen . In multizentrischen Studien konnte gezeigt werden , dass Protokolle sowohl fuer die Erkennung des fruehesten Zeitpunkts zur Entwoehnung als auch fuer die Gestaltung der Entwoehnung erfolgversprechender sein koennen , als die alleinige klinische Einschaetzung und Betreuung der behandelnden Aerzte , so dass solche Protokolle wuenschenswert erscheinen . Es kann heute keine wissenschaftlich begruendete Praeferenz fuer ein bestimmtes Verfahren der Entwoehnung festgestellt werden , da sowohl T-Stueck-Versuche als auch die Anwendung einer geringen inspiratorischen Druckunterstuetzung zu guten Ergebnissen gefuehrt haben , wenn sie standardisiert durchgefuehrt wurden . Aus pathophysiologischen Ueberlegungen mag die Anwendung assistierter Verfahren zur Kompensation der zusaetzlichen , durch das Beatmungssystem bedingten Atemarbeit sinnvoll erscheinen .

[ "Die", "Entwoehnung", "von", "der", "Beatmung", "gestaltet", "sich", "bei", "ca", ".", "20", "%", "der", "beatmeten", "Patienten", "schwierig", "und", "sehr", "zeitintensiv", ",", "so", "dass", "sie", "von", "grosser", "Bedeutung", "fuer", "die", "moderne", "Intensivmedizin", "ist", ".", "Zur", "Vermeidung", "beatmungsassoziierter", "Komplikationen", "sollte", "die", "Entwoehnung", "so", "zuegig", "wie", "moeglich", "erfolgen", ".", "In", "multizentrischen", "Studien", "konnte", "gezeigt", "werden", ",", "dass", "Protokolle", "sowohl", "fuer", "die", "Erkennung", "des", "fruehesten", "Zeitpunkts", "zur", "Entwoehnung", "als", "auch", "fuer", "die", "Gestaltung", "der", "Entwoehnung", "erfolgversprechender", "sein", "koennen", ",", "als", "die", "alleinige", "klinische", "Einschaetzung", "und", "Betreuung", "der", "behandelnden", "Aerzte", ",", "so", "dass", "solche", "Protokolle", "wuenschenswert", "erscheinen", ".", "Es", "kann", "heute", "keine", "wissenschaftlich", "begruendete", "Praeferenz", "fuer", "ein", "bestimmtes", "Verfahren", "der", "Entwoehnung", "festgestellt", "werden", ",", "da", "sowohl", "T", "-", "Stueck", "-", "Versuche", "als", "auch", "die", "Anwendung", "einer", "geringen", "inspiratorischen", "Druckunterstuetzung", "zu", "guten", "Ergebnissen", "gefuehrt", "haben", ",", "wenn", "sie", "standardisiert", "durchgefuehrt", "wurden", ".", "Aus", "pathophysiologischen", "Ueberlegungen", "mag", "die", "Anwendung", "assistierter", "Verfahren", "zur", "Kompensation", "der", "zusaetzlichen", ",", "durch", "das", "Beatmungssystem", "bedingten", "Atemarbeit", "sinnvoll", "erscheinen", "." ]

[ "umlsterm" ]

5'-iodoresiniferatoxin is a compound, PKC is a protein, chelerythrine is a compound, chloride is a compound

DS.d920_task0

Sentence: These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O" ]

These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg).

[ "These", "evoked", "expressions", "at", "both", "molecular", "and", "cellular", "levels", "were", "significantly", "inhibited", "after", "TRPV(1", ")", "receptors", "were", "blocked", "by", "5'-iodoresiniferatoxin", "(", "5", "microg", ")", "or", "PKC", "was", "inhibited", "by", "chelerythrine", "chloride", "(", "5", "microg", ")", "." ]

[ "compound", "protein" ]

5'-iodoresiniferatoxin is a compound, PKC is a protein, chelerythrine is a compound, chloride is a compound

DS.d920_task1

Sentence: These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg). Instructions: please typing these entity words according to sentence: 5'-iodoresiniferatoxin, PKC, chelerythrine, chloride Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O" ]

These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg).

[ "These", "evoked", "expressions", "at", "both", "molecular", "and", "cellular", "levels", "were", "significantly", "inhibited", "after", "TRPV(1", ")", "receptors", "were", "blocked", "by", "5'-iodoresiniferatoxin", "(", "5", "microg", ")", "or", "PKC", "was", "inhibited", "by", "chelerythrine", "chloride", "(", "5", "microg", ")", "." ]

[ "compound", "protein" ]

5'-iodoresiniferatoxin, PKC, chelerythrine, chloride

DS.d920_task2

Sentence: These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O" ]

These evoked expressions at both molecular and cellular levels were significantly inhibited after TRPV(1) receptors were blocked by 5'-iodoresiniferatoxin (5 microg) or PKC was inhibited by chelerythrine chloride (5 microg).

[ "These", "evoked", "expressions", "at", "both", "molecular", "and", "cellular", "levels", "were", "significantly", "inhibited", "after", "TRPV(1", ")", "receptors", "were", "blocked", "by", "5'-iodoresiniferatoxin", "(", "5", "microg", ")", "or", "PKC", "was", "inhibited", "by", "chelerythrine", "chloride", "(", "5", "microg", ")", "." ]

[ "compound", "protein" ]

insulin is a protein, glucose is a compound

DS.d1499_task0

Sentence: Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells.

[ "Activation", "of", "the", "Na+/K+-ATPase", "by", "insulin", "and", "glucose", "as", "a", "putative", "negative", "feedback", "mechanism", "in", "pancreatic", "beta", "-", "cells", "." ]

[ "protein", "compound" ]

insulin is a protein, glucose is a compound

DS.d1499_task1

Sentence: Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells. Instructions: please typing these entity words according to sentence: insulin, glucose Options: compound, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells.

[ "Activation", "of", "the", "Na+/K+-ATPase", "by", "insulin", "and", "glucose", "as", "a", "putative", "negative", "feedback", "mechanism", "in", "pancreatic", "beta", "-", "cells", "." ]

[ "protein", "compound" ]

insulin, glucose

DS.d1499_task2

Sentence: Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Activation of the Na+/K+-ATPase by insulin and glucose as a putative negative feedback mechanism in pancreatic beta-cells.

[ "Activation", "of", "the", "Na+/K+-ATPase", "by", "insulin", "and", "glucose", "as", "a", "putative", "negative", "feedback", "mechanism", "in", "pancreatic", "beta", "-", "cells", "." ]

[ "protein", "compound" ]

healthy is a Condition, Healthy , without allergies and with the age of 18 years or above is a Scope, patients is a Person, Burn injury exceeding 6 - 8 Total Burned Surface Area % is a Scope

NCT02952378_inc_task0

Sentence: For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area % Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Condition

[ "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]

For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %

[ "For", "healthy", "individuals", ":", "Healthy", ",", "without", "allergies", "and", "with", "the", "age", "of", "18", "years", "or", "above", ".", "\n", "For", "patients", ":", "Burn", "injury", "exceeding", "6", "-", "8", "Total", "Burned", "Surface", "Area", "%", "\n" ]

[ "Scope", "Measurement", "Value", "Condition", "Person", "Negation" ]

healthy is a Condition, Healthy , without allergies and with the age of 18 years or above is a Scope, patients is a Person, Burn injury exceeding 6 - 8 Total Burned Surface Area % is a Scope

NCT02952378_inc_task1

Sentence: For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area % Instructions: please typing these entity words according to sentence: healthy, Healthy , without allergies and with the age of 18 years or above, patients, Burn injury exceeding 6 - 8 Total Burned Surface Area % Options: Scope, Person, Condition

[ "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]

For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %

[ "For", "healthy", "individuals", ":", "Healthy", ",", "without", "allergies", "and", "with", "the", "age", "of", "18", "years", "or", "above", ".", "\n", "For", "patients", ":", "Burn", "injury", "exceeding", "6", "-", "8", "Total", "Burned", "Surface", "Area", "%", "\n" ]

[ "Scope", "Measurement", "Value", "Condition", "Person", "Negation" ]

healthy, Healthy , without allergies and with the age of 18 years or above, patients, Burn injury exceeding 6 - 8 Total Burned Surface Area %

NCT02952378_inc_task2

Sentence: For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area % Instructions: please extract entity words from the input sentence

[ "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]

For healthy individuals: Healthy, without allergies and with the age of 18 years or above. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %

[ "For", "healthy", "individuals", ":", "Healthy", ",", "without", "allergies", "and", "with", "the", "age", "of", "18", "years", "or", "above", ".", "\n", "For", "patients", ":", "Burn", "injury", "exceeding", "6", "-", "8", "Total", "Burned", "Surface", "Area", "%", "\n" ]

[ "Scope", "Measurement", "Value", "Condition", "Person", "Negation" ]

Blutdruck is an umlsterm, Blutdrucks is an umlsterm, Blutdruckanstieg is an umlsterm, Weisskittel- is an umlsterm, Praxishochdruck is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Hypertonie is an umlsterm, Prognose is an umlsterm, Bluthochdruckpatienten is an umlsterm, Behandlung is an umlsterm, Blutdrucksenkung is an umlsterm, Medikamente is an umlsterm

MedizinischeKlinik.00950254.ger.abstr_task0

Sentence: Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben .

[ "Der", "menschliche", "Blutdruck", "unterliegt", "nicht", "nur", "infolge", "koerperlicher", "und", "psychischer", "Aktivitaet", "oder", "pharmakologischer", "Massnahmen", ",", "sondern", "auch", "spontan", "mehr", "oder", "weniger", "ausgepraegten", "Schwankungen", ".", "Diese", "Variabilitaet", "des", "arteriellen", "Blutdrucks", "ist", "sowohl", "von", "pathophysiologischem", "als", "auch", "von", "klinischem", "Interesse", ".", "Ein", "weithin", "bekanntes", "Beispiel", "fuer", "einen", "ausgepraegten", "Blutdruckanstieg", "ist", "als", "Weisskittel-", "oder", "Praxishochdruck", "\"", "\"", "gelaeufig", ".", "Diese", "gelegentlich", "ausgepraegte", "Blutdruckvariabilitaet", "kann", "durchaus", "Folgen", "fuer", "die", "Diagnostik", "und", "Therapie", "einer", "arteriellen", "Hypertonie", "haben", ".", "Einige", "Studien", "haben", "darueber", "hinaus", "gezeigt", ",", "dass", "das", "Ausmass", "hypertoner", "Endorganschaeden", "und", "auch", "die", "Prognose", "von", "Bluthochdruckpatienten", "signifikant", "mit", "der", "zirkadianen", "Blutdruckvariabilitaet", "assoziiert", "sind", ".", "Vor", "diesem", "Hintergrund", "ist", "zu", "diskutieren", ",", "inwieweit", "eine", "optimale", "antihypertensive", "Behandlung", "neben", "der", "eigentlichen", "Blutdrucksenkung", "auch", "die", "Blutdruckvariabilitaet", "optimieren", "muss", ",", "zumal", "die", "bislang", "untersuchten", "antihypertensiven", "Medikamente", ",", "wenn", "ueberhaupt", ",", "einen", "unguenstigen", "Effekt", "auf", "die", "Blutdruckvariabilitaet", "ausueben", "." ]

[ "umlsterm" ]

Blutdruck is an umlsterm, Blutdrucks is an umlsterm, Blutdruckanstieg is an umlsterm, Weisskittel- is an umlsterm, Praxishochdruck is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Hypertonie is an umlsterm, Prognose is an umlsterm, Bluthochdruckpatienten is an umlsterm, Behandlung is an umlsterm, Blutdrucksenkung is an umlsterm, Medikamente is an umlsterm

MedizinischeKlinik.00950254.ger.abstr_task1

Sentence: Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben . Instructions: please typing these entity words according to sentence: Blutdruck, Blutdrucks, Blutdruckanstieg, Weisskittel-, Praxishochdruck, Diagnostik, Therapie, Hypertonie, Prognose, Bluthochdruckpatienten, Behandlung, Blutdrucksenkung, Medikamente Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben .

[ "Der", "menschliche", "Blutdruck", "unterliegt", "nicht", "nur", "infolge", "koerperlicher", "und", "psychischer", "Aktivitaet", "oder", "pharmakologischer", "Massnahmen", ",", "sondern", "auch", "spontan", "mehr", "oder", "weniger", "ausgepraegten", "Schwankungen", ".", "Diese", "Variabilitaet", "des", "arteriellen", "Blutdrucks", "ist", "sowohl", "von", "pathophysiologischem", "als", "auch", "von", "klinischem", "Interesse", ".", "Ein", "weithin", "bekanntes", "Beispiel", "fuer", "einen", "ausgepraegten", "Blutdruckanstieg", "ist", "als", "Weisskittel-", "oder", "Praxishochdruck", "\"", "\"", "gelaeufig", ".", "Diese", "gelegentlich", "ausgepraegte", "Blutdruckvariabilitaet", "kann", "durchaus", "Folgen", "fuer", "die", "Diagnostik", "und", "Therapie", "einer", "arteriellen", "Hypertonie", "haben", ".", "Einige", "Studien", "haben", "darueber", "hinaus", "gezeigt", ",", "dass", "das", "Ausmass", "hypertoner", "Endorganschaeden", "und", "auch", "die", "Prognose", "von", "Bluthochdruckpatienten", "signifikant", "mit", "der", "zirkadianen", "Blutdruckvariabilitaet", "assoziiert", "sind", ".", "Vor", "diesem", "Hintergrund", "ist", "zu", "diskutieren", ",", "inwieweit", "eine", "optimale", "antihypertensive", "Behandlung", "neben", "der", "eigentlichen", "Blutdrucksenkung", "auch", "die", "Blutdruckvariabilitaet", "optimieren", "muss", ",", "zumal", "die", "bislang", "untersuchten", "antihypertensiven", "Medikamente", ",", "wenn", "ueberhaupt", ",", "einen", "unguenstigen", "Effekt", "auf", "die", "Blutdruckvariabilitaet", "ausueben", "." ]

[ "umlsterm" ]

Blutdruck, Blutdrucks, Blutdruckanstieg, Weisskittel-, Praxishochdruck, Diagnostik, Therapie, Hypertonie, Prognose, Bluthochdruckpatienten, Behandlung, Blutdrucksenkung, Medikamente

MedizinischeKlinik.00950254.ger.abstr_task2

Sentence: Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der menschliche Blutdruck unterliegt nicht nur infolge koerperlicher und psychischer Aktivitaet oder pharmakologischer Massnahmen , sondern auch spontan mehr oder weniger ausgepraegten Schwankungen . Diese Variabilitaet des arteriellen Blutdrucks ist sowohl von pathophysiologischem als auch von klinischem Interesse . Ein weithin bekanntes Beispiel fuer einen ausgepraegten Blutdruckanstieg ist als Weisskittel- oder Praxishochdruck " " gelaeufig . Diese gelegentlich ausgepraegte Blutdruckvariabilitaet kann durchaus Folgen fuer die Diagnostik und Therapie einer arteriellen Hypertonie haben . Einige Studien haben darueber hinaus gezeigt , dass das Ausmass hypertoner Endorganschaeden und auch die Prognose von Bluthochdruckpatienten signifikant mit der zirkadianen Blutdruckvariabilitaet assoziiert sind . Vor diesem Hintergrund ist zu diskutieren , inwieweit eine optimale antihypertensive Behandlung neben der eigentlichen Blutdrucksenkung auch die Blutdruckvariabilitaet optimieren muss , zumal die bislang untersuchten antihypertensiven Medikamente , wenn ueberhaupt , einen unguenstigen Effekt auf die Blutdruckvariabilitaet ausueben .

[ "Der", "menschliche", "Blutdruck", "unterliegt", "nicht", "nur", "infolge", "koerperlicher", "und", "psychischer", "Aktivitaet", "oder", "pharmakologischer", "Massnahmen", ",", "sondern", "auch", "spontan", "mehr", "oder", "weniger", "ausgepraegten", "Schwankungen", ".", "Diese", "Variabilitaet", "des", "arteriellen", "Blutdrucks", "ist", "sowohl", "von", "pathophysiologischem", "als", "auch", "von", "klinischem", "Interesse", ".", "Ein", "weithin", "bekanntes", "Beispiel", "fuer", "einen", "ausgepraegten", "Blutdruckanstieg", "ist", "als", "Weisskittel-", "oder", "Praxishochdruck", "\"", "\"", "gelaeufig", ".", "Diese", "gelegentlich", "ausgepraegte", "Blutdruckvariabilitaet", "kann", "durchaus", "Folgen", "fuer", "die", "Diagnostik", "und", "Therapie", "einer", "arteriellen", "Hypertonie", "haben", ".", "Einige", "Studien", "haben", "darueber", "hinaus", "gezeigt", ",", "dass", "das", "Ausmass", "hypertoner", "Endorganschaeden", "und", "auch", "die", "Prognose", "von", "Bluthochdruckpatienten", "signifikant", "mit", "der", "zirkadianen", "Blutdruckvariabilitaet", "assoziiert", "sind", ".", "Vor", "diesem", "Hintergrund", "ist", "zu", "diskutieren", ",", "inwieweit", "eine", "optimale", "antihypertensive", "Behandlung", "neben", "der", "eigentlichen", "Blutdrucksenkung", "auch", "die", "Blutdruckvariabilitaet", "optimieren", "muss", ",", "zumal", "die", "bislang", "untersuchten", "antihypertensiven", "Medikamente", ",", "wenn", "ueberhaupt", ",", "einen", "unguenstigen", "Effekt", "auf", "die", "Blutdruckvariabilitaet", "ausueben", "." ]

[ "umlsterm" ]

recent onset rheumatoid arthritis is a participant, role is an outcome, disability , illness perceptions , pain and coping is an outcome

1398_task0

Sentence: The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome, participant

[ "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "B-outcome", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]

The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping .

[ "The", "course", "of", "depression", "in", "recent", "onset", "rheumatoid", "arthritis", ":", "the", "predictive", "role", "of", "disability", ",", "illness", "perceptions", ",", "pain", "and", "coping", "." ]

[ "outcome", "participant" ]

recent onset rheumatoid arthritis is a participant, role is an outcome, disability , illness perceptions , pain and coping is an outcome

1398_task1

Sentence: The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping . Instructions: please typing these entity words according to sentence: recent onset rheumatoid arthritis, role, disability , illness perceptions , pain and coping Options: outcome, participant

[ "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "B-outcome", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]

The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping .

[ "The", "course", "of", "depression", "in", "recent", "onset", "rheumatoid", "arthritis", ":", "the", "predictive", "role", "of", "disability", ",", "illness", "perceptions", ",", "pain", "and", "coping", "." ]

[ "outcome", "participant" ]

recent onset rheumatoid arthritis, role, disability , illness perceptions , pain and coping

1398_task2

Sentence: The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "B-outcome", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]

The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and coping .

[ "The", "course", "of", "depression", "in", "recent", "onset", "rheumatoid", "arthritis", ":", "the", "predictive", "role", "of", "disability", ",", "illness", "perceptions", ",", "pain", "and", "coping", "." ]

[ "outcome", "participant" ]

coronary artery occlusion is an umlsterm, angioplasty is an umlsterm, PTCA is an umlsterm, heparin is an umlsterm, aspirin is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, syndromes is an umlsterm, risk is an umlsterm, vessel is an umlsterm, thrombus is an umlsterm, role is an umlsterm, pathogenesis is an umlsterm, vessel is an umlsterm, Dipyridamole is an umlsterm, dilatation is an umlsterm, arteries is an umlsterm, platelet aggregation is an umlsterm, aspirin is an umlsterm, therapy is an umlsterm, dipyridamole is an umlsterm, incidence is an umlsterm, coronary artery occlusion is an umlsterm, PTCA is an umlsterm, Secondary is an umlsterm, myocardial infarction is an umlsterm, grafting is an umlsterm, death is an umlsterm

ZfuerKardiologie.70860961.eng.abstr_task0

Sentence: Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death .

[ "Even", "in", "the", "era", "of", "coronary", "stenting", ",", "acute", "coronary", "artery", "occlusion", "continues", "to", "represent", "a", "significant", "limitation", "of", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", ".", "Despite", "application", "of", "heparin", "and", "aspirin", ",", "abrupt", "vessel", "closure", "still", "occurs", "in", "2", "-", "8", "%", ",", "depending", "on", "the", "definition", "applied", ".", "Especially", "patients", "receiving", "PTCA", "for", "acute", "coronary", "syndromes", "are", "at", "high", "risk", "for", "abrupt", "vessel", "closure", ".", "The", "formation", "of", "an", "intracoronary", "thrombus", "plays", "a", "central", "role", "in", "the", "pathogenesis", "of", "abrupt", "vessel", "closure", ".", "Dipyridamole", "induces", "dilatation", "of", "coronary", "arteries", "and", "prevents", "platelet", "aggregation", "by", "a", "mechanism", "that", "differs", "from", "that", "of", "aspirin", ".", "The", "primary", "purpose", "of", "the", "study", "was", "to", "evaluate", "whether", "adjunctive", "local", "intracoronary", "therapy", "with", "dipyridamole", "could", "reduce", "the", "incidence", "of", "coronary", "artery", "occlusion", "following", "PTCA", ".", "Secondary", "endpoints", "were", "defined", "as", "myocardial", "infarction", ",", "necessity", "for", "bypass", "grafting", ",", "and", "death", "." ]

[ "umlsterm" ]

coronary artery occlusion is an umlsterm, angioplasty is an umlsterm, PTCA is an umlsterm, heparin is an umlsterm, aspirin is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, syndromes is an umlsterm, risk is an umlsterm, vessel is an umlsterm, thrombus is an umlsterm, role is an umlsterm, pathogenesis is an umlsterm, vessel is an umlsterm, Dipyridamole is an umlsterm, dilatation is an umlsterm, arteries is an umlsterm, platelet aggregation is an umlsterm, aspirin is an umlsterm, therapy is an umlsterm, dipyridamole is an umlsterm, incidence is an umlsterm, coronary artery occlusion is an umlsterm, PTCA is an umlsterm, Secondary is an umlsterm, myocardial infarction is an umlsterm, grafting is an umlsterm, death is an umlsterm

ZfuerKardiologie.70860961.eng.abstr_task1

Sentence: Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death . Instructions: please typing these entity words according to sentence: coronary artery occlusion, angioplasty, PTCA, heparin, aspirin, vessel, patients, PTCA, syndromes, risk, vessel, thrombus, role, pathogenesis, vessel, Dipyridamole, dilatation, arteries, platelet aggregation, aspirin, therapy, dipyridamole, incidence, coronary artery occlusion, PTCA, Secondary, myocardial infarction, grafting, death Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death .

[ "Even", "in", "the", "era", "of", "coronary", "stenting", ",", "acute", "coronary", "artery", "occlusion", "continues", "to", "represent", "a", "significant", "limitation", "of", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", ".", "Despite", "application", "of", "heparin", "and", "aspirin", ",", "abrupt", "vessel", "closure", "still", "occurs", "in", "2", "-", "8", "%", ",", "depending", "on", "the", "definition", "applied", ".", "Especially", "patients", "receiving", "PTCA", "for", "acute", "coronary", "syndromes", "are", "at", "high", "risk", "for", "abrupt", "vessel", "closure", ".", "The", "formation", "of", "an", "intracoronary", "thrombus", "plays", "a", "central", "role", "in", "the", "pathogenesis", "of", "abrupt", "vessel", "closure", ".", "Dipyridamole", "induces", "dilatation", "of", "coronary", "arteries", "and", "prevents", "platelet", "aggregation", "by", "a", "mechanism", "that", "differs", "from", "that", "of", "aspirin", ".", "The", "primary", "purpose", "of", "the", "study", "was", "to", "evaluate", "whether", "adjunctive", "local", "intracoronary", "therapy", "with", "dipyridamole", "could", "reduce", "the", "incidence", "of", "coronary", "artery", "occlusion", "following", "PTCA", ".", "Secondary", "endpoints", "were", "defined", "as", "myocardial", "infarction", ",", "necessity", "for", "bypass", "grafting", ",", "and", "death", "." ]

[ "umlsterm" ]

coronary artery occlusion, angioplasty, PTCA, heparin, aspirin, vessel, patients, PTCA, syndromes, risk, vessel, thrombus, role, pathogenesis, vessel, Dipyridamole, dilatation, arteries, platelet aggregation, aspirin, therapy, dipyridamole, incidence, coronary artery occlusion, PTCA, Secondary, myocardial infarction, grafting, death

ZfuerKardiologie.70860961.eng.abstr_task2

Sentence: Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Even in the era of coronary stenting , acute coronary artery occlusion continues to represent a significant limitation of percutaneous transluminal coronary angioplasty ( PTCA ) . Despite application of heparin and aspirin , abrupt vessel closure still occurs in 2-8% , depending on the definition applied . Especially patients receiving PTCA for acute coronary syndromes are at high risk for abrupt vessel closure . The formation of an intracoronary thrombus plays a central role in the pathogenesis of abrupt vessel closure . Dipyridamole induces dilatation of coronary arteries and prevents platelet aggregation by a mechanism that differs from that of aspirin . The primary purpose of the study was to evaluate whether adjunctive local intracoronary therapy with dipyridamole could reduce the incidence of coronary artery occlusion following PTCA . Secondary endpoints were defined as myocardial infarction , necessity for bypass grafting , and death .

[ "Even", "in", "the", "era", "of", "coronary", "stenting", ",", "acute", "coronary", "artery", "occlusion", "continues", "to", "represent", "a", "significant", "limitation", "of", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", ".", "Despite", "application", "of", "heparin", "and", "aspirin", ",", "abrupt", "vessel", "closure", "still", "occurs", "in", "2", "-", "8", "%", ",", "depending", "on", "the", "definition", "applied", ".", "Especially", "patients", "receiving", "PTCA", "for", "acute", "coronary", "syndromes", "are", "at", "high", "risk", "for", "abrupt", "vessel", "closure", ".", "The", "formation", "of", "an", "intracoronary", "thrombus", "plays", "a", "central", "role", "in", "the", "pathogenesis", "of", "abrupt", "vessel", "closure", ".", "Dipyridamole", "induces", "dilatation", "of", "coronary", "arteries", "and", "prevents", "platelet", "aggregation", "by", "a", "mechanism", "that", "differs", "from", "that", "of", "aspirin", ".", "The", "primary", "purpose", "of", "the", "study", "was", "to", "evaluate", "whether", "adjunctive", "local", "intracoronary", "therapy", "with", "dipyridamole", "could", "reduce", "the", "incidence", "of", "coronary", "artery", "occlusion", "following", "PTCA", ".", "Secondary", "endpoints", "were", "defined", "as", "myocardial", "infarction", ",", "necessity", "for", "bypass", "grafting", ",", "and", "death", "." ]

[ "umlsterm" ]

monosodium urate is a compound, leucine is a compound, pyrin is a protein

DS.d115_task0

Sentence: Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.

[ "Recent", "studies", "suggest", "that", "crystals", "of", "monosodium", "urate", "(", "MSU", ")", ",", "deposited", "in", "joints", "of", "patients", "with", "acute", "gouty", "arthritis", ",", "activate", "the", "NACHT", "domain", ",", "leucine", "-", "rich", "repeat", "and", "pyrin", "domain", "-", "containing", "protein", "(", "NALP)3", "inflammasome", "." ]

[ "compound", "protein" ]

monosodium urate is a compound, leucine is a compound, pyrin is a protein

DS.d115_task1

Sentence: Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome. Instructions: please typing these entity words according to sentence: monosodium urate, leucine, pyrin Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.

[ "Recent", "studies", "suggest", "that", "crystals", "of", "monosodium", "urate", "(", "MSU", ")", ",", "deposited", "in", "joints", "of", "patients", "with", "acute", "gouty", "arthritis", ",", "activate", "the", "NACHT", "domain", ",", "leucine", "-", "rich", "repeat", "and", "pyrin", "domain", "-", "containing", "protein", "(", "NALP)3", "inflammasome", "." ]

[ "compound", "protein" ]

monosodium urate, leucine, pyrin

DS.d115_task2

Sentence: Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.

[ "Recent", "studies", "suggest", "that", "crystals", "of", "monosodium", "urate", "(", "MSU", ")", ",", "deposited", "in", "joints", "of", "patients", "with", "acute", "gouty", "arthritis", ",", "activate", "the", "NACHT", "domain", ",", "leucine", "-", "rich", "repeat", "and", "pyrin", "domain", "-", "containing", "protein", "(", "NALP)3", "inflammasome", "." ]

[ "compound", "protein" ]

Muskelgruppen is an umlsterm, Anschlagzeit is an umlsterm, Atracurium is an umlsterm, Muskelgruppen is an umlsterm, Atracurium is an umlsterm

DerAnaesthesist.90480602.ger.abstr_task0

Sentence: Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden .

[ "Fragestellung", ":", "Muskelrelaxanzien", "zeigen", "ein", "unterschiedliches", "pharmakodynamisches", "Wirkungsprofil", "an", "verschiedenen", "Muskelgruppen", ".", "Am", "M.", "adductor", "pollicis", "hat", "Cisatracurium", ",", "bis", "auf", "eine", "laengere", "Anschlagzeit", ",", "ein", "vergleichbares", "pharmakodynamisches", "Profil", "wie", "Atracurium", ".", "Untersuchungen", "an", "anderen", "Muskelgruppen", "wurden", "fuer", "Cisatracurium", "bisher", "nicht", "durchgefuehrt", ".", "In", "der", "vorliegenden", "klinischen", "Studie", "sollte", "daher", "die", "neuromuskulaere", "Wirkung", "von", "Cisatracurium", "am", "M.", "orbicularis", "oculi", "(", "OO", ")", "-", "dessen", "neuromuskulaere", "Reaktion", "annaehernd", "derjenigen", "des", "Diaphragmas", "und", "der", "Larynxmuskulatur", "entspricht", "-", "und", "am", "M.", "adductor", "pollicis", "(", "AP", ")", "im", "Vergleich", "mit", "Atracurium", "untersucht", "werden", "." ]

[ "umlsterm" ]

Muskelgruppen is an umlsterm, Anschlagzeit is an umlsterm, Atracurium is an umlsterm, Muskelgruppen is an umlsterm, Atracurium is an umlsterm

DerAnaesthesist.90480602.ger.abstr_task1

Sentence: Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden . Instructions: please typing these entity words according to sentence: Muskelgruppen, Anschlagzeit, Atracurium, Muskelgruppen, Atracurium Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden .

[ "Fragestellung", ":", "Muskelrelaxanzien", "zeigen", "ein", "unterschiedliches", "pharmakodynamisches", "Wirkungsprofil", "an", "verschiedenen", "Muskelgruppen", ".", "Am", "M.", "adductor", "pollicis", "hat", "Cisatracurium", ",", "bis", "auf", "eine", "laengere", "Anschlagzeit", ",", "ein", "vergleichbares", "pharmakodynamisches", "Profil", "wie", "Atracurium", ".", "Untersuchungen", "an", "anderen", "Muskelgruppen", "wurden", "fuer", "Cisatracurium", "bisher", "nicht", "durchgefuehrt", ".", "In", "der", "vorliegenden", "klinischen", "Studie", "sollte", "daher", "die", "neuromuskulaere", "Wirkung", "von", "Cisatracurium", "am", "M.", "orbicularis", "oculi", "(", "OO", ")", "-", "dessen", "neuromuskulaere", "Reaktion", "annaehernd", "derjenigen", "des", "Diaphragmas", "und", "der", "Larynxmuskulatur", "entspricht", "-", "und", "am", "M.", "adductor", "pollicis", "(", "AP", ")", "im", "Vergleich", "mit", "Atracurium", "untersucht", "werden", "." ]

[ "umlsterm" ]

Muskelgruppen, Anschlagzeit, Atracurium, Muskelgruppen, Atracurium

DerAnaesthesist.90480602.ger.abstr_task2

Sentence: Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Fragestellung : Muskelrelaxanzien zeigen ein unterschiedliches pharmakodynamisches Wirkungsprofil an verschiedenen Muskelgruppen . Am M. adductor pollicis hat Cisatracurium , bis auf eine laengere Anschlagzeit , ein vergleichbares pharmakodynamisches Profil wie Atracurium . Untersuchungen an anderen Muskelgruppen wurden fuer Cisatracurium bisher nicht durchgefuehrt . In der vorliegenden klinischen Studie sollte daher die neuromuskulaere Wirkung von Cisatracurium am M. orbicularis oculi ( OO ) - dessen neuromuskulaere Reaktion annaehernd derjenigen des Diaphragmas und der Larynxmuskulatur entspricht - und am M. adductor pollicis ( AP ) im Vergleich mit Atracurium untersucht werden .

[ "Fragestellung", ":", "Muskelrelaxanzien", "zeigen", "ein", "unterschiedliches", "pharmakodynamisches", "Wirkungsprofil", "an", "verschiedenen", "Muskelgruppen", ".", "Am", "M.", "adductor", "pollicis", "hat", "Cisatracurium", ",", "bis", "auf", "eine", "laengere", "Anschlagzeit", ",", "ein", "vergleichbares", "pharmakodynamisches", "Profil", "wie", "Atracurium", ".", "Untersuchungen", "an", "anderen", "Muskelgruppen", "wurden", "fuer", "Cisatracurium", "bisher", "nicht", "durchgefuehrt", ".", "In", "der", "vorliegenden", "klinischen", "Studie", "sollte", "daher", "die", "neuromuskulaere", "Wirkung", "von", "Cisatracurium", "am", "M.", "orbicularis", "oculi", "(", "OO", ")", "-", "dessen", "neuromuskulaere", "Reaktion", "annaehernd", "derjenigen", "des", "Diaphragmas", "und", "der", "Larynxmuskulatur", "entspricht", "-", "und", "am", "M.", "adductor", "pollicis", "(", "AP", ")", "im", "Vergleich", "mit", "Atracurium", "untersucht", "werden", "." ]

[ "umlsterm" ]

cdc-2 is a Protein, cyclin E is a Protein, CD23 is a Protein, cyclin D2 is a Protein, CD40 is a Protein, IL4 is a Protein

384_task0

Sentence: The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.

[ "The", "normal", "cell", "cycle", "activation", "program", "is", "exploited", "during", "the", "infection", "of", "quiescent", "B", "lymphocytes", "by", "Epstein", "-", "Barr", "virus", ".", "\n", "B", "lymphocytes", "in", "the", "peripheral", "circulation", "are", "maintained", "in", "a", "non", "-", "proliferative", "state", ".", "Antigen", "recognition", "stimulates", "limited", "proliferation", ",", "whereas", "infection", "with", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "results", "in", "continual", "proliferation", "and", "the", "outgrowth", "of", "immortal", "cell", "lines", ".", "Because", "it", "is", "not", "clear", "at", "which", "point", "in", "cell", "cycle", "the", "peripheral", "B", "lymphocytes", "are", "arrested", ",", "we", "characterized", "the", "expression", "of", "several", "cell", "cycle", "-", "associated", "genes", "in", "quiescent", "and", "stimulated", "cells", ".", "We", "show", "that", "the", "expression", "of", "four", "cell", "genes", ",", "cdc-2", ",", "cyclin", "E", ",", "CD23", ",", "and", "cyclin", "D2", ",", "are", "up", "-", "regulated", "approximately", "100-fold", "as", "a", "result", "of", "EBV", "-", "mediated", "immortalization", ".", "Because", "these", "genes", "play", "a", "positive", "role", "in", "cell", "proliferation", ",", "we", "suggest", "that", "this", "regulatory", "switch", "contributes", "to", "controlling", "entry", "into", "the", "cell", "cycle", ".", "Transient", "stimulation", "of", "quiescent", "B", "lymphocytes", "with", "either", "a", "cocktail", "of", "anti", "-", "CD40", ",", "anti", "-", "IgM", ",", "and", "IL4", ",", "or", "EBV", "results", "in", "the", "rapid", "expression", "of", "the", "same", "four", "genes", ",", "suggesting", "that", ",", "after", "infection", ",", "EBV", "exploits", "the", "normal", "program", "of", "B", "-", "lymphocyte", "cell", "cycle", "activation", "." ]

[ "Protein" ]

cdc-2 is a Protein, cyclin E is a Protein, CD23 is a Protein, cyclin D2 is a Protein, CD40 is a Protein, IL4 is a Protein

384_task1

Sentence: The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation. Instructions: please typing these entity words according to sentence: cdc-2, cyclin E, CD23, cyclin D2, CD40, IL4 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.

[ "The", "normal", "cell", "cycle", "activation", "program", "is", "exploited", "during", "the", "infection", "of", "quiescent", "B", "lymphocytes", "by", "Epstein", "-", "Barr", "virus", ".", "\n", "B", "lymphocytes", "in", "the", "peripheral", "circulation", "are", "maintained", "in", "a", "non", "-", "proliferative", "state", ".", "Antigen", "recognition", "stimulates", "limited", "proliferation", ",", "whereas", "infection", "with", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "results", "in", "continual", "proliferation", "and", "the", "outgrowth", "of", "immortal", "cell", "lines", ".", "Because", "it", "is", "not", "clear", "at", "which", "point", "in", "cell", "cycle", "the", "peripheral", "B", "lymphocytes", "are", "arrested", ",", "we", "characterized", "the", "expression", "of", "several", "cell", "cycle", "-", "associated", "genes", "in", "quiescent", "and", "stimulated", "cells", ".", "We", "show", "that", "the", "expression", "of", "four", "cell", "genes", ",", "cdc-2", ",", "cyclin", "E", ",", "CD23", ",", "and", "cyclin", "D2", ",", "are", "up", "-", "regulated", "approximately", "100-fold", "as", "a", "result", "of", "EBV", "-", "mediated", "immortalization", ".", "Because", "these", "genes", "play", "a", "positive", "role", "in", "cell", "proliferation", ",", "we", "suggest", "that", "this", "regulatory", "switch", "contributes", "to", "controlling", "entry", "into", "the", "cell", "cycle", ".", "Transient", "stimulation", "of", "quiescent", "B", "lymphocytes", "with", "either", "a", "cocktail", "of", "anti", "-", "CD40", ",", "anti", "-", "IgM", ",", "and", "IL4", ",", "or", "EBV", "results", "in", "the", "rapid", "expression", "of", "the", "same", "four", "genes", ",", "suggesting", "that", ",", "after", "infection", ",", "EBV", "exploits", "the", "normal", "program", "of", "B", "-", "lymphocyte", "cell", "cycle", "activation", "." ]

[ "Protein" ]

cdc-2, cyclin E, CD23, cyclin D2, CD40, IL4

384_task2

Sentence: The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.

[ "The", "normal", "cell", "cycle", "activation", "program", "is", "exploited", "during", "the", "infection", "of", "quiescent", "B", "lymphocytes", "by", "Epstein", "-", "Barr", "virus", ".", "\n", "B", "lymphocytes", "in", "the", "peripheral", "circulation", "are", "maintained", "in", "a", "non", "-", "proliferative", "state", ".", "Antigen", "recognition", "stimulates", "limited", "proliferation", ",", "whereas", "infection", "with", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "results", "in", "continual", "proliferation", "and", "the", "outgrowth", "of", "immortal", "cell", "lines", ".", "Because", "it", "is", "not", "clear", "at", "which", "point", "in", "cell", "cycle", "the", "peripheral", "B", "lymphocytes", "are", "arrested", ",", "we", "characterized", "the", "expression", "of", "several", "cell", "cycle", "-", "associated", "genes", "in", "quiescent", "and", "stimulated", "cells", ".", "We", "show", "that", "the", "expression", "of", "four", "cell", "genes", ",", "cdc-2", ",", "cyclin", "E", ",", "CD23", ",", "and", "cyclin", "D2", ",", "are", "up", "-", "regulated", "approximately", "100-fold", "as", "a", "result", "of", "EBV", "-", "mediated", "immortalization", ".", "Because", "these", "genes", "play", "a", "positive", "role", "in", "cell", "proliferation", ",", "we", "suggest", "that", "this", "regulatory", "switch", "contributes", "to", "controlling", "entry", "into", "the", "cell", "cycle", ".", "Transient", "stimulation", "of", "quiescent", "B", "lymphocytes", "with", "either", "a", "cocktail", "of", "anti", "-", "CD40", ",", "anti", "-", "IgM", ",", "and", "IL4", ",", "or", "EBV", "results", "in", "the", "rapid", "expression", "of", "the", "same", "four", "genes", ",", "suggesting", "that", ",", "after", "infection", ",", "EBV", "exploits", "the", "normal", "program", "of", "B", "-", "lymphocyte", "cell", "cycle", "activation", "." ]

[ "Protein" ]

neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ) is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA

405_task0

Sentence: Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida.

[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "65", "años", ",", "alérgico", "al", "contraste", "yodado", ",", "exfumador", "con", "un", "consumo", "acumulado", "de", "70", "paquetes", "-", "año", ",", "sin", "hábito", "enólico", "ni", "factores", "de", "riesgo", "cardiovascular", ".", "Como", "antecedentes", "presentaba", "gota", "y", "litiasis", "renales", "de", "repetición", ";", "sin", "intervenciones", "quirúrgicas", ".", "Como", "medicación", "habitual", ":", "alopurinol", ",", "pregabalina", "y", "paracetamol", ".", "\n", "Su", "historia", "oncológica", "empieza", "en", "febrero", "de", "2016", ",", "estando", "asintomático", ",", "acude", "a", "un", "centro", "privado", "para", "realizar", "una", "analítica", "de", "control", ",", "en", "la", "que", "se", "objetiva", "un", "CEA", "elevado", "(", "788", "μg", "/", "l", ";", "normal", "<", "5,0", ")", ".", "Se", "indica", "realización", "de", "colonoscopia", ",", "que", "descarta", "neoplasia", "de", "colon", ".", "Tras", "ello", ",", "se", "realiza", "un", "TC", "toracoabdominal", ",", "en", "la", "que", "se", "observan", "3", "nódulos", "pulmonares", ",", "uno", "subpleural", "anterior", "en", "lóbulo", "superior", "derecho", ",", "irregular", "de", "24", "x", "17", "mm", ",", "otro", "espiculado", "yuxtacisural", "en", "lóbulo", "inferior", "izquierdo", "(", "LII", ")", "de", "18", "x", "13", "mm", ",", "y", "el", "último", "subsólido", "en", "LII", ".", "Además", ",", "se", "observan", "múltiples", "adenopatías", "patológicas", "supra", "e", "infradiafragmáticas", ".", "Ante", "estos", "hallazgos", ",", "se", "deriva", "a", "nuestro", "centro", ",", "donde", ",", "en", "comité", ",", "se", "decide", "la", "realización", "de", "mediastinoscopia", "para", "obtener", "diagnóstico", "histológico", ".", "Se", "puncionan", "dos", "adenopatías", "del", "nivel", "6", ",", "cuyo", "análisis", "anatomopatológico", "resulta", "positivo", "para", "adenocarcinoma", "de", "origen", "pulmonar", "(", "CK7", "y", "TTF1", "positivos", ")", ",", "cuya", "biología", "molecular", "es", "EFGR", "wild", "type", "y", "ALK", "no", "traslocado", ".", "\n", "Es", "valorado", "como", "adenocarcinoma", "de", "pulmón", "estadio", "IV", "(", "T1bN3M1b", ")", "y", ",", "dentro", "de", "comité", ",", "se", "decide", "iniciar", "tratamiento", "de", "1L", "dentro", "del", "ensayo", "clínico", "GO29436", "(", "CBCDA", "-", "taxol", "+", "bevacizumab", "vs", ".", "CBCDA", "-", "tazol", "+", "atezolizumab", "con", "o", "sin", "bevacizumab", ")", ",", "siendo", "aleatorizado", "a", "la", "rama", "CBCDA", "-", "taxol", "+", "bevacizumab", ".", "Se", "administraron", "6", "ciclos", "de", "CBCDA", "-", "taxol", "+", "bevacizumab", "cada", "3", "semanas", "(", "C1", "el", "06/05/2016", ",", "y", "C6", "25/08/2018", ")", ",", "sin", "toxicidades", "destacables", ".", "Posteriormente", ",", "continuó", "con", "bevacizumab", "de", "mantenimiento", "trisemanal", ",", "hasta", "aparición", "de", "toxicidad", "inaceptable", "o", "progresión", "de", "la", "enfermedad", ",", "presentando", "como", "mejor", "resultado", "una", "respuesta", "parcial", "del", "67", "%", "según", "criterios", "RECIST", "1,1", "el", "05/12/2016", ",", "manteniendo", "dicha", "respuesta", "en", "los", "TC", "posteriores", ".", "Continúa", "recibiendo", "bevacizumab", "de", "mantenimiento", "bien", "tolerado", ",", "hasta", "el", "C34", "(", "05/04/2018", ")", ",", "cuando", "aparece", "elevación", "de", "las", "transaminasas", "G1", ".", "Según", "el", "protocolo", "del", "estudio", ",", "se", "permite", "continuar", "con", "el", "tratamiento", ",", "por", "lo", "que", "se", "administra", "dicho", "ciclo", ".", "Tres", "semanas", "más", "tarde", ",", "el", "paciente", "acude", "a", "valorar", "el", "C35", ",", "el", "cual", "no", "se", "puede", "administrar", "debido", "a", "un", "empeoramiento", "de", "la", "hipertransaminasemia", "hasta", "G4", ".", "Es", "valorado", "en", "este", "momento", "como", "toxicidad", "farmacológica", "vs", ".", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "realiza", "un", "TC", "toracoabdominal", "que", "muestra", "enfermedad", "estable", "sin", "afectación", "hepática", ".", "\n", "El", "10/05/2018", "el", "paciente", "consulta", "por", "aparición", "de", "dolor", "en", "hipocondrio", "derecho", ",", "sin", "fiebre", "ni", "otra", "sintomatología", ".", "Se", "realiza", "analítica", "persistiendo", "hipertransaminasemia", "G4", ",", "con", "aparición", "de", "hiperbilirrubinemia", "G3", "y", "elevación", "de", "enzimas", "de", "colestasis", "G3", ".", "Se", "realiza", "ecografía", "abdominal", "urgente", "que", "muestra", "discreta", "dilatación", "de", "vía", "biliar", "intrahepática", "sin", "objetivar", "litiasis", "ni", "otra", "causa", "obstructiva", ".", "Ante", "la", "ausencia", "de", "signos", "de", "alarma", "en", "ese", "momento", ",", "se", "decide", "completar", "el", "estudio", "de", "forma", "ambulatoria", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "vuelve", "a", "consulta", "a", "los", "5", "días", "por", "persistencia", "del", "dolor", ",", "además", "de", "aparición", "de", "fiebre", ",", "prurito", ",", "coluria", ",", "acolia", "e", "ictericia", ".", "En", "la", "exploración", "física", ",", "destacaba", "ictericia", "conjuntiva", "y", "dolor", "en", "hipocondrio", "derecho", "con", "Murphy", "negativo", ".", "El", "resto", "de", "la", "exploración", "física", "fue", "anodina", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "nueva", "analítica", "en", "la", "que", "se", "observa", "un", "incremento", "de", "la", "bilirrubina", "hasta", "129", "mmol", "/", "l", ",", "además", "de", "un", "aumento", "de", "reactantes", "de", "fase", "aguda", "(", "PCR", "y", "leucocitosis", ")", ".", "Se", "repite", "la", "ecografía", "abdominal", ",", "sin", "cambios", "respecto", "a", "la", "previa", ".", "En", "esta", "ocasión", ",", "se", "orienta", "como", "colangitis", ",", "se", "inicia", "antibioterapia", "empírica", "con", "ertapenem", ",", "y", "se", "decide", "ingreso", "hospitalario", "para", "continuar", "tratamiento", "y", "completar", "estudio", "de", "hepatopatía", ".", "\n", "Como", "diagnóstico", "diferencial", "de", "la", "alteración", "de", "la", "bioquímica", "hepática", ",", "se", "plantearon", "las", "siguientes", "etiologías", ":", "infecciosa", "(", "vírica", ")", ",", "alcohólica", ",", "farmacológica", ",", "metabólica", "(", "enfermedad", "de", "Wilson", ",", "hemocromatosis", ",", "déficit", "de", "alfa-1", "antitripsina", ")", ",", "autoinmune", ",", "litiasis", "y", "neoplásica", ".", "Por", "ello", ",", "en", "primer", "lugar", "se", "realizaron", "serologías", "que", "descartaron", "etiología", "viral", "(", "VHA", ",", "VHB", ",", "VHC", ",", "VHE", ",", "HIV", ",", "CMV", "y", "VEB", ")", ".", "Posteriormente", ",", "se", "realizó", "estudio", "de", "Cu", ",", "ferritina", "y", "alfa-1", "antitripsina", ",", "con", "valores", "dentro", "de", "la", "normalidad", ",", "lo", "que", "descartó", "causa", "metabólica", ".", "Además", ",", "se", "realizó", "despistaje", "de", "etiología", "autoinmune", "con", "determinación", "de", "anticuerpos", "resultando", "todos", "negativos", ".", "El", "paciente", "no", "era", "consumidor", "de", "alcohol", ",", "por", "lo", "que", "se", "descartó", "de", "forma", "razonable", "la", "etiología", "enólica", ".", "Para", "descartar", "etiología", "tumoral", ",", "se", "realizó", "una", "PET", "/", "TC", ",", "no", "mostró", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "la", "etiología", "tumoral", "parecía", "poco", "probable", ".", "Más", "adelante", "se", "completó", "estudio", "mediante", "colangio", "-", "RM", "que", "mostró", "dilatación", "de", "la", "vía", "biliar", "intrahepática", ",", "sin", "litiasis", "ni", "lesiones", "tumorales", "responsables", "de", "dicha", "dilatación", ".", "Fue", "en", "dicha", "prueba", "donde", "se", "detectaron", "alteraciones", "de", "la", "vía", "biliar", "intrahepática", "sugestivas", "de", "colangitis", "esclerosante", "(", "CE", ")", ".", "\n", "El", "diagnóstico", "definitivo", "de", "CE", "debería", "ser", "por", "biopsia", "hepática", ",", "pero", "se", "consensuó", "que", ",", "dada", "la", "intensa", "colestasis", "del", "paciente", ",", "el", "alto", "riesgo", "de", "sangrado", "no", "superaba", "el", "beneficio", "potencial", "de", "un", "diagnóstico", "definitivo", ",", "motivo", "por", "el", "cual", "no", "se", "realizó", "dicha", "la", "biopsia", ".", "\n\n", "Diagnóstico", "\n", "Existen", "dos", "tipos", "fundamentales", "de", "CE", ":", "la", "primaria", "(", "diagnóstico", "de", "exclusión", ")", "y", "la", "secundaria", ".", "De", "entre", "las", "etiologías", "de", "la", "CES", "a", "descartar", "en", "nuestro", "paciente", ",", "las", "más", "destacables", "serían", "neoplásica", "y", "la", "farmacológica", ".", "En", "nuestro", "paciente", "ya", "se", "habían", "realizado", "una", "TC", "toracoabdominal", "y", "una", "PET", "/", "TC", "que", "descartaban", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "orientó", "como", "diagnóstico", "más", "probable", "CES", "farmacológico", "probablemente", "por", "bevacizumab", ".", "Aunque", "la", "CES", "por", "bevacizumab", "no", "es", "una", "toxicidad", "descrita", "en", "ficha", "médica", ",", "sí", "que", "existen", "dos", "case", "reports", "publicados", "en", "la", "literatura", "que", "relacionan", "este", "fármaco", "con", "dicho", "efecto", "adverso", ".", "\n\n", "Tratamiento", "\n", "Ante", "esta", "sospecha", "diagnóstica", "se", "empezó", "tratamiento", "específico", "con", "prednisona", ",", "y", "sintomático", "con", "resincolestiramina", "y", "fenobarbital", ",", "sin", "mejoría", "de", "la", "función", "hepática", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "el", "paciente", "asoció", "un", "cuadro", "de", "insuficiencia", "renal", "e", "hipertensión", "arterial", "(", "HTA", ")", ".", "Como", "parte", "del", "estudio", "de", "dicha", "alteración", ",", "se", "realizó", "un", "estudio", "de", "orina", "en", "24", "horas", "que", "detectó", "proteinuria", "(", "proteínas", "5,23", "g", "/", "día", ")", ",", "con", "microhematuria", "en", "el", "sedimento", "urinario", ".", "Ante", "estos", "hallazgos", ",", "y", "bajo", "la", "sospecha", "de", "glomerulopatía", ",", "se", "decidió", "realizar", "nuevo", "despistaje", "de", "autoinmunidad", "con", "anticuerpos", "negativos", ",", "y", "complemento", "e", "inmunoglobulinas", "dentro", "de", "la", "normalidad", ".", "Para", "el", "diagnóstico", "definitivo", "se", "realizó", "una", "biopsia", "renal", ",", "cuyo", "resultado", "fue", "de", "glomerulonefritis", "con", "depósitos", "de", "IgA", "y", "lambda", ",", "depósitos", "de", "lípidos", "y", "células", "espumosas", "en", "glomérulos", "y", "microangiopatía", "trombótica", "(", "MAT", ")", "con", "afectación", "exclusiva", "glomerular", ".", "La", "etiología", "de", "dichos", "hallazgos", "nuevamente", ",", "en", "el", "contexto", "de", "nuestro", "paciente", ",", "podría", "ser", "secundaria", "a", "neoplasia", "o", "a", "bevacizumab", ".", "Valorándose", "en", "este", "momento", "como", "HTA", ",", "síndrome", "nefrótico", "y", "MAT", "secundarios", "a", "bevacizumab", ",", "ya", "que", "los", "tres", "son", "efectos", "adversos", "conocidos", "de", "este", "fármaco", ",", "sin", "poder", "establecer", "la", "etiología", "de", "la", "glomerulonefritis", "IgA.", "\n", "Por", "otra", "parte", ",", "en", "los", "sucesivos", "controles", "se", "observó", "un", "aumento", "de", "la", "ferritina", "y", "los", "triglicéridos", "que", ",", "junto", "con", "la", "Anatomía", "Patológica", "obtenida", "de", "la", "biopsia", "renal", ",", "podría", "ser", "compatible", "con", "un", "síndrome", "hemofagocítico", ".", "Sin", "embargo", ",", "no", "cumplía", "criterios", "diagnósticos", ",", "como", "fiebre", ",", "esplenomegalia", "o", "citopenias", ",", "por", "lo", "que", "se", "decidió", "no", "completar", "el", "estudio", "mediante", "aspirado", "de", "médula", "ósea", ",", "por", "lo", "que", "no", "fue", "posible", "confirmar", "dicha", "sospecha", "diagnóstica", ".", "\n", "Finalmente", ",", "el", "paciente", "presentó", "evolución", "tórpida", "con", "empeoramiento", "grave", "de", "la", "función", "hepática", "y", "renal", "a", "pesar", "del", "tratamiento", "instaurado", ",", "con", "desarrollo", "de", "fracaso", "multiorgánico", ",", "siendo", "finalmente", "exitus", ".", "Se", "decidió", "solicitar", "necropsia", "para", "confirmar", "la", "etiología", "del", "cuadro", "que", "había", "sufrido", "el", "paciente", "en", "sus", "últimas", "semanas", "de", "vida", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ) is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, neoplásica is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA

405_task1

Sentence: Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida. Instructions: please typing these entity words according to sentence: neoplasia, adenocarcinoma, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ), neoplásica, tumoral, tumoral, tumorales, neoplásica, neoplasia Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida.

[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "65", "años", ",", "alérgico", "al", "contraste", "yodado", ",", "exfumador", "con", "un", "consumo", "acumulado", "de", "70", "paquetes", "-", "año", ",", "sin", "hábito", "enólico", "ni", "factores", "de", "riesgo", "cardiovascular", ".", "Como", "antecedentes", "presentaba", "gota", "y", "litiasis", "renales", "de", "repetición", ";", "sin", "intervenciones", "quirúrgicas", ".", "Como", "medicación", "habitual", ":", "alopurinol", ",", "pregabalina", "y", "paracetamol", ".", "\n", "Su", "historia", "oncológica", "empieza", "en", "febrero", "de", "2016", ",", "estando", "asintomático", ",", "acude", "a", "un", "centro", "privado", "para", "realizar", "una", "analítica", "de", "control", ",", "en", "la", "que", "se", "objetiva", "un", "CEA", "elevado", "(", "788", "μg", "/", "l", ";", "normal", "<", "5,0", ")", ".", "Se", "indica", "realización", "de", "colonoscopia", ",", "que", "descarta", "neoplasia", "de", "colon", ".", "Tras", "ello", ",", "se", "realiza", "un", "TC", "toracoabdominal", ",", "en", "la", "que", "se", "observan", "3", "nódulos", "pulmonares", ",", "uno", "subpleural", "anterior", "en", "lóbulo", "superior", "derecho", ",", "irregular", "de", "24", "x", "17", "mm", ",", "otro", "espiculado", "yuxtacisural", "en", "lóbulo", "inferior", "izquierdo", "(", "LII", ")", "de", "18", "x", "13", "mm", ",", "y", "el", "último", "subsólido", "en", "LII", ".", "Además", ",", "se", "observan", "múltiples", "adenopatías", "patológicas", "supra", "e", "infradiafragmáticas", ".", "Ante", "estos", "hallazgos", ",", "se", "deriva", "a", "nuestro", "centro", ",", "donde", ",", "en", "comité", ",", "se", "decide", "la", "realización", "de", "mediastinoscopia", "para", "obtener", "diagnóstico", "histológico", ".", "Se", "puncionan", "dos", "adenopatías", "del", "nivel", "6", ",", "cuyo", "análisis", "anatomopatológico", "resulta", "positivo", "para", "adenocarcinoma", "de", "origen", "pulmonar", "(", "CK7", "y", "TTF1", "positivos", ")", ",", "cuya", "biología", "molecular", "es", "EFGR", "wild", "type", "y", "ALK", "no", "traslocado", ".", "\n", "Es", "valorado", "como", "adenocarcinoma", "de", "pulmón", "estadio", "IV", "(", "T1bN3M1b", ")", "y", ",", "dentro", "de", "comité", ",", "se", "decide", "iniciar", "tratamiento", "de", "1L", "dentro", "del", "ensayo", "clínico", "GO29436", "(", "CBCDA", "-", "taxol", "+", "bevacizumab", "vs", ".", "CBCDA", "-", "tazol", "+", "atezolizumab", "con", "o", "sin", "bevacizumab", ")", ",", "siendo", "aleatorizado", "a", "la", "rama", "CBCDA", "-", "taxol", "+", "bevacizumab", ".", "Se", "administraron", "6", "ciclos", "de", "CBCDA", "-", "taxol", "+", "bevacizumab", "cada", "3", "semanas", "(", "C1", "el", "06/05/2016", ",", "y", "C6", "25/08/2018", ")", ",", "sin", "toxicidades", "destacables", ".", "Posteriormente", ",", "continuó", "con", "bevacizumab", "de", "mantenimiento", "trisemanal", ",", "hasta", "aparición", "de", "toxicidad", "inaceptable", "o", "progresión", "de", "la", "enfermedad", ",", "presentando", "como", "mejor", "resultado", "una", "respuesta", "parcial", "del", "67", "%", "según", "criterios", "RECIST", "1,1", "el", "05/12/2016", ",", "manteniendo", "dicha", "respuesta", "en", "los", "TC", "posteriores", ".", "Continúa", "recibiendo", "bevacizumab", "de", "mantenimiento", "bien", "tolerado", ",", "hasta", "el", "C34", "(", "05/04/2018", ")", ",", "cuando", "aparece", "elevación", "de", "las", "transaminasas", "G1", ".", "Según", "el", "protocolo", "del", "estudio", ",", "se", "permite", "continuar", "con", "el", "tratamiento", ",", "por", "lo", "que", "se", "administra", "dicho", "ciclo", ".", "Tres", "semanas", "más", "tarde", ",", "el", "paciente", "acude", "a", "valorar", "el", "C35", ",", "el", "cual", "no", "se", "puede", "administrar", "debido", "a", "un", "empeoramiento", "de", "la", "hipertransaminasemia", "hasta", "G4", ".", "Es", "valorado", "en", "este", "momento", "como", "toxicidad", "farmacológica", "vs", ".", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "realiza", "un", "TC", "toracoabdominal", "que", "muestra", "enfermedad", "estable", "sin", "afectación", "hepática", ".", "\n", "El", "10/05/2018", "el", "paciente", "consulta", "por", "aparición", "de", "dolor", "en", "hipocondrio", "derecho", ",", "sin", "fiebre", "ni", "otra", "sintomatología", ".", "Se", "realiza", "analítica", "persistiendo", "hipertransaminasemia", "G4", ",", "con", "aparición", "de", "hiperbilirrubinemia", "G3", "y", "elevación", "de", "enzimas", "de", "colestasis", "G3", ".", "Se", "realiza", "ecografía", "abdominal", "urgente", "que", "muestra", "discreta", "dilatación", "de", "vía", "biliar", "intrahepática", "sin", "objetivar", "litiasis", "ni", "otra", "causa", "obstructiva", ".", "Ante", "la", "ausencia", "de", "signos", "de", "alarma", "en", "ese", "momento", ",", "se", "decide", "completar", "el", "estudio", "de", "forma", "ambulatoria", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "vuelve", "a", "consulta", "a", "los", "5", "días", "por", "persistencia", "del", "dolor", ",", "además", "de", "aparición", "de", "fiebre", ",", "prurito", ",", "coluria", ",", "acolia", "e", "ictericia", ".", "En", "la", "exploración", "física", ",", "destacaba", "ictericia", "conjuntiva", "y", "dolor", "en", "hipocondrio", "derecho", "con", "Murphy", "negativo", ".", "El", "resto", "de", "la", "exploración", "física", "fue", "anodina", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "nueva", "analítica", "en", "la", "que", "se", "observa", "un", "incremento", "de", "la", "bilirrubina", "hasta", "129", "mmol", "/", "l", ",", "además", "de", "un", "aumento", "de", "reactantes", "de", "fase", "aguda", "(", "PCR", "y", "leucocitosis", ")", ".", "Se", "repite", "la", "ecografía", "abdominal", ",", "sin", "cambios", "respecto", "a", "la", "previa", ".", "En", "esta", "ocasión", ",", "se", "orienta", "como", "colangitis", ",", "se", "inicia", "antibioterapia", "empírica", "con", "ertapenem", ",", "y", "se", "decide", "ingreso", "hospitalario", "para", "continuar", "tratamiento", "y", "completar", "estudio", "de", "hepatopatía", ".", "\n", "Como", "diagnóstico", "diferencial", "de", "la", "alteración", "de", "la", "bioquímica", "hepática", ",", "se", "plantearon", "las", "siguientes", "etiologías", ":", "infecciosa", "(", "vírica", ")", ",", "alcohólica", ",", "farmacológica", ",", "metabólica", "(", "enfermedad", "de", "Wilson", ",", "hemocromatosis", ",", "déficit", "de", "alfa-1", "antitripsina", ")", ",", "autoinmune", ",", "litiasis", "y", "neoplásica", ".", "Por", "ello", ",", "en", "primer", "lugar", "se", "realizaron", "serologías", "que", "descartaron", "etiología", "viral", "(", "VHA", ",", "VHB", ",", "VHC", ",", "VHE", ",", "HIV", ",", "CMV", "y", "VEB", ")", ".", "Posteriormente", ",", "se", "realizó", "estudio", "de", "Cu", ",", "ferritina", "y", "alfa-1", "antitripsina", ",", "con", "valores", "dentro", "de", "la", "normalidad", ",", "lo", "que", "descartó", "causa", "metabólica", ".", "Además", ",", "se", "realizó", "despistaje", "de", "etiología", "autoinmune", "con", "determinación", "de", "anticuerpos", "resultando", "todos", "negativos", ".", "El", "paciente", "no", "era", "consumidor", "de", "alcohol", ",", "por", "lo", "que", "se", "descartó", "de", "forma", "razonable", "la", "etiología", "enólica", ".", "Para", "descartar", "etiología", "tumoral", ",", "se", "realizó", "una", "PET", "/", "TC", ",", "no", "mostró", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "la", "etiología", "tumoral", "parecía", "poco", "probable", ".", "Más", "adelante", "se", "completó", "estudio", "mediante", "colangio", "-", "RM", "que", "mostró", "dilatación", "de", "la", "vía", "biliar", "intrahepática", ",", "sin", "litiasis", "ni", "lesiones", "tumorales", "responsables", "de", "dicha", "dilatación", ".", "Fue", "en", "dicha", "prueba", "donde", "se", "detectaron", "alteraciones", "de", "la", "vía", "biliar", "intrahepática", "sugestivas", "de", "colangitis", "esclerosante", "(", "CE", ")", ".", "\n", "El", "diagnóstico", "definitivo", "de", "CE", "debería", "ser", "por", "biopsia", "hepática", ",", "pero", "se", "consensuó", "que", ",", "dada", "la", "intensa", "colestasis", "del", "paciente", ",", "el", "alto", "riesgo", "de", "sangrado", "no", "superaba", "el", "beneficio", "potencial", "de", "un", "diagnóstico", "definitivo", ",", "motivo", "por", "el", "cual", "no", "se", "realizó", "dicha", "la", "biopsia", ".", "\n\n", "Diagnóstico", "\n", "Existen", "dos", "tipos", "fundamentales", "de", "CE", ":", "la", "primaria", "(", "diagnóstico", "de", "exclusión", ")", "y", "la", "secundaria", ".", "De", "entre", "las", "etiologías", "de", "la", "CES", "a", "descartar", "en", "nuestro", "paciente", ",", "las", "más", "destacables", "serían", "neoplásica", "y", "la", "farmacológica", ".", "En", "nuestro", "paciente", "ya", "se", "habían", "realizado", "una", "TC", "toracoabdominal", "y", "una", "PET", "/", "TC", "que", "descartaban", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "orientó", "como", "diagnóstico", "más", "probable", "CES", "farmacológico", "probablemente", "por", "bevacizumab", ".", "Aunque", "la", "CES", "por", "bevacizumab", "no", "es", "una", "toxicidad", "descrita", "en", "ficha", "médica", ",", "sí", "que", "existen", "dos", "case", "reports", "publicados", "en", "la", "literatura", "que", "relacionan", "este", "fármaco", "con", "dicho", "efecto", "adverso", ".", "\n\n", "Tratamiento", "\n", "Ante", "esta", "sospecha", "diagnóstica", "se", "empezó", "tratamiento", "específico", "con", "prednisona", ",", "y", "sintomático", "con", "resincolestiramina", "y", "fenobarbital", ",", "sin", "mejoría", "de", "la", "función", "hepática", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "el", "paciente", "asoció", "un", "cuadro", "de", "insuficiencia", "renal", "e", "hipertensión", "arterial", "(", "HTA", ")", ".", "Como", "parte", "del", "estudio", "de", "dicha", "alteración", ",", "se", "realizó", "un", "estudio", "de", "orina", "en", "24", "horas", "que", "detectó", "proteinuria", "(", "proteínas", "5,23", "g", "/", "día", ")", ",", "con", "microhematuria", "en", "el", "sedimento", "urinario", ".", "Ante", "estos", "hallazgos", ",", "y", "bajo", "la", "sospecha", "de", "glomerulopatía", ",", "se", "decidió", "realizar", "nuevo", "despistaje", "de", "autoinmunidad", "con", "anticuerpos", "negativos", ",", "y", "complemento", "e", "inmunoglobulinas", "dentro", "de", "la", "normalidad", ".", "Para", "el", "diagnóstico", "definitivo", "se", "realizó", "una", "biopsia", "renal", ",", "cuyo", "resultado", "fue", "de", "glomerulonefritis", "con", "depósitos", "de", "IgA", "y", "lambda", ",", "depósitos", "de", "lípidos", "y", "células", "espumosas", "en", "glomérulos", "y", "microangiopatía", "trombótica", "(", "MAT", ")", "con", "afectación", "exclusiva", "glomerular", ".", "La", "etiología", "de", "dichos", "hallazgos", "nuevamente", ",", "en", "el", "contexto", "de", "nuestro", "paciente", ",", "podría", "ser", "secundaria", "a", "neoplasia", "o", "a", "bevacizumab", ".", "Valorándose", "en", "este", "momento", "como", "HTA", ",", "síndrome", "nefrótico", "y", "MAT", "secundarios", "a", "bevacizumab", ",", "ya", "que", "los", "tres", "son", "efectos", "adversos", "conocidos", "de", "este", "fármaco", ",", "sin", "poder", "establecer", "la", "etiología", "de", "la", "glomerulonefritis", "IgA.", "\n", "Por", "otra", "parte", ",", "en", "los", "sucesivos", "controles", "se", "observó", "un", "aumento", "de", "la", "ferritina", "y", "los", "triglicéridos", "que", ",", "junto", "con", "la", "Anatomía", "Patológica", "obtenida", "de", "la", "biopsia", "renal", ",", "podría", "ser", "compatible", "con", "un", "síndrome", "hemofagocítico", ".", "Sin", "embargo", ",", "no", "cumplía", "criterios", "diagnósticos", ",", "como", "fiebre", ",", "esplenomegalia", "o", "citopenias", ",", "por", "lo", "que", "se", "decidió", "no", "completar", "el", "estudio", "mediante", "aspirado", "de", "médula", "ósea", ",", "por", "lo", "que", "no", "fue", "posible", "confirmar", "dicha", "sospecha", "diagnóstica", ".", "\n", "Finalmente", ",", "el", "paciente", "presentó", "evolución", "tórpida", "con", "empeoramiento", "grave", "de", "la", "función", "hepática", "y", "renal", "a", "pesar", "del", "tratamiento", "instaurado", ",", "con", "desarrollo", "de", "fracaso", "multiorgánico", ",", "siendo", "finalmente", "exitus", ".", "Se", "decidió", "solicitar", "necropsia", "para", "confirmar", "la", "etiología", "del", "cuadro", "que", "había", "sufrido", "el", "paciente", "en", "sus", "últimas", "semanas", "de", "vida", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

neoplasia, adenocarcinoma, adenocarcinoma de pulmón estadio IV ( T1bN3M1b ), neoplásica, tumoral, tumoral, tumorales, neoplásica, neoplasia

405_task2

Sentence: Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Se trata de un varón de 65 años, alérgico al contraste yodado, exfumador con un consumo acumulado de 70 paquetes-año, sin hábito enólico ni factores de riesgo cardiovascular. Como antecedentes presentaba gota y litiasis renales de repetición; sin intervenciones quirúrgicas. Como medicación habitual: alopurinol, pregabalina y paracetamol. Su historia oncológica empieza en febrero de 2016, estando asintomático, acude a un centro privado para realizar una analítica de control, en la que se objetiva un CEA elevado (788 μg/l; normal < 5,0). Se indica realización de colonoscopia, que descarta neoplasia de colon. Tras ello, se realiza un TC toracoabdominal, en la que se observan 3 nódulos pulmonares, uno subpleural anterior en lóbulo superior derecho, irregular de 24 x 17 mm, otro espiculado yuxtacisural en lóbulo inferior izquierdo (LII) de 18 x 13 mm, y el último subsólido en LII. Además, se observan múltiples adenopatías patológicas supra e infradiafragmáticas. Ante estos hallazgos, se deriva a nuestro centro, donde, en comité, se decide la realización de mediastinoscopia para obtener diagnóstico histológico. Se puncionan dos adenopatías del nivel 6, cuyo análisis anatomopatológico resulta positivo para adenocarcinoma de origen pulmonar (CK7 y TTF1 positivos), cuya biología molecular es EFGR wild type y ALK no traslocado. Es valorado como adenocarcinoma de pulmón estadio IV (T1bN3M1b) y, dentro de comité, se decide iniciar tratamiento de 1L dentro del ensayo clínico GO29436 (CBCDA-taxol + bevacizumab vs. CBCDA-tazol + atezolizumab con o sin bevacizumab), siendo aleatorizado a la rama CBCDA-taxol + bevacizumab. Se administraron 6 ciclos de CBCDA-taxol + bevacizumab cada 3 semanas (C1 el 06/05/2016, y C6 25/08/2018), sin toxicidades destacables. Posteriormente, continuó con bevacizumab de mantenimiento trisemanal, hasta aparición de toxicidad inaceptable o progresión de la enfermedad, presentando como mejor resultado una respuesta parcial del 67 % según criterios RECIST 1,1 el 05/12/2016, manteniendo dicha respuesta en los TC posteriores. Continúa recibiendo bevacizumab de mantenimiento bien tolerado, hasta el C34 (05/04/2018), cuando aparece elevación de las transaminasas G1. Según el protocolo del estudio, se permite continuar con el tratamiento, por lo que se administra dicho ciclo. Tres semanas más tarde, el paciente acude a valorar el C35, el cual no se puede administrar debido a un empeoramiento de la hipertransaminasemia hasta G4. Es valorado en este momento como toxicidad farmacológica vs. progresión de la enfermedad, por lo que se realiza un TC toracoabdominal que muestra enfermedad estable sin afectación hepática. El 10/05/2018 el paciente consulta por aparición de dolor en hipocondrio derecho, sin fiebre ni otra sintomatología. Se realiza analítica persistiendo hipertransaminasemia G4, con aparición de hiperbilirrubinemia G3 y elevación de enzimas de colestasis G3. Se realiza ecografía abdominal urgente que muestra discreta dilatación de vía biliar intrahepática sin objetivar litiasis ni otra causa obstructiva. Ante la ausencia de signos de alarma en ese momento, se decide completar el estudio de forma ambulatoria. Exploración física El paciente vuelve a consulta a los 5 días por persistencia del dolor, además de aparición de fiebre, prurito, coluria, acolia e ictericia. En la exploración física, destacaba ictericia conjuntiva y dolor en hipocondrio derecho con Murphy negativo. El resto de la exploración física fue anodina. Pruebas complementarias Se realiza una nueva analítica en la que se observa un incremento de la bilirrubina hasta 129 mmol/l, además de un aumento de reactantes de fase aguda (PCR y leucocitosis). Se repite la ecografía abdominal, sin cambios respecto a la previa. En esta ocasión, se orienta como colangitis, se inicia antibioterapia empírica con ertapenem, y se decide ingreso hospitalario para continuar tratamiento y completar estudio de hepatopatía. Como diagnóstico diferencial de la alteración de la bioquímica hepática, se plantearon las siguientes etiologías: infecciosa (vírica), alcohólica, farmacológica, metabólica (enfermedad de Wilson, hemocromatosis, déficit de alfa-1 antitripsina), autoinmune, litiasis y neoplásica. Por ello, en primer lugar se realizaron serologías que descartaron etiología viral (VHA, VHB, VHC, VHE, HIV, CMV y VEB). Posteriormente, se realizó estudio de Cu, ferritina y alfa-1 antitripsina, con valores dentro de la normalidad, lo que descartó causa metabólica. Además, se realizó despistaje de etiología autoinmune con determinación de anticuerpos resultando todos negativos. El paciente no era consumidor de alcohol, por lo que se descartó de forma razonable la etiología enólica. Para descartar etiología tumoral, se realizó una PET/TC, no mostró progresión de la enfermedad, por lo que la etiología tumoral parecía poco probable. Más adelante se completó estudio mediante colangio-RM que mostró dilatación de la vía biliar intrahepática, sin litiasis ni lesiones tumorales responsables de dicha dilatación. Fue en dicha prueba donde se detectaron alteraciones de la vía biliar intrahepática sugestivas de colangitis esclerosante (CE). El diagnóstico definitivo de CE debería ser por biopsia hepática, pero se consensuó que, dada la intensa colestasis del paciente, el alto riesgo de sangrado no superaba el beneficio potencial de un diagnóstico definitivo, motivo por el cual no se realizó dicha la biopsia. Diagnóstico Existen dos tipos fundamentales de CE: la primaria (diagnóstico de exclusión) y la secundaria. De entre las etiologías de la CES a descartar en nuestro paciente, las más destacables serían neoplásica y la farmacológica. En nuestro paciente ya se habían realizado una TC toracoabdominal y una PET/TC que descartaban progresión de la enfermedad, por lo que se orientó como diagnóstico más probable CES farmacológico probablemente por bevacizumab. Aunque la CES por bevacizumab no es una toxicidad descrita en ficha médica, sí que existen dos case reports publicados en la literatura que relacionan este fármaco con dicho efecto adverso. Tratamiento Ante esta sospecha diagnóstica se empezó tratamiento específico con prednisona, y sintomático con resincolestiramina y fenobarbital, sin mejoría de la función hepática. Evolución Durante el ingreso, el paciente asoció un cuadro de insuficiencia renal e hipertensión arterial (HTA). Como parte del estudio de dicha alteración, se realizó un estudio de orina en 24 horas que detectó proteinuria (proteínas 5,23 g/día), con microhematuria en el sedimento urinario. Ante estos hallazgos, y bajo la sospecha de glomerulopatía, se decidió realizar nuevo despistaje de autoinmunidad con anticuerpos negativos, y complemento e inmunoglobulinas dentro de la normalidad. Para el diagnóstico definitivo se realizó una biopsia renal, cuyo resultado fue de glomerulonefritis con depósitos de IgA y lambda, depósitos de lípidos y células espumosas en glomérulos y microangiopatía trombótica (MAT) con afectación exclusiva glomerular. La etiología de dichos hallazgos nuevamente, en el contexto de nuestro paciente, podría ser secundaria a neoplasia o a bevacizumab. Valorándose en este momento como HTA, síndrome nefrótico y MAT secundarios a bevacizumab, ya que los tres son efectos adversos conocidos de este fármaco, sin poder establecer la etiología de la glomerulonefritis IgA. Por otra parte, en los sucesivos controles se observó un aumento de la ferritina y los triglicéridos que, junto con la Anatomía Patológica obtenida de la biopsia renal, podría ser compatible con un síndrome hemofagocítico. Sin embargo, no cumplía criterios diagnósticos, como fiebre, esplenomegalia o citopenias, por lo que se decidió no completar el estudio mediante aspirado de médula ósea, por lo que no fue posible confirmar dicha sospecha diagnóstica. Finalmente, el paciente presentó evolución tórpida con empeoramiento grave de la función hepática y renal a pesar del tratamiento instaurado, con desarrollo de fracaso multiorgánico, siendo finalmente exitus. Se decidió solicitar necropsia para confirmar la etiología del cuadro que había sufrido el paciente en sus últimas semanas de vida.

[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "65", "años", ",", "alérgico", "al", "contraste", "yodado", ",", "exfumador", "con", "un", "consumo", "acumulado", "de", "70", "paquetes", "-", "año", ",", "sin", "hábito", "enólico", "ni", "factores", "de", "riesgo", "cardiovascular", ".", "Como", "antecedentes", "presentaba", "gota", "y", "litiasis", "renales", "de", "repetición", ";", "sin", "intervenciones", "quirúrgicas", ".", "Como", "medicación", "habitual", ":", "alopurinol", ",", "pregabalina", "y", "paracetamol", ".", "\n", "Su", "historia", "oncológica", "empieza", "en", "febrero", "de", "2016", ",", "estando", "asintomático", ",", "acude", "a", "un", "centro", "privado", "para", "realizar", "una", "analítica", "de", "control", ",", "en", "la", "que", "se", "objetiva", "un", "CEA", "elevado", "(", "788", "μg", "/", "l", ";", "normal", "<", "5,0", ")", ".", "Se", "indica", "realización", "de", "colonoscopia", ",", "que", "descarta", "neoplasia", "de", "colon", ".", "Tras", "ello", ",", "se", "realiza", "un", "TC", "toracoabdominal", ",", "en", "la", "que", "se", "observan", "3", "nódulos", "pulmonares", ",", "uno", "subpleural", "anterior", "en", "lóbulo", "superior", "derecho", ",", "irregular", "de", "24", "x", "17", "mm", ",", "otro", "espiculado", "yuxtacisural", "en", "lóbulo", "inferior", "izquierdo", "(", "LII", ")", "de", "18", "x", "13", "mm", ",", "y", "el", "último", "subsólido", "en", "LII", ".", "Además", ",", "se", "observan", "múltiples", "adenopatías", "patológicas", "supra", "e", "infradiafragmáticas", ".", "Ante", "estos", "hallazgos", ",", "se", "deriva", "a", "nuestro", "centro", ",", "donde", ",", "en", "comité", ",", "se", "decide", "la", "realización", "de", "mediastinoscopia", "para", "obtener", "diagnóstico", "histológico", ".", "Se", "puncionan", "dos", "adenopatías", "del", "nivel", "6", ",", "cuyo", "análisis", "anatomopatológico", "resulta", "positivo", "para", "adenocarcinoma", "de", "origen", "pulmonar", "(", "CK7", "y", "TTF1", "positivos", ")", ",", "cuya", "biología", "molecular", "es", "EFGR", "wild", "type", "y", "ALK", "no", "traslocado", ".", "\n", "Es", "valorado", "como", "adenocarcinoma", "de", "pulmón", "estadio", "IV", "(", "T1bN3M1b", ")", "y", ",", "dentro", "de", "comité", ",", "se", "decide", "iniciar", "tratamiento", "de", "1L", "dentro", "del", "ensayo", "clínico", "GO29436", "(", "CBCDA", "-", "taxol", "+", "bevacizumab", "vs", ".", "CBCDA", "-", "tazol", "+", "atezolizumab", "con", "o", "sin", "bevacizumab", ")", ",", "siendo", "aleatorizado", "a", "la", "rama", "CBCDA", "-", "taxol", "+", "bevacizumab", ".", "Se", "administraron", "6", "ciclos", "de", "CBCDA", "-", "taxol", "+", "bevacizumab", "cada", "3", "semanas", "(", "C1", "el", "06/05/2016", ",", "y", "C6", "25/08/2018", ")", ",", "sin", "toxicidades", "destacables", ".", "Posteriormente", ",", "continuó", "con", "bevacizumab", "de", "mantenimiento", "trisemanal", ",", "hasta", "aparición", "de", "toxicidad", "inaceptable", "o", "progresión", "de", "la", "enfermedad", ",", "presentando", "como", "mejor", "resultado", "una", "respuesta", "parcial", "del", "67", "%", "según", "criterios", "RECIST", "1,1", "el", "05/12/2016", ",", "manteniendo", "dicha", "respuesta", "en", "los", "TC", "posteriores", ".", "Continúa", "recibiendo", "bevacizumab", "de", "mantenimiento", "bien", "tolerado", ",", "hasta", "el", "C34", "(", "05/04/2018", ")", ",", "cuando", "aparece", "elevación", "de", "las", "transaminasas", "G1", ".", "Según", "el", "protocolo", "del", "estudio", ",", "se", "permite", "continuar", "con", "el", "tratamiento", ",", "por", "lo", "que", "se", "administra", "dicho", "ciclo", ".", "Tres", "semanas", "más", "tarde", ",", "el", "paciente", "acude", "a", "valorar", "el", "C35", ",", "el", "cual", "no", "se", "puede", "administrar", "debido", "a", "un", "empeoramiento", "de", "la", "hipertransaminasemia", "hasta", "G4", ".", "Es", "valorado", "en", "este", "momento", "como", "toxicidad", "farmacológica", "vs", ".", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "realiza", "un", "TC", "toracoabdominal", "que", "muestra", "enfermedad", "estable", "sin", "afectación", "hepática", ".", "\n", "El", "10/05/2018", "el", "paciente", "consulta", "por", "aparición", "de", "dolor", "en", "hipocondrio", "derecho", ",", "sin", "fiebre", "ni", "otra", "sintomatología", ".", "Se", "realiza", "analítica", "persistiendo", "hipertransaminasemia", "G4", ",", "con", "aparición", "de", "hiperbilirrubinemia", "G3", "y", "elevación", "de", "enzimas", "de", "colestasis", "G3", ".", "Se", "realiza", "ecografía", "abdominal", "urgente", "que", "muestra", "discreta", "dilatación", "de", "vía", "biliar", "intrahepática", "sin", "objetivar", "litiasis", "ni", "otra", "causa", "obstructiva", ".", "Ante", "la", "ausencia", "de", "signos", "de", "alarma", "en", "ese", "momento", ",", "se", "decide", "completar", "el", "estudio", "de", "forma", "ambulatoria", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "vuelve", "a", "consulta", "a", "los", "5", "días", "por", "persistencia", "del", "dolor", ",", "además", "de", "aparición", "de", "fiebre", ",", "prurito", ",", "coluria", ",", "acolia", "e", "ictericia", ".", "En", "la", "exploración", "física", ",", "destacaba", "ictericia", "conjuntiva", "y", "dolor", "en", "hipocondrio", "derecho", "con", "Murphy", "negativo", ".", "El", "resto", "de", "la", "exploración", "física", "fue", "anodina", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "nueva", "analítica", "en", "la", "que", "se", "observa", "un", "incremento", "de", "la", "bilirrubina", "hasta", "129", "mmol", "/", "l", ",", "además", "de", "un", "aumento", "de", "reactantes", "de", "fase", "aguda", "(", "PCR", "y", "leucocitosis", ")", ".", "Se", "repite", "la", "ecografía", "abdominal", ",", "sin", "cambios", "respecto", "a", "la", "previa", ".", "En", "esta", "ocasión", ",", "se", "orienta", "como", "colangitis", ",", "se", "inicia", "antibioterapia", "empírica", "con", "ertapenem", ",", "y", "se", "decide", "ingreso", "hospitalario", "para", "continuar", "tratamiento", "y", "completar", "estudio", "de", "hepatopatía", ".", "\n", "Como", "diagnóstico", "diferencial", "de", "la", "alteración", "de", "la", "bioquímica", "hepática", ",", "se", "plantearon", "las", "siguientes", "etiologías", ":", "infecciosa", "(", "vírica", ")", ",", "alcohólica", ",", "farmacológica", ",", "metabólica", "(", "enfermedad", "de", "Wilson", ",", "hemocromatosis", ",", "déficit", "de", "alfa-1", "antitripsina", ")", ",", "autoinmune", ",", "litiasis", "y", "neoplásica", ".", "Por", "ello", ",", "en", "primer", "lugar", "se", "realizaron", "serologías", "que", "descartaron", "etiología", "viral", "(", "VHA", ",", "VHB", ",", "VHC", ",", "VHE", ",", "HIV", ",", "CMV", "y", "VEB", ")", ".", "Posteriormente", ",", "se", "realizó", "estudio", "de", "Cu", ",", "ferritina", "y", "alfa-1", "antitripsina", ",", "con", "valores", "dentro", "de", "la", "normalidad", ",", "lo", "que", "descartó", "causa", "metabólica", ".", "Además", ",", "se", "realizó", "despistaje", "de", "etiología", "autoinmune", "con", "determinación", "de", "anticuerpos", "resultando", "todos", "negativos", ".", "El", "paciente", "no", "era", "consumidor", "de", "alcohol", ",", "por", "lo", "que", "se", "descartó", "de", "forma", "razonable", "la", "etiología", "enólica", ".", "Para", "descartar", "etiología", "tumoral", ",", "se", "realizó", "una", "PET", "/", "TC", ",", "no", "mostró", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "la", "etiología", "tumoral", "parecía", "poco", "probable", ".", "Más", "adelante", "se", "completó", "estudio", "mediante", "colangio", "-", "RM", "que", "mostró", "dilatación", "de", "la", "vía", "biliar", "intrahepática", ",", "sin", "litiasis", "ni", "lesiones", "tumorales", "responsables", "de", "dicha", "dilatación", ".", "Fue", "en", "dicha", "prueba", "donde", "se", "detectaron", "alteraciones", "de", "la", "vía", "biliar", "intrahepática", "sugestivas", "de", "colangitis", "esclerosante", "(", "CE", ")", ".", "\n", "El", "diagnóstico", "definitivo", "de", "CE", "debería", "ser", "por", "biopsia", "hepática", ",", "pero", "se", "consensuó", "que", ",", "dada", "la", "intensa", "colestasis", "del", "paciente", ",", "el", "alto", "riesgo", "de", "sangrado", "no", "superaba", "el", "beneficio", "potencial", "de", "un", "diagnóstico", "definitivo", ",", "motivo", "por", "el", "cual", "no", "se", "realizó", "dicha", "la", "biopsia", ".", "\n\n", "Diagnóstico", "\n", "Existen", "dos", "tipos", "fundamentales", "de", "CE", ":", "la", "primaria", "(", "diagnóstico", "de", "exclusión", ")", "y", "la", "secundaria", ".", "De", "entre", "las", "etiologías", "de", "la", "CES", "a", "descartar", "en", "nuestro", "paciente", ",", "las", "más", "destacables", "serían", "neoplásica", "y", "la", "farmacológica", ".", "En", "nuestro", "paciente", "ya", "se", "habían", "realizado", "una", "TC", "toracoabdominal", "y", "una", "PET", "/", "TC", "que", "descartaban", "progresión", "de", "la", "enfermedad", ",", "por", "lo", "que", "se", "orientó", "como", "diagnóstico", "más", "probable", "CES", "farmacológico", "probablemente", "por", "bevacizumab", ".", "Aunque", "la", "CES", "por", "bevacizumab", "no", "es", "una", "toxicidad", "descrita", "en", "ficha", "médica", ",", "sí", "que", "existen", "dos", "case", "reports", "publicados", "en", "la", "literatura", "que", "relacionan", "este", "fármaco", "con", "dicho", "efecto", "adverso", ".", "\n\n", "Tratamiento", "\n", "Ante", "esta", "sospecha", "diagnóstica", "se", "empezó", "tratamiento", "específico", "con", "prednisona", ",", "y", "sintomático", "con", "resincolestiramina", "y", "fenobarbital", ",", "sin", "mejoría", "de", "la", "función", "hepática", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "el", "paciente", "asoció", "un", "cuadro", "de", "insuficiencia", "renal", "e", "hipertensión", "arterial", "(", "HTA", ")", ".", "Como", "parte", "del", "estudio", "de", "dicha", "alteración", ",", "se", "realizó", "un", "estudio", "de", "orina", "en", "24", "horas", "que", "detectó", "proteinuria", "(", "proteínas", "5,23", "g", "/", "día", ")", ",", "con", "microhematuria", "en", "el", "sedimento", "urinario", ".", "Ante", "estos", "hallazgos", ",", "y", "bajo", "la", "sospecha", "de", "glomerulopatía", ",", "se", "decidió", "realizar", "nuevo", "despistaje", "de", "autoinmunidad", "con", "anticuerpos", "negativos", ",", "y", "complemento", "e", "inmunoglobulinas", "dentro", "de", "la", "normalidad", ".", "Para", "el", "diagnóstico", "definitivo", "se", "realizó", "una", "biopsia", "renal", ",", "cuyo", "resultado", "fue", "de", "glomerulonefritis", "con", "depósitos", "de", "IgA", "y", "lambda", ",", "depósitos", "de", "lípidos", "y", "células", "espumosas", "en", "glomérulos", "y", "microangiopatía", "trombótica", "(", "MAT", ")", "con", "afectación", "exclusiva", "glomerular", ".", "La", "etiología", "de", "dichos", "hallazgos", "nuevamente", ",", "en", "el", "contexto", "de", "nuestro", "paciente", ",", "podría", "ser", "secundaria", "a", "neoplasia", "o", "a", "bevacizumab", ".", "Valorándose", "en", "este", "momento", "como", "HTA", ",", "síndrome", "nefrótico", "y", "MAT", "secundarios", "a", "bevacizumab", ",", "ya", "que", "los", "tres", "son", "efectos", "adversos", "conocidos", "de", "este", "fármaco", ",", "sin", "poder", "establecer", "la", "etiología", "de", "la", "glomerulonefritis", "IgA.", "\n", "Por", "otra", "parte", ",", "en", "los", "sucesivos", "controles", "se", "observó", "un", "aumento", "de", "la", "ferritina", "y", "los", "triglicéridos", "que", ",", "junto", "con", "la", "Anatomía", "Patológica", "obtenida", "de", "la", "biopsia", "renal", ",", "podría", "ser", "compatible", "con", "un", "síndrome", "hemofagocítico", ".", "Sin", "embargo", ",", "no", "cumplía", "criterios", "diagnósticos", ",", "como", "fiebre", ",", "esplenomegalia", "o", "citopenias", ",", "por", "lo", "que", "se", "decidió", "no", "completar", "el", "estudio", "mediante", "aspirado", "de", "médula", "ósea", ",", "por", "lo", "que", "no", "fue", "posible", "confirmar", "dicha", "sospecha", "diagnóstica", ".", "\n", "Finalmente", ",", "el", "paciente", "presentó", "evolución", "tórpida", "con", "empeoramiento", "grave", "de", "la", "función", "hepática", "y", "renal", "a", "pesar", "del", "tratamiento", "instaurado", ",", "con", "desarrollo", "de", "fracaso", "multiorgánico", ",", "siendo", "finalmente", "exitus", ".", "Se", "decidió", "solicitar", "necropsia", "para", "confirmar", "la", "etiología", "del", "cuadro", "que", "había", "sufrido", "el", "paciente", "en", "sus", "últimas", "semanas", "de", "vida", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

psoriasis is a DISEASE, psoriasis is a DISEASE, psoriasis is a DISEASE

example-188_task0

Sentence: Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DISEASE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O" ]

Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.

[ "Effect", "of", "Efalizumab", "on", "neutrophil", "and", "monocyte", "functions", "in", "patients", "with", "psoriasis", ".", " ", "We", "evaluated", "the", "effect", "of", "efalizumab", "on", "neutrophil", "and", "monocyte", "functions", ".", "The", "in", "vitro", "pre", "-", "incubation", "with", "efalizumab", "concentrations", "similar", "to", "those", "reached", "during", "in", "vivo", "therapy", "almost", "completely", "saturated", "CD11a", "binding", "sites", "without", "affecting", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "or", "CD128b", ".", "There", "was", "a", "significant", "reduction", "in", "the", "chemotactic", "activity", "of", "the", "pre", "-", "treated", "cells", "toward", "three", "different", "chemo", "-", "attractants", ",", "whereas", "their", "phagocytic", "capacity", "and", "production", "of", "oxygen", "radicals", "remained", "unchanged", ".", "One", "month", "after", "the", "administration", "of", "efalizumab", "to", "five", "patients", "with", "psoriasis", "(", "T1", ")", "circulating", "neutrophil", "counts", "increased", "by", "34", "%", "from", "pre", "-", "therapy", "(", "T0", ")", "with", "no", "change", "in", "the", "number", "of", "monocytes", ".", "In", "the", "same", "patients", "the", "CD11a", "binding", "sites", "on", "phagocytes", "were", ">", "90", "%", "saturated", ",", "and", "there", "was", "also", "a", "significant", "down", "-", "modulation", "on", "neutrophils", "(", "44", "%", "of", "T0", ")", "and", "monocytes", "(", "63", "%", "of", "T0", ")", ".", "In", "line", "with", "in", "vitro", "results", ",", "efalizumab", "treatment", "caused", "a", "significant", "deficiency", "in", "the", "chemotactic", "properties", "of", "neutrophils", "and", "monocytes", ",", "but", "no", "changes", "in", "phagocytosis", ",", "oxidative", "burst", ",", "production", "of", "pro", "-", "inflammatory", "cytokines", "or", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "and", "CD128b", ".", "Our", "findings", "suggest", "that", "neutrophils", "and", "monocytes", "may", "be", "among", "the", "targets", "of", "efalizumab", "activity", "in", "patients", "with", "psoriasis", "." ]

[ "DISEASE" ]

psoriasis is a DISEASE, psoriasis is a DISEASE, psoriasis is a DISEASE

example-188_task1

Sentence: Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis. Instructions: please typing these entity words according to sentence: psoriasis, psoriasis, psoriasis Options: DISEASE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O" ]

Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.

[ "Effect", "of", "Efalizumab", "on", "neutrophil", "and", "monocyte", "functions", "in", "patients", "with", "psoriasis", ".", " ", "We", "evaluated", "the", "effect", "of", "efalizumab", "on", "neutrophil", "and", "monocyte", "functions", ".", "The", "in", "vitro", "pre", "-", "incubation", "with", "efalizumab", "concentrations", "similar", "to", "those", "reached", "during", "in", "vivo", "therapy", "almost", "completely", "saturated", "CD11a", "binding", "sites", "without", "affecting", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "or", "CD128b", ".", "There", "was", "a", "significant", "reduction", "in", "the", "chemotactic", "activity", "of", "the", "pre", "-", "treated", "cells", "toward", "three", "different", "chemo", "-", "attractants", ",", "whereas", "their", "phagocytic", "capacity", "and", "production", "of", "oxygen", "radicals", "remained", "unchanged", ".", "One", "month", "after", "the", "administration", "of", "efalizumab", "to", "five", "patients", "with", "psoriasis", "(", "T1", ")", "circulating", "neutrophil", "counts", "increased", "by", "34", "%", "from", "pre", "-", "therapy", "(", "T0", ")", "with", "no", "change", "in", "the", "number", "of", "monocytes", ".", "In", "the", "same", "patients", "the", "CD11a", "binding", "sites", "on", "phagocytes", "were", ">", "90", "%", "saturated", ",", "and", "there", "was", "also", "a", "significant", "down", "-", "modulation", "on", "neutrophils", "(", "44", "%", "of", "T0", ")", "and", "monocytes", "(", "63", "%", "of", "T0", ")", ".", "In", "line", "with", "in", "vitro", "results", ",", "efalizumab", "treatment", "caused", "a", "significant", "deficiency", "in", "the", "chemotactic", "properties", "of", "neutrophils", "and", "monocytes", ",", "but", "no", "changes", "in", "phagocytosis", ",", "oxidative", "burst", ",", "production", "of", "pro", "-", "inflammatory", "cytokines", "or", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "and", "CD128b", ".", "Our", "findings", "suggest", "that", "neutrophils", "and", "monocytes", "may", "be", "among", "the", "targets", "of", "efalizumab", "activity", "in", "patients", "with", "psoriasis", "." ]

[ "DISEASE" ]

psoriasis, psoriasis, psoriasis

example-188_task2

Sentence: Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "O" ]

Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.

[ "Effect", "of", "Efalizumab", "on", "neutrophil", "and", "monocyte", "functions", "in", "patients", "with", "psoriasis", ".", " ", "We", "evaluated", "the", "effect", "of", "efalizumab", "on", "neutrophil", "and", "monocyte", "functions", ".", "The", "in", "vitro", "pre", "-", "incubation", "with", "efalizumab", "concentrations", "similar", "to", "those", "reached", "during", "in", "vivo", "therapy", "almost", "completely", "saturated", "CD11a", "binding", "sites", "without", "affecting", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "or", "CD128b", ".", "There", "was", "a", "significant", "reduction", "in", "the", "chemotactic", "activity", "of", "the", "pre", "-", "treated", "cells", "toward", "three", "different", "chemo", "-", "attractants", ",", "whereas", "their", "phagocytic", "capacity", "and", "production", "of", "oxygen", "radicals", "remained", "unchanged", ".", "One", "month", "after", "the", "administration", "of", "efalizumab", "to", "five", "patients", "with", "psoriasis", "(", "T1", ")", "circulating", "neutrophil", "counts", "increased", "by", "34", "%", "from", "pre", "-", "therapy", "(", "T0", ")", "with", "no", "change", "in", "the", "number", "of", "monocytes", ".", "In", "the", "same", "patients", "the", "CD11a", "binding", "sites", "on", "phagocytes", "were", ">", "90", "%", "saturated", ",", "and", "there", "was", "also", "a", "significant", "down", "-", "modulation", "on", "neutrophils", "(", "44", "%", "of", "T0", ")", "and", "monocytes", "(", "63", "%", "of", "T0", ")", ".", "In", "line", "with", "in", "vitro", "results", ",", "efalizumab", "treatment", "caused", "a", "significant", "deficiency", "in", "the", "chemotactic", "properties", "of", "neutrophils", "and", "monocytes", ",", "but", "no", "changes", "in", "phagocytosis", ",", "oxidative", "burst", ",", "production", "of", "pro", "-", "inflammatory", "cytokines", "or", "the", "membrane", "expression", "of", "CD11b", ",", "CD128a", "and", "CD128b", ".", "Our", "findings", "suggest", "that", "neutrophils", "and", "monocytes", "may", "be", "among", "the", "targets", "of", "efalizumab", "activity", "in", "patients", "with", "psoriasis", "." ]

[ "DISEASE" ]

Europe is an umlsterm, ultrasonography is an umlsterm, diagnostic is an umlsterm, peritoneal lavage is an umlsterm, survey is an umlsterm, patients is an umlsterm, trauma is an umlsterm, patients is an umlsterm, emergency is an umlsterm, trauma is an umlsterm, operating room is an umlsterm, ultrasonography is an umlsterm, hemoperitoneum is an umlsterm, patients is an umlsterm, ultrasonography is an umlsterm, computed tomography is an umlsterm, evaluation is an umlsterm, sonography is an umlsterm, pathology is an umlsterm, hemoperitoneum is an umlsterm

DerRadiologe.80380693.eng.abstr_task0

Sentence: In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) .

[ "In", "Europe", "ultrasonography", "has", "displaced", "diagnostic", "peritoneal", "lavage", "(", "DPL", ")", "in", "the", "primary", "survey", "of", "polytraumatized", "patients", "with", "suspected", "abdominal", "trauma", ".", "Hemodynamically", "unstable", "patients", "who", "are", "brought", "to", "the", "emergency", "room", "with", "blunt", "abdominal", "trauma", "will", "go", "directly", "to", "the", "operating", "room", "after", "a", "rapid", "ultrasonography", "examination", "with", "evidence", "of", "hemoperitoneum", ".", "In", "hemodynamically", "stable", "patients", ",", "in", "addition", "to", "ultrasonography", ",", "computed", "tomography", "can", "be", "done", ".", "This", "is", "especially", "efficient", "if", "evaluation", "with", "sonography", "is", "not", "completely", "possible", "or", "shows", "little", "pathology", "(", "e.g", ".", "small", "amounts", "of", "hemoperitoneum", ")", "." ]

[ "umlsterm" ]

Europe is an umlsterm, ultrasonography is an umlsterm, diagnostic is an umlsterm, peritoneal lavage is an umlsterm, survey is an umlsterm, patients is an umlsterm, trauma is an umlsterm, patients is an umlsterm, emergency is an umlsterm, trauma is an umlsterm, operating room is an umlsterm, ultrasonography is an umlsterm, hemoperitoneum is an umlsterm, patients is an umlsterm, ultrasonography is an umlsterm, computed tomography is an umlsterm, evaluation is an umlsterm, sonography is an umlsterm, pathology is an umlsterm, hemoperitoneum is an umlsterm

DerRadiologe.80380693.eng.abstr_task1

Sentence: In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) . Instructions: please typing these entity words according to sentence: Europe, ultrasonography, diagnostic, peritoneal lavage, survey, patients, trauma, patients, emergency, trauma, operating room, ultrasonography, hemoperitoneum, patients, ultrasonography, computed tomography, evaluation, sonography, pathology, hemoperitoneum Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) .

[ "In", "Europe", "ultrasonography", "has", "displaced", "diagnostic", "peritoneal", "lavage", "(", "DPL", ")", "in", "the", "primary", "survey", "of", "polytraumatized", "patients", "with", "suspected", "abdominal", "trauma", ".", "Hemodynamically", "unstable", "patients", "who", "are", "brought", "to", "the", "emergency", "room", "with", "blunt", "abdominal", "trauma", "will", "go", "directly", "to", "the", "operating", "room", "after", "a", "rapid", "ultrasonography", "examination", "with", "evidence", "of", "hemoperitoneum", ".", "In", "hemodynamically", "stable", "patients", ",", "in", "addition", "to", "ultrasonography", ",", "computed", "tomography", "can", "be", "done", ".", "This", "is", "especially", "efficient", "if", "evaluation", "with", "sonography", "is", "not", "completely", "possible", "or", "shows", "little", "pathology", "(", "e.g", ".", "small", "amounts", "of", "hemoperitoneum", ")", "." ]

[ "umlsterm" ]

Europe, ultrasonography, diagnostic, peritoneal lavage, survey, patients, trauma, patients, emergency, trauma, operating room, ultrasonography, hemoperitoneum, patients, ultrasonography, computed tomography, evaluation, sonography, pathology, hemoperitoneum

DerRadiologe.80380693.eng.abstr_task2

Sentence: In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

In Europe ultrasonography has displaced diagnostic peritoneal lavage ( DPL ) in the primary survey of polytraumatized patients with suspected abdominal trauma . Hemodynamically unstable patients who are brought to the emergency room with blunt abdominal trauma will go directly to the operating room after a rapid ultrasonography examination with evidence of hemoperitoneum . In hemodynamically stable patients , in addition to ultrasonography , computed tomography can be done . This is especially efficient if evaluation with sonography is not completely possible or shows little pathology ( e.g. small amounts of hemoperitoneum ) .

[ "In", "Europe", "ultrasonography", "has", "displaced", "diagnostic", "peritoneal", "lavage", "(", "DPL", ")", "in", "the", "primary", "survey", "of", "polytraumatized", "patients", "with", "suspected", "abdominal", "trauma", ".", "Hemodynamically", "unstable", "patients", "who", "are", "brought", "to", "the", "emergency", "room", "with", "blunt", "abdominal", "trauma", "will", "go", "directly", "to", "the", "operating", "room", "after", "a", "rapid", "ultrasonography", "examination", "with", "evidence", "of", "hemoperitoneum", ".", "In", "hemodynamically", "stable", "patients", ",", "in", "addition", "to", "ultrasonography", ",", "computed", "tomography", "can", "be", "done", ".", "This", "is", "especially", "efficient", "if", "evaluation", "with", "sonography", "is", "not", "completely", "possible", "or", "shows", "little", "pathology", "(", "e.g", ".", "small", "amounts", "of", "hemoperitoneum", ")", "." ]

[ "umlsterm" ]

Behandlung is an umlsterm, Patienten is an umlsterm, Autoimmunkrankheiten is an umlsterm, Tierexperimentelle is an umlsterm, Fallberichte is an umlsterm, Patienten is an umlsterm, Stammzelltransplantation is an umlsterm, Rheumatismus is an umlsterm, Blut- is an umlsterm, Knochenmarktransplantation is an umlsterm, gezieltes is an umlsterm, Zeit is an umlsterm, Fallberichte is an umlsterm

ZfuerRheumatologie.70560173.ger.abstr_task0

Sentence: Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen .

[ "Autologe", "und", "allogene", "Stammzelltransplantationen", "werden", "heute", "intensiv", "diskutiert", "als", "moegliche", "Behandlung", "fuer", "Patienten", "mit", "schweren", "Autoimmunkrankheiten", ".", "Tierexperimentelle", "Daten", "und", "Fallberichte", "von", "Patienten", "mit", "gebesserter", "Autoimmunkrankheit", "nach", "Stammzelltransplantation", "wegen", "einer", "anderen", "Erkrankung", "unterstuetzen", "dieses", "Konzept", ".", "Um", "moeglichst", "bald", "klare", "Antworten", "auf", "die", "vielen", "offenen", "Fragen", "zu", "erhalten", ",", "haben", "die", "Europaeische", "Liga", "gegen", "Rheumatismus", "EULAR", "und", "die", "Europaeische", "Gruppe", "fuer", "Blut-", "und", "Knochenmarktransplantation", "EBMT", "gemeinsam", "Richtlinien", "fuer", "ein", "gezieltes", "Vorgehen", "erarbeitet", ".", "Sie", "werden", "hier", "vorgestellt", ".", "Klare", "Daten", "fehlen", "zur", "Zeit", ".", "Die", "noch", "vereinzelten", "Fallberichte", "sehen", "vielversprechend", "aus", "und", "erste", "Studien", "sind", "in", "Vorbereitung", ".", "In", "wenigen", "Jahren", "sollte", "es", "bei", "koordiniertem", "Vorgehen", "moeglich", "sein", ",", "den", "Stellenwert", "dieser", "Behandlungsmethode", "beurteilen", "zu", "koennen", "." ]

[ "umlsterm" ]

Behandlung is an umlsterm, Patienten is an umlsterm, Autoimmunkrankheiten is an umlsterm, Tierexperimentelle is an umlsterm, Fallberichte is an umlsterm, Patienten is an umlsterm, Stammzelltransplantation is an umlsterm, Rheumatismus is an umlsterm, Blut- is an umlsterm, Knochenmarktransplantation is an umlsterm, gezieltes is an umlsterm, Zeit is an umlsterm, Fallberichte is an umlsterm

ZfuerRheumatologie.70560173.ger.abstr_task1

Sentence: Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen . Instructions: please typing these entity words according to sentence: Behandlung, Patienten, Autoimmunkrankheiten, Tierexperimentelle, Fallberichte, Patienten, Stammzelltransplantation, Rheumatismus, Blut-, Knochenmarktransplantation, gezieltes, Zeit, Fallberichte Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen .

[ "Autologe", "und", "allogene", "Stammzelltransplantationen", "werden", "heute", "intensiv", "diskutiert", "als", "moegliche", "Behandlung", "fuer", "Patienten", "mit", "schweren", "Autoimmunkrankheiten", ".", "Tierexperimentelle", "Daten", "und", "Fallberichte", "von", "Patienten", "mit", "gebesserter", "Autoimmunkrankheit", "nach", "Stammzelltransplantation", "wegen", "einer", "anderen", "Erkrankung", "unterstuetzen", "dieses", "Konzept", ".", "Um", "moeglichst", "bald", "klare", "Antworten", "auf", "die", "vielen", "offenen", "Fragen", "zu", "erhalten", ",", "haben", "die", "Europaeische", "Liga", "gegen", "Rheumatismus", "EULAR", "und", "die", "Europaeische", "Gruppe", "fuer", "Blut-", "und", "Knochenmarktransplantation", "EBMT", "gemeinsam", "Richtlinien", "fuer", "ein", "gezieltes", "Vorgehen", "erarbeitet", ".", "Sie", "werden", "hier", "vorgestellt", ".", "Klare", "Daten", "fehlen", "zur", "Zeit", ".", "Die", "noch", "vereinzelten", "Fallberichte", "sehen", "vielversprechend", "aus", "und", "erste", "Studien", "sind", "in", "Vorbereitung", ".", "In", "wenigen", "Jahren", "sollte", "es", "bei", "koordiniertem", "Vorgehen", "moeglich", "sein", ",", "den", "Stellenwert", "dieser", "Behandlungsmethode", "beurteilen", "zu", "koennen", "." ]

[ "umlsterm" ]

Behandlung, Patienten, Autoimmunkrankheiten, Tierexperimentelle, Fallberichte, Patienten, Stammzelltransplantation, Rheumatismus, Blut-, Knochenmarktransplantation, gezieltes, Zeit, Fallberichte

ZfuerRheumatologie.70560173.ger.abstr_task2

Sentence: Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Autologe und allogene Stammzelltransplantationen werden heute intensiv diskutiert als moegliche Behandlung fuer Patienten mit schweren Autoimmunkrankheiten . Tierexperimentelle Daten und Fallberichte von Patienten mit gebesserter Autoimmunkrankheit nach Stammzelltransplantation wegen einer anderen Erkrankung unterstuetzen dieses Konzept . Um moeglichst bald klare Antworten auf die vielen offenen Fragen zu erhalten , haben die Europaeische Liga gegen Rheumatismus EULAR und die Europaeische Gruppe fuer Blut- und Knochenmarktransplantation EBMT gemeinsam Richtlinien fuer ein gezieltes Vorgehen erarbeitet . Sie werden hier vorgestellt . Klare Daten fehlen zur Zeit . Die noch vereinzelten Fallberichte sehen vielversprechend aus und erste Studien sind in Vorbereitung . In wenigen Jahren sollte es bei koordiniertem Vorgehen moeglich sein , den Stellenwert dieser Behandlungsmethode beurteilen zu koennen .

[ "Autologe", "und", "allogene", "Stammzelltransplantationen", "werden", "heute", "intensiv", "diskutiert", "als", "moegliche", "Behandlung", "fuer", "Patienten", "mit", "schweren", "Autoimmunkrankheiten", ".", "Tierexperimentelle", "Daten", "und", "Fallberichte", "von", "Patienten", "mit", "gebesserter", "Autoimmunkrankheit", "nach", "Stammzelltransplantation", "wegen", "einer", "anderen", "Erkrankung", "unterstuetzen", "dieses", "Konzept", ".", "Um", "moeglichst", "bald", "klare", "Antworten", "auf", "die", "vielen", "offenen", "Fragen", "zu", "erhalten", ",", "haben", "die", "Europaeische", "Liga", "gegen", "Rheumatismus", "EULAR", "und", "die", "Europaeische", "Gruppe", "fuer", "Blut-", "und", "Knochenmarktransplantation", "EBMT", "gemeinsam", "Richtlinien", "fuer", "ein", "gezieltes", "Vorgehen", "erarbeitet", ".", "Sie", "werden", "hier", "vorgestellt", ".", "Klare", "Daten", "fehlen", "zur", "Zeit", ".", "Die", "noch", "vereinzelten", "Fallberichte", "sehen", "vielversprechend", "aus", "und", "erste", "Studien", "sind", "in", "Vorbereitung", ".", "In", "wenigen", "Jahren", "sollte", "es", "bei", "koordiniertem", "Vorgehen", "moeglich", "sein", ",", "den", "Stellenwert", "dieser", "Behandlungsmethode", "beurteilen", "zu", "koennen", "." ]

[ "umlsterm" ]

Lithotripsiegeraete is an umlsterm, Harnsteinbehandlung is an umlsterm, Lithotripsiesystemen is an umlsterm, Lithotripsiesysteme is an umlsterm, Therapien is an umlsterm, Komplikationen is an umlsterm, Haematome is an umlsterm, Mortalitaet is an umlsterm, Komplikationen is an umlsterm, Wahrscheinlichkeiten is an umlsterm, Steinzentren is an umlsterm

DerUrologeA.70360217.ger.abstr_task0

Sentence: Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist .

[ "Transportable", "Lithotripsiegeraete", "werden", "in", "zunehmendem", "Masse", "in", "urologischen", "Kliniken", "zur", "Harnsteinbehandlung", "eingesetzt", ",", "wenn", "kein", "festinstallierter", "Lithotriptor", "vorhanden", "ist", "bzw", ".", "eine", "solche", "Anschaffung", "als", "unrentabel", "angesehen", "wird", ".", "In", "der", "vorliegenden", "Studie", "wird", "ueberprueft", ",", "inwieweit", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "der", "ESWL", "mit", "transportablen", "Lithotripsiesystemen", "von", "den", "bekannten", "Komplikationsdichten", "aus", "etablierten", "Zentren", "verschieden", "ist", ".", "An", "bis", "zu", "54", "Kliniken", "wurde", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "transportabler", "Lithotripsiesysteme", "von", "1993", "-", "1995", "bei", "insgesamt", "12", "901", "Therapien", "erfasst", ".", "Schwerwiegende", "Komplikationen", "ergaben", "sich", "in", "insgesamt", "85", "Faellen", "(", "0,66", "%", ")", ".", "Die", "Mehrzahl", "davon", "(", "n", "=", "64", ")", "waren", "intra-", "oder", "perirenale", "Haematome", ";", "3", "mal", "musste", "nephrektomiert", "werden", ".", "Die", "Mortalitaet", "lag", "bei", "0", "%", ".", "Fuer", "die", "einzelnen", "Komplikationen", "lassen", "sich", "aus", "diesen", "Fallzahlen", "Wahrscheinlichkeiten", "ihres", "Auftretens", "berechnen", ".", "Insgesamt", "zeigt", "die", "Untersuchung", ",", "dass", "die", "ESWL", "mit", "mobilen", "Systemen", "mit", "der", "gleichen", "geringen", "Komplikationsrate", "angewendet", "werden", "kann", ",", "wie", "sie", "von", "etablierten", "Steinzentren", "bekannt", "ist", "." ]

[ "umlsterm" ]

Lithotripsiegeraete is an umlsterm, Harnsteinbehandlung is an umlsterm, Lithotripsiesystemen is an umlsterm, Lithotripsiesysteme is an umlsterm, Therapien is an umlsterm, Komplikationen is an umlsterm, Haematome is an umlsterm, Mortalitaet is an umlsterm, Komplikationen is an umlsterm, Wahrscheinlichkeiten is an umlsterm, Steinzentren is an umlsterm

DerUrologeA.70360217.ger.abstr_task1

Sentence: Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist . Instructions: please typing these entity words according to sentence: Lithotripsiegeraete, Harnsteinbehandlung, Lithotripsiesystemen, Lithotripsiesysteme, Therapien, Komplikationen, Haematome, Mortalitaet, Komplikationen, Wahrscheinlichkeiten, Steinzentren Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist .

[ "Transportable", "Lithotripsiegeraete", "werden", "in", "zunehmendem", "Masse", "in", "urologischen", "Kliniken", "zur", "Harnsteinbehandlung", "eingesetzt", ",", "wenn", "kein", "festinstallierter", "Lithotriptor", "vorhanden", "ist", "bzw", ".", "eine", "solche", "Anschaffung", "als", "unrentabel", "angesehen", "wird", ".", "In", "der", "vorliegenden", "Studie", "wird", "ueberprueft", ",", "inwieweit", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "der", "ESWL", "mit", "transportablen", "Lithotripsiesystemen", "von", "den", "bekannten", "Komplikationsdichten", "aus", "etablierten", "Zentren", "verschieden", "ist", ".", "An", "bis", "zu", "54", "Kliniken", "wurde", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "transportabler", "Lithotripsiesysteme", "von", "1993", "-", "1995", "bei", "insgesamt", "12", "901", "Therapien", "erfasst", ".", "Schwerwiegende", "Komplikationen", "ergaben", "sich", "in", "insgesamt", "85", "Faellen", "(", "0,66", "%", ")", ".", "Die", "Mehrzahl", "davon", "(", "n", "=", "64", ")", "waren", "intra-", "oder", "perirenale", "Haematome", ";", "3", "mal", "musste", "nephrektomiert", "werden", ".", "Die", "Mortalitaet", "lag", "bei", "0", "%", ".", "Fuer", "die", "einzelnen", "Komplikationen", "lassen", "sich", "aus", "diesen", "Fallzahlen", "Wahrscheinlichkeiten", "ihres", "Auftretens", "berechnen", ".", "Insgesamt", "zeigt", "die", "Untersuchung", ",", "dass", "die", "ESWL", "mit", "mobilen", "Systemen", "mit", "der", "gleichen", "geringen", "Komplikationsrate", "angewendet", "werden", "kann", ",", "wie", "sie", "von", "etablierten", "Steinzentren", "bekannt", "ist", "." ]

[ "umlsterm" ]

Lithotripsiegeraete, Harnsteinbehandlung, Lithotripsiesystemen, Lithotripsiesysteme, Therapien, Komplikationen, Haematome, Mortalitaet, Komplikationen, Wahrscheinlichkeiten, Steinzentren

DerUrologeA.70360217.ger.abstr_task2

Sentence: Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Transportable Lithotripsiegeraete werden in zunehmendem Masse in urologischen Kliniken zur Harnsteinbehandlung eingesetzt , wenn kein festinstallierter Lithotriptor vorhanden ist bzw. eine solche Anschaffung als unrentabel angesehen wird . In der vorliegenden Studie wird ueberprueft , inwieweit die Komplikationsrate bei diskontinuierlicher Anwendung der ESWL mit transportablen Lithotripsiesystemen von den bekannten Komplikationsdichten aus etablierten Zentren verschieden ist . An bis zu 54 Kliniken wurde die Komplikationsrate bei diskontinuierlicher Anwendung transportabler Lithotripsiesysteme von 1993-1995 bei insgesamt 12 901 Therapien erfasst . Schwerwiegende Komplikationen ergaben sich in insgesamt 85 Faellen ( 0,66 % ) . Die Mehrzahl davon ( n = 64 ) waren intra- oder perirenale Haematome ; 3 mal musste nephrektomiert werden . Die Mortalitaet lag bei 0 % . Fuer die einzelnen Komplikationen lassen sich aus diesen Fallzahlen Wahrscheinlichkeiten ihres Auftretens berechnen . Insgesamt zeigt die Untersuchung , dass die ESWL mit mobilen Systemen mit der gleichen geringen Komplikationsrate angewendet werden kann , wie sie von etablierten Steinzentren bekannt ist .

[ "Transportable", "Lithotripsiegeraete", "werden", "in", "zunehmendem", "Masse", "in", "urologischen", "Kliniken", "zur", "Harnsteinbehandlung", "eingesetzt", ",", "wenn", "kein", "festinstallierter", "Lithotriptor", "vorhanden", "ist", "bzw", ".", "eine", "solche", "Anschaffung", "als", "unrentabel", "angesehen", "wird", ".", "In", "der", "vorliegenden", "Studie", "wird", "ueberprueft", ",", "inwieweit", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "der", "ESWL", "mit", "transportablen", "Lithotripsiesystemen", "von", "den", "bekannten", "Komplikationsdichten", "aus", "etablierten", "Zentren", "verschieden", "ist", ".", "An", "bis", "zu", "54", "Kliniken", "wurde", "die", "Komplikationsrate", "bei", "diskontinuierlicher", "Anwendung", "transportabler", "Lithotripsiesysteme", "von", "1993", "-", "1995", "bei", "insgesamt", "12", "901", "Therapien", "erfasst", ".", "Schwerwiegende", "Komplikationen", "ergaben", "sich", "in", "insgesamt", "85", "Faellen", "(", "0,66", "%", ")", ".", "Die", "Mehrzahl", "davon", "(", "n", "=", "64", ")", "waren", "intra-", "oder", "perirenale", "Haematome", ";", "3", "mal", "musste", "nephrektomiert", "werden", ".", "Die", "Mortalitaet", "lag", "bei", "0", "%", ".", "Fuer", "die", "einzelnen", "Komplikationen", "lassen", "sich", "aus", "diesen", "Fallzahlen", "Wahrscheinlichkeiten", "ihres", "Auftretens", "berechnen", ".", "Insgesamt", "zeigt", "die", "Untersuchung", ",", "dass", "die", "ESWL", "mit", "mobilen", "Systemen", "mit", "der", "gleichen", "geringen", "Komplikationsrate", "angewendet", "werden", "kann", ",", "wie", "sie", "von", "etablierten", "Steinzentren", "bekannt", "ist", "." ]

[ "umlsterm" ]

Funktionsdiagnostik is an umlsterm, Blasen- is an umlsterm, Harntrakt is an umlsterm, Nierenfunktion is an umlsterm, Harnkontinenz is an umlsterm, Blasenentleerung is an umlsterm, Patienten is an umlsterm, Geburt is an umlsterm, Spina bifida is an umlsterm, Myelomeningozele is an umlsterm

DerUrologeA.90380010.ger.abstr_task0

Sentence: Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]

Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt .

[ "Neurogene", "Blasenentleerungsstoerungen", "im", "Kindesalter", "sind", "in", "der", "Mehrzahl", "der", "Faelle", "Folgen", "dysrhapischer", "Hemmungsmissbildungen", ".", "Die", "urologische", "Funktionsdiagnostik", "zielt", "in", "erster", "Linie", "auf", "die", "Feststellung", "der", "mit", "der", "Grunderkrankung", "verbundenen", "Blasen-", "und", "Sphinkterfunktion", "sowie", "assoziierter", "Stoerungen", "am", "oberen", "Harntrakt", ".", "Therapeutisches", "Hauptziel", "bleibt", "neben", "dem", "Erhalt", "der", "Nierenfunktion", "das", "Erreichen", "der", "Harnkontinenz", "und", "eine", "individuell", "angepasste", "Form", "der", "Blasenentleerung", ",", "die", "auch", "den", "uebrigen", "koerperlichen", "Behinderungen", "sowie", "der", "sozialen", "und", "persoenlichen", "Situation", "des", "Betroffenen", "Rechnung", "traegt", ".", "Anhand", "von", "190", "Patienten", ",", "die", "seit", "Geburt", "in", "unserer", "Klinik", "betreut", "werden", ",", "wird", "die", "Entwicklung", "der", "neurogenen", "Blasenfunktionsstoerung", "durch", "Spina", "bifida", "und", "Myelomeningozele", "aufgezeigt", "." ]

[ "umlsterm" ]

Funktionsdiagnostik is an umlsterm, Blasen- is an umlsterm, Harntrakt is an umlsterm, Nierenfunktion is an umlsterm, Harnkontinenz is an umlsterm, Blasenentleerung is an umlsterm, Patienten is an umlsterm, Geburt is an umlsterm, Spina bifida is an umlsterm, Myelomeningozele is an umlsterm

DerUrologeA.90380010.ger.abstr_task1

Sentence: Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt . Instructions: please typing these entity words according to sentence: Funktionsdiagnostik, Blasen-, Harntrakt, Nierenfunktion, Harnkontinenz, Blasenentleerung, Patienten, Geburt, Spina bifida, Myelomeningozele Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]

Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt .

[ "Neurogene", "Blasenentleerungsstoerungen", "im", "Kindesalter", "sind", "in", "der", "Mehrzahl", "der", "Faelle", "Folgen", "dysrhapischer", "Hemmungsmissbildungen", ".", "Die", "urologische", "Funktionsdiagnostik", "zielt", "in", "erster", "Linie", "auf", "die", "Feststellung", "der", "mit", "der", "Grunderkrankung", "verbundenen", "Blasen-", "und", "Sphinkterfunktion", "sowie", "assoziierter", "Stoerungen", "am", "oberen", "Harntrakt", ".", "Therapeutisches", "Hauptziel", "bleibt", "neben", "dem", "Erhalt", "der", "Nierenfunktion", "das", "Erreichen", "der", "Harnkontinenz", "und", "eine", "individuell", "angepasste", "Form", "der", "Blasenentleerung", ",", "die", "auch", "den", "uebrigen", "koerperlichen", "Behinderungen", "sowie", "der", "sozialen", "und", "persoenlichen", "Situation", "des", "Betroffenen", "Rechnung", "traegt", ".", "Anhand", "von", "190", "Patienten", ",", "die", "seit", "Geburt", "in", "unserer", "Klinik", "betreut", "werden", ",", "wird", "die", "Entwicklung", "der", "neurogenen", "Blasenfunktionsstoerung", "durch", "Spina", "bifida", "und", "Myelomeningozele", "aufgezeigt", "." ]

[ "umlsterm" ]

Funktionsdiagnostik, Blasen-, Harntrakt, Nierenfunktion, Harnkontinenz, Blasenentleerung, Patienten, Geburt, Spina bifida, Myelomeningozele

DerUrologeA.90380010.ger.abstr_task2

Sentence: Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]

Neurogene Blasenentleerungsstoerungen im Kindesalter sind in der Mehrzahl der Faelle Folgen dysrhapischer Hemmungsmissbildungen . Die urologische Funktionsdiagnostik zielt in erster Linie auf die Feststellung der mit der Grunderkrankung verbundenen Blasen- und Sphinkterfunktion sowie assoziierter Stoerungen am oberen Harntrakt . Therapeutisches Hauptziel bleibt neben dem Erhalt der Nierenfunktion das Erreichen der Harnkontinenz und eine individuell angepasste Form der Blasenentleerung , die auch den uebrigen koerperlichen Behinderungen sowie der sozialen und persoenlichen Situation des Betroffenen Rechnung traegt . Anhand von 190 Patienten , die seit Geburt in unserer Klinik betreut werden , wird die Entwicklung der neurogenen Blasenfunktionsstoerung durch Spina bifida und Myelomeningozele aufgezeigt .

[ "Neurogene", "Blasenentleerungsstoerungen", "im", "Kindesalter", "sind", "in", "der", "Mehrzahl", "der", "Faelle", "Folgen", "dysrhapischer", "Hemmungsmissbildungen", ".", "Die", "urologische", "Funktionsdiagnostik", "zielt", "in", "erster", "Linie", "auf", "die", "Feststellung", "der", "mit", "der", "Grunderkrankung", "verbundenen", "Blasen-", "und", "Sphinkterfunktion", "sowie", "assoziierter", "Stoerungen", "am", "oberen", "Harntrakt", ".", "Therapeutisches", "Hauptziel", "bleibt", "neben", "dem", "Erhalt", "der", "Nierenfunktion", "das", "Erreichen", "der", "Harnkontinenz", "und", "eine", "individuell", "angepasste", "Form", "der", "Blasenentleerung", ",", "die", "auch", "den", "uebrigen", "koerperlichen", "Behinderungen", "sowie", "der", "sozialen", "und", "persoenlichen", "Situation", "des", "Betroffenen", "Rechnung", "traegt", ".", "Anhand", "von", "190", "Patienten", ",", "die", "seit", "Geburt", "in", "unserer", "Klinik", "betreut", "werden", ",", "wird", "die", "Entwicklung", "der", "neurogenen", "Blasenfunktionsstoerung", "durch", "Spina", "bifida", "und", "Myelomeningozele", "aufgezeigt", "." ]

[ "umlsterm" ]

Age is a Person, 60 - 85 years is a Value, right - handed is a Observation, Major depression is a Condition, unipolar is a Qualifier, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria is a Scope, Age is a Person, onset of first episode is a Condition, = 50 years is a Value, three is a Multiplier, depressive episodes is a Condition, depression is a Condition, 24-Item Hamilton Depression Rating Scale is a Measurement, HDRS is a Measurement, = 20 is a Value

NCT01728194_inc_task0

Sentence: Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Observation, Multiplier, Scope, Measurement

[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Multiplier", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "O", "O" ]

Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.

[ "Age", ":", "60", "-", "85", "years", ",", "right", "-", "handed", ";", "\n", "Diagnosis", ":", "Major", "depression", ",", "unipolar", "(", "by", "Structured", "Clinical", "Interview", "for", "Diagnostic", "and", "Statistical", "Manual", "(", "DSM)IV", "(", "SCID", "-", "R", ")", "and", "DSM", "-", "IV", "criteria", ")", ";", "\n", "Age", "of", "onset", "of", "first", "episode", "=", "50", "years", "with", "up", "to", "three", "depressive", "episodes", ";", "\n", "Severity", "of", "depression", ":", "A", "24-Item", "Hamilton", "Depression", "Rating", "Scale", "(", "HDRS", ")", "=", "20", ".", "\n" ]

[ "Scope", "Measurement", "Condition", "Observation", "Value", "Qualifier", "Multiplier", "Person" ]

Age is a Person, 60 - 85 years is a Value, right - handed is a Observation, Major depression is a Condition, unipolar is a Qualifier, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria is a Scope, Age is a Person, onset of first episode is a Condition, = 50 years is a Value, three is a Multiplier, depressive episodes is a Condition, depression is a Condition, 24-Item Hamilton Depression Rating Scale is a Measurement, HDRS is a Measurement, = 20 is a Value

NCT01728194_inc_task1

Sentence: Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20. Instructions: please typing these entity words according to sentence: Age, 60 - 85 years, right - handed, Major depression, unipolar, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria, Age, onset of first episode, = 50 years, three, depressive episodes, depression, 24-Item Hamilton Depression Rating Scale, HDRS, = 20 Options: Condition, Qualifier, Value, Person, Observation, Multiplier, Scope, Measurement

[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Multiplier", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "O", "O" ]

Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.

[ "Age", ":", "60", "-", "85", "years", ",", "right", "-", "handed", ";", "\n", "Diagnosis", ":", "Major", "depression", ",", "unipolar", "(", "by", "Structured", "Clinical", "Interview", "for", "Diagnostic", "and", "Statistical", "Manual", "(", "DSM)IV", "(", "SCID", "-", "R", ")", "and", "DSM", "-", "IV", "criteria", ")", ";", "\n", "Age", "of", "onset", "of", "first", "episode", "=", "50", "years", "with", "up", "to", "three", "depressive", "episodes", ";", "\n", "Severity", "of", "depression", ":", "A", "24-Item", "Hamilton", "Depression", "Rating", "Scale", "(", "HDRS", ")", "=", "20", ".", "\n" ]

[ "Scope", "Measurement", "Condition", "Observation", "Value", "Qualifier", "Multiplier", "Person" ]

Age, 60 - 85 years, right - handed, Major depression, unipolar, Structured Clinical Interview for Diagnostic and Statistical Manual ( DSM)IV ( SCID - R ) and DSM - IV criteria, Age, onset of first episode, = 50 years, three, depressive episodes, depression, 24-Item Hamilton Depression Rating Scale, HDRS, = 20

NCT01728194_inc_task2

Sentence: Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20. Instructions: please extract entity words from the input sentence

[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Multiplier", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "O", "O" ]

Age: 60-85 years, right-handed; Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria); Age of onset of first episode = 50 years with up to three depressive episodes; Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.

[ "Age", ":", "60", "-", "85", "years", ",", "right", "-", "handed", ";", "\n", "Diagnosis", ":", "Major", "depression", ",", "unipolar", "(", "by", "Structured", "Clinical", "Interview", "for", "Diagnostic", "and", "Statistical", "Manual", "(", "DSM)IV", "(", "SCID", "-", "R", ")", "and", "DSM", "-", "IV", "criteria", ")", ";", "\n", "Age", "of", "onset", "of", "first", "episode", "=", "50", "years", "with", "up", "to", "three", "depressive", "episodes", ";", "\n", "Severity", "of", "depression", ":", "A", "24-Item", "Hamilton", "Depression", "Rating", "Scale", "(", "HDRS", ")", "=", "20", ".", "\n" ]

[ "Scope", "Measurement", "Condition", "Observation", "Value", "Qualifier", "Multiplier", "Person" ]

Patienten is an umlsterm, Leitende Arzt is an umlsterm, Rechtsprechung is an umlsterm, Organisation is an umlsterm, Arzt is an umlsterm

DerGynaekologe.90320927.ger.abstr_task0

Sentence: Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben .

[ "Fuer", "Schaeden", "an", "Patienten", "durch", "Organisationsfehler", "in", "seiner", "Abteilung", "muss", "der", "Leitende", "Arzt", ",", "in", "der", "Regel", "der", "Chefarzt", ",", "haften", ".", "In", "der", "Rechtsprechung", "genuegt", "bereits", "die", "Vermutung", ",", "dass", "ein", "Fehler", "aufgrund", "einer", "mangelnden", "Organisation", "entstanden", "ist", ",", "um", "den", "Verantwortlichen", "-", "naemlich", "den", "Chefarzt", "-", "haftbar", "zu", "machen", ".", "Daher", "muss", "der", "Leitendende", "Arzt", "in", "der", "Lage", "sein", ",", "strukturelle", "Organisationsmaengel", "zu", "erkennen", "und", "diese", "durch", "Schulung", "seiner", "Mitarbeiter", "zu", "beheben", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Leitende Arzt is an umlsterm, Rechtsprechung is an umlsterm, Organisation is an umlsterm, Arzt is an umlsterm

DerGynaekologe.90320927.ger.abstr_task1

Sentence: Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben . Instructions: please typing these entity words according to sentence: Patienten, Leitende Arzt, Rechtsprechung, Organisation, Arzt Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben .

[ "Fuer", "Schaeden", "an", "Patienten", "durch", "Organisationsfehler", "in", "seiner", "Abteilung", "muss", "der", "Leitende", "Arzt", ",", "in", "der", "Regel", "der", "Chefarzt", ",", "haften", ".", "In", "der", "Rechtsprechung", "genuegt", "bereits", "die", "Vermutung", ",", "dass", "ein", "Fehler", "aufgrund", "einer", "mangelnden", "Organisation", "entstanden", "ist", ",", "um", "den", "Verantwortlichen", "-", "naemlich", "den", "Chefarzt", "-", "haftbar", "zu", "machen", ".", "Daher", "muss", "der", "Leitendende", "Arzt", "in", "der", "Lage", "sein", ",", "strukturelle", "Organisationsmaengel", "zu", "erkennen", "und", "diese", "durch", "Schulung", "seiner", "Mitarbeiter", "zu", "beheben", "." ]

[ "umlsterm" ]

Patienten, Leitende Arzt, Rechtsprechung, Organisation, Arzt

DerGynaekologe.90320927.ger.abstr_task2

Sentence: Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fuer Schaeden an Patienten durch Organisationsfehler in seiner Abteilung muss der Leitende Arzt , in der Regel der Chefarzt , haften . In der Rechtsprechung genuegt bereits die Vermutung , dass ein Fehler aufgrund einer mangelnden Organisation entstanden ist , um den Verantwortlichen - naemlich den Chefarzt - haftbar zu machen . Daher muss der Leitendende Arzt in der Lage sein , strukturelle Organisationsmaengel zu erkennen und diese durch Schulung seiner Mitarbeiter zu beheben .

[ "Fuer", "Schaeden", "an", "Patienten", "durch", "Organisationsfehler", "in", "seiner", "Abteilung", "muss", "der", "Leitende", "Arzt", ",", "in", "der", "Regel", "der", "Chefarzt", ",", "haften", ".", "In", "der", "Rechtsprechung", "genuegt", "bereits", "die", "Vermutung", ",", "dass", "ein", "Fehler", "aufgrund", "einer", "mangelnden", "Organisation", "entstanden", "ist", ",", "um", "den", "Verantwortlichen", "-", "naemlich", "den", "Chefarzt", "-", "haftbar", "zu", "machen", ".", "Daher", "muss", "der", "Leitendende", "Arzt", "in", "der", "Lage", "sein", ",", "strukturelle", "Organisationsmaengel", "zu", "erkennen", "und", "diese", "durch", "Schulung", "seiner", "Mitarbeiter", "zu", "beheben", "." ]

[ "umlsterm" ]

self - reported is a Qualifier, healthy is a Condition, adults is a Person, between is a Value, ages is a Person, fluent in English is a Observation

NCT02589353_inc_task0

Sentence: self-reported healthy adults between the ages of 18-60 who are fluent in English. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Observation

[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "B-Person", "B-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O" ]

self-reported healthy adults between the ages of 18-60 who are fluent in English.

[ "self", "-", "reported", "healthy", "adults", "between", "the", "ages", "of", "18", "-", "60", "who", "are", "fluent", "in", "English", ".", "\n" ]

[ "Observation", "Qualifier", "Condition", "Value", "Person" ]

self - reported is a Qualifier, healthy is a Condition, adults is a Person, between is a Value, ages is a Person, fluent in English is a Observation

NCT02589353_inc_task1

Sentence: self-reported healthy adults between the ages of 18-60 who are fluent in English. Instructions: please typing these entity words according to sentence: self - reported, healthy, adults, between, ages, fluent in English Options: Condition, Qualifier, Value, Person, Observation

[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "B-Person", "B-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O" ]

self-reported healthy adults between the ages of 18-60 who are fluent in English.

[ "self", "-", "reported", "healthy", "adults", "between", "the", "ages", "of", "18", "-", "60", "who", "are", "fluent", "in", "English", ".", "\n" ]

[ "Observation", "Qualifier", "Condition", "Value", "Person" ]

self - reported, healthy, adults, between, ages, fluent in English

NCT02589353_inc_task2

Sentence: self-reported healthy adults between the ages of 18-60 who are fluent in English. Instructions: please extract entity words from the input sentence

[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "B-Person", "B-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O" ]

self-reported healthy adults between the ages of 18-60 who are fluent in English.

[ "self", "-", "reported", "healthy", "adults", "between", "the", "ages", "of", "18", "-", "60", "who", "are", "fluent", "in", "English", ".", "\n" ]

[ "Observation", "Qualifier", "Condition", "Value", "Person" ]

Etanercept is a Intervention_Pharmacological, adults is a Participant_Age, rheumatoid arthritis : is a Participant_Condition, safety is a Outcome_Other, efficacy is a Outcome_Other, etanercept is a Intervention_Pharmacological, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) is a Participant_Condition, 714 is a Participant_Sample-size, 581 is a Participant_Sample-size, 388 is a Participant_Sample-size, Rates of serious adverse events is a Outcome_Adverse-effects, serious infections is a Outcome_Adverse-effects, cancer is a Outcome_Physical, deaths is a Outcome_Mortality, 356 is a Participant_Sample-size, response rates is a Outcome_Other, 167 is a Participant_Sample-size, Doses is a Outcome_Other, safety profile is a Outcome_Other, rates of adverse events is a Outcome_Adverse-effects

25688_task0

Sentence: Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Pharmacological", "O", "O", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .

[ "Etanercept", "treatment", "in", "adults", "with", "established", "rheumatoid", "arthritis", ":", "7", "years", "of", "clinical", "experience", ".", "OBJECTIVE", "To", "evaluate", "safety", "and", "efficacy", "of", "longterm", "etanercept", "treatment", "in", "patients", "with", "disease", "modifying", "antirheumatic", "drug", "(", "DMARD", ")", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Safety", "results", "are", "reported", "for", "714", "patients", "who", "received", "etanercept", "in", "one", "of", "7", "initial", "trials", "or", "a", "longterm", "extension", ".", "Efficacy", "results", "are", "reported", "for", "581", "patients", "who", "enrolled", "in", "the", "extension", ".", "RESULTS", "Of", "the", "714", "patients", "enrolled", "in", "the", "initial", "trials", ",", "581", "(", "81", "%", ")", "enrolled", "in", "the", "extension", ",", "and", "388", "(", "54", "%", ")", "patients", "are", "continuing", "to", "receive", "etanercept", "therapy", ".", "The", "longest", "individual", "treatment", "was", "8.2", "years", ",", "with", "3139", "total", "patient", "-", "years", "of", "etanercept", "exposure", ".", "Rates", "of", "serious", "adverse", "events", "(", "overall", "rate=14.8", "events/100", "patient", "-", "yrs", ")", ",", "serious", "infections", "(", "overall", "rate=4.2", "events/100", "patient", "-", "yrs", ")", ",", "cancer", "(", "overall", "rate=1.0", "events/100", "patient", "-", "yrs", ")", ",", "and", "deaths", "(", "overall", "rate=0.7", "events/100", "patient", "-", "yrs", ")", "were", "stable", "each", "year", ",", "through", "8", "years", "of", "etanercept", "exposure", ".", "For", "356", "patients", "who", "completed", "6", "years", "of", "etanercept", "treatment", ",", "response", "rates", "were", "ACR20=73", "%", ",", "ACR50=52", "%", ",", "ACR70=27", "%", ",", "DAS28", "CRP", "good", "response=52", "%", ",", "and", "DAS28", "CRP", "remission=37", "%", "of", "patients", ".", "Similar", "responses", "occurred", "in", "167", "patients", "who", "completed", "Year", "7", ".", "Doses", "of", "concomitant", "methotrexate", "or", "corticosteroids", "were", "reduced", "in", "many", "patients", "who", "maintained", "clinical", "responses", ".", "CONCLUSION", "The", "safety", "profile", "of", "etanercept", "was", "consistent", "over", "time", ",", "with", "rates", "of", "adverse", "events", "similar", "to", "those", "reported", "for", "patients", "with", "RA", "in", "general", ".", "Durable", "clinical", "responses", "were", "observed", "in", "some", "patients", "for", "7", "years", "or", "more", ".", "The", "benefit", "-", "to", "-", "risk", "ratio", "for", "longterm", "etanercept", "treatment", "remains", "highly", "favorable", "." ]

[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]

Etanercept is a Intervention_Pharmacological, adults is a Participant_Age, rheumatoid arthritis : is a Participant_Condition, safety is a Outcome_Other, efficacy is a Outcome_Other, etanercept is a Intervention_Pharmacological, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) is a Participant_Condition, 714 is a Participant_Sample-size, 581 is a Participant_Sample-size, 388 is a Participant_Sample-size, Rates of serious adverse events is a Outcome_Adverse-effects, serious infections is a Outcome_Adverse-effects, cancer is a Outcome_Physical, deaths is a Outcome_Mortality, 356 is a Participant_Sample-size, response rates is a Outcome_Other, 167 is a Participant_Sample-size, Doses is a Outcome_Other, safety profile is a Outcome_Other, rates of adverse events is a Outcome_Adverse-effects

25688_task1

Sentence: Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable . Instructions: please typing these entity words according to sentence: Etanercept, adults, rheumatoid arthritis :, safety, efficacy, etanercept, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ), 714, 581, 388, Rates of serious adverse events, serious infections, cancer, deaths, 356, response rates, 167, Doses, safety profile, rates of adverse events Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Pharmacological", "O", "O", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .

[ "Etanercept", "treatment", "in", "adults", "with", "established", "rheumatoid", "arthritis", ":", "7", "years", "of", "clinical", "experience", ".", "OBJECTIVE", "To", "evaluate", "safety", "and", "efficacy", "of", "longterm", "etanercept", "treatment", "in", "patients", "with", "disease", "modifying", "antirheumatic", "drug", "(", "DMARD", ")", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Safety", "results", "are", "reported", "for", "714", "patients", "who", "received", "etanercept", "in", "one", "of", "7", "initial", "trials", "or", "a", "longterm", "extension", ".", "Efficacy", "results", "are", "reported", "for", "581", "patients", "who", "enrolled", "in", "the", "extension", ".", "RESULTS", "Of", "the", "714", "patients", "enrolled", "in", "the", "initial", "trials", ",", "581", "(", "81", "%", ")", "enrolled", "in", "the", "extension", ",", "and", "388", "(", "54", "%", ")", "patients", "are", "continuing", "to", "receive", "etanercept", "therapy", ".", "The", "longest", "individual", "treatment", "was", "8.2", "years", ",", "with", "3139", "total", "patient", "-", "years", "of", "etanercept", "exposure", ".", "Rates", "of", "serious", "adverse", "events", "(", "overall", "rate=14.8", "events/100", "patient", "-", "yrs", ")", ",", "serious", "infections", "(", "overall", "rate=4.2", "events/100", "patient", "-", "yrs", ")", ",", "cancer", "(", "overall", "rate=1.0", "events/100", "patient", "-", "yrs", ")", ",", "and", "deaths", "(", "overall", "rate=0.7", "events/100", "patient", "-", "yrs", ")", "were", "stable", "each", "year", ",", "through", "8", "years", "of", "etanercept", "exposure", ".", "For", "356", "patients", "who", "completed", "6", "years", "of", "etanercept", "treatment", ",", "response", "rates", "were", "ACR20=73", "%", ",", "ACR50=52", "%", ",", "ACR70=27", "%", ",", "DAS28", "CRP", "good", "response=52", "%", ",", "and", "DAS28", "CRP", "remission=37", "%", "of", "patients", ".", "Similar", "responses", "occurred", "in", "167", "patients", "who", "completed", "Year", "7", ".", "Doses", "of", "concomitant", "methotrexate", "or", "corticosteroids", "were", "reduced", "in", "many", "patients", "who", "maintained", "clinical", "responses", ".", "CONCLUSION", "The", "safety", "profile", "of", "etanercept", "was", "consistent", "over", "time", ",", "with", "rates", "of", "adverse", "events", "similar", "to", "those", "reported", "for", "patients", "with", "RA", "in", "general", ".", "Durable", "clinical", "responses", "were", "observed", "in", "some", "patients", "for", "7", "years", "or", "more", ".", "The", "benefit", "-", "to", "-", "risk", "ratio", "for", "longterm", "etanercept", "treatment", "remains", "highly", "favorable", "." ]

[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]

Etanercept, adults, rheumatoid arthritis :, safety, efficacy, etanercept, disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ), 714, 581, 388, Rates of serious adverse events, serious infections, cancer, deaths, 356, response rates, 167, Doses, safety profile, rates of adverse events

25688_task2

Sentence: Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "O", "O", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .

[ "Etanercept", "treatment", "in", "adults", "with", "established", "rheumatoid", "arthritis", ":", "7", "years", "of", "clinical", "experience", ".", "OBJECTIVE", "To", "evaluate", "safety", "and", "efficacy", "of", "longterm", "etanercept", "treatment", "in", "patients", "with", "disease", "modifying", "antirheumatic", "drug", "(", "DMARD", ")", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Safety", "results", "are", "reported", "for", "714", "patients", "who", "received", "etanercept", "in", "one", "of", "7", "initial", "trials", "or", "a", "longterm", "extension", ".", "Efficacy", "results", "are", "reported", "for", "581", "patients", "who", "enrolled", "in", "the", "extension", ".", "RESULTS", "Of", "the", "714", "patients", "enrolled", "in", "the", "initial", "trials", ",", "581", "(", "81", "%", ")", "enrolled", "in", "the", "extension", ",", "and", "388", "(", "54", "%", ")", "patients", "are", "continuing", "to", "receive", "etanercept", "therapy", ".", "The", "longest", "individual", "treatment", "was", "8.2", "years", ",", "with", "3139", "total", "patient", "-", "years", "of", "etanercept", "exposure", ".", "Rates", "of", "serious", "adverse", "events", "(", "overall", "rate=14.8", "events/100", "patient", "-", "yrs", ")", ",", "serious", "infections", "(", "overall", "rate=4.2", "events/100", "patient", "-", "yrs", ")", ",", "cancer", "(", "overall", "rate=1.0", "events/100", "patient", "-", "yrs", ")", ",", "and", "deaths", "(", "overall", "rate=0.7", "events/100", "patient", "-", "yrs", ")", "were", "stable", "each", "year", ",", "through", "8", "years", "of", "etanercept", "exposure", ".", "For", "356", "patients", "who", "completed", "6", "years", "of", "etanercept", "treatment", ",", "response", "rates", "were", "ACR20=73", "%", ",", "ACR50=52", "%", ",", "ACR70=27", "%", ",", "DAS28", "CRP", "good", "response=52", "%", ",", "and", "DAS28", "CRP", "remission=37", "%", "of", "patients", ".", "Similar", "responses", "occurred", "in", "167", "patients", "who", "completed", "Year", "7", ".", "Doses", "of", "concomitant", "methotrexate", "or", "corticosteroids", "were", "reduced", "in", "many", "patients", "who", "maintained", "clinical", "responses", ".", "CONCLUSION", "The", "safety", "profile", "of", "etanercept", "was", "consistent", "over", "time", ",", "with", "rates", "of", "adverse", "events", "similar", "to", "those", "reported", "for", "patients", "with", "RA", "in", "general", ".", "Durable", "clinical", "responses", "were", "observed", "in", "some", "patients", "for", "7", "years", "or", "more", ".", "The", "benefit", "-", "to", "-", "risk", "ratio", "for", "longterm", "etanercept", "treatment", "remains", "highly", "favorable", "." ]

[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]

Abstract is an umlsterm, female is an umlsterm, patient is an umlsterm, itching is an umlsterm, dermatitis is an umlsterm, disease is an umlsterm, Therapy is an umlsterm, DADPS is an umlsterm, lymph node is an umlsterm, enlargement is an umlsterm, splenomegaly is an umlsterm, lymph node is an umlsterm, biopsy is an umlsterm, Histopathology is an umlsterm, lymph node is an umlsterm, bone marrow is an umlsterm, diagnosis is an umlsterm, angioimmunoblastic lymphadenopathy is an umlsterm, T - cell lymphoma is an umlsterm, skin is an umlsterm, lymphoma is an umlsterm, skin is an umlsterm, cells is an umlsterm, case report is an umlsterm, skin is an umlsterm, literature is an umlsterm

DerHautarzt.40450562.eng.abstr_task0

Sentence: Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature .

[ "Abstract", ".", "A", "62-year", "-", "old", "female", "patient", "presented", "with", "bullous", ",", "intensely", "itching", "cutaneous", "lesions", ",", "which", "clinically", "and", "histopathologically", "resembled", "dermatitis", "herpetiformis", "(", "Duhring", "'s", "disease", ")", ".", "Therapy", "with", "DADPS", "was", "unsuccessful", ".", "Because", "of", "associated", "cervical", "lymph", "node", "enlargement", "and", "splenomegaly", ",", "a", "lymph", "node", "biopsy", "was", "taken", ".", "Histopathology", "of", "a", "lymph", "node", "and", "of", "the", "bone", "marrow", "confirmed", "the", "diagnosis", ":", "angioimmunoblastic", "lymphadenopathy", "(", "AILD", ")", "-type", "T", "-", "cell", "lymphoma", ".", "Intensely", "pruritic", "associated", "skin", "eruptions", "are", "typical", "for", "this", "peculiar", "kind", "of", "lymphoma", ".", "These", "skin", "lesions", "are", "due", "to", "inflammatory", "cells", "and", "not", "to", "neoplastic", "infiltrations", ".", "This", "case", "report", "is", "the", "first", "report", "of", "AILD", "with", "bullous", "skin", "lesions", "to", "appear", "in", "the", "literature", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, female is an umlsterm, patient is an umlsterm, itching is an umlsterm, dermatitis is an umlsterm, disease is an umlsterm, Therapy is an umlsterm, DADPS is an umlsterm, lymph node is an umlsterm, enlargement is an umlsterm, splenomegaly is an umlsterm, lymph node is an umlsterm, biopsy is an umlsterm, Histopathology is an umlsterm, lymph node is an umlsterm, bone marrow is an umlsterm, diagnosis is an umlsterm, angioimmunoblastic lymphadenopathy is an umlsterm, T - cell lymphoma is an umlsterm, skin is an umlsterm, lymphoma is an umlsterm, skin is an umlsterm, cells is an umlsterm, case report is an umlsterm, skin is an umlsterm, literature is an umlsterm

DerHautarzt.40450562.eng.abstr_task1

Sentence: Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature . Instructions: please typing these entity words according to sentence: Abstract, female, patient, itching, dermatitis, disease, Therapy, DADPS, lymph node, enlargement, splenomegaly, lymph node, biopsy, Histopathology, lymph node, bone marrow, diagnosis, angioimmunoblastic lymphadenopathy, T - cell lymphoma, skin, lymphoma, skin, cells, case report, skin, literature Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature .

[ "Abstract", ".", "A", "62-year", "-", "old", "female", "patient", "presented", "with", "bullous", ",", "intensely", "itching", "cutaneous", "lesions", ",", "which", "clinically", "and", "histopathologically", "resembled", "dermatitis", "herpetiformis", "(", "Duhring", "'s", "disease", ")", ".", "Therapy", "with", "DADPS", "was", "unsuccessful", ".", "Because", "of", "associated", "cervical", "lymph", "node", "enlargement", "and", "splenomegaly", ",", "a", "lymph", "node", "biopsy", "was", "taken", ".", "Histopathology", "of", "a", "lymph", "node", "and", "of", "the", "bone", "marrow", "confirmed", "the", "diagnosis", ":", "angioimmunoblastic", "lymphadenopathy", "(", "AILD", ")", "-type", "T", "-", "cell", "lymphoma", ".", "Intensely", "pruritic", "associated", "skin", "eruptions", "are", "typical", "for", "this", "peculiar", "kind", "of", "lymphoma", ".", "These", "skin", "lesions", "are", "due", "to", "inflammatory", "cells", "and", "not", "to", "neoplastic", "infiltrations", ".", "This", "case", "report", "is", "the", "first", "report", "of", "AILD", "with", "bullous", "skin", "lesions", "to", "appear", "in", "the", "literature", "." ]

[ "umlsterm" ]

Abstract, female, patient, itching, dermatitis, disease, Therapy, DADPS, lymph node, enlargement, splenomegaly, lymph node, biopsy, Histopathology, lymph node, bone marrow, diagnosis, angioimmunoblastic lymphadenopathy, T - cell lymphoma, skin, lymphoma, skin, cells, case report, skin, literature

DerHautarzt.40450562.eng.abstr_task2

Sentence: Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Abstract . A 62-year-old female patient presented with bullous , intensely itching cutaneous lesions , which clinically and histopathologically resembled dermatitis herpetiformis ( Duhring's disease ) . Therapy with DADPS was unsuccessful . Because of associated cervical lymph node enlargement and splenomegaly , a lymph node biopsy was taken . Histopathology of a lymph node and of the bone marrow confirmed the diagnosis : angioimmunoblastic lymphadenopathy ( AILD ) -type T-cell lymphoma . Intensely pruritic associated skin eruptions are typical for this peculiar kind of lymphoma . These skin lesions are due to inflammatory cells and not to neoplastic infiltrations . This case report is the first report of AILD with bullous skin lesions to appear in the literature .

[ "Abstract", ".", "A", "62-year", "-", "old", "female", "patient", "presented", "with", "bullous", ",", "intensely", "itching", "cutaneous", "lesions", ",", "which", "clinically", "and", "histopathologically", "resembled", "dermatitis", "herpetiformis", "(", "Duhring", "'s", "disease", ")", ".", "Therapy", "with", "DADPS", "was", "unsuccessful", ".", "Because", "of", "associated", "cervical", "lymph", "node", "enlargement", "and", "splenomegaly", ",", "a", "lymph", "node", "biopsy", "was", "taken", ".", "Histopathology", "of", "a", "lymph", "node", "and", "of", "the", "bone", "marrow", "confirmed", "the", "diagnosis", ":", "angioimmunoblastic", "lymphadenopathy", "(", "AILD", ")", "-type", "T", "-", "cell", "lymphoma", ".", "Intensely", "pruritic", "associated", "skin", "eruptions", "are", "typical", "for", "this", "peculiar", "kind", "of", "lymphoma", ".", "These", "skin", "lesions", "are", "due", "to", "inflammatory", "cells", "and", "not", "to", "neoplastic", "infiltrations", ".", "This", "case", "report", "is", "the", "first", "report", "of", "AILD", "with", "bullous", "skin", "lesions", "to", "appear", "in", "the", "literature", "." ]

[ "umlsterm" ]

Lap4 is a protein, cadmium is a compound

DS.d854_task0

Sentence: Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]

Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress.

[ "Here", ",", "we", "proposed", "that", "Lap4", ",", "a", "vacuolar", "amino", "peptidase", ",", "is", "involved", "in", "glutathione", "catabolism", "under", "cadmium", "stress", "." ]

[ "compound", "protein" ]

Lap4 is a protein, cadmium is a compound

DS.d854_task1

Sentence: Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress. Instructions: please typing these entity words according to sentence: Lap4, cadmium Options: compound, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]

Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress.

[ "Here", ",", "we", "proposed", "that", "Lap4", ",", "a", "vacuolar", "amino", "peptidase", ",", "is", "involved", "in", "glutathione", "catabolism", "under", "cadmium", "stress", "." ]

[ "compound", "protein" ]

Lap4, cadmium

DS.d854_task2

Sentence: Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]

Here, we proposed that Lap4, a vacuolar amino peptidase, is involved in glutathione catabolism under cadmium stress.

[ "Here", ",", "we", "proposed", "that", "Lap4", ",", "a", "vacuolar", "amino", "peptidase", ",", "is", "involved", "in", "glutathione", "catabolism", "under", "cadmium", "stress", "." ]

[ "compound", "protein" ]

Twenty - two patients with a history of recently diagnosed RA of less than 2 years is a participant, clinical outcome and process measures is an outcome

1357_task0

Sentence: Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome, participant

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .

[ "Twenty", "-", "two", "patients", "with", "a", "history", "of", "recently", "diagnosed", "RA", "of", "less", "than", "2", "years", "were", "assessed", "on", "a", "variety", "of", "clinical", "outcome", "and", "process", "measures", "on", "six", "assessment", "occasions", "over", "a", "21-month", "period", "." ]

[ "participant", "outcome" ]

Twenty - two patients with a history of recently diagnosed RA of less than 2 years is a participant, clinical outcome and process measures is an outcome

1357_task1

Sentence: Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period . Instructions: please typing these entity words according to sentence: Twenty - two patients with a history of recently diagnosed RA of less than 2 years, clinical outcome and process measures Options: outcome, participant

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .

[ "Twenty", "-", "two", "patients", "with", "a", "history", "of", "recently", "diagnosed", "RA", "of", "less", "than", "2", "years", "were", "assessed", "on", "a", "variety", "of", "clinical", "outcome", "and", "process", "measures", "on", "six", "assessment", "occasions", "over", "a", "21-month", "period", "." ]

[ "participant", "outcome" ]

Twenty - two patients with a history of recently diagnosed RA of less than 2 years, clinical outcome and process measures

1357_task2

Sentence: Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period . Instructions: please extract entity words from the input sentence

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .

[ "Twenty", "-", "two", "patients", "with", "a", "history", "of", "recently", "diagnosed", "RA", "of", "less", "than", "2", "years", "were", "assessed", "on", "a", "variety", "of", "clinical", "outcome", "and", "process", "measures", "on", "six", "assessment", "occasions", "over", "a", "21-month", "period", "." ]

[ "participant", "outcome" ]

Arp1 is a protein, Golgi - associated betaIII is a protein-isoform, spectrin is a protein-family, Arp1 is a protein, betaIII spectrin is a protein-isoform

1.0alpha7.train.510_task0

Sentence: To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-isoform, protein, protein-family

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "O", "O" ]

To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin.

[ " ", "To", "test", "this", "hypothesis", ",", "we", "have", "examined", "the", "interaction", "of", " ", "Arp1", "with", "the", "Golgi", "-", "associated", "betaIII", "isoform", "of", " ", "spectrin", "and", "demonstrated", "that", " ", "Arp1", "binds", "directly", "to", " ", "betaIII", "spectrin", ".", " " ]

[ "protein-isoform", "protein-family", "organelle", "protein" ]

Arp1 is a protein, Golgi - associated betaIII is a protein-isoform, spectrin is a protein-family, Arp1 is a protein, betaIII spectrin is a protein-isoform

1.0alpha7.train.510_task1

Sentence: To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin. Instructions: please typing these entity words according to sentence: Arp1, Golgi - associated betaIII, spectrin, Arp1, betaIII spectrin Options: protein-isoform, protein, protein-family

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "O", "O" ]

To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin.

[ " ", "To", "test", "this", "hypothesis", ",", "we", "have", "examined", "the", "interaction", "of", " ", "Arp1", "with", "the", "Golgi", "-", "associated", "betaIII", "isoform", "of", " ", "spectrin", "and", "demonstrated", "that", " ", "Arp1", "binds", "directly", "to", " ", "betaIII", "spectrin", ".", " " ]

[ "protein-isoform", "protein-family", "organelle", "protein" ]

Arp1, Golgi - associated betaIII, spectrin, Arp1, betaIII spectrin

1.0alpha7.train.510_task2

Sentence: To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "O", "O" ]

To test this hypothesis, we have examined the interaction of Arp1 with the Golgi-associated betaIII isoform of spectrin and demonstrated that Arp1 binds directly to betaIII spectrin.

[ " ", "To", "test", "this", "hypothesis", ",", "we", "have", "examined", "the", "interaction", "of", " ", "Arp1", "with", "the", "Golgi", "-", "associated", "betaIII", "isoform", "of", " ", "spectrin", "and", "demonstrated", "that", " ", "Arp1", "binds", "directly", "to", " ", "betaIII", "spectrin", ".", " " ]

[ "protein-isoform", "protein-family", "organelle", "protein" ]

Group cognitive behavioural therapy is a Intervention_Other, and is a Intervention_Pharmacological, group recreational activity is a Intervention_Other, adults is a Participant_Age, autism spectrum disorders is a Participant_Condition, groups of 6 - 8 patients is a Participant_Sample-size, 68 is a Participant_Sample-size, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health is a Outcome_Physical, psychiatric symptoms is a Outcome_Physical, dropout rate is a Outcome_Physical, efficacy is a Outcome_Other, Cognitive behavioural therapy is a Intervention_Educational

61594_task0

Sentence: Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Intervention_Pharmacological", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout .

[ "Group", "cognitive", "behavioural", "therapy", "and", "group", "recreational", "activity", "for", "adults", "with", "autism", "spectrum", "disorders", ":", "a", "preliminary", "randomized", "controlled", "trial", ".", "Although", "adults", "with", "autism", "spectrum", "disorder", "are", "an", "increasingly", "identified", "patient", "population", ",", "few", "treatment", "options", "are", "available", ".", "This", "preliminary", "randomized", "controlled", "open", "trial", "with", "a", "parallel", "design", "developed", "two", "group", "interventions", "for", "adults", "with", "autism", "spectrum", "disorders", "and", "intelligence", "within", "the", "normal", "range", ":", "cognitive", "behavioural", "therapy", "and", "recreational", "activity", ".", "Both", "interventions", "comprised", "36", "weekly", "3-h", "sessions", "led", "by", "two", "therapists", "in", "groups", "of", "6", "-", "8", "patients", ".", "A", "total", "of", "68", "psychiatric", "patients", "with", "autism", "spectrum", "disorders", "participated", "in", "the", "study", ".", "Outcome", "measures", "were", "Quality", "of", "Life", "Inventory", ",", "Sense", "of", "Coherence", "Scale", ",", "Rosenberg", "Self", "-", "Esteem", "Scale", "and", "an", "exploratory", "analysis", "on", "measures", "of", "psychiatric", "health", ".", "Participants", "in", "both", "treatment", "conditions", "reported", "an", "increased", "quality", "of", "life", "at", "post", "-", "treatment", "(", "d", "=", "0.39", ",", "p", "<", "0.001", ")", ",", "with", "no", "difference", "between", "interventions", ".", "No", "amelioration", "of", "psychiatric", "symptoms", "was", "observed", ".", "The", "dropout", "rate", "was", "lower", "with", "cognitive", "behavioural", "therapy", "than", "with", "recreational", "activity", ",", "and", "participants", "in", "cognitive", "behavioural", "therapy", "rated", "themselves", "as", "more", "generally", "improved", ",", "as", "well", "as", "more", "improved", "regarding", "expression", "of", "needs", "and", "understanding", "of", "difficulties", ".", "Both", "interventions", "appear", "to", "be", "promising", "treatment", "options", "for", "adults", "with", "autism", "spectrum", "disorder", ".", "The", "interventions", "'", "similar", "efficacy", "may", "be", "due", "to", "the", "common", "elements", ",", "structure", "and", "group", "setting", ".", "Cognitive", "behavioural", "therapy", "may", "be", "additionally", "beneficial", "in", "terms", "of", "increasing", "specific", "skills", "and", "minimizing", "dropout", "." ]

[ "Outcome_Physical", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Participant_Age", "Intervention_Pharmacological" ]

Group cognitive behavioural therapy is a Intervention_Other, and is a Intervention_Pharmacological, group recreational activity is a Intervention_Other, adults is a Participant_Age, autism spectrum disorders is a Participant_Condition, groups of 6 - 8 patients is a Participant_Sample-size, 68 is a Participant_Sample-size, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health is a Outcome_Physical, psychiatric symptoms is a Outcome_Physical, dropout rate is a Outcome_Physical, efficacy is a Outcome_Other, Cognitive behavioural therapy is a Intervention_Educational

61594_task1

Sentence: Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout . Instructions: please typing these entity words according to sentence: Group cognitive behavioural therapy, and, group recreational activity, adults, autism spectrum disorders, groups of 6 - 8 patients, 68, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health, psychiatric symptoms, dropout rate, efficacy, Cognitive behavioural therapy Options: Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Intervention_Pharmacological", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout .

[ "Group", "cognitive", "behavioural", "therapy", "and", "group", "recreational", "activity", "for", "adults", "with", "autism", "spectrum", "disorders", ":", "a", "preliminary", "randomized", "controlled", "trial", ".", "Although", "adults", "with", "autism", "spectrum", "disorder", "are", "an", "increasingly", "identified", "patient", "population", ",", "few", "treatment", "options", "are", "available", ".", "This", "preliminary", "randomized", "controlled", "open", "trial", "with", "a", "parallel", "design", "developed", "two", "group", "interventions", "for", "adults", "with", "autism", "spectrum", "disorders", "and", "intelligence", "within", "the", "normal", "range", ":", "cognitive", "behavioural", "therapy", "and", "recreational", "activity", ".", "Both", "interventions", "comprised", "36", "weekly", "3-h", "sessions", "led", "by", "two", "therapists", "in", "groups", "of", "6", "-", "8", "patients", ".", "A", "total", "of", "68", "psychiatric", "patients", "with", "autism", "spectrum", "disorders", "participated", "in", "the", "study", ".", "Outcome", "measures", "were", "Quality", "of", "Life", "Inventory", ",", "Sense", "of", "Coherence", "Scale", ",", "Rosenberg", "Self", "-", "Esteem", "Scale", "and", "an", "exploratory", "analysis", "on", "measures", "of", "psychiatric", "health", ".", "Participants", "in", "both", "treatment", "conditions", "reported", "an", "increased", "quality", "of", "life", "at", "post", "-", "treatment", "(", "d", "=", "0.39", ",", "p", "<", "0.001", ")", ",", "with", "no", "difference", "between", "interventions", ".", "No", "amelioration", "of", "psychiatric", "symptoms", "was", "observed", ".", "The", "dropout", "rate", "was", "lower", "with", "cognitive", "behavioural", "therapy", "than", "with", "recreational", "activity", ",", "and", "participants", "in", "cognitive", "behavioural", "therapy", "rated", "themselves", "as", "more", "generally", "improved", ",", "as", "well", "as", "more", "improved", "regarding", "expression", "of", "needs", "and", "understanding", "of", "difficulties", ".", "Both", "interventions", "appear", "to", "be", "promising", "treatment", "options", "for", "adults", "with", "autism", "spectrum", "disorder", ".", "The", "interventions", "'", "similar", "efficacy", "may", "be", "due", "to", "the", "common", "elements", ",", "structure", "and", "group", "setting", ".", "Cognitive", "behavioural", "therapy", "may", "be", "additionally", "beneficial", "in", "terms", "of", "increasing", "specific", "skills", "and", "minimizing", "dropout", "." ]

[ "Outcome_Physical", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Participant_Age", "Intervention_Pharmacological" ]

Group cognitive behavioural therapy, and, group recreational activity, adults, autism spectrum disorders, groups of 6 - 8 patients, 68, Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self - Esteem Scale and an exploratory analysis on measures of psychiatric health, psychiatric symptoms, dropout rate, efficacy, Cognitive behavioural therapy

61594_task2

Sentence: Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Intervention_Pharmacological", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial . Although adults with autism spectrum disorder are an increasingly identified patient population , few treatment options are available . This preliminary randomized controlled open trial with a parallel design developed two group interventions for adults with autism spectrum disorders and intelligence within the normal range : cognitive behavioural therapy and recreational activity . Both interventions comprised 36 weekly 3-h sessions led by two therapists in groups of 6-8 patients . A total of 68 psychiatric patients with autism spectrum disorders participated in the study . Outcome measures were Quality of Life Inventory , Sense of Coherence Scale , Rosenberg Self-Esteem Scale and an exploratory analysis on measures of psychiatric health . Participants in both treatment conditions reported an increased quality of life at post-treatment ( d = 0.39 , p < 0.001 ) , with no difference between interventions . No amelioration of psychiatric symptoms was observed . The dropout rate was lower with cognitive behavioural therapy than with recreational activity , and participants in cognitive behavioural therapy rated themselves as more generally improved , as well as more improved regarding expression of needs and understanding of difficulties . Both interventions appear to be promising treatment options for adults with autism spectrum disorder . The interventions ' similar efficacy may be due to the common elements , structure and group setting . Cognitive behavioural therapy may be additionally beneficial in terms of increasing specific skills and minimizing dropout .

[ "Group", "cognitive", "behavioural", "therapy", "and", "group", "recreational", "activity", "for", "adults", "with", "autism", "spectrum", "disorders", ":", "a", "preliminary", "randomized", "controlled", "trial", ".", "Although", "adults", "with", "autism", "spectrum", "disorder", "are", "an", "increasingly", "identified", "patient", "population", ",", "few", "treatment", "options", "are", "available", ".", "This", "preliminary", "randomized", "controlled", "open", "trial", "with", "a", "parallel", "design", "developed", "two", "group", "interventions", "for", "adults", "with", "autism", "spectrum", "disorders", "and", "intelligence", "within", "the", "normal", "range", ":", "cognitive", "behavioural", "therapy", "and", "recreational", "activity", ".", "Both", "interventions", "comprised", "36", "weekly", "3-h", "sessions", "led", "by", "two", "therapists", "in", "groups", "of", "6", "-", "8", "patients", ".", "A", "total", "of", "68", "psychiatric", "patients", "with", "autism", "spectrum", "disorders", "participated", "in", "the", "study", ".", "Outcome", "measures", "were", "Quality", "of", "Life", "Inventory", ",", "Sense", "of", "Coherence", "Scale", ",", "Rosenberg", "Self", "-", "Esteem", "Scale", "and", "an", "exploratory", "analysis", "on", "measures", "of", "psychiatric", "health", ".", "Participants", "in", "both", "treatment", "conditions", "reported", "an", "increased", "quality", "of", "life", "at", "post", "-", "treatment", "(", "d", "=", "0.39", ",", "p", "<", "0.001", ")", ",", "with", "no", "difference", "between", "interventions", ".", "No", "amelioration", "of", "psychiatric", "symptoms", "was", "observed", ".", "The", "dropout", "rate", "was", "lower", "with", "cognitive", "behavioural", "therapy", "than", "with", "recreational", "activity", ",", "and", "participants", "in", "cognitive", "behavioural", "therapy", "rated", "themselves", "as", "more", "generally", "improved", ",", "as", "well", "as", "more", "improved", "regarding", "expression", "of", "needs", "and", "understanding", "of", "difficulties", ".", "Both", "interventions", "appear", "to", "be", "promising", "treatment", "options", "for", "adults", "with", "autism", "spectrum", "disorder", ".", "The", "interventions", "'", "similar", "efficacy", "may", "be", "due", "to", "the", "common", "elements", ",", "structure", "and", "group", "setting", ".", "Cognitive", "behavioural", "therapy", "may", "be", "additionally", "beneficial", "in", "terms", "of", "increasing", "specific", "skills", "and", "minimizing", "dropout", "." ]

[ "Outcome_Physical", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Participant_Sample-size", "Outcome_Other", "Participant_Age", "Intervention_Pharmacological" ]

fluticasone propionate is a CHEMICAL

9563368_task0

Sentence: Development of fluticasone propionate and comparison with other inhaled corticosteroids. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]

Development of fluticasone propionate and comparison with other inhaled corticosteroids.

[ "Development", "of", "fluticasone", "propionate", "and", "comparison", "with", "other", "inhaled", "corticosteroids", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

fluticasone propionate is a CHEMICAL

9563368_task1

Sentence: Development of fluticasone propionate and comparison with other inhaled corticosteroids. Instructions: please typing these entity words according to sentence: fluticasone propionate Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]

Development of fluticasone propionate and comparison with other inhaled corticosteroids.

[ "Development", "of", "fluticasone", "propionate", "and", "comparison", "with", "other", "inhaled", "corticosteroids", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

fluticasone propionate

9563368_task2

Sentence: Development of fluticasone propionate and comparison with other inhaled corticosteroids. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]

Development of fluticasone propionate and comparison with other inhaled corticosteroids.

[ "Development", "of", "fluticasone", "propionate", "and", "comparison", "with", "other", "inhaled", "corticosteroids", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

Granulocyte - macrophage colony - stimulating factor is a Intervention_Pharmacological, influenza vaccination is a Intervention_Pharmacological, stem cell transplant is a Participant_Condition, granulocyte - macrophage colony - stimulating factor ( GM - CSF ) is a Intervention_Physical, serological response is a Outcome_Physical, 117 is a Participant_Sample-size, undergone stem cell transplantation is a Participant_Condition, SCT is a Participant_Condition, vaccine response is a Outcome_Physical, levels of influenza hemagglutination - inhibition ( HAI ) antibodies is a Outcome_Physical, IgG antibodies is a Outcome_Physical, ELISA is a Outcome_Physical, antibody response is a Outcome_Physical, influenza A is a Outcome_Physical, SCT patients is a Participant_Condition, influenza B vaccine is a Intervention_Pharmacological

2670_task0

Sentence: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent .

[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "as", "immunomodulating", "factor", "together", "with", "influenza", "vaccination", "in", "stem", "cell", "transplant", "patients", ".", "The", "effect", "of", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "on", "the", "serological", "response", "at", "influenza", "vaccination", "was", "studied", "in", "117", "patients", "who", "had", "undergone", "stem", "cell", "transplantation", "(", "SCT", ")", ".", "The", "vaccine", "response", "was", "evaluated", "as", "significant", "increases", "in", "levels", "of", "influenza", "hemagglutination", "-", "inhibition", "(", "HAI", ")", "antibodies", "and", "of", "IgG", "antibodies", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "There", "was", "no", "difference", "in", "antibody", "response", "to", "either", "influenza", "A", "or", "B", "in", "64", "patients", "who", "received", "GM", "-", "CSF", "at", "vaccination", ",", "compared", "with", "the", "53", "who", "did", "not", ".", "In", "the", "subgroup", "of", "allogeneic", "SCT", "patients", ",", "HAI", "showed", "that", "the", "response", "rate", "to", "the", "influenza", "B", "vaccine", "was", "significantly", "higher", "in", "the", "treatment", "group", "(", "P", "<", ".05", ")", ".", "ELISA", "showed", "that", "autologous", "SCT", "patients", "with", "breast", "cancer", "who", "received", "GM", "-", "CSF", "had", "a", "better", "response", "to", "influenza", "A", "(", "P", "<", ".05", ")", "and", "B", "(", "P", "<", ".01", ")", ".", "At", "early", "vaccination", ",", "4", "-", "12", "months", "after", "stem", "cell", "transplantation", ",", "these", "responses", "were", "more", "pronounced", ".", "GM", "-", "CSF", "appears", "to", "improve", "the", "response", "to", "influenza", "vaccination", "in", "some", "groups", "of", "SCT", "patients", ",", "but", "only", "to", "a", "limited", "extent", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

Granulocyte - macrophage colony - stimulating factor is a Intervention_Pharmacological, influenza vaccination is a Intervention_Pharmacological, stem cell transplant is a Participant_Condition, granulocyte - macrophage colony - stimulating factor ( GM - CSF ) is a Intervention_Physical, serological response is a Outcome_Physical, 117 is a Participant_Sample-size, undergone stem cell transplantation is a Participant_Condition, SCT is a Participant_Condition, vaccine response is a Outcome_Physical, levels of influenza hemagglutination - inhibition ( HAI ) antibodies is a Outcome_Physical, IgG antibodies is a Outcome_Physical, ELISA is a Outcome_Physical, antibody response is a Outcome_Physical, influenza A is a Outcome_Physical, SCT patients is a Participant_Condition, influenza B vaccine is a Intervention_Pharmacological

2670_task1

Sentence: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent . Instructions: please typing these entity words according to sentence: Granulocyte - macrophage colony - stimulating factor, influenza vaccination, stem cell transplant, granulocyte - macrophage colony - stimulating factor ( GM - CSF ), serological response, 117, undergone stem cell transplantation, SCT, vaccine response, levels of influenza hemagglutination - inhibition ( HAI ) antibodies, IgG antibodies, ELISA, antibody response, influenza A, SCT patients, influenza B vaccine Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent .

[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "as", "immunomodulating", "factor", "together", "with", "influenza", "vaccination", "in", "stem", "cell", "transplant", "patients", ".", "The", "effect", "of", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "on", "the", "serological", "response", "at", "influenza", "vaccination", "was", "studied", "in", "117", "patients", "who", "had", "undergone", "stem", "cell", "transplantation", "(", "SCT", ")", ".", "The", "vaccine", "response", "was", "evaluated", "as", "significant", "increases", "in", "levels", "of", "influenza", "hemagglutination", "-", "inhibition", "(", "HAI", ")", "antibodies", "and", "of", "IgG", "antibodies", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "There", "was", "no", "difference", "in", "antibody", "response", "to", "either", "influenza", "A", "or", "B", "in", "64", "patients", "who", "received", "GM", "-", "CSF", "at", "vaccination", ",", "compared", "with", "the", "53", "who", "did", "not", ".", "In", "the", "subgroup", "of", "allogeneic", "SCT", "patients", ",", "HAI", "showed", "that", "the", "response", "rate", "to", "the", "influenza", "B", "vaccine", "was", "significantly", "higher", "in", "the", "treatment", "group", "(", "P", "<", ".05", ")", ".", "ELISA", "showed", "that", "autologous", "SCT", "patients", "with", "breast", "cancer", "who", "received", "GM", "-", "CSF", "had", "a", "better", "response", "to", "influenza", "A", "(", "P", "<", ".05", ")", "and", "B", "(", "P", "<", ".01", ")", ".", "At", "early", "vaccination", ",", "4", "-", "12", "months", "after", "stem", "cell", "transplantation", ",", "these", "responses", "were", "more", "pronounced", ".", "GM", "-", "CSF", "appears", "to", "improve", "the", "response", "to", "influenza", "vaccination", "in", "some", "groups", "of", "SCT", "patients", ",", "but", "only", "to", "a", "limited", "extent", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

Granulocyte - macrophage colony - stimulating factor, influenza vaccination, stem cell transplant, granulocyte - macrophage colony - stimulating factor ( GM - CSF ), serological response, 117, undergone stem cell transplantation, SCT, vaccine response, levels of influenza hemagglutination - inhibition ( HAI ) antibodies, IgG antibodies, ELISA, antibody response, influenza A, SCT patients, influenza B vaccine

2670_task2

Sentence: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients . The effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF ) on the serological response at influenza vaccination was studied in 117 patients who had undergone stem cell transplantation ( SCT ) . The vaccine response was evaluated as significant increases in levels of influenza hemagglutination-inhibition ( HAI ) antibodies and of IgG antibodies measured by enzyme-linked immunosorbent assay ( ELISA ) . There was no difference in antibody response to either influenza A or B in 64 patients who received GM-CSF at vaccination , compared with the 53 who did not . In the subgroup of allogeneic SCT patients , HAI showed that the response rate to the influenza B vaccine was significantly higher in the treatment group ( P < .05 ) . ELISA showed that autologous SCT patients with breast cancer who received GM-CSF had a better response to influenza A ( P < .05 ) and B ( P < .01 ) . At early vaccination , 4-12 months after stem cell transplantation , these responses were more pronounced . GM-CSF appears to improve the response to influenza vaccination in some groups of SCT patients , but only to a limited extent .

[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "as", "immunomodulating", "factor", "together", "with", "influenza", "vaccination", "in", "stem", "cell", "transplant", "patients", ".", "The", "effect", "of", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "on", "the", "serological", "response", "at", "influenza", "vaccination", "was", "studied", "in", "117", "patients", "who", "had", "undergone", "stem", "cell", "transplantation", "(", "SCT", ")", ".", "The", "vaccine", "response", "was", "evaluated", "as", "significant", "increases", "in", "levels", "of", "influenza", "hemagglutination", "-", "inhibition", "(", "HAI", ")", "antibodies", "and", "of", "IgG", "antibodies", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "There", "was", "no", "difference", "in", "antibody", "response", "to", "either", "influenza", "A", "or", "B", "in", "64", "patients", "who", "received", "GM", "-", "CSF", "at", "vaccination", ",", "compared", "with", "the", "53", "who", "did", "not", ".", "In", "the", "subgroup", "of", "allogeneic", "SCT", "patients", ",", "HAI", "showed", "that", "the", "response", "rate", "to", "the", "influenza", "B", "vaccine", "was", "significantly", "higher", "in", "the", "treatment", "group", "(", "P", "<", ".05", ")", ".", "ELISA", "showed", "that", "autologous", "SCT", "patients", "with", "breast", "cancer", "who", "received", "GM", "-", "CSF", "had", "a", "better", "response", "to", "influenza", "A", "(", "P", "<", ".05", ")", "and", "B", "(", "P", "<", ".01", ")", ".", "At", "early", "vaccination", ",", "4", "-", "12", "months", "after", "stem", "cell", "transplantation", ",", "these", "responses", "were", "more", "pronounced", ".", "GM", "-", "CSF", "appears", "to", "improve", "the", "response", "to", "influenza", "vaccination", "in", "some", "groups", "of", "SCT", "patients", ",", "but", "only", "to", "a", "limited", "extent", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

LDL is a GENE-N, Cholesterol is a CHEMICAL, low - density lipoprotein is a GENE-N, cholesterol is a CHEMICAL, LDL is a GENE-N, HMG - CoA reductase is a GENE-Y, LDL is a GENE-N, LDL is a GENE-N, LDL is a GENE-N, ezetimibe is a CHEMICAL, bile acid is a CHEMICAL, fibrates is a CHEMICAL, LDL is a GENE-N, LDL is a GENE-N

32226_task0

Sentence: LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "B-GENE-N", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.

[ "LDL", "Cholesterol", "Goals", "in", "High", "-", "Risk", "Patients", ":", "How", "Low", "Do", "We", "Go", "and", "How", "Do", "We", "Get", "There", "?", "\n", "It", "is", "widely", "recognised", "that", "low", "-", "density", "lipoprotein", "cholesterol", "(", "LDL", "-", "C", ")", "is", "one", "of", "the", "most", "important", "and", "modifiable", "risk", "factors", "for", "cardiovascular", "disease", "(", "CVD", ")", ".", "Statins", "(", "HMG", "-", "CoA", "reductase", "inhibitors", ")", "have", "consistently", "been", "shown", "to", "decrease", "both", "LDL", "-", "C", "and", "CVD", "risk", "in", "almost", "all", "patient", "categories", ",", "with", "the", "exception", "of", "heart", "and", "kidney", "failure", "as", "well", "as", "advanced", "aortic", "stenosis", ".", "As", "a", "consequence", ",", "statins", "have", "become", "the", "cornerstone", "in", "current", "prevention", "guidelines", ".", "In", "patients", "who", "do", "not", "reach", "the", "LDL", "-", "C", "target", ",", "combination", "therapy", "with", "additional", "LDL", "-", "C", "lowering", "drugs", "(", "e.g", ".", "ezetimibe", ",", "bile", "acid", "sequestrants", "or", "fibrates", ")", "should", "be", "considered", ".", "Guidelines", "provide", "different", "LDL", "-", "C", "levels", "to", "strive", "for", ",", "depending", "on", "the", "CVD", "risk", ".", "In", "this", "review", ",", "we", "describe", "the", "rationale", "for", "these", "LDL", "-", "C", "targets", "and", "how", "these", "goals", "might", "be", "reached", "by", "current", "and", "future", "therapies", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

LDL is a GENE-N, Cholesterol is a CHEMICAL, low - density lipoprotein is a GENE-N, cholesterol is a CHEMICAL, LDL is a GENE-N, HMG - CoA reductase is a GENE-Y, LDL is a GENE-N, LDL is a GENE-N, LDL is a GENE-N, ezetimibe is a CHEMICAL, bile acid is a CHEMICAL, fibrates is a CHEMICAL, LDL is a GENE-N, LDL is a GENE-N

32226_task1

Sentence: LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies. Instructions: please typing these entity words according to sentence: LDL, Cholesterol, low - density lipoprotein, cholesterol, LDL, HMG - CoA reductase, LDL, LDL, LDL, ezetimibe, bile acid, fibrates, LDL, LDL Options: GENE-Y, GENE-N, CHEMICAL

[ "B-GENE-N", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.

[ "LDL", "Cholesterol", "Goals", "in", "High", "-", "Risk", "Patients", ":", "How", "Low", "Do", "We", "Go", "and", "How", "Do", "We", "Get", "There", "?", "\n", "It", "is", "widely", "recognised", "that", "low", "-", "density", "lipoprotein", "cholesterol", "(", "LDL", "-", "C", ")", "is", "one", "of", "the", "most", "important", "and", "modifiable", "risk", "factors", "for", "cardiovascular", "disease", "(", "CVD", ")", ".", "Statins", "(", "HMG", "-", "CoA", "reductase", "inhibitors", ")", "have", "consistently", "been", "shown", "to", "decrease", "both", "LDL", "-", "C", "and", "CVD", "risk", "in", "almost", "all", "patient", "categories", ",", "with", "the", "exception", "of", "heart", "and", "kidney", "failure", "as", "well", "as", "advanced", "aortic", "stenosis", ".", "As", "a", "consequence", ",", "statins", "have", "become", "the", "cornerstone", "in", "current", "prevention", "guidelines", ".", "In", "patients", "who", "do", "not", "reach", "the", "LDL", "-", "C", "target", ",", "combination", "therapy", "with", "additional", "LDL", "-", "C", "lowering", "drugs", "(", "e.g", ".", "ezetimibe", ",", "bile", "acid", "sequestrants", "or", "fibrates", ")", "should", "be", "considered", ".", "Guidelines", "provide", "different", "LDL", "-", "C", "levels", "to", "strive", "for", ",", "depending", "on", "the", "CVD", "risk", ".", "In", "this", "review", ",", "we", "describe", "the", "rationale", "for", "these", "LDL", "-", "C", "targets", "and", "how", "these", "goals", "might", "be", "reached", "by", "current", "and", "future", "therapies", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

LDL, Cholesterol, low - density lipoprotein, cholesterol, LDL, HMG - CoA reductase, LDL, LDL, LDL, ezetimibe, bile acid, fibrates, LDL, LDL

32226_task2

Sentence: LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies. Instructions: please extract entity words from the input sentence

[ "B-GENE-N", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.

[ "LDL", "Cholesterol", "Goals", "in", "High", "-", "Risk", "Patients", ":", "How", "Low", "Do", "We", "Go", "and", "How", "Do", "We", "Get", "There", "?", "\n", "It", "is", "widely", "recognised", "that", "low", "-", "density", "lipoprotein", "cholesterol", "(", "LDL", "-", "C", ")", "is", "one", "of", "the", "most", "important", "and", "modifiable", "risk", "factors", "for", "cardiovascular", "disease", "(", "CVD", ")", ".", "Statins", "(", "HMG", "-", "CoA", "reductase", "inhibitors", ")", "have", "consistently", "been", "shown", "to", "decrease", "both", "LDL", "-", "C", "and", "CVD", "risk", "in", "almost", "all", "patient", "categories", ",", "with", "the", "exception", "of", "heart", "and", "kidney", "failure", "as", "well", "as", "advanced", "aortic", "stenosis", ".", "As", "a", "consequence", ",", "statins", "have", "become", "the", "cornerstone", "in", "current", "prevention", "guidelines", ".", "In", "patients", "who", "do", "not", "reach", "the", "LDL", "-", "C", "target", ",", "combination", "therapy", "with", "additional", "LDL", "-", "C", "lowering", "drugs", "(", "e.g", ".", "ezetimibe", ",", "bile", "acid", "sequestrants", "or", "fibrates", ")", "should", "be", "considered", ".", "Guidelines", "provide", "different", "LDL", "-", "C", "levels", "to", "strive", "for", ",", "depending", "on", "the", "CVD", "risk", ".", "In", "this", "review", ",", "we", "describe", "the", "rationale", "for", "these", "LDL", "-", "C", "targets", "and", "how", "these", "goals", "might", "be", "reached", "by", "current", "and", "future", "therapies", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

alpha - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, cadherin is a Gene/protein/RNA

846_task0

Sentence: Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.

[ "Transfection", "of", "alpha", "-", "catenin", "-", "deficient", "colon", "carcinoma", "cells", "recruited", "E", "-", "cadherin", "and", "beta", "-", "catenin", "to", "cell", "-", "cell", "contacts", "and", "functional", "cadherin", "-", "mediated", "cell", "-", "cell", "adhesion", "was", "restored", "in", "this", "way", "." ]

[ "Gene/protein/RNA" ]

alpha - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, cadherin is a Gene/protein/RNA

846_task1

Sentence: Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way. Instructions: please typing these entity words according to sentence: alpha - catenin, E - cadherin, beta - catenin, cadherin Options: Gene/protein/RNA

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.

[ "Transfection", "of", "alpha", "-", "catenin", "-", "deficient", "colon", "carcinoma", "cells", "recruited", "E", "-", "cadherin", "and", "beta", "-", "catenin", "to", "cell", "-", "cell", "contacts", "and", "functional", "cadherin", "-", "mediated", "cell", "-", "cell", "adhesion", "was", "restored", "in", "this", "way", "." ]

[ "Gene/protein/RNA" ]

alpha - catenin, E - cadherin, beta - catenin, cadherin

846_task2

Sentence: Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.

[ "Transfection", "of", "alpha", "-", "catenin", "-", "deficient", "colon", "carcinoma", "cells", "recruited", "E", "-", "cadherin", "and", "beta", "-", "catenin", "to", "cell", "-", "cell", "contacts", "and", "functional", "cadherin", "-", "mediated", "cell", "-", "cell", "adhesion", "was", "restored", "in", "this", "way", "." ]

[ "Gene/protein/RNA" ]

implantation is an umlsterm, eyeball is an umlsterm, United States is an umlsterm, hydroxyapatite is an umlsterm, orbital implant is an umlsterm, Germany is an umlsterm, aim is an umlsterm, postoperative complications is an umlsterm, cosmetic is an umlsterm

DerOpthalmologe.00970091.eng.abstr_task0

Sentence: Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results .

[ "Background", ":", "Since", "its", "first", "implantation", "as", "an", "eyeball", "replacement", "in", "the", "United", "States", "in", "1985", ",", "hydroxyapatite", "has", "been", "rarely", "used", "as", "an", "orbital", "implant", "in", "Germany", ".", "The", "aim", "of", "the", "study", "was", "to", "collect", "data", "on", "long", "-", "term", "tolerance", ",", "postoperative", "complications", "and", "the", "cosmetic", "end", "results", "." ]

[ "umlsterm" ]

implantation is an umlsterm, eyeball is an umlsterm, United States is an umlsterm, hydroxyapatite is an umlsterm, orbital implant is an umlsterm, Germany is an umlsterm, aim is an umlsterm, postoperative complications is an umlsterm, cosmetic is an umlsterm

DerOpthalmologe.00970091.eng.abstr_task1

Sentence: Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results . Instructions: please typing these entity words according to sentence: implantation, eyeball, United States, hydroxyapatite, orbital implant, Germany, aim, postoperative complications, cosmetic Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results .

[ "Background", ":", "Since", "its", "first", "implantation", "as", "an", "eyeball", "replacement", "in", "the", "United", "States", "in", "1985", ",", "hydroxyapatite", "has", "been", "rarely", "used", "as", "an", "orbital", "implant", "in", "Germany", ".", "The", "aim", "of", "the", "study", "was", "to", "collect", "data", "on", "long", "-", "term", "tolerance", ",", "postoperative", "complications", "and", "the", "cosmetic", "end", "results", "." ]

[ "umlsterm" ]

implantation, eyeball, United States, hydroxyapatite, orbital implant, Germany, aim, postoperative complications, cosmetic

DerOpthalmologe.00970091.eng.abstr_task2

Sentence: Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Background : Since its first implantation as an eyeball replacement in the United States in 1985 , hydroxyapatite has been rarely used as an orbital implant in Germany . The aim of the study was to collect data on long-term tolerance , postoperative complications and the cosmetic end results .

[ "Background", ":", "Since", "its", "first", "implantation", "as", "an", "eyeball", "replacement", "in", "the", "United", "States", "in", "1985", ",", "hydroxyapatite", "has", "been", "rarely", "used", "as", "an", "orbital", "implant", "in", "Germany", ".", "The", "aim", "of", "the", "study", "was", "to", "collect", "data", "on", "long", "-", "term", "tolerance", ",", "postoperative", "complications", "and", "the", "cosmetic", "end", "results", "." ]

[ "umlsterm" ]